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ABSTRACT 
 Lung cancer is the second most common cancer type and is associated with high 
mortality rates. The survival rate for lung cancer patients has increased slowly in the last decade 
mainly as the result of the development of novel targeted and immune therapies. However, non-
small cell lung cancer patients lacking known or actionable driver mutations and small cell lung 
cancer patients with recurrent disease are still in urgent need of new therapies. Drug 
repurposing is an efficient way to identify new therapies since it uses clinically relevant small 
molecule drugs. Determination of off-targets of small molecules is a novel approach towards 
drug repurposing as unintended targets can play important roles for a new clinical application. 
Here we apply functional proteomics and systems pharmacology approaches to determine 
target profiles and differential mechanisms of action, independent of the intended targets, of 
small molecules with similar chemical structures. Using chemical proteomics, we elucidated the 
differential target profiles of two clinical CDK4/6 inhibitors: palbociclib and ribociclib. We 
observed that palbociclib, but not ribociclib, is a dual protein and lipid kinase inhibitor that in 
addition to the intended cell cycle pathway modulates the PI3K/AKT and autophagy pathways. 
Furthermore, we investigated the off-targets of two MET/VEGFR inhibitors, foretinib and 
cabozantinib. Foretinib, but not cabozantinib, was found to reduce cell viability and induce cell 
cycle arrest and apoptosis in lung cancer cell lines. Using a systems pharmacology approach, 
which included chemical proteomics, phosphoproteomics and RNA-Seq, integrated data 
analysis and subsequent functional validation revealed a complex polypharmacology 
mechanism of action of foretinib, which involves the simultaneous inhibition of MEK, AURKB 
and FER protein kinases. Because AURKB is an important protein kinase for the proliferation of 
MYC-amplified small cell lung cancer cells, we were able to design a drug combination of 
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foretinib with barasertib, a much more potent AURKB inhibitor, that enhanced specifically the 
cell death of MYC-amplified small cell lung cancer cells. In summary, we show that small 
structural changes of closely related clinical drugs can result in pronounced differences in their 
target profiles and anticancer activities through differential polypharmacology mechanisms and 
that an integrated systems pharmacology approach can identify new repurposing opportunities 
for these drugs in cancers with high unmet medical need. 
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CHAPTER ONE: 
 
INTRODUCTION 
 
Lung cancer 
Statistics for 2017 
 Among the 1,688,780 estimated new cases of cancer in 2017 in the US, lung and 
bronchus cancer constitutes the second most common cancer type with an estimated 222,500 
new cases – 13.2% of all cancer cases in 2017 (National Cancer Institute) (Fig. 1). It is 
estimated that 155,870 patients will die of this type of cancer, which corresponds to 25.7% of all 
cancer related deaths estimated for 2017 (Howlader et al. 2017, Siegel, 2017). Based on data 
from SEER 18 2007-2013 (Surveillance, Epidemiology, and End Results Program), the 5 year 
survival rate for lung and bronchus cancer is only 19.5%. 
            
Fig. 1: Percentage of new cases for cancer in 2017: estimated percentage of new cases based on the 
cancer type. According to the National Institute of Cancer “Lung” is the second most prevalent cancer 
type with 13.2%. 
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 Compared to 1975, the survival rate for lung patients have increased significantly (7%) in 
2013 (Table. 1) due to the approval of targeted therapies, such as epidermal growth factor 
receptor (EGFR) inhibitors in 2004 and anaplastic lymphoma kinase (ALK) tyrosine kinase 
inhibitors in 2007, and more recently with immunotherapy; however, lung cancer is still a major 
unmet medical need.  
Table 1. 5-Year relative survival for lung cancer by year of diagnosis 
 
SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Based on follow-up of patients in 2014. (Howlader et al. 2017) 
 
Types of Lung Cancer 
 Lung cancer is divided into two major types: non-small cancer lung cancer (NSCLC) and 
small cell lung cancer (SCLC).  
 NSCLC corresponds to approximately 85% of all lung cancers and presents a 5-year 
survival rate of 15% (Ettinger et al. 2013, Chen et al. 2014). NSCLC is further classified into 
three major subtypes: 
Lung adenocarcinoma (LUAD): It is the most common subtype of NSCLC 
corresponding to approximately 47% of this type of cancer. Histologically, LUAD is 
characterized by granular cells. Normally it arises in distal airways and it has been suggested 
that this cancer subtype is originating from club cells or alveolar epithelial type 2 cells (Chen et 
al, 2014, Howlader et al. 2017). Lung adenocarcinoma is highly associated with smoking, which 
leads to nucleotide transversions (C>A, C>T). This type of NSCLC presents high rates of 
somatic mutations, with several being actionable mutations for available targeted treatments, 
such as with EGFR and ALK inhibitors. However, most lung adenocarcinomas lack a detectable 
driver mutation or present mutations in KRAS thereby depending on conventional chemotherapy 
(Cancer Genome Atlas 2014).  
Lung squamous cell carcinoma (LUSQ): According to SEER 2010-2014, LUSQ 
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represents 23% of all lung cancer cases. It is characterized by differentiation of squamous cells 
in proximity to airways; the histology of these cells resembles the cells from the pseudostratified 
columnar epithelium on the trachea and upper airways (Chen et al. 2014, Howlader et al. 2017). 
This type of lung cancer is highly associated with smoking, but presents few actionable 
mutations, and targeted therapies developed for LUAD are ineffective in LUSQ (Cancer 
Genome Atlas 2012). 
Large cell neuroendocrine carcinoma (LCNEC): this subtype of lung cancer is less 
frequent, representing only approximately 1.6% of lung cancer cases (Howlader et al. 2017). It 
develops in any region of the lung and it is known to be highly aggressive, spreading faster than 
LUAD and LUSQ. It has a lower 5 year survival rate and there is a lack of samples in tissue 
banks to be studied (Fernandez-Cuesta et al. 2016, Okui et al. 2017). Immunohistochemistry 
staining defines this tumor as having characteristics of neuroendocrine tumor and large cell 
carcinoma morphology: cell size at least 3 times bigger than for small cell lung cancer, granular 
chromatin pattern, organoid growth pattern, low nuclear/cytoplasmic ratio and abundant 
necrosis (Battafarano et al. 2005, Fasano et al. 2015). In addition, this tumor subtype is often 
incorrectly classified since it can coexist with other subtypes of NSCLC (Fasano et al. 2015, 
Fernandez-Cuesta et al. 2016). 
Other types of non-small cell lung cancer are: carcinoid tumor, pleomorphic, salivary 
gland carcinoma and classified carcinoma. 
 SCLC accounts for about 15% of lung cancer and it is known for its fast growth and 
metastasis at early stages (Rodriguez et al. 2010, Howlader et al. 2017). SCLC can rarely be 
removed surgically, making the molecular characterization of these tumors difficult. However, 
SCLC presents neuroendocrine markers so it is believed that the type of tumor originates from 
neuroendocrine cells from the airways of the lung (Park et al. 2011). Patients with SCLC 
commonly respond very well to treatment; however, most patients relapse after 1 year of 
treatment, which results in a 5-year survival of only approximately 6% (Codony-Servat et al 
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2016, Howlader et al. 2017). This lung tumor type is highly associated with cigarette smoking, 
having mutation signatures related to exposure to carcinogens from tobacco, but no actionable 
mutation. It has been declared a recalcitrant cancer by the National Cancer Institute (NCI) 
(National Cancer Institute 2014).  
Treatment 
 Treatment for NSCLC 
 Statistically, patients whose tumors are detected at an early stage present a better 
survival rate as tumors can be resected by surgery (Howlader et al. 2017) (Fig. 2A). However, 
most of the lung cancer cases are detected at advanced stage (IV) where metastases are 
already present, and surgery therefore is not an effective option (Fig. 2B).  
 
 
Fig. 2: A. 5-Year relative survival for patients with lung cancer: Statistically, patients have a better survival 
when diagnosed in the early stage of the disease (primary site = 55.6%) than patients diagnosed at a late 
stage (distant metastasis = 4.5%). B. Percentage of lung cancer by stage: More than 50 % of lung cancer 
patients are diagnosed at late stages of the disease (57%) (Howlader et al. 2017). 
 
 The treatment for advanced stage lung cancer (stage IIIB, IIIC and IV) has improved in 
recent years. This is the result of advancement in knowledge about the genomic 
characterization of the tumors, which includes mutations, translocations and gene 
amplifications. The development of molecularly targeted therapies has especially improved the 
treatment of NSCLC (Fig. 3). 
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Fig. 3: Timeline of approved drugs: schematic representation of the available treatment for NSCLC based 
on the year of approval by the FDA. (FDA, Thomas et al. 2015).  
 
 In 2004, studies showed that patients with somatic mutations resulting in deletion within 
exon 19 or mutation in exon 21 (L858R) of the EGFR gene responded better to gefitinib, an 
EGFR tyrosine kinase inhibitor (Kobayashi et al 2005). Unfortunately, in 2005 it was observed 
that patients receiving EGFR inhibitors could develop resistance to these compounds through a 
secondary mutation or activation of bypass signaling (Hirsch et al 2016, Ou et al 2017). The 
most common secondary EGFR mutation is T790M. This so-called “gatekeeper” mutant EGFR 
can be inhibited by third-generation EGFR inhibitors. Osimertinib is the leading compound of the 
third-generation agents and it binds irreversibly to EGFR T790M and activated EGFR mutants, 
but not to the wild-type EGFR (Hirsch et al 2016). However, resistance mutations, such as 
EGFR C797S and G796S/R, which are unable to bind osimertinib, have been reported (Ou et al 
2017). Activation of bypass signaling mechanisms of resistance results in the activation and 
tumor dependence on a different pathway, such as MET or ERBB2 signaling, which sustains 
cancer cell survival and growth (Shi et al. 2016; Morgillo et al. 2016). 
 Studies have shown that several other genetic alterations are important in the 
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development of NSCLC (Thomas et al. 2015, Hirsch et al. 2017) (Fig. 4).  
                                      
Fig. 4: Percentage of mutations in NSCLC: display of frequent mutations found in 706 (62%) of 1144 
patients. All tumor samples annotated with sequencing and copy number data (from the pan-lung-cancer 
TCGA data from MSKCC, 2016 from c-BioPortal).  
 
 KRAS is with approximately 32% the most commonly mutated gene in lung cancer 
(Cancer Genome Atlas 2014). Despite numerous attempts to target these mutations with small 
molecule drugs, clinical trials have been disappointing. A possible reason for this failure in 
clinical trials is that lung cancer patients present several different mutations in KRAS, which may 
lead to activation of different signaling pathways (Ihle et al. 2012). Therefore, targeting just one 
downstream pathway of KRAS, such as the mitogen-activated protein kinases (MAPK) pathway, 
e.g. with the MEK (mitogen-activated protein kinase kinase) inhibitor trametinib may not be 
sufficient to inhibit all KRAS-mediated signaling. In addition, KRAS mutations coexist with 
multiple other mutations, such as TP53 or CDNK2A/B, inducing different gene expression 
profiles, which require different therapies or combination therapies (Hirsch et al. 2016). 
 BRAF is a major component in the MAPK signaling pathway downstream of KRAS. The 
most common mutation in BRAF is V600E, although there are many others in lung cancer. 
Therapy with inhibitors of BRAF kinase activity showed promising results in clinical trials with 
42% of patients expressing responses. However, compensatory increase in RAS pathway 
signaling was observed resulting in development of resistance (Litvak et al, 2014, Hyman et al. 
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2015). More recently, combination therapy of the BRAF inhibitor dabrafenib with the MEK 
inhibitor trametinib showed partial responses in 32% of patients and stable disease in 40% of 
patients, which led to its approval by the FDA for patients with metastatic disease presenting the 
BRAF V600E mutation (Scheuer et al 2017).  
 Another type of genetic alteration common in lung cancer cells are chromosomal 
translocations, which result in the rearrangement of genes from non-homologous chromosomes. 
Translocations commonly found in NSCLC include the receptor tyrosine kinase genes ALK, 
ROS1 and RET. 
 The anaplastic lymphoma kinase (ALK) gene translocation results in the fusion of the 
EML4 gene on the exons 6 or 13 with the ALK gene on exon 20 inducing activation of ALK 
kinase activity. The ALK inhibitor crizotinib is the first-line treatment for ALK-positive lung cancer 
patients. The response rate for ALK-positive patients treated with crizotinib was 74% versus 
45% for patients treated with chemotherapy. However, patients almost inevitably, develop 
resistance for instance through acquisition of secondary mutations including L1196M and 
C1156Y (Drizou et al. 2017). To inhibit these resistant mutations, second-generation ALK 
inhibitors were developed and nowadays three are FDA (U.S. Food and Drugs Administration) 
approved: ceritinib, alectinib and most recently brigatinib. 
 Crizotinib was also approved for the treatment of ROS1-positive metastatic NSCLC 
patients. The activation of ROS1 (c-ros oncogene 1) kinase occurs by chromosomal 
translocation generating gene fusions, which results in the constitutive activation of ROS1 
(Charest et al. 2003). Currently, L2026M and G2032R resistant mutations were identified in 
patients treated with crizotinib for ROS1 fusions, which illustrates the need for additional 
therapies for these groups of patients (Awad et al. 2013, Yun Wu et. al 2017). 
 RET is a receptor tyrosine kinase which plays a role in the proliferation of papillary 
thyroid tumor cells. In 2011, the first fusion, KIF5B-RET, was described in NSCLC as result of a 
pericentric inversion in chromosome 10 (Sabari et al. 2017). Fusion of RET induces a constitute 
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dimerization of the protein and consequently activation of the kinase and its downstream 
signaling pathways, such as MAPK and AKT kinase signaling (Sabari et al. 2017). Two FDA 
approved therapies have been shown to inhibit RET kinase, cabozantinib and vandetanib 
(Drilon 2013 et al., Sabari et al. 2017, Wang et al. 2017). 
 MET is a receptor tyrosine kinase involved in the proliferation, migration, and metastasis 
of lung cancer. It is activated upon the binding of the cytokine hepatocyte growth factor (HGF). 
Both genes encoding for the receptor MET and its ligand HGF are localized on the chromosome 
7q. In lung cancer, MET is over activated trough several mechanisms: gene amplification, 
mutation and overexpression. Amplification occurs by increase of chromosome copy number. 
Mutations occur specially in the semaphorin domain and the juxtamembrane (JM) domain. The 
semaphorin domain is localized in the extracellular domain of the MET receptor and it is 
encoded by exon 2. This domain is important for receptor dimerization and its activation (Ma et 
al. 2005, Saqid et al. 2013). Mutations in the JM domain, such as mutation in the Y1003 
phosphosite prevents the recruitment of CBL (an E3 ubiquitin ligase) and consequently inhibits 
the lysosomal degradation of MET resulting in increased stabilization of the receptor and its 
activation (Ma et al. 2005, Saqid et al. 2013, Pilloto et al. 2017). In addition, splicing of exon 14 
results in the deletion of a negative regulatory portion of JM domain, which includes the Y1003 
phosphorylation site and consequently favor activation of the receptor tyrosine kinase. Finally, 
overexpression of MET can also be a result of the loss of heterozygosity of the c-CBL gene (Ma 
et al. 2005, Saqid et al. 2013, Pilloto et al. 2017). 
 Although the overall survival of patients with NSCLC has slowly increased, this reflects 
the treatment with new targeted therapies used mainly in the treatment of lung 
adenocarcinomas with actionable mutations. However, novel therapies are necessary for the 
subtypes lacking actionable mutations.  
 SCLC treatment 
 Even though the tumor, node and metastasis (TNM) staging has been adopted for small 
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cell lung cancer (SCLC) in 2007, the prognosis and treatment for this type of lung cancer remain 
divided into only two classes: limited disease (LD) or extensive disease (ED) (Waqar et al. 
2017). Limited disease is located within one single radiation port and involves tumors located on 
the hemithorax, the mediastinum and the supraclavicular region, including the lymph nodes. All 
other patients are included in the extensive disease group (Rodriguez et al. 2010). 
Approximately, 30 to 40% of the SCLC are diagnosed as LD and present a median overall 
survival time of 15 to 20 month, while the survival rate of ED patients varies from 8 to 13 months 
only (Qiu et al. 2017).  
 Treatment for SCLC has not improved in the last forty years and still relies on 
conventional chemotherapies with platinum drugs plus etoposide and radiotherapy (Rodrigues 
et al. 2010). Even though initial response rates are high, disease recurrence is seen in almost 
all patients within a few months and the 5-year survival rate is only 6%. Recurrent SCLC tumors 
are divided into two groups: “resistant” or “sensitive” depending of the time of the recurrence 
from the completion of the first-line chemotherapy treatment (Waquar et al. 2017). Patients that 
relapse after 90 days of treatment with platinum and etoposide are considered “sensitive” and 
are eligible to receive this same chemotherapy again, although, even “sensitive” patients still 
have low survival. However, patients that recur within 3 months after chemotherapy are 
classified as “resistant” and have just topotecan as second-line therapy (Rodriguez et al. 2010, 
Waquar et al. 2017). 
 SCLC is one of the most highly mutated cancers and almost all SCLC tumors display 
mutations that are non-targetable, such as loss-of-function mutations in the tumor suppressors 
TP53 and RB1 (Rodriguez et al. 2010). Loss of TP53 renders the cell cycle unable to arrest and 
reduces apoptosis in the cell, while deletion of RB1 facilitates the progression of the cell cycle 
(Qiu et al. 2017). Analysis of copy number alteration also revealed amplification of the tyrosine 
kinase gene FGFR1 (fibroblast growth factor receptor 1) and IRS2 (insulin receptor substrate 2), 
as well as the MYC family genes (George et al. 2015). MYC amplification is associated with 
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poor survival and stage of disease (Kaur et al. 2016, Winter et al. 2012, Kim et al. 2006, 
Fiorentino et al. 2016, Iwakawa et al. 2013). MYC amplification was detected in 36% (16/44) of 
SCLC lines established from treated patients and in 11% (7/52) of SCLC lines from untreated 
patients (Kaur et al, 2016). In addition, high-levels of MYC amplification using FISH were 
detected in 5.5% of primary SCLC tissues (Sos et al. 2012). Studies have reported that MYC-
amplified SCLC cells are more sensitive to BET or Aurora kinase B inhibitors compared to 
unamplified cells, which suggests MYC as a biomarker (Kaur et al. 2016, Sos et al. 2012, 
Delmare et al. 2011, Fowler et al. 2014, Hook et al. 2012, Li et al, 2016). 
 Immunotherapy 
 One of the hallmarks of cancer is the capacity of cancer cells to evade destruction by the 
immune system that occurs through inhibition of T cell signaling, avoiding immune detection or 
suppressing T cell action regarding tumor clearance (Hanahan t al. 2011). 
 One mechanism to prevent immune detection is by the stimulation of regulatory T-cells 
(Treg), which inhibits the proliferation and activation of the effector T cell (CD8+ T-cell-mediated 
cytotoxic killing). NSCLC tumors produce high levels of CCL20, a chemokine that recruits Treg 
cells to the tumor microenvironment and consequently induces tolerance to effector T cells 
(Malhotra et al. 2017). 
 The activation of T cells occurs by the stimulation of the CD28 receptor after binding of 
the ligands CD80 and CD86. To counteract the activation of T cells, avoid an overactivation and 
promote tolerance, T cells also express immune-checkpoints on its membrane. 
 The cytotoxic T-lymphocyte antigen-4 (CTLA4), one of the most studied immune-
checkpoints, presents a higher affinity for the binding to CD80 and CD86 compared to CD28; as 
a consequence, the competition for these ligands leads to inhibition of T-cell activation (Fife et 
al. 2008, Malhotra et al. 2017). Two humanized monoclonal antibodies against CTLA4 are in 
clinical trials for NSCLC: ipilimumab and tremelimumab. Until now, tremelimumab didn’t show 
any improvement in the treatment of NSCLC patients. However, a phase III clinical trial in 
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combination with a PD-L1 antibody, durvalumab, is ongoing (ClinicalTrials.gov NCT02453282). 
 The programed death -1 receptor (PD-1) is another immune checkpoint and, in contrast 
to CTLA-4, is not only expressed on T cells, but also present in B and natural killer (NK) cells 
(Fife et al. 2008, Pardoll et al. 2016, Malhotra et al. 2017). PD-1 has two ligands: PD-L1 and 
PD-L2 (Fife et al. 2008). Nowadays there are two human anti-PD-1 IgG4 monoclonal antibodies 
and one humanized IgG1 monoclonal antibody against PD-L1 approved for treatment of 
NSCLC: nivolumab, pembrolizumab and atezolizumab, respectively. The response rate in 
NSCLC patients was only 20% with nivolumab, indicating the need to still understand which 
patients will respond to immune checkpoint inhibitors and even more importantly find alternative 
therapies for patients who do not respond to immunotherapy (Brahmer et al. 2015). This last 
category includes patients with autoimmune diseases as immune checkpoint antibodies can 
cause immune dysregulation, which potentiates pre-existing autoimmune diseases that can be 
life-threatening (Cooper et al. 2017). 
 Because the response rate to chemotherapy is intially high in SCLC patients, it is a 
challenge to evaluate the efficacy of immunotherapy as a first-line therapy for these patients 
(Lehman et al. 2017). However, since there is a lack of options as second-line therapy for these 
patients, several clinical trials are ongoing to evaluate the use of immunotherapy as 
maintenance, in combination with chemotherapy or alone as second-line (Lehaman et al 2017, 
Tartarone et al. 2017). A phase 3 clinical trial evaluated the efficacy of nivolumab (PD-1 
antibody) alone or in combination with ipilimumab (CTLA4 antibody) after completition of 
chemotherapy (ClinicalTrials.gov NCT02538666). A phase III study investigates the combination 
of carboplatin plus etoposide with atezolizumab (ClinicalTrials.gov NCT02763579). Another 
study for relapsed SCLC patients investigates the combination of paclitaxel with pembrolizumab 
(ClinicalTrials.gov NCT02551432). Finally, tremelimumab (PD-L1 antibody) and durvalumab 
(CTLA4 antibody) have been investigated in combination with radiotherapy in relapsed patients 
(ClinicalTrials.gov NCT02701400). 
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Medical needs 
Even with the improvement in the treatment 
of NSCLC in response to initially successful targeted 
drugs, such as erlotinib (EGFR inhibitor) or crizotinib 
(ALK inhibitor), these therapies are not always 
sufficient to treat a complex disease such as cancer. 
Cancer cells normally present multiple mutations 
and have numerous deregulated pathways, which 
sustain growth, survival and metastasis of the tumor. 
 Regarding NSCLC, there are several driver 
mutations, such as in KRAS, that are not currently 
actionable with drugs, and another 24% of NSCLC 
tumors are missing a known driver mutation. 
Altogether, these patients urgently require identification of new actionable targets and 
development of new therapies. In addition, patients develop resistance by many activation 
bypass pathways or acquisition of secondary mutations, which could allow development of 
targeted therapy approaches (Fig.5) (Cancer Genome Atlas 2014). 
 The lack of targeted therapies for SCLC results from its highly mutated genetic 
background and the absence of actionable driver mutations. Topotecan, the only second-line 
therapy available, was FDA approved in 1998 and improved survival only to 5.3 months 
compared to supportive care, which has a survival of 2.2 months (Rodrigues et al. 2010). No 
other clinical trial showed improvement on survival and no actionable oncogene mutations have 
been identified for this type of lung cancer.  
 A deeper understanding of the mechanistic development of lung cancer, including 
pathway dependency, will be crucial for the advancement of treatment and identification of 
urgently needed new therapies. 
Fig. 5: Mutations of 230 
adenocarcinomas: blue are potential 
new oncogene mutations, in red the 
mutations found on MAPK signaling 
pathway and in green percentage of 
tumors without driver oncogenes. 
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Drug off-targets 
 One of the obstacles to improve survival is that it takes a long time to develop new drug 
therapies to target novel genetic alterations discovered by the scientific research community. 
The average time to have a novel compound approved from the beginning of research to 
regulatory review is 11.4-13.5 years (Sleire et al. 2017). In addition, the development cost per 
compound can be anywhere from 161 million to 1.8 billion US dollars (Sleire et al. 2017). 
Furthermore, less than 15% of the compounds entering clinical trials are eventually approved 
(Corsello et al. 2017). An alternative way to address this issue is the repurposing of already 
approved therapies either as single or combination therapies to treat late stage tumors and/or to 
overcome resistance. Nonetheless, to determine which tumors would respond to these 
therapies, it is necessary to identify the relevant targets of these therapies and pathways 
underlying the observed activity for each tumor type. 
 In cancer treatment, protein kinase inhibitors have been the most important and 
developed inhibitors. Kinases are proteins that phosphorylate other proteins. They transfer the 
terminal phosphate group from the adenosine triphosphate (ATP) to serine, threonine or 
tyrosine residues of substrate proteins. Protein kinases mediate important signal transduction 
pathways and are essential in the regulation of many hallmarks of cancer, such as uncontrolled 
cell growth, lack of differentiation and aberrant metabolism, transcription, cytoskeletal 
rearrangement, cell motility and apoptosis (Shchemelinin et al. 2006, Manning et al. 2002, 
Hanahan et al. 2011). 
 Currently, the human protein kinome contains approximately 550 kinases, which are 
classified based on the residue they phosphorylate: serine/threonine kinases and/or tyrosine 
kinases, with the last one being further divided into receptor and non-receptor tyrosine kinases.  
 The receptor tyrosine kinases (RTK) present a transmembrane region responsible for 
localizing them to the plasma membrane so that the receptor domain extends to the 
extracellular compartment and the catalytic kinase domain into the cytosol. The Non-receptor 
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tyrosine kinases lack the transmembrane domain and are localized at the inner surface of the 
plasma membrane, cytosol or in some cases even the nucleus (Shchemelinin et al. 2006). 
 Furthermore, kinases can be classified based on the sequence similarity of their catalytic 
domain. The human kinome is therefore divided into: a. the AGC group containing the protein 
kinases A, G and C families; b. the CAMK family that 
includes Ca2+/CAM-dependent protein kinases; c. the 
CK1 group with the casein kinases, the tau tubulin 
kinase (TTBK) and the vaccinia-related kinases (VRK) 
families; d. the CMGC family that includes CDK, 
MAPK, GSK3 and CLKs; e. the STE family – MAP2K, 
MAP3K, and MAP4K families; f. TKs – tyrosine 
kinases, the TKL family consisting of  tyrosine kinase-
like proteins such as the mixed-lineage kinase (MLK), 
LIMK/TESK (LISK), interleukin-1 receptor-associated 
kinase (IRAK), RAF, receptor-interacting protein kinase 
(RIPK) and activin and TGF-receptors (STRK) families 
(Manning et al., 2002) (Fig.6). 
Protein kinases share a secondary structure containing a bi-lobed catalytic core with a 
deep cleft for the binding of ATP (Zhang 2009). In this pocket, the triphosphate group of ATP 
binds in the hydrophilic channel that extends to the target binding site facilitating the reaction. 
Kinases also have an activation loop containing a DFG (Asp-Phe-Gly) motif important for the 
regulation of the kinases (Zhang et al. 2009, Martin et al. 2012). The activation loop of kinases 
is also regulated by phosphorylation and undergoes conformational changes from the active 
DFG-in, which is normally phosphorylated and catalytically activated, to the DFG-out 
conformation where the activation loop blocks the binding of the substrate protein (Zhang et al. 
2009, Martin et al. 2012) (Fig. 7). The activation of the RTKs is initiated by the binding of an 
Fig. 6: The human kinome tree: the 7 
families that divide the kinases by 
sequence similarity (Cell Signaling). 
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extracellular ligand to the receptor, which induces 
oligomerization of the receptor and disruption of the 
inhibitory effect of the juxtamembrane region to the 
kinase domain (Shchemelinin et al. 2006). This 
results in the autophosphorylation of the kinase and 
recruitment of a diverse set of proteins that activate 
various intracellular signaling pathways.  
 Kinase inhibitors can be arranged into 
different classes: type I, type II, allosteric and 
covalent. The type I class includes inhibitors that 
bind to the active form of the kinase and are known 
to be ATP mimetics. Type II inhibitors bind to the inactive form of the kinase; they bind to a 
hydrophobic site exposed by the DGF-out conformation of the inactivated kinases. Allosteric 
inhibitors bind to sites outside the ATP binding pocket resulting in conformational changes that 
inhibit the binding of ATP to the protein. Finally, covalent inhibitors form irreversible bonds within 
or close to the active site of the kinase (Zhang et al. 2009). However, it is proposed that type II 
or allosteric inhibitors are most selective.  
 Independent of the type of the kinase inhibitor, several small molecule kinase inhibitors 
have been shown to inhibit, in addition to their cognate (intended) targets, several other kinases 
with different potencies, which result in drug off-targets. Drug off-targets are usually unintended 
and can be also undesired targets.  
 Undesired targets occur when compound targets proteins, inhibition of which causes 
side effects or a reduction of efficacy. An example of side effects caused by kinase inhibitor off-
targets is the inhibition of AMP-activated protein kinase (AMPK) by sunitinib. Sunitinib is a 
multikinase inhibitor designed to target vascular endothelial and platelet-derived growth factor 
receptor tyrosine kinases (VEGFR and PDGFR) with IC50 values of 80 nM and 2 nM, 
Fig. 7: Conformation change of the ATP 
activation loop upon binding of kinase 
inhibitor: In the DFG-in confirmation 
(yellow), the activation loop is far from the 
ATP site. In the DFG-out conformation 
(red) the activation loop flips by 180º and 
its N-terminus is located above the kinase 
active site. 
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respectively (Sun et al. 2003). However, sunitinib also targets AMPK (IC50= 216 nM), a kinase 
involved in the metabolic homeostasis of the heart, inhibition of which resulted in mitochondrial 
damage and consequently cardiotoxicity (Kerkela et al. 2009).  
 Unintended off-targets are all the proteins inhibited by a compound, excluding the 
proteins, which the compound was designed to target. Many unintended targets can cause an 
off-target effect with biological relevance. However, not all off-targets effects are detrimental as 
it can be for instance advantageous to inhibit multiple targets in a cancer cell. The study of off-
targets or unknown targets of these inhibitors can also help us to better elucidate their 
mechanism of action (MoA) and potentially repurpose them for new clinical applications, such 
as for a different type of cancer. 
 A good example for the successful repurposing of a kinase inhibitor due to inhibition of 
unintended targets is crizotinib. Crizotinib was first developed by Pfizer as a MET inhibitor with 
an inhibitory constant (ki) of 4 nM and shown to be 100-fold selective against 90% of a panel of 
120 kinases. However, when tested in different cancer cell types, it was observed that crizotinib 
also inhibited the phosphorylation of NPM-ALK and accordingly the growth of human Karpas299 
lymphoma cells with an IC50 of 24 nM, indicating that this compound also targets ALK fusion cell 
lines as an off-target (Zou et al., 2007). A kinase screen confirmed that crizotinib was a dual 
kinase inhibitor of MET (IC50= 8 nM) and ALK (IC50= 20 nM) (Cui et al. 2011). Also, a clinical trial 
of crizotinib in ALK-positive NSCLC patients showed a significant increase in the overall 
response rate and duration of response (Kwak et al. 2010). In addition, a retrospective study 
showed that ALK-positive NSCLC patients treated with crizotinib presented higher survival rates 
than ALK-positive NSCLC patients who received chemotherapy; also, the survival of patients 
treated with crizotinib was defined as similar to the EGFR-positive patients after given an EGFR 
inhibitor, an important targeted therapy in NSCLC (Shaw et al. 2011). Thus, the increase in the 
response rate with crizotinib led to accelerated approval by the FDA for the treatment of locally 
advanced or metastatic ALK-positive NSCLC patients.  
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 Surprisingly, the application for crizotinib went even further with a report showing that the 
HCC78 cell line, which features a ROS1 rearrangement, was sensitive to crizotinib and that a 
ROS1-positive NSCLC patient had a complete response after treatment with crizotinib. 
(Bergethon et al. 2012). This evidence was confirmed when a study with ROS1-positive NSCLC 
showed an objective response rate of 72%, with 3 complete responses, 33 partial responses 
and 9 stable diseases, and a median progression-free survival of 19.2 months (Shaw et al. 
2014). In 2016, crizotinib was FDA approved for ROS1-positive metastatic NSCLC patients. 
Importantly, the receptor tyrosine kinase ROS1 was not part of the panel of kinases initially 
screened by Pfizer; this highlights the importance of broadly characterizing the off-target profiles 
of kinase inhibitors in order to be able to identify all opportunities to repurpose them. 
 The concept of polypharmacology, which describes a biological response of a small 
molecule compound being achieved by affecting two or more targets (Hopkins 2008), has 
gained interest in the treatment of cancer. This is the result of an increase in knowledge of the 
complexity of this disease. Cancer is a heterogeneous disease, in which cells depend on 
multiple different pathways and are capable to switch their reliance and create mechanisms of 
resistance to overcome the effects of targeted therapies. Understanding polypharmacology can 
help us to identify off-targets that are relevant for a tumor cell. This may result in the 
repurposing of the respective drug to different tumor types. Also, the ability of a compound to 
act on multiple targets can result in a biologically synergistic effect since it may modulate 
several relevant pathways simultaneously. Thus, such a polypharmacology effect may induce a 
durable disease control with possibly less side effects. In addition, the use of a compound with a 
polypharmacology MoA makes it easier to control the pharmacokinetics and pharmacodynamics 
of the compound since it is a single chemical entity (Gentile et al. 2017, Anighoro et al. 2014).  
 However, in many cases a compound with a polypharmacology MoA is not potent 
enough against every functionally important target to induce potent cell death of tumor cells. 
Understanding its MoA can be nonetheless used to design and optimize combination therapies 
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for cancer treatment, especially for tumor types lacking a strong oncogene driver. Combination 
therapy that is based on the knowledge of the relevant pathways for a specific type of tumors 
can also decrease the toxicity, if synergy is achieved by using lower doses of each single 
compound. 
Integrated analysis for identification of off-targets 
Mass spectrometry-based proteomics approaches 
 In most cases, the specificity of drugs is determined by screening them against a panel 
of proteins within a specific class of enzymes or receptors, such as protein kinases, HDACs, or 
GPCRs. However, the human proteome contains 10’s of 1000 of the proteoforms and there is a 
high degree of tissue and cell type specificity. In light of the considerations discussed above, to 
more fully understand the MoA of a compound it is necessary to study not only its intended 
target(s), but also its unintended/off-targets as well as the signaling pathways involved in 
mediating its anticancer effect. Ideally suited to address these challenges, mass spectrometry 
(MS)-based proteomics has advanced significantly over the last two decades and become an 
important tool to dissect the complexity of cell signaling. MS is an unbiased method and can 
provide specificity and high sensitivity information about a complex sample in a physiological 
setting (Morris et al. 2014).  
 Mass spectrometry accurately measures the mass-to-charge ratio (m/z) of peptides or 
proteins providing a quantitative and qualitative measurement; it is divided into two categories: 
top-down and bottom-up (Chait et al. 2006). The top-down approach is used to identify intact 
proteins, while the bottom-up approach requires the digestion of proteins into peptides before 
analysis by MS (Walsh et al. 2010, Dudley et al. 2014). The most commonly MS-based 
proteomics approach used is the bottom-up method, because it is difficult to distinguish large 
proteins with similar composition based only on their mass, which however is facilitated by 
breaking up the proteins into peptides (Chait et al. 2006, Walsh et al. 2010). The most common 
method of enzymatic digestion in bottom-up MS is using trypsin, which is a protease that 
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cleaves peptides at the carboxyl terminus of the lysine or arginine, except when either are 
followed by proline. After digestion, peptides are separated by liquid chromatography (LC) 
coupled and acquired by electrospray ionization and tandem MS (MS/MS) (Cox et al. 2008). 
 Chemical proteomics is a MS-based proteomic approach used to identify targets of small 
molecule drugs and it can be divided into two types: drug affinity purification and activity-based 
probe profiling (ABPP).  
 Compound-centric chemical proteomics (CCCP) is a type of drug affinity 
chromatography followed by MS, which uses small molecules as affinity probes to enrich for and 
identify bound proteins. CCCP consists of immobilizing a small molecule on a matrix, such as 
sepharose, which then is incubated with the cell lysate (Rix et al. 2009). The protein elution 
occurs after several washes to eliminate unbound proteins and can be performed using 
denaturing agents, detergents and salts. In-gel digestion is performed using SDS-PAGE and a 
protease to provide the peptides for LC-MS/MS (Fig. 8). 
 
Fig. 8: Compound-centric chemical proteomics: schematic of CCCP procedure where a drug is 
chemically modified to be able to bind to the beads (drug matrix) before incubation with cell lysate. SDS-
PAGE- based gel-digestion is performed and peptides are identified by mass spectrometry. 
 
 To study the effects of a compound, part of the lysate is pre-treated with the 
unmodified/free compound prior to incubation with the matrix containing the immobilized 
compound. This approach allows the free compound to bind first to the targeted proteins 
preventing their binding to the matrix-bound compound. A difference in MS/MS spectrum counts 
between the pre-treated sample and the untreated sample is indicative of specific drug-protein 
interactions. Unfortunately, the spectrum count does not reflect the potency with which the 
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compound inhibits the specific protein and an enzymatic assay is necessary to prioritize the 
targeted proteins. On the other hand, one advantage of CCCP is that this technique allows us to 
identify not only the direct targets of a small molecule but also capture protein complexes that 
may help to understand molecular MoA of these compounds since different protein complexes 
can lead to effects on different signaling pathways (Rix et al. 2009).  
 Spectrum counting is based on the total number of MS/MS spectra of individual peptides 
corresponding to a specific protein (Keller et al. 2002, Zybailov et al. 2006). However, larger 
proteins normally have more detectable peptides than smaller proteins, which indicates that the 
protein size influences the spectrum count (Paoletti et al. 2006, Zybailov et al. 2006). To create 
a more statistically meaningful analysis, the normalized spectral abundance factor (NSAF) is 
used to determine the relative abundance of a protein in a sample. First, the spectral abundance 
factor (SAF) is calculated by dividing the spectral counts of a protein by its molecular weight or 
number of amino acids. The NSAF of a protein is then calculated by dividing the protein SAF by 
the sum of all protein SAFs in the sample. The natural logarithm of the NSAF has been shown 
to generate a normal distribution, which can be used for subsequent statistical analysis (Paoletti 
et al. 2006, Zybailov et al. 2006).  
 Significance analysis of interactome (SAINT) is a computational tool that uses a 
probability-based model to establish statistical analysis to score protein interactions. Using the 
spectral count of the prey protein it determines the probability of interaction with its bait, which 
often is a protein and in our study is the compound of interest. SAINT scores the protein-
compound interaction by joint modeling of the entire data, so this way it can score not only the 
prey-bait interaction, but also interactions of either of them. It also classifies interactions to be 
likely true or false. A suitable negative control is used to determine the spectral count 
distribution for false interaction. The normalization is performed using the protein size and the 
total number of spectra for normalization (Choi et al. 2011). 
 Activity-based probe profiling (ABPP) is an approach that takes advantage of specific 
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substrates of enzyme activities of certain protein classes to create covalent chemical probes for 
their enrichment. In the case of kinases, the enrichment is done using a desthiobiotinylated 
ATP-mimetic probe, which results in a modification of a lysine residue near the ATP-binding 
pocket of active kinases. After the digestion of proteins, peptide enrichment is done using 
streptavidin agarose. Biotinylated peptides can then be identified by MS (Barlow et al. 2007, 
Adachi et al. 2014) (Fig. 9). 
  
Fig. 9: Activity-based probe profiling: schematic representation of the ABPP approach where treated cell 
lysates are incubated with a desthiobiotin-ATP probe and digested. Peptides are selected using 
streptavidin agarose resin and injected into the mass spectrometer for peptide identification 
 
 This approach allows the evaluation of the expression and activity of kinases in their 
biological context (Adachi et al. 2014, Fang et al. 2015). To study a kinase inhibitor, the cell 
lysate is treated with the inhibitor before being incubated with the ATP-probe. This strategy 
allows the binding of the compound to the active kinase, which blocks the access of the ATP-
probe to the active site of the kinase. Reduced detection of the labeled peptide in the treated 
sample in comparison to the control sample indicates possible targets and downstream 
signaling kinases (Fang et al. 2015). Ideally, this approach enables differentiation of active and 
inactive kinases, which helps understanding the molecular MoA of kinases inhibitors. In 
addition, the use of specific probes reduces sample complexity and increases sensitivity 
(Colinge et al. 2012, Adachi et al. 2014).  
 Phosphoproteomics identifies phosphorylation sites using MS. This leads us to 
understand which signaling pathway has been perturbed upon drug treatment. This information 
in combination with the information about the drug targets (intended/off-target) improves our 
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understanding of the MoA of a compound. The detection of phosphorylated sites from a 
complex biological sample that contains low amounts of phosphorylated proteins masked by 
other abundant components, such as salts, lipids and non-phosphorylated proteins, requires 
enrichment, such as immunoaffnity and metal affinity chromatography (IMAC), of proteins after 
protein digestion and purification. Quantification of phosphopeptides can be achieved through 
metabolic or chemical labeling or label-free methods (Fig. 10) (Wang et al. 2015).  
 
Fig. 10: Phosphoproteomics approach: schematic representation of the label-free - immunoaffinity 
precipitation (IAP) using a phospho-tyrosine antibody - in combination with the chemical labeling 
technique - tandem mass tag (TMT) using the 6 plex - to define the global proteome (tyrosine, serine and 
threonine phosphosites) by MS. 
 
 Immunoaffinity enrichment is performed using a specific antibody to pre-select the 
phosphorylation site or the phosphopeptide motif before analysis on the tandem mass 
spectrometry (Morris et al. 2013). This technique is normally used to study phosphotyrosine 
residues since there are good commercially available antibodies for this type of post-
translational modification. On the other hand, protein tyrosine phosphorylation corresponds to 
only 1% of all phosphorylation, which therefore requires a large amount of protein as starting 
material. (Dudley et al. 2014). 
 Immobilized metal affinity chromatography (IMAC) is one of the most commonly used 
enrichment methods for global phosphoproteomics. IMAC can be performed in water or buffer 
and doesn’t require protein denaturation (Dudley et al. 2014). It is based on the selection of 
phosphopeptides by ion pair formation between the negative charge of the phosphopeptides 
and the positive charge of the immobilized cation on the chromatography column. The Fe3+ is 
the most common metal ion used with IMAC, but there are also columns with Ga3+, Zr4+ and Ti4+ 
(Dudley et al. 2014, Fila et al. 2012). The non-specific binding of acidic peptides, such as those 
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containing glutamic acid and aspartic acid, to the metal ions is reduced by using 0.1% 
trifluoroacetic acid (TFA) in 50% acetronitrile as loading buffer (Dudley et al. 2014).  
 Chemical labeling: this proteomic approach uses stable isotope labeling to quantify the 
peptides since the ratio of the intensity of each labeled peptide is proportional to its quantity 
(Rigbolt et al. 2012). This approach allows the detection of the global phosphoproteome: 
tyrosine, serine and threonine. The chemical labeling can be done by conjugating isobaric mass 
tags to the peptides. 
 Tandem mass tag (TMT) is one of the isobaric labeling methods and consists of the 
same chemical structure with different isotopes in various positions within the molecule. Each 
tag has a reporter ion linked to the mass normalization group and a reactive group. During the 
collision-induced dissociation (CID) this linker is cleaved and the reporter ion is released as a 
specific isotopic fragment that can be quantified by MS/MS. The mass normalization group 
balances the mass of the tags and the reactive group contains a reactive chemical functionality 
that covalently binds to the free amine at the amino-terminus of peptides and epsilon-amino 
functions of lysine residues (Thompson et al. 2003, Dayon et al. 2008, Chahrour et al. 2015). 
Because different samples will be labeled with different isotope-containing tags, the samples 
can be pooled and analyzed concomitantly in the MS. The tag-labeled peptides appear in the 
MS1 as one single peak at the same m/z value and present the same retention time during 
liquid chromatography as they are one and the same chemical entity. However, the labeled 
peptides can be distinguished by the differential mass shifts of the specific reporter ions, which 
appear as individual peaks in MS/MS scans (Savitski et al. 2013, Rauniyar et al. 2014). 
 Alternatively, stable isotope labels can be introduced metabolically using “Stable isotope 
labeling by amino acids in cell culture” (SILAC), which requires growing the cells in culture with 
an amino acid-deficient medium containing an essential amino acid, such as lysine, which is 
labeled with stable isotopes used by the cells to produce proteins that will be labeled (Ong et al. 
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2002). The quantification of the peptides is done by comparing the intensity of the ion signal 
between “heavy” vs “light” labeled peptides in the MS1 spectra (Savitski et al. 2013). 
 High pH reversed-phase chromatography with fraction concatenation (pooling equal 
interval RPLC fractions) has been shown to improve the quality of the peptides because it can 
be performed with samples still containing salts and other reagents, which decreases sample 
loss during washings and reduces sample preparation time. Furthermore, the combined 
fractions increase the proteome coverage since it pools early, middle and late fractions eluted 
within the same time window (Yang et al. 2012). 
 During the fragmentation with the low-energy collision-induced dissociation (CID), 
phosphoserine and phosphothreonine can lose their phosphate groups making its localization 
impossible. However, if these residues go through β-elimination of phosphoric acid, 
phosphoserine becomes dehydroalanine and phosphothreonine becomes dehydroaminobutyric 
acid, which are identified as modification sites and thus indicates the correct site of 
phosphorylation. Also, in the electron transfer dissociation (ETD) where electrons are 
transferred to peptides from fluoranthene radical-anions generated in a chemical ionization 
source, peptides are fragmented between the nitrogen of the amide bond and the chiral carbon 
maintaining the phosphorylation and thus enabling the localization of the phosphorylation sites 
(Fang et al. 2010). 
 Peptide identification and quantification 
 Skyline is a software developed to quantify MS/MS data. It has the ability to digest 
proteins and fragments peptides in silico to select ion peak intensity of direct peptides and 
precursors (McLean et al. 2010). Skyline also allows users to build their own spectral library 
from the MS/MS dataset after it has been analyzed by a search engine, such as MASCOT or 
MaxQuant (McLean et al. 2010, Egertson et al. 2015). In the presence of an internal standard, 
Skyline can determine ratios between peptides and the standard. However, in the absence of a 
standard, the MS1 isotopic peaks (M, M+1, M+2) matching the most intense ions are selected and 
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compared with the spectra for ion ratio verification (McLean et al. 2010). These MS1 isotopic 
peaks are grouped by precursor and displayed in a chromatography graph from where the 
Sequence Specific Retention Calculator (SSRCalc) based on hydrophobicity scores defines the 
retention time of peptides, which can be used for its identification and elimination of false 
positive MS/MS identification (McLean et al. 2010, Egertson et al. 2015, Krokhin et al. 2010). 
 Protein identification and quantification 
 There are several algorithms and computer programs developed for protein identification 
from MS data using sequence databases. In these searches, MS data are assigned to proteins 
based on the peptide mass or fragment ion mass according to the cleavage pattern expected 
based on the protease used (Walsh et al. 2010, Perkins et al. 1999). MASCOT is a search 
engine that scores protein identification by evaluating the peptide molecular weight after 
digestion, comparing the peptide mass to amino acid sequence data (sequence query) and 
MS/MS ion search; the use of these three searches increases the sensitivity (Perkins et al. 
1999). However, one of the limitations of this approach are false positives that can occur in the 
presence of duplicated peaks caused by noise, bad peak picking or even modifications on the 
peptides. To minimize this issue, false discovery rate (FDR) selection is applied to eliminate all 
the peptides for which the probability of correct identification is lower than the FDR determined. 
FDR is determined by searching decoy databases and statistical analysis (Perkins et al. 1999, 
Li et al. 2009). 
 MaxQuant is a publicly available computer program used to quantify, score and assign 
peptides to proteins (Cox et al. 2008). It identifies the MS/MS spectra and creates a 3D peak 
over the m/z-retention time to estimate the intensity and weight mass of the peptides (Cox et al. 
2008, Cox et al. 2011). MaxQuant uses Andromeda as a search engine, which also determines 
the mass-dependent recalibration based on preliminary database search improving the 
identification of cofragmented peptides (Cox et al. 2011). The readout is a raw list of scored 
peptide candidates per spectrum and their corresponding protein (Cox et al. 2011). This engine 
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allows the user to specify protein modifications of interest, number of modifications and missed 
cleavages, and to choose the protein sequence database to search; which increases the 
specificity of the identification (Cox et al. 2011). In the case of neutral loss mentioned above, 
Andromeda reports for each modification the presence or absence of a peak in the MS/MS 
spectrum. In other words, the score is calculated including neutral losses as well as excluding 
them and the highest score is selected (Cox et al. 2011). MaxQuant calculates the FDR using 
the posterior error probability (PEP), which evaluates the probability of being a false positive 
based on the peptide identification score and the length of the peptide (Cox et al. 2011). Finally, 
to correct for unequal protein loading in the LC-MS, a normalization of peptide ratios is required 
and can be done uploading the peptide intensity file from MaxQuant to IRON (Iterative Rank-
Order Normalization) available on the Galaxy bioinformatic tool suite (Welsh et al. 2013, 
Blankenberg et al. 2010, Hillman-Jackson et al. 2012). 
 Scaffold is a bioinformatic tool that interprets the database-search engine analysis, such 
as MASCOT, into probabilities of peptide identification following the Peptide Prophet algorithm 
(Searle et al. 2010). In this statistical model, each peptide assigned to a spectrum is also 
validated against all other assignments within the dataset and is given a probability of being 
correct assuming that the number of the spectra follows a standard statistical distribution; it also 
takes in account the database search score and the number of cleavages (Keller et al. 2002). 
Once peptide probabilities are determined, Scaffold uses the Protein Prophet algorithm to score 
the protein depending on the protein grouping and how many peptides are assigned to each 
protein (Searle et al. 2010, Nesvizhskii et al. 2003). In Scaffold: (1) a peptide that can be 
assigned to multiple proteins is designated to the most probable protein; (2) proteins for which 
peptide probabilities differ in less than 0.95 and represent unique peptides are grouped 
together; (3) peptides that are shared by several proteins and represent unique peptides are 
grouped as a protein cluster. Scaffold ranks proteins according to the probabilities of assigned 
peptide groups (SumProb), which represents the protein confidence (Keller et al. 2002).  
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RNA-sequencing 
 RNA-sequencing (RNA-Seq) is a next generation sequencing (NGS) approach that 
enables the genome-wide measurement of gene expression. RNA-Seq is based on the 
quantification of the sequencing of the cDNA derived from messenger RNA (mRNA). Firstly, 
RNA is extracted from the sample and its quality is verified by the RNA integrity number (RIN). 
RIN uses capillary gel electrophoresis to verify degradation of the RNA by calculating the ratio 
between 28S to 18S ribosomal bands; if degradation is observed, the RIN value will be closer to 
1 (Kukurba et al. 2015, Conesa et al. 2016). Agilent Bioanalyzer is a software designed to 
calculate RIN and displays the gel picture as well as a table with the measurements from the 
detected peaks, such as concentration, size and purity (Kukurba et al. 2015). However, because 
the largest percentage of RNA is ribosomal RNA (~90%), an enrichment for the mRNA (1-2%) 
through selection of polyadenylated RNA by poly-T oligos linked to magnetic bead is 
recommended (Kukurba et al. 2015, Wang et al. 2009).   
 The following step in the RNA-Seq approach is the creation of the RNA-Seq library, 
which involves the reverse-transcription of RNA to cDNA, fragmentation or amplification with 
random primers and ligation using adaptors. This step is NGS platform-dependent (Kukurba et 
al. 2015). Fragmentation can be done by RNA hydrolysis or nebulization or by cDNA 
fragmentation using DNAse I treatment or sonication (Kukurba et al. 2015, Wang et al. 2009). 
An important aspect is the sequencing depth, which requires between 30-40 million reads for a 
good quantity of gene expression (Kukurba et al. 2015, Wang et al. 2009). Finally, to identify 
genes it is necessary to perform alignment of the reads to the database containing the reference 
genome; which is expected to match between 70-90% (Wang et al. 2009). There are several 
RNA-Seq alignment tools, such as htseq-count, GSNAP, MapSplice, RUM, STAR and TopHat 
(Wang et al. 2009). Another quality-control for a library is the CG content, which is expected to 
be uniform between replicates and may indicate PCR bias if it is not similar (Kukurba et al. 
2015, Wang et al. 2009, Conesa et al. 2016) (Fig.11). 
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Fig. 11: RNA-Seq schematic: Cells are 
harvested and total RNA is extracted. 
Incubation with magnetic beads 
containing on its surface poly-T oligos 
selects polyadenylated RNA (mRNA), 
which then is converted to cDNA. DNA is 
used to create the sequencing library 
that includes fragmentation, amplification 
and ligation. The short sequences are 
then amplified using PCR and 
sequencing is determined using a 
reference genome. 
 There are two types of NGS sequencing 
methods: ensemble-based (sequence many DNA 
molecules) and single-molecule-based (sequence only 
one DNA molecule). In the first approach, multiple 
DNA molecules are immobilized on the surface of a 
glass flow cell, where they are copied and amplified 
using fluorescence-labeled reversible-terminator 
nucleotides (Kukurba et al. 2015). The advantage of 
this technique is the low error rate. However, because 
it requires amplification by polymerase chain reaction 
(PCR), controls are required to avoid bias (Kukurba et 
al. 2015, Wang et al. 2009). The single-molecule-
based sequencing uses DNA polymerase to 
enzymatically add the fluorescence-labeled 
nucleotides to the synthesized strand, which allows 
signal to be detected in real-time by zero-mode 
waveguide nanostructure arrays. The advantage of this approach is that it does not require PCR 
and is able to produce long sequences. However, it produces higher error rates created by 
deletions and insertions, which can lead to misalignment (Kukurba et al. 2015, Wang et al. 
2009). 
Systems biology 
 To identify the mechanism of action of compounds suspected to act through off-target 
mechanisms, it is necessary to use an unbiased proteome- and genome-wide, such as systems 
biology, approach. However, besides the challenge to handle a large amount of data produced 
by proteomics, the interpretation of the biological significance of these genes, proteins and their 
post-translational modifications have to be explored in depth by bioinformatics. The selected two 
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proteomics techniques, chemical proteomics and phosphoproteomics, are complementary and 
together provide a higher level of confidence in identifying the most significantly altered 
signaling pathways by combining the affected kinases with their downstream phosphorylation 
signals. Also, since a protein can regulate signaling through different transcription factors based 
on its protein complex or transient protein-protein interaction, the addition of transcriptome 
changes as provided by RNA-seq can improve the identification and selection of pathways. 
 This approach is based on integrated data analysis, which includes the selection of a 
protein list defined by statistical tools, the study of protein-protein interactions and phosphosite 
regulations, identification of mechanistically relevant pathways using databases and, finally, the 
combination of these pathways to propose a mechanism of action with bioinformatic 
visualization tools (Fig. 12).  
 Several statistical tools are available to prioritize proteins after their quantification and 
identification.  
 The “Database for annotation, visualization and integrated discovery” (DAVID) 
associates gene/protein lists with biological annotation followed by enrichment of genes that can 
be mapped to pathways. DAVID uses singular enrichment analysis (SEA) and modular 
enrichment analysis (MEA) as enrichment tools. SEA provides a p-value based on term-by-term 
annotation in a linear mode and MEA integrates the network discovery algorithm (Huang et al. 
2009, Huang et al. 2009). In addition, DAVID provides more than 40 annotation categories that 
can be used for enrichment, such as protein-protein interactions, biological pathways and 
disease associations. It also queries several pathway databases, such as “Kyoto Encyclopedia 
of Genes and Genomes” (KEGG), BioCarta and Reactome (Huang et al. 2009).  
 Gene set enrichment analysis (GSEA) is an analytical method that focusses on gene 
sets that have a common biological function, chromosomal location and/or regulation. A gene 
expression data analysis normally provides us with a list of genes with differential expression 
between two samples (treated vs untreated). Looking only at the fold change between samples 
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does not always answer a biological question, since a small fold change does not mean it is not 
biologicallly relevant. In biology, several small changes in gene expression in the same pathway 
may be more relevant than a big single change in a particular gene.  
                                                    
 
 
Fig. 12: Systematic scheme of the integrated data analysis approach: data comparing foretinib vs 
cabozantinib by chemical proteomics, phosphoptoteomics and RNA-Seq were combined and analyzed 
using GSEA. Foretinib kinase targets shared in regulated pathways were further validated. 
 
 GSEA overcomes this limitation by evaluating gene sets based on biochemical pathways 
or coexpression data already published, which resulted in an inventory with more than 1,325 
biological gene sets. GSEA assigns the p-value using an empirical phenotype-based 
permutation, which maintains the gene-gene correlation, and results in a better biological 
assessment. The false positive rate (FDR) calculates the probability that a set of genes 
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represents a false positive in its corresponding normalized enrichment score, which is the 
degree that a set of genes is overexpressed in the entire dataset (Subramanian et al. 2005, 
Mootha et al. 2003). 
 Cytoscape is a software tool used for visualization of networks. It enables integration of 
molecular networks with additional attributes, such as expression values or clustering (Shannon 
et al. 2008, Smoot et al. 2011). Cytoscape displays the genes/proteins as nodes and their 
interactions as edges (Shannon et al. 2008). With Cytoscape it is possible to customize the 
network visualization by designing its nodes and edges and selecting the data to be displayed 
using attributes. Data can also be selected using data filtering, such as Minimum Neighbors 
filter and Local Distance filter, which select data based on the number of interactions and the 
distance of edges between nodes (Shannon et al. 2008, Smoot et al. 2011, Cline et al. 2007). 
 cBioPortal is a bioinformatic tool used to explore and visualize multiple genomic data 
types. It combines data from more than 5,000 tumor samples including multiple tumor types. 
cBioPotal integrates data from somatic mutations, DNA copy number alterations (CNAs), mRNA 
and microRNA, epigenetic changes (DNA methylation), and in some cases protein and 
phosphoprotein levels. Copy-number alterations are determined with the algorithm GISTIC 
(Genomic Identification of Significant Targets in Cancer), which identifies possible somatic copy-
number alterations by evaluating the frequency and amplitude of observed events (Mermel et al. 
2012). Data for proteins and phosphoproteins are collected from reverse phase protein array 
(RPPA) experiments. The z score for mRNA expression is determined by comparing a gene’s 
RNA expression to the distribution reference population, which can be the expression of that 
gene in normal adjacent tissue or to all tumors that are diploid for that gene. The z value is pre-
calculated; however, the default setting threshold (2 standard deviations) can be modified. The 
significance of changes in expression is determined by Fisher’s exact test. The data is classified 
into genes that are mutated, homozygously deleted, amplified and into relative mRNA 
expression. In addition, this software allows the comparison of gene expression between 
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several tumor types. Finally, cBioPortal can be used to visualize networks through the Pathways 
Commons Project, which includes the Human Reference Protein Database (HPRD), Reactome, 
National Cancer Institute (NCI)-Nature and Memorial Sloan-Kettering Cancer Center (MSKCC) 
Cancer Cell Map. The network ranks genes according to their level of alteration and integrates 
the frequency of mutations, DNA copy number and mRNA expression (Cerami et al. 2012, Gao 
et al. 2013). 
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CHAPTER TWO: 
 
CHEMOPROTEOMICS REVEALS NOVEL PROTEIN AND LIPID PROTEIN TARGETS OF 
CLINICAL CDK4/6 INHIBITORS IN LUNG CANCER 
Note to reader 
 Portions of this chapter have been previously published. Reprinted with permission from 
ACS Chem. Biol., 2015, 10 (12), pp 2680–2686. Copyright 2015 American Chemical Society. 
(Appendix M) 
CDK4/6 inhibitors in lung cancer 
 The cell cycle is a multi-step biological process that regulates cell growth and 
division. The molecular mechanism that controls the cell cycle is highly conserved from 
unicellular eukaryotes such as yeast to complez metazoans (Nurse. 2000). Specifically, it is 
divided into four phases: In G1 cells undergo metabolic changes and cytoplasmic organelles are 
replicated, in S DNA is duplicated and “synthesized”, in G2 cells continue to grow in preparation 
of cell division and in M cell divides into two genetically identical daughter cells (Nurse. 1976, 
Ingham et al. 2017). The progression of cells through the different phases of the cell cycle is 
promoted by enzymes called cyclin-dependent kinases (CDKs). The first CDK’s cell cycle 
regulatory mechanism was described in yeast (Nurse. 1975). These studies focused in 
understanding the changes in DNA synthesis and cell size by comparing a temperature-
sensitive mutant strain cdc9-50 of the fission yeast Schizosaccharomyces pombe to the wild-
type yeast strain. After the observation that the mutant cells divided at half the wild type size, 
further studies indicated that different cell division cycle (CDC) proteins, which includes CDKs 
and phosphatases, were responsible to regulate DNA synthesis (cdc 10), nuclear division (cdc 
1, 2, 5, 6 and 13), early cell plate formation (cdc 7, 11, 14 and 15) and late cell plate formation 
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(cdc 3, 4, 8 and 12) in yeast (Nurse et al. 1976). This led to the understanding that CDK1 (also 
known as CDC2 protein kinase), which is required in G1 to assure cell division and in G2 for the 
control of mitosis, was activated by the Cdc25p protein phosphatase and inhibited by the protein 
kinase Wee1p (Nurse and Thuriaux. 1980, Nurse and Bisset. 1981, Gould and Nurse. 1989, 
Nurse. 1990). CDKs induce cell cycle progression after binding to their catalytic partners, the 
cyclins, leading to phosphorylation of downstream signaling proteins that are essential for the 
transition of cells to the next phase of the cycle (Asghar et al. 2015) Cyclins were first described 
in a study about proteins that changed expression during the cell cycle in fertilized eggs (Evans 
et al., 1983). Here, it was shown that cyclins are periodically synthesized and degraded, and 
their regulation depends on the continuation of the cell cycle. Specific CDK-cyclin complexes 
operate during the different phases. For instance, CDK4 and CDK6 interact with cyclin D1, D2 
and D3 to promote the progression of cells in G1, while the CDK2-cyclin E complex regulates 
the entry of cells into the S phase (Ingham et al. 2017) (Fig. 13). The activity of the CDK-cyclin 
complexes in normal cells is highly regulated by two classes of inhibitors: the INK4 inhibitors 
(p15, p16, p18 and p19) that specifically interfere with the interaction between CDK4/6 and D 
types of cyclins and the CIP/KIP CDK inhibitors (p21, p27 and p57) that target preferentially the 
CDK2-cyclin A/E and the CDK1-cyclin B complexes (Kim et al. 2006).  
 CDKs 4 and 6 (CDK4/6) are serine threonine kinases that, once in complex with 
cyclin D, phosphorylate the retinoblastoma (Rb) protein inducing progression to S phase. Rb 
function is tightly regulated by its degree of phosphorylation; when it is unphosphorylated, Rb 
binds to the transactivation domain of E2F family transcription factors and consequently recruits 
histone deacetylases, which inhibit transcription. On the other hand, CDK4/6-cyclin D initiates 
Rb phosphorylation on Ser 780 resulting in conformational changes on the Rb protein that 
inhibit the binding of the histone deacetylase, which enables hyperphosphorylation and 
degradation of Rb by CDK2-cyclin E and finally E2F transcription factor release that induces the 
entry to the phase S of the cell cycle (Ingham et al. 2017, Fry et al. 2004, Rader et al. 2013). 
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Fig. 13: Regulation of the cell cycle by CDK4/6. Mitogenic signals stimulate CDK4/6 to start the cell 
cycle, while antiproliferative checkpoints inhibit CDK4 and CDK6 activity or induce the expression of its 
inhibitor p16INK4A. CDK4/6 complexes initiate the phosphorylation (P) of the tumor suppressor 
retinoblastoma protein (Rb), thereby inducing gene expression by the E2F family of transcription factors. 
In this context, CDK4/6 initiate transcription and stability of E-type and A-type cyclins and the subsequent 
activation of CDK2 that contributes to the further phosphorylation of Rb and the initiation of DNA 
replication. Further checkpoints can directly inhibit CDK2 activity or induce the CDK-interacting 
protein/kinase inhibitory protein (CIP/KIP) class of inhibitors (p21CIP1 and p27KIP1) that bind to and inhibit 
CDK2–cyclin complexes. With the completion of DNA replication, CDK1–CycA and CDK1–CycB 
complexes form to phosphorylate targets in G2 phase. (Modified from Asghar et al, 2015). 
 
 Due to the critical role of CDK-cyclin complexes and their inhibitors in the regulation 
of cell proliferation, it is not surprising that tumors harbor abnormalities in components of the cell 
cycle machinery. For example, the loss of the CDK4 inhibitor gene - CDKN2A - is a frequent 
genetic event in glioblastomas, melanomas and pancreatic carcinomas (Brennan et al. 2013, 
Cancer Genome Atlas 2015). In breast tumors instead, somatic copy gains of CYCLIN D1 and 
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CDK4 are often found in estrogen and progesterone receptor positive tumors as well as in c-
ERBB2-amplified breast cancers, while loss of the tumor suppressor retinoblastoma (RB1) and 
gain of CYCLIN E are commonly reported in triple negative breast tumors (Genome Atlas 2012).  
 Similarly, alterations in genes involved in the regulation of the cell cycle are 
commonly found in lung cancer. Specifically, it has been reported that the inactivation of the 
CDKN2A gene occurs in up to 72% of squamous cell lung cancers (Hammerman et al. 2012). 
This is particularly interesting because, in contrast to lung adenocarcinoma (LUAD) where 
kinase inhibitors were designed to target known oncogenic drivers, such as EFGR, still no 
targeted therapies are approved for squamous cell lung cancer (LUSQ).  
 Several attempts have been made in the past 20 years to develop compounds that 
could specifically inhibit the activity of the CDK enzymes (Ingham et al. 2017). However, the first 
generation of CDK inhibitors (i.e., alvocidib by Sanofi-Aventis and seliciclib by Cyclacel) were 
relatively nonspecific and consequently showed considerable toxicities and extremely low 
clinical activity in multiple clinical trials against solid tumors (Asghar et al. 2015). Second 
generation CDK inhibitors have been developed later with the aim of increasing the selectivity 
against different CDK enzymes. Dinaciclib was developed as a potent and specific inhibitor of 
CDK1, 2, 5 and 9 and it is one of the first second generation CDK inhibitors to be evaluated in 
clinical trials (Winter et al. 2012). However, after a promising phase I trial in multiple 
malignancies, in which dinaciclib treatment resulted in stable disease with tolerable toxicity, 
phase II trials in NSCLC were extremely disappointing, showing no activity as monotherapy 
rather supporting the study of CDK4/6 inhibitors in combination therapy (Stephenson et al. 
2014). 
 Recently, three CDK4/6 ATP-competitive inhibitors (CDK4/6i) have entered clinical trials: 
abemaciclib (LY2825219), palbociclib (PD0332991) and ribociclib (LEE011). At the time that this 
research was conducted, only palbociclib was FDA approved in combination with letrozole for 
hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) 
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postmenopausal women with metastatic breast cancer based on increased progression-free 
survival (PFS) in the PALOMA-1 trial (Finn et al. 2015). However, all three CDK4/6i were in 
clinical trials for lung cancer, with palbociclib being included in the phase II/III Lung-MAP 
umbrella trial in squamous cell lung cancer (Herbst et al. 2015).  
 In 2016, palbociclib received extended approval in combination with fulvestrant for HR+, 
HER2-breast cancer patients whose disease progressed after treatment with endocrine therapy 
(Turner et al. 2015). In addition, in 2017, based on the confirmatory increase in PFS of 
palbociclib plus letrozole vs letrozole treatment (PALOMA-2) and the phase III clinical trial 
(MONALEESA-2), the combination therapy of palbociclib and ribociclib, respectively, with 
letrozole was approved as first-line for postmenopausal women with HR+, HER2- advanced or 
metastatic breast cancer (Finn et al. 2016, Hortobagyi et al. 2016). Finally, in September 2017, 
abemaciclib was also approved in combination with fulvestrant to treat HR+, HER2- advanced 
or metastatic breast cancer patients that had progressed on hormone-directed therapy 
(MONARCH 2). However, abemaciclib was also approved as single therapy for HR+, HER2- 
patients that progressed on hormone-directed therapy and prior chemotherapy after presenting 
metastasis (MONARCH 1) (Tolaney et al. 2015, Dickler et al. 2016). Table 2 describes the 
currently ongoing trials of CDK4/6i in lung cancer (Ingham et al. 2017).  
 Although abemaciclib, palbociclib and ribociclib were designed to be mechanistically 
similar, an in vitro kinase binding profile of abemaciclib against a kinome-wide panel revealed 
multiple additional targets (Gelbert et al. 2014). No comprehensive target profiles of palbociclib 
and ribociclib were available at the time our study was conducted (Fry et al. 2004, Rader et al. 
2013).  
 Considering the potential of CKD4/6i as therapy for LUSQ, the identification of 
undescribed targets of palbociclib and ribociclib can be useful to underline the difference in the 
mechanism of action between the CDK4/6i in LUSQ and to help to design combination 
therapies. 
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Table 2: A summary of ongoing CDK4/6i trials for lung cancer and solid tumors (Ingham et al. 
2017) 
 Drug combination Phase Trial 
Palbociclib 
Solid tumors FU plus oxaliplatin I NCT01522989 
Solid tumor Including 
stage IIIB NSCLC 
Carboplatin or cisplatin I NCT02897375 
Solid tumors Taselisib or pictilisib I NCT02389842 
Solid tumors (EGFR, 
HER2-4 alterations) 
Neratinib I NCT03065387 
NSCLC (KRAS mutation) PD-0325901 (MEK 1/2 Inhibitor) I/II NCT02022982 
Squamous lung cancer 
with PI3K dependence 
PF-05212384 (PI3K/mTOR inhibitor) I NCT03065062 
Ribociclib    
NSCLC (ALK mutation) Ceritinib I/II NCT02292550 
Abemaciclib    
Solid tumors LY3300054 (anti–PD-L1) I NCT02791334 
Solid tumors (RAS/MAPK 
alteration), including 
NSCLC 
LY3214996 
(ERK1/2 inhibitor) 
I NCT02857270 
NSCLC Stage IV NSCLC Pembroluzimab I NCT02779751 
Stage IV NSCLC Necitumumab I NCT02411591 
Stage IV NSCLC 
Pemetrexed, gemcitabine, ramucirumab or 
pembroluzimab 
I NCT02079636 
  
Experimental Design 
 We first tested palbociclib, ribociclib and abemaciclib in several LUSQ cell lines to verify 
their potency for inhibition of cellular viability. In addition, western blotting of cells treated with 
the CDK4/6i was performed for the downstream tumor suppressor Rb. A decrease of 
phosphorylation confirmed the cellular activity of the drugs in cells and inhibition of the intended 
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targets. Since palbociclib and ribociclib showed differences in their ability to reduce cellular 
viability, a chemical proteomics approach - compound-centric chemical proteomics (CCCP) - 
was used to define the differential target profiles of both drugs. In addition, to verify clinical 
relevance of these profiles, chemical proteomics was also performed in two lung primary tumor 
samples and differential target profile between palbociclib and ribociclib was confirmed and 
compared to the cell line data. We used bioinformatic and statistical tools, such as NSAF and 
SAINT, to prioritize targets. In vitro kinase assays were performed to confirm new targets. 
 Since the CCCP approach selects direct and indirect (protein complexes) targets, we 
queried the ConsensusPathDB database, which contains known protein-protein interactions, to 
determine protein complexes and differentiate direct from indirect targets. The knowledge of 
protein complexes is useful to evaluate pathways that are responsible for the MoA of these 
compounds. The potentially functionally relevant pathways of the new targets were investigated 
using DAVID. Finally, pathways were validated using commercially available tools, such as 
antibodies for the new targets and their downstream targets, which could be detected by 
western blot, and define changes in protein levels. Commercial kits were used for measurement 
of cellular activity regarding regulation of autophagy. 
 Furthermore, TCGA data, available through cBioPortal, was used to investigate the 
percentage of genetic alterations in the cognate and new targets in LUSQ and LUAD. This 
analysis suggested the relevance of these targets in the treatment of these types of lung cancer, 
especially in LUSQ, for which palbociclib was in clinical trial.  
 
Materials and Methods 
Cell culture and reagents  
H157, H520, H2170 and H596 cells were provided by the Moffitt Lung Cancer Center of 
Excellence Cell Line Core. Cells were cultured in RPMI 1640 media containing 10% FBS 
(complete RPMI). Abemaciclib (LY2835219; Selleckchem), Compound C (Sigma-Aldrich), 
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palbociclib (PD0332991), ribociclib (LEE011), I-BET151, AZD8055, LY294002, BKM120 and 
CAL101 (all Chemietek) were dissolved in DMSO (10 mM). Hydroxychloroquine was a kind gift 
from Dr. John Cleveland (Moffitt Cancer Center) and was dissolved in distilled water (20 mM).  
 Viability assays  
Cell viability assays were performed with CellTiter-Glo Luminescent Cell Viability Assay 
(Promega) by adding 15 µl of the 1:25 diluted stock per well. Inhibitors were diluted in complete 
RPMI to the final concentration as indicated. Cell lines were plated at a density of 1000 
cells/well in a 384-well microtiter plate (Fisher), treated with drug after 24 hours and grown for 
another 72 hours before addition of CellTiter-Glo reagent. Plates were read on a M5 
Spectramax plate reader (Molecular Devices) and GraphPad Prism was used to analyze data.  
Immunoblotting 
Cells were lysed with lysis buffer (0.20% NP40, 50 mM Tris pH 7.5, 5% Glycerol, 1.5 mM 
MgCl and 100 mM NaCl) with addition of Roche cOmplete protease inhibitor cocktail and 
phosphatase inhibitor cocktail 2 (Sigma, #P5726). Lysates were denaturated and separated by 
SDS-PAGE and immunoblotting was performed with primary antibodies against actin (Sigma, 
A5441), pRb(S780) (Cell Signaling, #8180), Rb (Santa Cruz, sc-102), pAkt(S473) (Cell 
Signaling, #9271), Akt (Cell Signaling, #9272), pGSK3α/β(S21/9) (Cell Signaling, #8566), 
GSK3β (Cell Signaling, #9315), or LC3B (Cell Signaling, #2775). Pulldown samples were 
probed for CDK4 (Santa Cruz, sc-23896), CDK6 (Santa Cruz, sc-177), CDK9 (Santa Cruz, sc-
8338), Casein Kinase II α/α’ (Santa Cruz, sc-136281), PI3-kinase p110δ (Santa Cruz, sc-7176), 
PIK3R4 (Cell Signaling, #14580) and GAK (MBL, M057-3). Secondary antibodies were anti-
rabbit and anti-mouse (GE Healthcare). Images were acquired using an Odyssey FC Imager 
(LI-COR) and quantified using Image J.  
Kinase assays 
In vitro kinase inhibition assays and IC50 determinations were performed on the Reaction 
Biology Kinase Hotspot platform using 10 μM ATP. Assays were performed in duplicate (except 
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for PIK3C3). IC50 values were determined using 10 dose 3-fold serial dilution series at 20 μM. 
PIK3CD inhibition was additionally determined on the Eurofins Kinase Profiler™ platform using 
10 µM ATP and a 3-fold drug dilution series starting at 30 µM.  
 Chemical synthesis  
c-Palbociclib  
Palbociclib (1) (4.8 mg, 9.92 µmol, 1 equivalent) was dissolved in 300 µL of DMF, then 
Boc aminopropyl bromide (4.7 mg, 19.83 µmol, 2 equivalents) and triethylamine (ET3N, 5.0 mg, 
49.6 µmol, 5 equivalents) were added. The reaction was stirred at 55°C overnight. LC-MS was 
used to monitor the formation of product at 605.4 m/z. The reaction was extracted with ethyl 
acetate and 0.1 M NaHCO3 pH 8.0, dried with sodium sulfate, filtered and concentrated in 
vacuo. Boc-c-palbociclib (2) was dissolved in a 1:1 mixture of dichloromethane (DCM) and 
methanol, then DMT beads (Silica Mets DMT, 66 mg, 39.68 µmol, 4 equivalents) were added to 
2. The reaction was stirred at 45°C overnight and then filtered through celite. Silica gel 
chromatography (2-10% MeOH in DCM) was used to purify 2. LC-MS was used to select the 
fraction containing 2. Finally, c-palbociclib (3) was obtained by deprotection with 20% 
trifluoroacetic acid (TFA) in DCM. The reaction was stirred at room temperature for 30 minutes 
and dried in vacuo to yield the TFA salt (1.43 mg, 30% overall yield) as a bright yellow residue. 
1H NMR (400 MHz, d6-DMSO) δ 10.13 (s, 1H), 8.94 (s, 1H), 8.04 (d, J = 2.8 Hz, 1H), 7.83 (d, J 
= 8.8 Hz, 1H), 7.46 (dd, J= 9.2, 2.8 Hz, 1H), 5.85-5.75 (m, 1H), 3.56-3.50 (m, 2H), 3.16 (s, 4H), 
2.845 (dd, J = 13.2, 7.6 Hz, 4H), 2.52-2.40 (m, 7H), 2.29 (s, 3H), 2.27-2.19 (m, 2H), 1.86 (s, 
2H), 1.74 (s, 4H), 1.56 (s, 2H). HRMS (ESI pos.) for C27H36N8O2 (M+H+) calculated 505.30340, 
found 505.30237, error ± 2.04 ppm; (M+Na+) calculated 527.28534, found 527.28548, error ± 
0.27 ppm.  
c-Ribociclib   
Ribociclib (4) (4.5 mg, 10.35 µmol, 1 equivalent) was dissolved in DMF, then Boc-
aminopropyl bromide (7.4 mg, 31.05 µmol, 3 equivalents) and triethylamine (ET3N, 5.05 mg, 50 
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µmol, 5 equivalents) were added. The reaction was stirred at room temperature overnight. LC-
MS analysis confirmed the formation of Boc-c-ribociclib (5) at 592.4 m/z. 5 was dissolved in 2 
mL methanol with DMT beads (133 mg, 80 µmol, 8 equivalents). The reaction was stirred at 
45°C overnight and then filtered through celite. Silica gel chromatography (5-20% MeOH in 
chloroform) was used to purify 5. Finally, c-ribociclib (6) was obtained by deprotection with 20% 
TFA. The reaction was stirred at room temperature for 30 minutes, dried in vacuo to yield the 
TFA salt (2.64 mg, 59% overall yield) as a colorless residue. 1H NMR (400 MHz, CD3OD) δ 8.96 
(s, 1H), 8.04 (dd, J= 9.6Hz, 2.8Hz,1H), 7.96 (d, J =2.4 Hz, 1H), 7.45 (d, J = 9.2 Hz, 1H), 6.82 (s, 
1H), 4.85-4.77 (m, 1H), 3.49 (m, 6H), 3.33-3.28 (m, 2H), 3.16 (d, J = 7.6 Hz, 6H), 3.07 (t, J= 16 
Hz, 2H), 2.51-2.41 (m, 2H), 2.21-2.05 (m, 8H), 1.74 (dd, J= 12.4, 5.6 Hz, 2 H). HRMS (ESI pos) 
for C26H37N9O (M+H+) calculated 492.31938, found 492.31896, error ±0.85 ppm; (M+Na+) 
calculated 514.30133, found 514.30146, error ±0.25 ppm. DMT beads were from Silicycle. 
Other reagents were obtained from Acros Organics. NMR analysis was performed with 
MestReNova.  
 Sample preparation and mass spectrometry  
H157 cells were lysed with the same buffer described for the immunoblotting methods. 
For lysis of primary tumor samples, cOmplete protease inhibitor cocktail (Roche) was included. 
NHS-activated sepharose beads for fast flow resin (GE Healthcare) were aliquoted to a 
final volume of 50 µl for each sample and then washed three times with HPLC-grade DMSO; 
samples were centrifuged at 100 xg for 1 minute between washes. Beads were treated with 
0.1% triethylamine to prevent protonation of the amino group. Immobilization of c-palbociclib 
and c-ribociclib was performed by adding 25 µl of 10 mM of each compound to their respective 
vials containing beads. Beads were incubated in the dark overnight at room temperature (RT) 
rotating at 10 rpm. After centrifugation, 10 µl of the supernatant was used to determine the 
coupling of the drug to the beads by LCMS analysis (14 minutes 5-95% MeOH gradient). 10 µl 
of the supernatant was transferred to a new tube, DMSO was evaporated and the sample was 
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re-suspended in 60 µl of HPLC-grade MeOH. If no drug was detected, beads were blocked with 
ethanolamine and rotated overnight at RT at 10 rpm. Beads were washed three times with 500 
µl DMSO following three washes with 1 ml of lysis buffer, with supernatant being removed after 
every wash subsequent to centrifugation at 100 xg for 1 minute.  
Competition was done by pre-treatment of total cell lysates with 20 μM or indicated 
range of concentrations of palbociclib or ribociclib for 30 minutes before addition of drug beads. 
After adding lysate to the beads, samples were rotated at 4°C for 2 hours. Samples were loaded 
onto Bio-spin disposable chromatography columns, washed with 7.5 ml of lysis buffer and 
eluted with 30 µl of 4x Laemmli buffer after boiling column for 5 minutes. 2/3 of the eluate were 
kept for MS analysis and the rest used for immunoblotting. 
Experiments were performed in duplicate using 5 mg protein per pulldown for H157 
lysates and 1 mg per pulldown for tumor sample lysates. SDS-PAGE (4-12% gradient gel) run 
at 125 V for 15 minutes was used to compact the samples. Gels were fixed for 1 hour with 
destaining/fixation buffer (10% MeOH, 5% glacial acetic acid). Samples were cut at 1-2 mm2 
pieces and shaken at 1000 rpm twice for 20 minutes with 1 ml HPLC-grade water; this helps to 
remove the SDS. Additional wash/shake was performed with 1 ml of 50 mM ammonium 
bicarbonate (Ambic)/50% MeOH for 20 minutes. Samples were reduced through 2 x 15 minutes 
incubation at 37°C with 100 µl of 2 mM tris(2-carboxyethyl)phosphine (TCEP) in 50 mM Ambic. 
Alkylation was performed by incubating samples twice for 20 minutes in the dark at RT with 100 
µl of 20 mM iodoacetamide in 50 mM Ambic. Samples were washed/shaken 3 x 15 minutes with 
200 µl 50 mM Ambic/50% MeOH. Samples were incubated with 250 µl of 50% acetonitrile 
(ACN) for 5 minutes at RT for dehydration. Subsequently, in gel-digestion was performed by 
incubating samples, overnight at 37°C, with trypsin in 30 mM Ambic at a final concentration of 
1.7 ng/µl. Peptides were extracted by shrinking gel slices twice with 50% ACN/0.1% TFA for 20 
minutes at room temperature and then twice with 100% ACN/0.1% TFA. Vacuum centrifugation 
was used to evaporate solvent. Samples were re-suspended in HPLC buffer A (2% ACN, 0.1% 
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formic acid (FA)). Tandem MS peptide sequencing was performed by a nanoflow liquid 
chromatograph (U3000, Dionex) coupled to an electrospray ion trap mass spectrometer (LTQ-
Orbitrap). The samples were loaded onto a pre-column (5 mm x 300 m ID packed with C18 
reversed-phase resin, 5 m, 100 Å) and washed for 8 minutes with aqueous 2% ACN and 
0.04% FA. Trapped peptides were eluted onto the analytical column, (C18, 75 µm ID x 15 cm, 
Pepmap 100, Dionex). The 120-minute gradient was programmed as: 95% solvent A (2% ACN 
+ 0.1% FA) for 8 minutes, solvent B (90% ACN + 0.1% FA) from 5% to 50% in 90 minutes, then 
solvent B from 50% to 90% B in 7 minutes and held at 90% for 5 minutes, followed by solvent B 
from 90% to 5% in 1 minute and re-equilibration for 10 minutes. The flow rate on the analytical 
column was 300 nl/min (1/1000 split from 300 l/min) Five tandem mass spectra were collected 
in a data-dependent manner following each survey scan. The MS scans were performed in the 
Orbitrap compartment to obtain accurate peptide mass measurement and the MS/MS scans 
were performed in the linear ion trap using 60 second exclusion for previously sampled peptide 
peaks. Sequest (Jimmy et al. 1994) and Mascot (Perkins et al. 1999) searches were performed 
against the Swiss-Prot 2014 (Nov) human database. Two missed trypsin cleavages were 
allowed. Carbamidomethylation of cysteine, and methionine oxidation were selected as variable 
modifications. Results were obtained in Scaffold 4.0, with mass tolerance set to 1.1 and 
fragment ion tolerance to 0.8. Data was analyzed by setting the minimum number of peptides to 
2 and protein and peptide thresholds to 95%. 
Data and bioinformatic analysis  
Protein prioritization was performed using SAINTexpress software (Version 3.4) and 
normalized spectral abundance factor (NSAF) values based on total exclusive unique spectral 
counts obtained from Scaffold (Finn et al. 2015, Herbst et al. 2015). Competition experiments 
with free untethered drug and ampicillin drug affinity chromatography experiments served as 
negative controls. Proteins with at least 2 spectra in both replicates were selected for analysis. 
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Pathway mapping was done using the DAVID Bioinformatics Resource 6.7 and aberrations in 
proteins/genes from significantly enriched pathways were queried using primary LUSQ data 
from TCGA through cBioPortal (Hammerman et al. 2012, Bantscheff et al. 2007). Interaction 
analysis on proteins with a minimum SAINT score of 0.75 was performed by querying known 
protein-protein interactions using the ConsensusPathDB database (http://consensuspathdb.org) 
and visualized in Cytoscape (Version 3.1) (Godl et al. 2003, Ong et al. 2009).  
 Autophagy assay 
Quantification of autophagosomes was measured using the Cyto-ID autophagy detection 
kit (Enzo) as recommended by the manufacturer. H157 and H520 were plated in a 96-well plate 
at a density of 12.000 cells/well and 40.000 cells/well respectively. After 24 hours, cells were 
treated with drug and incubated for another 3 hours before addition of Dual Detection Reagent 
solution in medium without phenol red but containing 10% FBS. Plates were read on a M5 
Spectramax plate reader (Molecular Devices) and GraphPad Prism was used to analyze data. 
 
Results and Discussion 
The potencies of abemaciclib, palbociclib and ribociclib for inhibition of cellular viability 
(IC50) were determined in several LUSQ cell lines (Fig 14a). This analysis showed that 
abemaciclib, the strongest CDK4 inhibitor with an in vitro kinase IC50 = 2 nM (Asghar et al. 2015, 
Gelbert et al. 2014), is more potent than palbociclib and ribociclib. Interestingly, despite the 
similarity between the chemical structures of palbociclib and ribociclib and their equal potencies 
for CDK4 inhibition (IC50[palbociclib]: 9-11 nM; IC50[ribociclib]: 10 nM) (Asghar et al. 2015), we 
observed that palbociclib is more potent in the LUSQ cell lines than ribociclib. The differential 
cellular activity between palbociclib and ribociclib is likely not the result of differences in cellular 
uptake, because both drugs were able to inhibit Rb phosphorylation at Ser780 in H157 cells 
(Fig 14b), consistent with other studies (Fry et al. 2004, Rader et al. 2013). 
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Fig. 14: A. Cell viability effects of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib on the 
H157, H2170, H520 and H596 cell lines and IC50 values after 72 hours of drug treatment. B. Effects on 
the level of phosphorylation on the Rb Ser780 in H157 cells after 4 and 24 hours of treatment with 1 µM 
and 5 µM of palbociclib (Palbo) and ribociclib (Ribo). Bottom panel: densitometry quantification of 
immunoblot signals for Ser780 Rb in relation to total Rb level. 
 
This comparison suggests that palbociclib may target additional proteins, beyond 
CDK4/6, that contribute to its overall cellular activity. Although previous studies have reported 
that patient plasma levels of palbociclib are up to 433 nM (Schwartz et al. 2011), which 
suggests limited single agent activity and the need for drug combinations in LUSQ, the 
intratumoral concentration may be much higher as studies reported that, in mouse tumors, 
palbociclib concentrations were as high as 52 µM (Ngugen et al. 2010). Thus, even moderate 
cellular activities may be clinically relevance. 
To determine the target profile of palbociclib and ribociclib in LUSQ, we applied an 
unbiased proteomic approach as described above, namely compound-centric chemical 
proteomics (CCCP). As this requires immobilization of the drug on affinity beads, we designed 
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coupleable drug analogues c-palbociclib (3) and c-ribociclib (6) (Fig.15a,b). 
 
Fig. 15: A and B. Synthetic scheme for generation of coupleable drug analogs: c-palbociclib (3) from 
palbociclib (1) and c-ribociclib (6) from ribociclib (4), respectively. C. Inhibition of CDK4 activity: in vitro 
kinase assays for CDK4/cyclin D1 for palbociclib and ribociclib and their coupleable analogues.  
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Based on available co-crystal data for palbociclib and CDK6 (pdb: 2EUF) (Fig.16) (Lu 
and Schulze-Gahmen 2006), to this end we modified the piperazine moiety shared by both 
drugs by introducing an aminopropyl linker. We hypothesized that this modification would not 
change the binding of these compounds to their targets since it was done in a solvent exposed 
region of the protein and should retain also the free electron pair of the amino group, which 
contributes to CDK6 binding (Lu et al. 2006). The activity of the coupleable compounds were 
confirmed by in vitro kinase assays for CDK4/cyclin D1 (Fig.15c), which, based on our previous 
experience with kinase inhibitors, should be valid for most other kinase targets as well (Remsing 
Rix et al. 2009).  
 
 
Fig.16: A. The crystal structure of PD0332991 bound to CDK6. Piperazine ring is highlighted in light red. 
B. Surface representation of palbociclib and the binding pocket of CDK6. Palbocicblib structure is shown 
in solid blue, the surface of the CDK6 pocket is partially transparent. Figure modified from Lu et al. 2006. 
 
Using compounds c-palbociclib and c-ribocicblib, we performed chemical proteomics 
(CCCP) in H157 cells. Ampicillin was used as a control since it should not interact with human 
proteins, which is a good control for false-positive binding proteins. In addition, we performed 
competition experiments where lysates were pre-treated with unmodified drug, i.e palbociclib or 
ribocicblib, before incubation with drug affinity beads. This last approach allows us to prioritize 
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targets since the most readily competed proteins are likely preferential targets. The selection 
criteria were i) an average ≥ 2 of exclusive unique spectral counts; ii) fold change ≥ 2 upon 
pretreatment with unmodified drug; iii) NSAF value higher than 0.001 and iv) not detected in 
ampicillin controls. Intriguingly, palbociclib was less specific than ribociclib interacting with more 
than twice as many protein kinases (Fig 17a). In addition, palbociclib also enriched several lipid 
kinases, which were not detected in ribociclib samples (Fig 17b).  
      
Fig. 17: Target overlap between palbociclib and ribociclib. A. Protein kinases – palbociclib interacted with 19 
unique kinases while ribociclib targeted 3 unique kinases and shared another 8 kinases with palbociclib. B. Lipid 
kinases – only palbociclib interacted with lipid kinases. 
 
Following our selection criteria, the potential protein kinase targets of palbociclib and 
ribociclib are displayed in the kinome tree (Fig. 18). Confirming the activity of our probe 
molecules, we were able to enrich for the canonical targets CDK4 and CDK6 with both c-
palbociclib and c-ribocicblib. Other shared target candidates between palbociclib and ribocicblib 
were FER, CDK9, PRDK2, CAMK2D, CAMK2G and FAK. In addition, ribociclib exclusively 
targeted the cyclin G-associated kinase (GAK), TNK1 and aurora kinase A (AURKA).  
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Even though we observed a few spectra of TNK1 in palbociclib samples (Appendix A), 
the pretreatment did not result in competition and TNK1 did not pass our selection criteria. 
AURKA has been enriched predominantly by ribociclib, but showed only partial competition 
upon pretreatment and for that reason was not given high priority as partial competition often 
indicates a weaker drug-protein interaction and/or higher cellular expression levels. The unique 
target candidates of palbociclib were casein kinase 2α1/2 (CSNK2α1/2, CK2α1/2), AMPKα1, 
PIK3R4, JNK1, TBK1 and GSK3β. ERK2 and JNK2 were also unique targets of palbociclib, but 
only partially competed. 
       
 
Fig. 18: Kinome tree: target profiles of palbociclib (A) and ribocicblib (B) in H157 cells. Kinases that fulfill all four 
selection criteria are displayed as large, those fulfilling three criteria as small nodes. Only kinases identified with at 
least 2 exclusive unique spectra per replicate are shown. NSAF is used to determine the abundance of protein in a 
sample. Illustration reproduced courtesy of Cell Signaling Technology (www.cellsignal.com).  
 
To further prioritize palbociclib and ribociclib target candidates, we used, in addition to 
the normalized spectrum abundance factor (NSAF), the significance analysis of interactome 
(SAINT). SAINT statistically evaluates the probability of a protein-protein and drug-protein 
interaction. This analysis confirmed GAK as a unique and novel target candidate of ribociclib 
and CSNK2α1, CSNK2α2 and PIK3R4 as new target candidates of palbociclib. Strikingly, 
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several lipid kinases, namely PIK3C3, PIP4K2A/B/C and PIK3CD, were also exclusively bound 
by palbociclib presenting strong competition upon pretreatment and high SAINT scores (Fig. 
19).  
         
 
Fig 19: Prioritization of target candidates of palbociclib (A) and ribociclib (B). Display of protein and lipid 
kinases based on NSAF values and SAINT scores, with the latter one being determined using ampicillin 
and drug competition as negative controls. Kinases with a SAINT score below 0.1 are not shown, Red (A) 
and blue (B) shaded areas represent the high priority space. Node size is proportional to total unique 
spectral counts. 
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To test if the same differential target profile between palbociclib and ribociclib also 
occurs in clinical samples, two primary tumor tissues from LUSQ patients (T1 and T2) were 
used to perform chemical proteomics (Appendices B and C). Since the amount of tumor tissue 
was not sufficient for ampicillin pulldowns, drug competition with palbociclib or ribociclib were 
the only negative controls used for analysis. We observed a substantial overlap between the 
targets of the H157 cell line and the two tumor samples (Fig. 20), which included CSNK2α1/2 
and the lipid kinases PIP4K2A/B/C as targets for palbociclib and CDK9 and GAK for ribocicblib. 
The kinase PYK2, which is highly expressed in hematopoietic cells, was only detected in the 
tumor samples. As we have observed before with other kinase inhibitors, it is more likely that 
this target originated from hematopoietic cells in the tumor microenvironment (Gridling et al. 
2014). 
 
Fig. 20. Comparison of palbociclib (A) and ribociclib (B) target profiles between H157 cell line and the two 
primary tumor samples (T1 and T2). Diagrams display overlapping and unique targets between the three 
samples. Each box beside the kinase name corresponds to H157, T1 and T2 samples, respectively. The 
color of the boxes indicates whether all the selection criteria was fulfilled (black), if it was observed, 
however did not fulfill all the criteria (grey) or it was not detected (white). Only kinases that fulfilled all the 
criteria in at least one sample are displayed. We used the same selection criteria described for the 
prioritization of kinases from the H157 cell line; in tumor samples the criteria iv was excluded since we did 
not perform the ampicillin pulldown.  
 
Kinases highlighted in red in Fig. 20 were chosen for further in vitro kinase activity 
analysis (Fig. 21a), using initially two doses of palbociclib or ribociclib as indicated. Thus, we 
confirmed that CDK9 is indeed targeted by both ribociclib and palbociclib, with ribociclib being 
approximately twice as potent against this kinase (IC50 = 219 nM) than palbociclib (IC50 = 449 
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nM). TNK1 is a new and potent target of ribociclib while AURKA is only weakly inhibited, which 
is consistent with our lower priority based on the partial competition by ribociclib. PIK3CD and 
CSNK2α2 were new targets of palbociclib. The IC50’s of these targets suggest at least partial 
inhibition under physiological conditions. Since there are no commercially available activity 
assays for GAK and PIK3R4, we performed dose-dependent binding competition in H157 cells 
to verify specific binding of these kinases to ribociclib and palbociclib. In this experiment, 
increasing doses of the unmodified drug was used to compete with the affinity beads and 
immunoblotting was used to detect decreases in the levels of the bound proteins (Fig. 21b). In 
addition, we also confirmed the specificity of these targets in the H157 pull-down samples. We 
by immunoblotting analysis were not able to do the same with the tumor samples because the 
available sample sizes were only enough to produce MS samples (Fig. 21c). 
    
Fig. 21: Validation of selected targets. A. In vitro kinase activity at two drug concentrations (in µM). Full 
dose-response and IC50s were determined for potent targets; # average IC50 using Reaction Biology IC50 
= 447 nM and Eurofins IC50 = 1848 nM B. Western Blot of drug affinity eluates with indicated 
concentration of unmodified drug as pretreatment. Relative quantification was measured by densitometry 
and signals were normalized to DMSO control of either palbociclib or ribociclib, whichever was higher, by 
comparison of the total cell lysate signal. C. Western Blot analysis of drug affinity elutes for the new 
targets of palbociclib and ribociclib. TCL: total cell lysates; AMP: ampicillin pulldown; PT: pretreatment  
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 Based on our MS data, CSNK2α1 and PIK3C3 showed strong interaction with 
palbociclib displaying high NSAF and SAINT scores. However, in vitro kinase assays showed 
that these kinases were only weakly inhibited by palbociclib (IC50 = 14.8 µM). Therefore, we 
hypothesize that these proteins are specific, but indirect binders of palbocicblib. In other words, 
we postulate that these proteins were detected by MS as the result of protein-protein 
interactions (PPI) with direct palbociclib targets, since the pulldowns are capable to select for 
protein complexes. To verify our hypothesis, we queried known PPI using the 
ConsensusPathDB database. For this analysis we selected proteins with SAINT scores ≥ 0.75 
and used Cytoscape to generate a hybrid drug-protein protein-interaction network (Fig. 22). 
This network supported our hypothesis as CSNK2α1 is known to be part of a protein complex 
containing CSNK2α2 and their regulatory subunit CSNK2B. Similarly, PIK3C3 (Vps34) is well 
known to interact with PIK3R4 (Vps15) in the vesicle nucleation step of the autophagosome 
formation (Levine et al. 2008). Since PIK3R4, one of the most predominant new target 
candidates of palbocicblib in H157, phosphorylates and activates PIK3C3, it is possible that 
PIK3C3 was detected by MS due its indirect enrichment by palbociclib via PIK3R4 (Stack et al. 
1995, Stack et al. 1993). In addition, two other proteins, namely beclin (BECN1) and UVRAG, 
which are known to interact with PIK3R4/PIK3C3 to form PIK3C3 complex II were also detected. 
This further supported the explanation that CCCP allows detection of stable protein complexes. 
In addition to PIK3C3, palbociclib, but not ribociblib, showed unique interactions with 
several other lipid kinases, such as PIP4K2A/B/C, which are involved in the phosphatidylinositol 
signaling pathway. To obtain insight into the biological relevance of the new targets, we queried 
the functional pathways inhibited by palbocicblib and ribociblib by searching the KEGG pathway 
database via the bioinformatic tool DAVID (Table 3, Appendix D). As expected, cell cycle 
signaling was one of the most significantly affected pathways, which was regulated by both 
drugs. In addition, palbociclib was related to the phosphatidylinositol signaling and autophagy 
pathways. 
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Fig. 22: Network and pathway analysis of proteome-wide drug interactomes in H157 cells. Direct 
and indirect drug-protein interactions of palbociclib and ribociclib are represented in black and grey 
edges, respectively. Shown in red are protein kinases, shown in orange are lipid kinases and additional 
identified proteins are displayed in grey. Known protein complexes are highlighted by red circles. Beige 
outlines indicate proteins as part of a specific biological pathway. 
 
Table 3. Pathways involved in the mechanism of action of palbociclib  
 
PIP4K2A/B/C catalyze the formation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) 
from PI(5)P (Emerling et al. 2013). PIK3CD in turn generates phosphatidylinositol 3,4,5-
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trisphosphate (PIP3) from PI(4,5)P2, a critical event in the activation of the AKT signaling 
cascade. The phosphoinositide 3-kinase (PI3K) family phosphorylates the 3-hydroxyl group of 
the inositol ring of the PI(4,5)P2 generating PI(3,4,5)P3. PI(3,4,5)P3 is recognized by the N-
terminal pleckstrin homology (PH) domain of AKT resulting in its translocation to the plasma 
membrane. In addition, PI(3,4,5)P3 recruits the phosphoinositide-dependent kinase 1 (PDK1), 
which phosphorylates AKT at Thr308 in the activation loop. Finally, in vitro studies have 
suggested that mTORC2 can be activated by PI(3,4,5)P3. However, once mTORC2 localizes to 
the plasma membrane, it fully activates AKT by phosphorylating Ser473 (Rudge et al. 2013, 
Rudge et al. 2016) (Fig. 23). Accordingly, treatment with palbociclib, but not ribociclib, inhibited 
the phosphorylation of AKT S473 and its downstream target GSK3β in a dose dependent 
manner with moderate potency (Fig. 24). 
 
Fig. 23: A. Lipid kinases and phosphatases involved in the AKT pathway. PIK3CD, a member of the 
phosphoinositide 3-kinase (PI3K) family adds a phosphate group to the 3-hydroxyl group of the inositol 
ring of the PI(4,5)P2 generating the PI(3,4,5)P3. In addition the PIP type I kinases (PIP5s) phosphorylate 
the 5-hydroxyl group of the PI(3,4)P2 also producing PI(3,4,5)P3. PI(3,4)P2 and PI(3,4,5)P3 are docking 
sites for PDK1, AKT and mTORC2 resulting in the activation of the AKT signaling pathway. On the other 
hand, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and the phosphoinositide 5-
phosphatase (INPP5) family dephosphorylates PI(3,4,5)P3 (Modified from Rudge et al. 2013 and 2016). 
Red indicates kinases and blue indicates phosphatases. Dashed line is based only in in vitro experiments 
and continued lines were validated by in vitro and in vivo experiments. 
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Fig. 24: Representative western blot of pSer473 AKT and pSer9/21 GSK3β in H157 and H520 cell lines 
treated for 4 hours with indicated doses of palbociclib, ribociclib (in µM). BKM120 (2 µM) and CAL101 (5 
µM) are potent pan- and -specific PI3K inhibitors and were used as controls. 
 
However, based on the observation that H157 and H520 cell lines are relatively 
insensitive to the more potent PI3K inhibitors BKM120 and CAL-101 (Fig. 29c), it is unlikely that 
inhibition of PIK3CD and PIP4K2A/B/C by palbociclib contributes to palbociclib’s cellular activity 
in these particular cells. However, PIK3CD has been shown to be an important target for some 
hematopoietic malignancies, such as mantle cell lymphoma (MCL), where palbociclib has been 
found to overcome drug resistance and is entering a clinical trial in combination with ibrutinib 
(Chiron et al. 2014). Since palbociclib is not a potent PIK3CD inhibitor, its clinical relevance in 
MCL will depend on if sufficiently high drug concentrations accumulate in malignant or 
supporting microenvironment cells, which based on preclinical studies could be possible 
(Nguyen et al. 2010). 
 It is well known that AMPK, CK2 and the PIK3R4/PIK3C3/BECN1/UVRAG complex play 
important roles in autophagy (Liang et al. 2007, Levine et al. 2008, Matsumoto et al. 2011). 
Upon activation of AMPK or inhibition of mTOR, the activation of the ULK complex containing 
the UNC-51-like kinases (ULK) results in the phosphorylation of the BECN1 protein. 
Phosphorylated BECN1 induces the activation of the kinase PIK3C3 (Vps34), which interacts 
with several proteins, including PIK3R4 (Vsp15) and UVRAG, forming PIK3C3 Complex II. 
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There are two ubiquitin-like systems involved in autophagy. The first one involves the Atg5-
Atg12-Atg16L complex that is responsible for the curvature of the growing phagophore complex 
by the recruitment of LC3B-II. The second ubiquitin-like system involves the formation of the 
microtubule-associated protein light chain 3 (LC3B). Upon autophagy activation, the full-length 
LC3B is cleaved by the cysteine protease Atg4 generating LC3B-I. LC3B-I is then activated by 
Atg-7 and transferred to Atg3 forming LC3B-II. LC3B-II inclusion on the growing phagophore 
and its conjugation to phosphatidylethanolamine (PE) depends on the Atg5-Atg12 heterodimer. 
LC3-II is found on both sides of the phagophore’s membrane and is important for the hemifusion 
of membranes and definition of the cargo for degradation. Since the synthesis of LC3B-II 
increases during autophagy, it makes LC3B-II an ideal readout for autophagy. On the level of 
the autophagosome, LC3B-II interacts with adaptor proteins, such as p62 that is important to 
maintain the selective uptake and degradation by promoting turnover of polyubiquitinated 
protein aggregates. A key kinase in this step of the autophagy mechanism is casein kinase 2 
(CK2), which phosphorylates p62 at Ser403 thereby increasing its affinity for polyubiquitinated 
proteins and consequently the cargo in the autophagosome (Glick et al. 2010, Matsumoto et al, 
2011, Cicchini et al. 2015) (Fig. 25).  
Indeed, immunoblotting analysis confirmed that palbociclib treatment increased lipidation 
of LC3 (LC3-II), a canonical readout of autophagy modulation, in H157 and particularly H520 
cells (Fig. 26a). Hydroxychloroquine (HCQ) is a known autophagy inhibitor. HCQ prevents the 
fusion of the autophagosome with the lysosome (Fig. 25), which results in the accumulation of 
the autophagosome, containing LC3B-II, in the cells by inhibiting its degradation. In contrast to 
ribociclib, palbociclib also increased the number of autophagic vesicles (Fig. 26b) as measured 
by the Cyto-ID fluorescence. Given the overall similar behavior to the autophagy inhibitor 
hydroxychloroquine (HCQ) (Fig. 26c), also in combination with the mTOR inhibitor AZD8055, 
and that AMPK, CK2 and the PIK3C3 complex II, which are inhibited by palbociclib, positively 
regulate autophagy, palbociclib likely also causes overall inhibition of autophagy. 
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Fig. 25: Autophagy mechanism. Autophagy is divided into three steps: induction, nucleation and 
elongation. Induction phase is marked by the activation of the ULK complex by AMPK or inhibition of 
mTOR. Nucleation involves the activation of the PI3KC3 complex and the formation of the first ubiquitin-
like system (Atg5-Atg12-Atg16L). The Atg5-Atg12-Atg16L complex induces elongation by adding the 
phosphatidylethanolamine (PE) to LC3B-I and by bringing the resulting LC3B-II to the membrane of the 
phagophore (Cicchini 2015, 21).  
 
 
Fig. 26: Palbociclib regulates autophagy. A. Representative western blot of LC3 from H157 and H520 
cell lines treated for 48 hours with indicated concentrations of palbociclib, ribociclib (in µM) or 
hydroxychloroquine (HCQ, 25 µM). Palbociclib and ribociclib concentrations in combination with 
hydroxychloroquine were 5 µM each. B. Quantitative analysis of autophagy vesicles in H157 and H520 
cell lines using Cyto-ID after 3 hours of treatment with indicated concentrations of palbociclib and 
ribociclib (in µM), HCQ (25 µM) and ADZ8055, a mTOR inhibitor and autophagy inducer (4 µM); Values 
were normalized to DMSO control and plotted as differences to DMSO. C. Quantitative analysis of 
autophagy vesicles in H157 after treatment of AZD8055 (4 µM) with palbociclib (5 µM), HCQ (25 µM). 
The same concentration of palbociclib and AZD8055 was used as single treatment. 
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Using cBioPortal, a bioinformatic tool to evaluate genomic alterations, we investigated 
the clinical attributes of the genes identified by chemical proteomics that were related to the cell 
cycle, phosphatidylinositol signaling and autophagy pathways by network interaction and 
pathway analysis of the TCGA data for lung cancer. It is notable that PIK3R4 is 
amplified/mutated in about 9% of LUSQ (Fig. 27a), (Hammerman et al. 2012) but not LUAD 
(Fig. 27b), and that PIK3R4 gene amplification statistically significantly co-occurs with 
amplification of GSK3β (Table 6). Moreover, USP13, which deubiquitinates BECN1 and 
stabilizes PIK3C3 complexes, (Liu et al. 2011) is predominantly amplified in LUSQ, but not 
LUAD.  
 
 
Fig. 27: Oncoprint for lung cancer LUSQ using cBioPortal. A. Oncoprint, for LUSQ, of mutations and 
putative copy-number alterations from GISTIC using all complete tumors from TCGA (Cancer Genome 
Atlas Research 2012). B. Oncoprint, for LUAD, of mutations and putative copy-number alterations from 
GISTIC using all complete tumors from TCGA (Cancer Genome Atlas Research 2014). 
 
This suggests that regulation of this pathway, which is affected specifically by 
palbociclib, may have functional consequences for a subset of LUSQ patients. Accordingly, 
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inhibiting CDK4/6 in combination with compound C (AMPK inhibitor) or LY294002 (PIK3C3 
inhibitor, used in lieu of available specific PIK3R4 inhibitors) causes a further reduction of H157 
and H520 viability (Fig. 28a, b). In other words, inhibition of AMPK and PIK3R4 by palbociclib 
may add to its CDK4/6-mediated anticancer activity in these cells. A potentially confounding 
factor in this analysis is lack of selectivity of the available tool compounds. Thus, although 
Compound C and LY294002 are the most suitable tool compounds to probe for AMPK and 
PIK3C3, respectively, they affect also several other targets. For instance, LY294002 inhibits 
several PI3Ks and BET proteins (Dittmann et al. 2014). Comparison with bioequivalent doses of 
BKM120, a pan-PI3K inhibitor, and I-BET151, a BET inhibitor, (Fig. 28c) still supports a 
contribution of PIK3C3 (and accordingly PIK3R4) towards LUSQ cell viability.  
 
Table 4. Co-occurrence of statistically significant genes in palbociclib-related pathway 
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Fig. 28: Viability of H157 and H520 cells after 72 hours of treatment. A. Treatment with ribociclib alone or in 
combination with Compound C (CC), an AMPK inhibitor, at 2.5 and 5 µM. B. Treatment with ribociclib alone or in 
combination with LY294002 (LY), a pan-PI3K inhibitor, at 10 and 25 µM. The combination index (CI) was calculated 
using Compusyn software and values above each bar represent combination treatment. CI values: 0.9-1.10 (nearly 
additive); 0.85-0.9 (slight synergism); 0.7-0.85 (moderate synergism) and 0.3-0.7 (synergism). C. Treatment with 
CAL-101 (selective PI3Kδ inhibitor), BKM-120 (pan-PI3K inhibitor) and I-BET151 (BET protein family inhibitor).  
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Conclusion 
Using a compound-centric chemical proteomics approach, we elucidated the proteome-
wide target profiles of the two clinical CDK4/6 inhibitors palbociclib and ribociclib in LUSQ. We 
identified ribociclib as a more specific inhibitor than palbociclib. Using bioinformatics tools for 
pathway analysis and identification of protein complexes, we observed that palbociclib is a dual 
protein and lipid kinase inhibitor, and that its additional targets, compared to ribocicblib, can 
modulate the PI3K/AKT and autophagy pathways in addition to canonical CDK4/6-Rb-E2F 
signaling. Considering the prevalence and relevance of alterations in these pathways in LUSQ 
and other cancers, palbociclib may in some cases have beneficial polypharmacology in addition 
to its primary targets CDK4/6.  
Further studies are required to determine the exact effects of palbociclib on autophagy and the 
cellular consequences of this. 
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CHAPTER THREE: 
 
ELUCIDATION OF THE COMPLEX MECHANISM OF ACTION OF FORETINIB IN LUNG 
CANCER 
Note to reader 
 Portions of this chapter have been submitted for publication and are currently in review. 
Dual VEGFR/MET inhibitors in lung cancer 
 The vascular endothelial growth factor (VEGF) family is one of the most studied growth 
factor family. It is composed of VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth 
factor (PLCG). In lung cancer, VEGF-A and VEGF-B are highly expressed especially in 
adenocarcinoma (Alevizalos et al. 2013). VEGFs are important for the proliferation of 
endothelial cells and for the increase of de novo blood vessels, processes known as 
angiogenesis and vasculogenesis, respectively. Angiogenesis is one of the hallmarks of cancer 
and it is important for tumor growth and metastasis since tumor cells must create a richer blood 
environment to meet their supplement for fast growth (Hanahan et al. 2011). VEGFs are 
secreted by tumor cells and tumor-associated stromal tissue (Shibuya et al. 2011). VEGF 
signaling is activated by the binding of VEGFs to their respective VEGFR receptors.  
VEGF-A has been shown to present a higher affinity for VEGFR-1 than for VEGFR-2. 
However, its binding to VEGFR-1 does not induce a strong activation of this receptor, indicating 
that the biological effect occurs mainly by its binding to the VEGFR-2 receptors (Olsson et al. 
2006). Interestingly, according to the Pan-Lung cancer database, VEGFR-2 is altered in about 
10% of NSCLC (Campbell et al. 2016).  
VEGFR-2 presents seven Ig-like extracellular domains and an intracellular domain. 
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Upon the binding of VEGF, the dimerization of the receptor results in its autophosphorylation 
(Tyr1054 and Tyr1059) creating docking sites for adaptor proteins. Phosphorylation on Tyr1175 
recruits PLCγ resulting in the increase of calcium and activation of protein kinase C (PKC) and 
consequently activation of the RAF/MEK/ERK signaling pathway. The RAS signaling cascade 
can also be activated by the binding of the adaptor protein GRB2 to the phosphorylated 
Tyr1214. In addition, VEGF-A leads to phosphorylation of the p85 subunit of PI3K inducing 
activation of AKT. Also, phosphorylation of the Tyr951 is recognized by the T-cell-specific 
adapter (TSAd) protein, which interacts with SRC family member proteins to activate the AKT 
signaling pathway and increases proliferation and survival of cancer cells (Olsson et al. 2006, 
Nilson et al. 2006). 
 There are several VEGFR-targeted therapies approved by the US Food and Drug 
Administration (FDA): bevacizumab (also known as Avastin) is a humanized anti-VEGF 
monoclonal antibody, while sorafenib and sunitinib are VEGFR tyrosine kinase inhibitors (Ellis et 
al. 2008). Bevacizumab was FDA approved on October 2006 in combination with carboplatin 
and paclitaxel as first-line treatment for unresectable, locally advanced, recurrent and/or 
metastatic non-squamous NSCLC patients (Piperdi et al. 2014). However, anti-VEGF therapy 
has shown modest results and eventually patients usually acquire resistance (Cascone et al. 
2017).  
MET is a tyrosine kinase receptor encoded by the mesenchymal-epithelial transition 
factor gene (c-MET) located on chromosome 7q31. MET is composed by an extracellular 
receptor formed by an alpha and beta-chain, with the last one containing the plexin, semaphorin 
(SEMA) and integrin cysteine-rich (PSI) domains (Maroun et al. 2014). The transmembrane 
domain of MET is important for the regulation of this receptor since phosphorylation of Tyr1003 
was shown to inhibit its activity. On the other hand, the intracellular domain presents diverse 
sites required for its activation and signaling.  
 The hepatocyte growth factor (HGF) binds to the MET receptor as a dimer thereby 
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inducing its activation, which results in the homodimerization or oligomerization of MET and 
consequently its autophosphorylation on tyrosines Tyr1234 and Tyr1235. Its activation also 
induces the phosphorylation of the tyrosines Tyr1349 and Tyr1356, docking sites for adaptor 
proteins, such as the growth factor receptor-bound protein 2 (GRB2) and the Src homology 2 
domain-containing (SHC) proteins (Maroun et al 2014, Raghav et al. 2012).  
 HGF is normally expressed in mesenchymal cells whereas MET is expressed by 
epithelial, endothelial and neural cells, as well as in melanocytes, hematopoietic progenitor 
cells, B cells and dendritic cell (Maroun et al. 2014). MET/HGF signaling plays a role in tumor 
proliferation, survival, migration, invasion and angiogenesis. In lung cancer, MET has been 
linked to poor survival since it is involved in resistance to radiotherapy and chemotherapies 
(Raghav et al. 2012). In NSCLC, MET and HGF are overexpressed in tumor tissue correlating 
with poor survival and unfavorable prognosis (Olivero et al. 1996, Zhang et al. 2012).  
 A gene expression study comparing sensitive and resistant NSCLC xenograft models to 
two VEGFR TKIs (cediranib and vandetanib) has shown that resistance can occur by changes 
in genes expression not only in tumor cells but also in the stromal cells. Stromal HGF gene 
expression was shown to be upregulated with both treatments and there was an increase of 
MET expression in the tumor cells. Xenograft tumors overexpressing MET were more resistant 
to treatment with cediranib and vandetanib than the control group. This indicates that dual 
inhibition of VEGFR and MET may improve tumor burden (Cascone et al. 2017). 
 Based on this rationale, two MET/VEGFR inhibitors were developed: cabozantinib and 
foretinib. Interestingly, they have very similar chemical structures with cabozantinib presenting a 
second methyl ether moiety in the solvent exposed region and foretinib featuring a morpholino 
ring in addition of the fluorophenyl ring (Fig. 30a). Both compounds are ATP-competitive 
inhibitors of MET and VEGFR-2. Whereas there is no x-ray co-crystal structure with 
cabozantinib, the x-ray co-crystal structure of foretinib with MET provided important insight for 
its binding mode. The binding of foretinib to MET is potent because of its interaction with a 
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pocket adjacent to the ATP-binding site, which changes the protein to its inactive “DFG-out” 
conformation (Fig. 30b, c) (Quian et al. 2009, Yakes et al. 2011).  
 
Fig. 29: A. Chemical structures of cabozantinib and foretinib: The molecular differences between these 
two compounds are highlighted in pink. Cabozantinib presents a second methyl ether, while foretinib has 
a fluorine and a morpholino ring. B. The X-ray crystal structure of foretinib in complex with MET: The 
activation loop is shown in pink and purple sticks. C. X-ray crystal structure of foretinib and MET protein: 
The phenyl 1223 (F1223) of the “DFG” (orange sticks) assume a new position underneath the 
fluorophenyl ring after the binding of foretinib. This results in a pseudo-inactivated conformation of the 
kinase and consequently its inhibition (Quian et al. 2009, Yakes et al. 2011).  
 
 Cabozantinib inhibits MET and VEGFR-2 with an IC50 of 1.3 and 0.035 nM, respectively. 
Foretinib was shown to be a more potent MET inhibitor with an IC50 of 0.4 nM and has an IC50 of 
0.86 nM for VEGFR-2. However, as these values have been determined on different platforms, 
both inhibitors should be considered similarly potent for MET and VEGFR-2. Furthermore, in 
vitro kinase assays have shown that cabozantinib and foretinib are multi-kinase inhibitors with 
broad selectivity profiles (Table 7) (Quian et al. 2009, Yakes et al. 2011, You et al. 2011). 
Consistent with targeting VEGFR-2, cabozantinib and foretinib have been shown to reduce 
proliferation and formation of endothelial vasculature in vitro and in vivo; and foretinib also 
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caused a decrease in metastasis in vivo (Quian et al. 2009, Zillhardt et al. 2011, Yakes et al. 
2011, Xiang et al. 2014).  
Table 5. Validated targets of foretinib and cabozantinib through in vitro kinase assays 
(Quian et al. 2009, Yakes et al. 2011, You et al. 2011) 
 
                                                 
 In November 2012, cabozantinib was approved for the treatment of metastatic medullary 
thyroid cancer after improving the progression-free survival to 11.2 months and achieving an 
overall response rate of 28% (Song et al. 2015). In April 2016, the FDA approved cabozantinib 
also for advanced renal cell carcinoma based on a study showing an increase in the median 
progression-free survival of 7.4 months and a median overall survival of 21.4 months in 
comparison to 3.8 and 16.5 months, respectively, for everolimus treated patients (Choueiri et al. 
2015).  
 In NSCLC, cabozantinib showed a response rate of 10% and 4.2 months of progression-
free survival (Neal et al. 2017). Also, cabozantinib and foretinib have been described to 
overcome crizotinib resistance in ROS1-fusion-positive patients. Both compounds can inhibit 
tumor growth of cells with G2032R-mutated CD74-ROS1. However, in this case cabozantinib 
was more potent than foretinib (Katayama et a. 2015, Davare et al. 2013). In addition, 
cabozantinib showed a 28% response rate and a median survival of 6 months for patients with 
RET-rearranged NSCLC, such as KIF5B-RET, TRIM33-RET and CLIP1-RET fusions but not the 
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CCDC6-RET or ERC1-RET fusions (Drilon et al. 2016).  
 The MET signaling pathway has also been implicated in the resistance to EGFR 
inhibitors (Zhang et al. 2012). Studies in vitro had suggested that MET inhibitors can re-
sensitize NSCLC to gefitinib and that the combination of cabozatinib with erlotinib could inhibit 
growth of MET-amplified NSCLC cells resistant to EGFR inhibitors (Wakelle et al. 2017). Clinical 
trials of cabozantinib plus erlotinib in NSCLC patients showed evidence of improvement of 
therapy with cabozantinib plus erlotinib compared to erlotinib alone with a median progression-
free survival of 4.7 months vs 1.8 months, respectively (Neal et al. 2017). Finally, a case report 
of a NSCLC patient featuring EGFR L858R and T790M mutations, and acquired MET mutations 
after treatment with osimertinib, showed that combination of osimertinib and cabozantinib can 
increase survival, but selected resistant MET D1228N clones (Kang et al. 2017).  
 Clinical development of foretinib was slower than cabozantinib. However, a phase I 
study showed that 55% of patients with medullary thyroid carcinoma treated with foretinib 
presented stable disease with a mean duration of 4 months (Eder et al. 2010). Phase II trials 
also revealed that foretinib treatment resulted in 30-50% stable disease in advanced breast and 
squamous cell carcinoma of the head and neck, respectively (Rayson, et al. 2016, Seiwert et al. 
2013). Also, a phase I study with foretinib in combination with erlotinib in NSCLC patients 
showed that 17.8% showed a partial response and 46.4% had stable disease with an average 
duration of 4.8 months. However, no particular oncogene mutation was associated with these 
responses (Leighl et al. 2017). 
 In 2011, Zillhardt et al. had shown that foretinib is able to inhibit proliferation and 
metastasis of ovarian cancer by inducing detachment of the cells and G2/M cell cycle arrest, 
which consequently resulted in apoptosis. In addition, another study in chronic myelogenous 
leukemia also showed that foretinib treatment resulted in G2/M cell cycle arrest, which resulted 
in a caspase-2 induced cell death in addition to the degradation of the kinase PLK1 via JNK 
pathways (Dufies et al. 2011). 
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Preliminary data  
 Through viability-based cellular drug screening across 26 NSCLC cell lines, we 
observed that despite the similarity of the chemical structures of foretinib and cabozantinib, 
foretinib was more potent than cabozantinib across a broad range of NSCLC cells (Fig. 30). In 
addition, foretinib’s cellular activity appeared to be independent of the inhibition of MET and/or 
VEGFR-2 since no inhibition of cell viability was observed with treatment of PF-04217903 and 
motesanib, potent inhibitors of MET and VEGFR-2, respectively. Furthermore, this activity was 
not correlated with the genetic background of these cells (Zou et al. 2012, Polverino et al. 2006, 
Kapur et al. 2014). 
      
Fig. 30: Compound screening data for foretinib and cabozantinib in NSCLC cells. Displayed above 
the table are the IC50 values for MET and VEGFR-2, known targets of foretinib (FORE) and cabozantinib 
(CABO), as well as of motesanib (MOTE - VEGFR-2 inhibitor) and PF-04217903 (PF - MET inhibitor). 
Readout was done after 72 hours of treatment with two doses of each compound (0.5 and 2.5 µM) in a 
total of 26 NSCLC cells with variable genetic background. Yellow represents lower cellular viability 
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Experimental Design 
 Based on our observations of different cellular activity between foretinib and 
cabozantinib in NSCLC, which is independent of their cognate/intended targets, we decided to 
further study the difference of the molecular mechanism between these two chemical 
analogues. 
 First, we generated dose-response curves for inhibition of viability of foretinib, 
cabozantinib, motesanib and PF-04217903 in 12 NSCLC cell lines to confirm the screening data 
and determine IC50 values. We also investigated the levels of phospho-MET and MET 
expression in 8 of these NSCLC cell lines.  
 We confirmed the activity of foretinib and cabozantinib in cells through inhibition of 
phospho-MET in comparison to treatment with PF-04217903, a potent and selective MET 
inhibitor. In addition, we also confirmed the cellular activity of cabozantinib by co-treatment of 
cabozantinib with verapamil, an efflux pump inhibitor, in a lung cancer cell line dependent on 
MET signaling. 
 Changes in signaling upon treatment of foretinib and cabozantinib were investigated with 
western blotting for phospho-tyrosine and phopho-AKT (Ser473). 
  We confirmed inhibition of viability on A427 cells, which are adherent cells, through a 
crystal violet based clonogenic assay. In this assay, cells were plated sparsely, so we could 
observe possible inhibition of colony formation upon treatment with foretinib and cabozantinib. 
In addition, we investigated, if foretinib or cabozantinib induced cell death by apoptosis. We 
analyzed western blots for PARP1 and caspase 3/7 cleavage, as well as quantified the 
fluorescence-detected activation of caspase 3/7 using automated fluorescence microscopy.  
 As the underlying MoA of foretinib was independent of its cognate targets we applied an 
unbiased, multi-layered systems pharmacology approach to identify the mechanistically relevant 
targets and pathways. 
 The direct target profiles of foretinib and cabozantinib were determined by compound 
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centric chemical proteomics. Kinase binding was evaluated based on the normalized spectrum 
abundance factor (NSAF) and compared with ABPP data. Since for foretinib there are kd values 
published, we used these available data to assist target prioritization. 
 The differential changes in signaling between foretinib and cabozantinib were studied by 
phosphoproteomics in H1155 cells, which included the label free pY proteomics (enrichment 
with phospho-tyrosine antibody) as well as TMT-6 plex-based global phosphoproteomics 
(enrichment with IMAC). 
 To complete our understanding in the changes in cellular signaling by foretinib, we also 
performed RNA-seq in the H1155 cells to investigate changes in gene expression.  
 Gene Set Enrichment Analysis was performed to integrate the three big data sets, 
chemical proteomics, phosphoproteomics and RNA-seq, and better determine differences in 
signaling pathways between cabozantinib and foretinib, which would support the difference in 
the mechanism of action. 
 Finally, the biological relevance of selected targets within these pathways was confirmed 
using tool compounds and RNA interference, as single treatment or in combination, to mimic the 
effects of foretinib in these cells. In addition, changes in downstream signaling of the foretinib 
targets were investigated via western blots or flow cytometry.  
 However, even though foretinib is more potent than cabozantinib in NSCLC, the cellular 
effect of foretinib is observed with relative high doses of treatment (0.1 - 1 µM). We therefore 
designed drug combinations to enhance foretinib’s cellular effect and decrease its concentration 
to match published plasma concentrations.  
 Because AURKB, one of the key targets of foretinib that we identified in the course of 
our study, has been shown to be biologically relevant in MYC-amplified small cell lung cancer 
(SCLC) cells, we investigated the effects of foretinib alone and in combination with barasertib 
(AURKB inhibitor) in SCLC cells. First, we generated dose-response curves of foretinib, 
cabozantinib, motesanib and PF-04217903 for inhibition of viability to confirm that foretinib’s 
73 
 
effect in SCLC was independent of VEGFR-2 and MET inhibition. Drug synergy was 
investigated through viability assays of combination of foretinib with barasertib, followed by 
western blotting for PARP1 and caspase 3/7 cleavage to confirm cell death by apoptosis. 
 
Materials and Methods 
Cell Culture 
The NSCLC cell lines - H1155, A427, H3122, H2170, Calu3, H23, H1437, HOP62, 
A549, H1299, HCC4006, H322, H2342, H157, Calu6, H1395, H650, HCC2935, H1648, H661 
and H2122 -  and the SCLC cell lines – H82, SW210.5, 16HV, H524, H69, DMS79, DMS114, 
86M1, H209 and N417 - were provided by the Moffitt Lung Cancer Center of Excellence Cell 
Line Core after been tested negative for mycoplasma and authenticated by short tandem repeat 
(STR) analysis. Cells were cultivated in RPMI-1640 media with 10% FBS (complete RPMI) and 
maintained in the incubator with 5%CO2 at 37°C.  
Compounds 
Foretinib (GSK1363089, EXEL2880, XL880; Chemietek), cabozantinib (XL184, BMS-
907351; Chemietek), motesanib free base (AMG-706; Selleckchem), PF-04217903 
(Selleckchem), barasertib (AZD1152-HQPA; Selleckchem), trametinib (GSK1120212; 
Chemietek), GSK1838705A (Selleckchem), PF-573228 (Selleckchem), linsitinib (OSI-906; 
Chemietek) and alisertib (MLN-8237; Selleckchem) were dissolved in DMSO (10 mM). Drug 
dilutions were made in DMSO as necessary. 
Viability assays  
To guarantee a confluence of approximately 90-95% after 3 days of treatment with 
DMSO, cells were generally plated with a density of 1,000 cells per well in a black, clear bottom 
384 well tissue culture plate (Fisher). A549 cells were plated with a density of 500 cells per well. 
After 24 hours, cells were drug treated and incubated for an additional 72 hours. Inhibitors were 
diluted in complete RPMI media to the desired final concentration as described in each 
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experiment. The viability of cells was measured with CellTiter-Glo Luminescent Cell Viability 
Assay reagent (Promega), which was added to the plates as 15 µl per well of 1:25 diluted stock. 
Plates were shaken at 400 rpm for 2 minutes and placed in the dark for another 10 minutes. A 
M5 Spectramax plate reader (Molecular Devices) using 500 ms integration was used to collect 
the data. Data was analyzed using GraphPad Prism and R. Values were normalized to the 
DMSO control of each drug dilution.  
Crystal violet assay 
A427 cells were plated at a density of 3,000 cells per well in a 6-well plate. After 24 
hours, cells were treated as indicated with complete RPMI media and were grown for an 
additional 9 days. Cells were fixed with 1 ml of methanol and stained with 0.1% crystal violet 
solution. Plates were imaged on a tabletop scanner. Crystal violet was extracted using methanol 
and quantified on a M5 Spectramax plate reader (Molecular Devices) using a readout of 540 
nm. Data was analyzed using GraphPad Prism. 
Cell cycle analysis 
H1155 and A427 cells were plated at a density of 4.5 x 105 cells per well. After 24 hours, 
cells were treated as indicated with complete RPMI media for 6 hours. Cells were harvested and 
incubated with Accutase (Fisher) for 5 minutes to disrupt cell aggregation. Cells were fixed with 
ice-cold 70% ethanol until use. Cells were stained with DAPI (4’,6-diamidino-2-phenylindole; 
Sigma D9542)/ 0.1% Triton X-100/PBS solution at a final concentration of 1 µg/ml. Cells were 
analyzed using a FACSCanto II benchtop analyzer (BD Biosciences) at 340 to 380 nm. Data 
was analyzed using ModFitLT V3.2.1 and Excel.  
Quantification of caspase 3/7 by fluorescence microscopy  
H1155 and A427 cell lines were plated at 1,000 cells per well in a black, clear bottom 
384 well tissue culture plate (Fisher). After 24 hours in the incubator, cells were treated as 
indicated with complete RPMI media containing 5 µM of Incucyte Caspase 3/7 reagent (Essen 
Bioscience #4440). Plates were placed in the Incucyte and scanned every 2 hours for green 
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fluorescence and in the phase channel up to a total of 72 hours. Experiments were done in 
technical triplicate and biological triplicate. Data was analyzed using the Incucyte Zoom 
software, which determined the phase and green object confluence of each well. Green object 
confluence was normalized to the phase object confluence. Further analyses were performed 
using GraphPad Prism.  
Immunoblotting 
Cells were lysed with lysis buffer (0.20% NP40, 50 mM Tris pH 7.5, 5% Glycerol, 1.5 mM 
MgCl2 and 100 mM NaCl) plus Roche cOmplete protease inhibitor cocktail and phosphatase 
inhibitor cocktail 2 (Sigma, #P5726). Lysates were separated by SDS-PAGE and 
immunoblotting was performed with primary antibodies against actin (Sigma, A5441), 
pMET(T1234/1235) (D26)XP (Cell Signaling, #3077), MET (D1C2)XP (Cell Signaling #8198), 
pAKT(S473) (Cell Signaling, #9271), Akt (Cell Signaling, #9272), p44/42MAPK(ERK1/2 - 
T202/204) (E10) (Cell Signaling, #9106), ERK1/2/MAP-Kinase (Sigma, #M5670), pY100 (Cell 
Signaling, #9411), FER (5D2) (Cell Signaling, #4268), pHistone H3(S10) (D2C8)XP (Cell 
Signaling, #3377), Histone H3 (D1H2)XP (Cell Signaling, #4499), cleaved caspase-3 (Asp175) 
(Cell Signaling, #9661), PARP1 (Cell Signaling, #9542), Aurora B/AIM-1 (BD Bioscience, 
#611082), pFAK(T397) (D20B1) (Cell Signaling, #8556), FAK (D2R2E) (Cell Signaling, 
#130095), c-Myc (9E10) (Thermo Science, MA1-980), pDelta-catenin(Y904) (Cell Signaling, 
#2910), Delta-catenin 1 (Cell Signaling, #4989). Secondary antibodies were anti-rabbit and anti-
mouse (GE Healthcare). Images were acquired using an Odyssey FC Imager (LI-COR) and 
quantified using Image J. 
Immunoprecipitation 
H1155 cells were plated at 4.5 x 106 cells per 100 mm dish/sample. After 24 hours, cells 
were treated as indicated for 3 hours. Lysates were prepared using the lysis buffer described 
above in the immunoblotting method. For each sample, 50 µl of Protein A/G beads Plus - 
Agarose (Santa Cruz, #sc-2003) was incubated horizontally at 4°C with 2 µl of pY100 (Cell 
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Signaling, #9411) antibody or normal mouse IgG (Santa Cruz, #sc-2025) for 4 hours.  Beads 
were washed three times with 1 ml lysis buffer, with spins at 1,000 xg for 1 minute at 4 °C 
between washes. A small portion of total cell lysate (TCL-100 µg) of each sample was kept 
aside to test for the presence of the protein of interest. The other 1 mg of protein of each sample 
was added to the coated beads and rotated at 4°C overnight. Subsequently, beads were spun 
at 1,000 xg for 2 minutes at 4°C and washed four times with 1 ml lysis buffer, again with spins at 
1,000 xg for 1 minute at 4°C between washes. The elution was performed by adding 20 µl of 4x 
Laemmli buffer, and denaturation at 90°C. Samples were spun at 14,000 xg for 1 minute and 
analyzed by SDS-PAGE, in comparison to the TCL samples. Immunoblotting was performed 
using the FER (5D2) (Cell Signaling, #4268) antibody. 
RNA interference 
siRNA SMART pool (Dharmacon) stocks were re-suspended at 20 µM with 1x siRNA 
buffer (1:5 Thermo Scientific 5x siRNA Buffer (B-002000-UB-100) with RNase-free water (B-
002000-WB-100)) and shaken at 37 °C for 1 hour. siRNA stocks were diluted to the desired final 
concentration in OptiMEM media (Fisher 31985062), depending of the cell line (Table 8), and 
incubated for 5 minutes. siRNA was incubated for additional 20 minutes in the respective well 
with the lipofectamine mix (OptiMEM media plus lipofectamine mix) at 1:1 ratio. For the A427 
cell line we used lipofectamine RNAiMax (Fisher 13-778-150) and for H1155 we used 
lipofectamine 2000 (Fisher 11668019).  A427 and H1155 cells were plated at 1.5 x 105 cell per 
well, left to attach for 24 hours and treated with trametinib (35 nM) or DMSO. Cells were 
counted with trypan blue (Sigma) in triplicate after 72 hours of treatment. Data was analyzed 
using Microsoft Excel and R. Leftover samples were used to confirm knockdown by western 
blotting. Additional wells were plated for the siAURKB and siNT, which were treated with 50 
mg/ml of nocodazole for 18 hours before harvest; samples were used for western blot analysis 
for AURKB.  All the samples received the same concentration of siRNA; non-target siRNA 
(siNT) was used to balance the amount of siRNA in all samples to match the concentration of 
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the double knockdown sample.  
Table 6. siRNA information provided by Dharmacon 
 
siRNA Final Concentration in cells 
ON-TARGET plus Non-target Pool (D-001810-10-20) 100 nM – H1155 
  40 nM – A427 
ON-TARGET plus Human MAP4K5 (11183) – SMARTPOOL 
(L-003589-00-0005) 
20 nM – H1155 
 
ON-TARGET plus Human AURKB (9212) – SMARTPOOL  
(L-003326-00-0005) 
80 nM – H1155 
20 nM – A427 
ON-TARGET plus Human FER (2241) – SMARTPOOL  
(L-003129-00-0005) 
20 nM – H1155 
20 nM – A427 
 
Kinase assays 
In vitro kinase inhibition assays were performed for two doses of foretinib and 
cabozantinib (0.05 µM and 0.25 µM); and IC50 values were determined using 10 µM ATP and a 
3-fold drug dilution series. Assays were performed in duplicate. The Reaction Biology Kinase 
Hotspot platform was used to determine the IC50 for the Aurora kinases (A/B/C) and MAP4K5, 
as well the two dose inhibition assay for MAP4K5. The Eurofins platform was used to determine 
the two dose inhibition for MET, CSK, cSRC, FAK, FER, JNK2α2, LYN and YES, Aurora kinase 
B, DDR2, IGF1R, IR and MEK1. IC50‘s for cSRC, DDR2, FER, LYN, MEK1 and YES were also 
determined on the Eurofins Kinase Profiler™ platform.  
Activity-based probe profiling (ABPP) 
The ATP-probe-based ABPP was performed using the PierceTM Enrichment Kit ATP 
Probe (ThermoFisher Scientific, # 88310). H1155 cells were lysed using a 10 M urea/Pierce IP 
lysis buffer containing protease and phosphatase inhibitors (1:100). Samples were sonicated for 
1 minute and then incubated for 10 minutes on ice. Samples were centrifuged at 16,000 rpm at 
4°C for 10 minutes. Buffer exchange was performed using Zeba spin desalting columns, which 
were prepared following manufacters instructions, and protein concentration was determined 
using Coomassie protein assay reagent (ThermoFisher Scientific). Extra  protease and 
phosphatase (1:100) was added to the lysates. Lysate was divided into 6 samples of 1 mg of 
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protein (duplicates of DMSO, cabozantinib and foretinib treatment) and 10 ul of 1 M MnCl2 were 
added to each sample. 20 µM of DMSO, foretinib or cabozantinib was added to the respective 
tubes and rotated for 15 minutes at room temperature. Desthiobiotin-ATP was added to each 
sample at a final concentration of 5 µM and incubated for 15 minutes at room temperature. 
Reduction and alkylation were performed as described by the manufacturer. Trypsin digestion 
(20 µg/µl) was performed at 37°C overnight. The 50% high capacity streptavidin agarose resin 
slurry (50 ul) was added to each sample and rotated for 1 h at room temperature. After washes, 
peptide elution was performed by adding three times 100 µl of elution buffer (50% ACN, 0.1% 
trifluoroacetic acid (TFA) to each sample. Samples were frozen and lyophilized in the speedvac. 
Samples were resuspended in 20 µl of 2% ACN in 0.1% TFA solution containig Thermo 
Scientific Pierce Retention Time Calibration Mixture (PRTC) in order to confirm correct 
operation of the LC-MS instrument. 
A nanoflow ultra high performance liquid chromatograph (RSLC, Dionex) coupled to an 
electrospray benchtop Orbitrap mass spectrometer (Q-Exactive plus, Thermo) was used to 
acquire MS/MS peptide sequences. The samples were loaded onto a pre-column (2 cm x 100 
µm ID packed with C18 reversed-phase resin, 5 µm, 100 Å) and washed for 8 minutes with 
aqueous 2% ACN and 0.04% TFA. The captured peptides were eluted onto the analytical 
column, (C18, 75 µm ID x 50 cm, 2 µm, 100 Å, Dionex). A 120-minute gradient was programmed 
as: 95% solvent A (2% ACN + 0.1% FA) for 8 minutes, solvent B (90% ACN + 0.1% FA) from 
5% to 38.5% in 90 minutes, then solvent B from 50% to 90% B in 7 minutes and held at 90% for 
5 minutes, followed by solvent B from 90% to 5% in 1 minute and re-equilibration for 10 
minutes. The flow rate on the analytical column was 300 nl/min. Sixteen tandem mass spectra 
were collected in a data-dependent manner following each survey scan. Both MS and MS/MS 
scans were performed in the Orbitrap part to ensure accurate mass measurement using 60 
second exclusion for previously sampled peptide peaks. Each sample was injected twice 
(technical replicates).  
79 
 
Samples were queried using MaxQuant 1.2.2.5. The fragment tolerance for MS/MS 
scans was set to 20 ppm. Desthiobiotin was set as a fix modification. The false discovery rate 
(FDR) was set to 0.05. All-ion fragmentation (AIF) was set to a correlation of 0.8 and the 
threshold for AIF FDR to 0.01.  
Chemical proteomics (CCCP) 
H1155 and A427 cells were lysed with the same buffer as described on the 
immunoblotting methods. Pulldowns were performed as described in the materials and methods 
section of chapter 2. Beads were incubated with 2.5 µl of c-foretinib or c-cabozantinib. Pre-
treatment was performed by incubating cell lysates with 20 µM of foretinib and cabozantinib. 
Experiments were performed in duplicate (H1155) or triplicate (A427) using 5 mg protein per 
pulldown. The samples were analyzed on a hybrid LTQ-Orbitrap mass spectrometer (Thermo 
Fisher) coupled to a nanoflow liquid chromatograph (PSLC, Dionex). Data was searched with 
Mascot (Matrix Science) against SwissProt 2015 (Dez.) and SwissProt 2016 (Jul.) for human 
protein database for H1155 and A427, respectively. For both searches, two missed trypsin 
cleavages were allowed. Carbamidomethylation of cysteine and methionine oxidation were 
selected as variable modifications. Results were transferred to Scaffold 4.0 and data was 
analyzed setting the minimum number of peptides as 2 and the protein and peptide threshold at 
95%. 
Phosphoproteomics 
For each of the six samples (foretinib, cabozantinib and DMSO – in duplicate), eleven 
150 mm dishes were plated with 1.5 x 107 H1155 cells. After 24 hours, plates were treated with 
1 µM of foretinib or cabozantinib for 3 hours; DMSO was used as control. Cells were harvested, 
washed with phosphate-buffered saline (PBS) and pellets from each treatment were combined. 
Phosphoproteomic samples were prepared following the PTMScan Kit Protocol (Cell Signaling). 
Cells were lysed with 5 ml of urea lysis buffer (20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium 
orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophophate) and sonicated three 
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times for 30 seconds using a Bradson sonifier disruptor 200 (output control: 1.5 and pulse: 35). 
Cells were left on ice for 1 minute between sonications. Samples were centrifuged at 10,000 xg 
for 30 minutes at 15°C. Protein concentration was determined using Coomassie protein assay 
reagent (Thermo Scientific). For reduction and alkylation, 1/278 volume of 1.25 M DTT was 
added to the lysates, mixed and incubated for 30 minutes at 55°C. Once at room temperature, 
1/10 volume of 100 mM iodoacetamide was added and incubated for 15 minutes at room 
temperature in the dark. Samples were diluted 3-fold with 20 mM HEPES (pH 8.0) to a final 
concentration of 2 M urea in each sample. Protein digestion was performed by adding 1/50 
volume of 2 mg/ml trypsin-TPCK (Worthington, #LS003740) in 1 mM HCl overnight at room 
temperature to each sample.  
Peptide purification was performed using Sep-Pak® C18 columns. Samples were 
acidified with 1/20 volume of 20% TFA to a final concentration of 1% TFA. Samples were 
centrifuged for 15 minutes at 1,780 xg at room temperature before being added to Sep-Pak 
columns (Waters WAT051910), which were prepared by washing with 5 mL of 100% ACN 
followed by sequential washes with 1 mL, 3 mL and 6 mL 0.1% TFA. After adding the peptide 
supernatant, columns were sequentially washed with 1 mL, 5 mL and 6 mL of 1 % TFA followed 
by a wash with 2 mL of 0.1 % TFA / 5% ACN. Elution of peptides was performed by washing the 
columns three times with 2 mL of 0.1% TFA / 40 % ACN. Eluates were collected in the same 
tube and then aliquoted for pY enrichment (20 mg per sample) or global phosphoproteomics 
(400 µg per sample). Samples were frozen at -80 °C overnight and lyophilized for two days to 
ensure that there was no TFA left in the samples.  
Tyrosine phosphoproteomics  
To collect the lyophilized peptides, samples were centrifuged for 5 minutes at 2,000 xg 
at room temperature. Samples were resuspended in 1.4 ml of immunoaffinity purification buffer 
(IAP, PTMScan IAP Buffer (10x) – Cell Signaling #9993, diluted to 1x with HPLC-grade water) 
and incubated for 5 minutes. Pellets were resuspended with a P1000 slowly to avoid bubbles 
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and the pH was checked to be close to neutral and not below 6.0. The peptide solution was 
centrifuged at 10,000 xg for 5 minutes at 4°C and kept on ice until beads were ready. Antibody-
beads [PTMScan® Phospho-Tyrosine Rabbit mAb (P-Tyr-1000)Kit, Cell Signaling #8803] were 
washed four times with 1 mL PBS and centrifuged at 1,000 xg at 4°C for 1 minute after each 
wash. Beads were re-suspended in 40 μl of PBS and the peptide solution was added to vials. 
Samples were sealed with parafilm and incubated for 2 hours at 4°C. Samples were centrifuged 
at 1,000 xg for 1 minute and supernatant was discarded. Beads were washed twice with 1 ml of 
IAP buffer and three times with 1 ml of HPLC-grade water; samples were centrifuged at 1,000 
xg for 1 minute between washes and supernatant was removed. Peptides were eluted with 100 
μl of 0.15% TFA after incubation for 10 minutes at room temperature, with mixes every 2 
minutes. After centrifugation for 1 minute at 1,000 xg, supernatant was collected into the 
respective tubes. Samples were evaporated using a speed vacuum centrifuge and resuspended 
in 2% ACN / 0.1% FA, which contained 5 fmol/µl of PRTC (Thermo Scientific Pierce Retention 
Time Calibration Mixture, PIERCE).  
Global phosphoproteomics  
TMT 6-plex was performed following the TMT Mass Tagging Kits and Reagent 
Instruction (Thermo Scientific Mass Tagging Kit, #90064). Lyophilized samples were 
resuspended with 200 µl of TEAB buffer (triethyl ammonium bicarbonate in HPLC-grade water) 
and vortexed for 30 minutes. TMT reagents were brought to room temperature and 41 µl of 
100% ACN was added to each 0.8 mg tube of the reagent (labels: 126, 127, 128, 129, 130, 
131), vortexed and incubated for 5 minutes at room temperature. Two of each label was added 
to one type of sample (126 and 127 – DMSO1/2; 128 and 129 – foretinib1/2; 130 and 131 – 
cabozantinib1/2) and incubated for 1 hour at room temperature. Label efficiency was confirmed 
by injecting approximately 2 µg of peptides into the LC-MS; all samples showed more than 
99.4% labelling efficiency. Reactions were quenched by adding 5% hydroxylamine to the 
sample and incubated for 15 minutes. Samples were combined and lyophilized overnight. 
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Samples were re-dissolved with 350 µl of 20 mM of ammonium formate (pH 10.0), vortexed for 
10 minutes and fractionated into 12 fractions. Peptides were lyophilized and pSTY peptides 
were enriched using an IMAC enrichment kit (Sigma I1408). Peptides were resuspended in 300 
µl of binding buffer and vortexed for 20 minutes. Samples were loaded on an equilibrated resin 
(20 µl of beads and 40 µl of resin) and incubated for 30 minutes at room temperature. Samples 
were centrifuged at 1,000 xg for 1 minute, supernatant was saved separately, and beads were 
washed twice with washing buffer 1 and 2, followed by one wash with HPLC-grade water. 
Samples were centrifuged at 1,000 xg for 1 minute at room temperature between washes. 
Peptides were eluted twice using the elution buffer (5 mM ammonium hydroxide, 5% ACN) after 
5 minutes incubation each. Eluates were combined and spun for 2 minutes at higher speed. 
Eluates were evaporated using a speed vacuum centrifuge and resuspended in 2% ACN / 0.1% 
FA to yield a protein concentration of 50 fmol/μL. Samples were spiked with PRTC. 
Mass spectrometry analysis  
Mass spectrometry analyses were performed as described for ABPP methods. pY and 
IMAC data were queried against the MaxQuant 1.2.2.5 and 1.5.2.8 database, respectively. The 
fragment tolerance for MS/MS scans was set to 20 ppm. Fixed modifications were 
carbamidomethylation of cysteine; variable modifications were set to oxidation of methionine 
and acetylation of the protein N-terminus. The false discovery rate (FDR) was set to 0.05. All-ion 
fragmentation (AIF) was set to a correlation of 0.8 and the threshold for AIF FDR to 0.01.  
RNA-Seq 
H1155 cells were plated at a density of 0.5 x 106 cells in a 35 mm dish/treatment. After 
24 hours, cells were treated with 1 µM of foretinib or cabozantinib for 4 hours and then 
collected, pelleted and kept on -80°C until all biological triplicates were harvested. DMSO 
treatment was used as control. RNA was extracted following manufacturer instructions (RNeasy 
Mini Kit – Qiagen, #74104), with the addition of an extra DNase digestion step to increase the 
quality of the RNA. This digestion was performed following the method in appendix E: DNase 
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digestion of RNA before RNA cleanup from the RNase-Free DNase Set (Qiagen, #79254). To 
87.5 µl of RNA sample was added 10 µl Buffer RDD and 2.5 µl DNase I stock solution (provided 
by the Moffitt’s Molecular Genomics Core). The sample volumes were brought up to 100 µl with 
RNase-free water and incubated at room temperature for 10 minutes before proceeding with the 
cleanup protocol of the RNeasy Mini Kit (Qiagen). Also, to assure better quality of RNA and to 
eliminate salt from the buffers, we performed an ethanol precipitation after RNA extraction. The 
volume of each sample was brought up to 200 µl and 1/10 volume (20 µl) of 5 M NaCl plus 2.5 
volumes (500 µl) of absolute ethanol were added prior to thorough vortexing. Samples were 
centrifuged at 1,000 xg for 10 minutes; the supernatant was discarded and pellets were washed 
with 500 µl of freshly diluted 75% ethanol in RNase-free water. Samples were centrifuged again 
at 1,000 xg for 10 minutes, supernatant was discarded, and samples were left to air-dry. 
Samples were resuspended in RNase-free water and analyzed by Nanodrop to verify the 
260/280 and 260/230 ratio > 1.8 and ~2.0. Before cDNA synthesis, RNA quality and quantity 
were verified by Agilent RNA Screen Tape System and Quant-iT Assays (Invitrogen). This 
verified the size, quantity and quality of the samples; it confirmed that the samples had not 
degraded during extraction and cleanup. Quant-iT was used to quantify the RNA in the samples 
and 100 ng per sample were used to start the cDNA synthesis. RNA-Seq library generation was 
performed following the Encore Complete RNA-Seq Library System protocol (Nugen). The 
KAPA library amplification kit for Illumina platform (KAPABiosystem) was used as described in 
the technical data sheet.  Beads were resuspended in 20 µl of elution buffer. RNA-Seq was 
performed on Illumina NextSeq 500 and htseq-count was used to count reads that were 
mapped to the genes. 
Data analysis 
Based on the scatterplot densities, a log2 abundance of 7.5 was selected as cutoff for 
the analysis of RNA-Seq data to avoid abundance noise. The selection criteria were: 1) either 
treatment group average must be > 7.5; 2) t-test < 0.01; 3)│fold change│≥ 1.5; 4) Hellinger 
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distance > 0.25. Genes that were significantly regulated in at least 1 of the 3 comparisons – fore 
vs DMSO + cabo, fore vs DMSO or fore vs cabo – were selected for further analysis. 
All MaxQuant proteomics analysis files were first filtered for peptides with PEP score < 
0.05. In addition, peptides were excluded, if the sum intensity was zero and/or contained (+) on 
the reverse sequence column. Data were then normalized using IRON (iterative rank-order 
normalization) (Welsh et al. 2013). Our analyses mainly focused on the comparison between 
foretinib versus cabozantinib treatment.  
In the ABPP analysis, first the technical duplicates were averaged within themselves, 
and then averaged between biological duplicate. Peptides with │fold change│ ≥ 1.5 and p-value 
< 0.05 were kept for further analysis.  
For the pY proteomics, after averaging between replicates, peptides with p-value < 0.1 
were used for further analysis. In addition, to overcome the missingness between duplicates in 
the dataset, we manually rescued peptides that 1) each treatment had 3 values for and the 
difference between them were less than 50%; 2) one treatment had 3 or 4 values for and the 
other only 2, but the ratio between the two values was less than 1.5 and the difference between 
treatment were less than 50%; 3) one treatment had 3 or 2 values for and the other treatment 
none. The cutoff for the global proteomics was +/- 2 average standard deviations.  
Kinases specifically binding to foretinib over cabozantinib in CCCP were prioritized using 
foretinib’s NSAF (normalized spectrum abundance factor) > 0.005 as additional criteria. We also 
compared the fold change between the two treatments, taking into consideration the available 
Kd values from the HMS (Harvard Medical School) LINCS (Library of Integrated Network-Based 
Cellular Signatures) dataset.  
Integrated data analysis of OMICS data was performed by entering the gene names into 
the GSEA database (Broad Institute) and querying canonical pathways and gene ontology (GO) 
gene sets, which included GO biological process, GO cellular component and GO molecular 
function. Data was exported to Excel, analyzed and visualized in R. 
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Chemical synthesis (performed by Moffitt Chemical Biology Core, Chemistry Unit) 
See Appendix E. 
Results and Discussion 
 Dose-response curves for inhibition of viability were determined and confirmed the 
differential potency between foretinib and cabozantinib (Fig. 31). Furthermore, several cell lines, 
including the most sensitive one to foretinib (H1155), did not express active MET signaling, as 
determined by western blot for phospho-MET (Fig. 32a). H1648 cells, which were moderately 
sensitive to foretinib (IC50 = 1.6 µM), were used as a positive control based on high expression 
of MET. Importantly, foretinib and cabozantinib, both potently reduced phosphorylation of MET 
in H1648 cells as did the MET inhibitor PF-04217903 (Fig. 32b). Taken together, this evidence 
supports the hypothesis that the mechanism of action of foretinib is independent of MET or 
VEGFR-2 signaling in these cells. 
 To confirm that cabozantinib was an active compound, we performed a dose-response 
curve for inhibition of viability of foretinib, cabozantinib, PF-04217903 and motesanib in EBC1 
cells, a lung cancer cell line reported to be dependent on MET signaling. As expected, since 
cabozantinib was able to decrease phospho-MET in the H1648, cabozantinib, as well as 
foretinib and PF-04217903, decreased cellular viability of EBC1 cells (Fig. 33a). In addition, to 
confirm that the lack in cellular activity of cabozantinib in other NSCLC cells was not a result of 
drug efflux mechanisms, we treated EBC1, H1155 and A427 cells with verapamil (efflux pump 
inhibitor) in combination with cabozantinib. We observed that the combination treatment 
increased cabozantinib’s cellular efficacy in EBC1 cells, which indicates that inhibiting the efflux 
pump proteins increases cabozantinib’s intracellular concentration (Fig 33b). However, no 
change in the viability curve was observed in the H1155 or A427 cells confirming that differential 
drug efflux of foretinib and cabozantinib is unlikely to be responsible for their differential cellular 
activity. (Fig. 33c, d). The slight decrease in viability in the A427 cells is the result of the effect 
of single agent verapamil in this cell, since the first point in the combination curves represents 
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the treatment with only verapamil (20 µM and 50 µM).  
 
Fig.31: Cellular viability of NSCLC cells comparing foretinib and cabozantinib. Dose response 
curves of foretinib, cabozantinib, PF-04217903 (MET inhibitor) and motesanib (VEGFR-2 inhibitor) after 
72 hours treatment and their respective IC50 values [µM]. Experiments were done as biological triplicates, 
except for the bottom three cell lines (H1944, H460 and HCC2935), which were performed as singlicates. 
Each replicate contained their technical replicates. 
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Fig. 32: Representative western blot of pMET (Y1234/1235) levels. A. Western blot of phospho-MET 
in several NSCLC cells. H1648 is used as control since they express high levels of MET protein. B. Dose 
response western blot of phospho-MET in H1648 cells after 1 hour treatment with 0.01 µM and 0.1 µM of 
foretinib (FORE), cabozantinib (CABO), PF-04217903 (PF) and 0.1 µM of motesanib (MOTE). 
 
 
Fig. 33: A. Dose response curves of foretinib (FORE), cabozantinib (CABO), PF-04217903 (PF- MET 
inhibitor) and motesaninb (MOTE – VEGFR-2 inhibitor) in EBC1 cells, which are MET signaling 
dependent. B, C and D. Dose response curves of cabozantinib (CABO) alone and in combination with 20 
µM or 50 µM of verapamil (efflux pump inhibitor) in the EBC1, H1155 and A427 cells, respectively. IC50 
values [µM] are displayed for each treatment. 
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 Finally, we investigated changes in tyrosine and serine phosphorylation upon treatment 
with foretinib and cabozantinib and noticed that foretinib more so than cabozantinib induced 
signaling changes in H1155 and A427 cells. Using a global phospho-tyrosine antibody, we 
observed that foretinib reduced phosphorylation more strongly than cabozantinib, especially in 
the H1155 cells. In addition, foretinib caused a more pronounced decrease of AKT 
phosphorylation (Ser473) in the H1155 and A427 cell lines than cabozantinib (Fig 34). 
                 
Fig. 34: Changes in protein phosphorylation levels in H1155 and A427 cells after 1 hour of drug 
treatment. Top panel: H1155 and A427 cells were treated with increasing doses of foretinib (FORE) or 
cabozantinb (CABO) as indicated, and blots were probed with a phospho-tyrosine antibody. Bottom 
panel: cells were treated with foretinib (FORE), cabozantinib (CABO), PF-04217903 (PF) or motesanib 
(MOTE) as indicated, and blots were probed for AKT phosphorylation (S473) and total AKT. Actin was 
used as loading control. 
 
 The differential cellular potency of foretinib compared to cabozantinib was confirmed by 
crystal violet assay on A427 cells. Foretinib inhibited the cellular growth in a dose dependent 
manner, while only slight effects on viability were observed with cabozantinib even at the 
highest dose (Fig 35a). In addition, foretinib, but not cabozantinib, induced apoptosis in H1155 
and A427 cells in a dose-dependent manner, as demonstrated by cleavage of PARP1 and 
caspase 3 (Fig. 35b). The induction of apoptosis by foretinib was confirmed by quantification of 
the fluorescence reagent for caspase 3/7 using the Incucyte live-cell imaging system (Fig. 35c). 
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Fig.35: A. Crystal violet assay in A427 cells. Cells were treated with the indicated doses of foretinib 
(FORE) and cabozantinib (CABO) for 10 days. Crystal violet dye was used to stain cells (left panel) and 
methanol was used to extract the dye, which was quantified using absorbance at 540 nm (right panel). B. 
Representative western blot for PARP1 and cleaved caspase 3. H1155 and A427 cells were treated with 
the indicated doses of foretinib (FORE) and cabozantinib (CABO) for 24 hours before harvest. 
Staurosporine (STAU) was used as positive control. C. Quantification of cleaved caspase 3/7 using 
fluorescence microscopy. H1155 and A427 cells were treated with 0.5 µM and 1 µM of foretinib or 
cabozantinib for 24 and 48 hours. Caspase 3/7 cleavage was measured by normalized green object 
confluence to the phase object confluence. The graph shows the changes in quantity of caspase 3/7 
cleavage after normalization to DMSO treatment. 
 
 To perform compound-centric chemical proteomics, tetherable analogues of foretinib (c-
foretinib) and cabozantinib (c-cabozantinib) were synthesized by Moffitt’s Chemical Biology 
Core through 8 and 6 chemical reaction steps, respectively (Fig. 36). CCCP was performed first 
with H1648 cells, which express high levels of MET. Western blotting of the eluates confirmed 
the retained ability of our tethered probes to bind MET. Consistently, pre-treatment with foretinib 
competed for the binding of MET and so no MET was found in the eluate of the competition 
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sample (Fig. 37a). In vitro kinase assays for MET are also used to confirm the activity of our 
probes in comparison with original foretinib and cabozantinib (Fig. 37b). This confirms that the 
addition of the linker to foretinib and cabozantinib was not interfering with their ability to bind to 
the cognate target, which suggests that it would also not interfere with the binding to any 
unknown targets.  
                        
Fig. 36: Synthetic scheme of tetherable compound analogues. A. Synthesis of c-cabozantinib (14). B. 
Synthesis of c-foretinib (24). 
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 Using chemical proteomics, a total of 89 kinases were detected, 41 of which had NSAF 
values > 0.005. Foretinb and cabozantinib shared most of their targets (Appendices F, G). 
However, foretinib appeared to be more potent for several of them, such as MAP4K5, CSK and 
FAK (Fig. 38a). This difference in potency of foretinib may be the result of more stable binding 
of foretinib in the ATP pocket of these kinases (Quian et al. 2009). Also, PERK (E2AK3), 
STK33, GSK3α, SMG1 and AMPKα1 were more predominantly pulled down by foretinib. 
However, these kinases showed only low NSAF (normalized spectrum abundance factor) 
values. Which indicates either low expression in the cells, low binding affinity to foretinib or both. 
Therefore, we used the available HMS (Harvard Medical School) LINCS (Library of Integrated 
Network-based Cellular Signatures) dataset (ID 20176) (Fabian et al. 2005, Davis et al, 2011), 
which contains dissociation constant (Kd) values for foretinib, to prioritize the differential targets 
between foretinib and cabozantinib. As observed in the specificity plot (Fig. 38b,c), PERK 
(E2AK3), STK33, GSK3α, SMG1 and AMPKα1 indeed present low Kds or the Kd was not 
determined (grey bubble).  
 
Fig. 37: Western blotting of drug affinity eluates using H1648 cells. A. Pulldowns were performed 
with c-foretinib (c-FORE) and c-cabozantinib (c-CABO), lysates were also pre-treated with foretinib (c-
FORE PT) or cabozantinib (c-CABO PT). TCL: total cell lysate. Eluates were probed for MET, the cognate 
target of cabozantinib and foretinib. B. Inhibition of MET activity: in vitro kinase assays for several doses 
of cabozantinib and foretinib and their tetherable analogues.  
 
 Interestingly, we did not observe any kinase that is mainly bound by foretinib over 
cabozantinib and shows high NSAF and low Kd values (dark grey highlighted area, upper right 
corner), supporting the statement that foretinib and cabozantinb have a very similar target 
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profile albeit with differential potency distribution. CSK, which was barely included in the dark 
grey highlighted area in the A427 target profile (Fig. 38c), presents a low Kd value (120 nM); 
and weak inhibition by foretinib in in vitro kinase assays (IC50 > 250 nM) (Fig. 38d). DDR2, 
according to its Kd one of the most potent binders of foretinib in H1155 cells (Fig. 38b) is not 
differentialy inhibited by foretinib and cabozantinib (Fig. 38d). MAP4K5 (M4K5) was the main 
detected kinase with high NSAF and low Kd (3.5 nM). However, RNA interference (siRNA) of 
MAP4K5 alone or in combination with cabozantinib did not have any effect on the viability of the 
cells, indicating that its inhibition does not account for the main difference in the mechanism of 
action between foretinib and cabozantinib (Fig. 38e). The next interesting targets, shared by 
H1155 and A427 cells with reasonable Kd and NSAF values were SRC, YES, MAP2K1/2 
(MEK1/2), and the Aurora kinases A and B (AURKA/B). 
 Finally, the comparison of foretinib and the pre-treatment samples in A427 cells 
confirmed that our analogue probes worked as expected since the highest fold change between 
c-foretinib (F) and pre-treated c-foretinib (PT) samples were obtained for MET and VEGFR-3, all 
known targets of foretinib. (Fig. 39a) These known targets of foretinib were not observed (MET) 
in H1155 or passed the defined cutoffs (VEGFR-3) supporting that foretinib’s mechanism in this 
cell line is independent of its cognate targets (Fig. 39b). 
 In an alternative approach, we also performed activity-based protein profiling (ABPP) of 
foretinib and cabozantinib in H1155 cells. A total of 195 kinase peptides were detected, 11 of 
which were discarded because of lack of intensity in DMSO (not activated in the cells), 32 
kinase peptides passed our cutoff and 8 of these were inhibited more strongly by foretinib than 
by cabozantinib (Appendix H). The comparison between foretinib and cabozantinib suggested 
MAP4K5, FER and MAP2K1 (MEK1) as main targets of foretinib that were specific over 
cabozantinb (Fig. 40a). In vitro kinase assays for foretinib and cabozantinib confirmed MEK1, 
YES, FER, AURKA and AURKB as the most differential targets between foretinib and 
cabozantinib with regard to potency (Fig. 40b). We included AURKB because one of the 
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detected peptides for AURKA (p-value = 0.059, fold change 0.6) in ABPP was also present in 
AURKB and in the CCCP dataset AURKB was more predominantly enriched from A427 cells 
than AURKA (Fig. 38c). 
        
Fig. 38: Chemical proteomics comparison between c-foretinib and c-cabozantinib. A. Kinome tree 
of foretinib (red) and cabozantinib (blue) targets presenting NSAF > 0.005. B and C. Specificity plot of the 
CCCP in H1155 and A427 cells; the y axis indicates the fold change between foretinib and cabozantinib 
(F/C) and the x axis is the NSAF for proteins presenting NSAF > 0.005 for foretinib (FORE) treatment. 
The highlighted dark grey areas represent high NSAF values and high fold change for F/C. D. In vitro 
kinase assays for CSK and DDR2 for two concentrations (0.5 and 2.5 µM) of foretinib (FORE, red) and 
cabozantinib (CABO, blue). E. H1155 viability assay by cell counting after treatment for 96 hours 
MAP4K5 siRNA and 72 hours of cabozantinib (CABO, 1 µM). siNT = non-targeting siRNA. All samples 
have the same amount of siRNA (20 nM), siNT was used to balance siRNA concentration in all samples. 
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Fig. 39: Chemical proteomics comparison between c-foretinib and pre-treated c-foretinib. A and B. 
Specificity plot of the CCCP in A427 (A) and H1155 (B) cells; displayed on the y axis is the fold change 
between foretinib and pre-treated foretinib (F/PT) and on the x axis is the NSAF for proteins presenting 
NSAF > 0.005 for foretinib (FORE) treatment. 
 
 
Fig. 40: A. Activity-based probe profiling (ABPP) analysis of foretinib vs cabozantinib. Annotated in the 
volcano plot, are the kinases presenting 1.5-fold change and p-values < 0.05, which also passed our 
cutoff in the CCCP dataset. Highlighted area represents the significant changes of foretinib vs 
cabozantinib treatment. B. Comparison of IC50 values for foretinib (FORE) and cabozantinib (CABO) for 
the suggested differential kinases by chemical proteomics.  
 
 In parallel to chemical proteomics, we performed global and phosphotyrosine 
phosphoproteomics to investigate signaling changes in H1155 cells after treatment with foretinib 
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and cabozantinib. In the label-free tyrosine phosphoproteomics dataset, a total of 484 peptides 
were detected, 250 of which had a PEP score < 0.05, and 108 passing the selection criteria 
(Appendix I). In the TMT-quantified global phosphoproteomics dataset, 9,934 peptides were 
detected, of which 8,819 presented a PEP score <0.05, and 409 peptides that passed our 
selection criteria were selected for further analysis (Appendix J). The waterfall plot (Fig. 41 a,b) 
comparing cabozantinib (blue) and foretinib (red) treatment showed multiple changes to be 
differential between cabozantinib and foretinib, such as in the palladin (PALLD), 
heterochromatin protein 1 (HP1A-CBX5), cyclin-dependent kinase 16 (CDK16/PCTAIRE1), 
DNA topoisomerase 2-alpha (TOP2A), mitogen-activated protein kinase 9 (JNK2), tyrosine-
protein kinases FER and LYN, and catenin delta-1 protein (CTNND1). No significant change 
was observed in GSK3α/β phosphorylation. We confirmed intensity for these peptides through 
extracted ion chromatogram analysis (Appendix K). 
 
Fig. 41: Phosphoproteomics data for H1155 cell after 3 hour treatment with 1 µM of foretinib and 
cabozantinib. A and B. Global (pSTY) and phosphotyrosine (pY) proteomics, respectively. Cabozantinib-
modulated peptides are represented in blue while foretinib-modulated peptides are shown in red. Proteins 
involved in pathways regulated by the indicated targets of foretinib in comparison to cabozantinib by 
CCCP were annotated.  
 
 HP1A interacts with the methylated lysine 9 of histone H3 through its N-terminus 
(Hiragami-Hamada et al., 2011). HP1A also binds to INCENP (inner centromere protein), which 
is part of the chromosomal passenger complex (CPC) with AURKB. The interaction of HP1A 
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and INCENP accelerates the activation of AURKB. Phosphorylated HP1A at Ser92 (S92) has 
been shown to be mainly bound in the CPC complex and localized at centromeres (Abe et al., 
2016).  
 TOP2A is a key protein in the strand passage reaction (SPR) that occurs towards the 
end of the chromosome segregation process. TOP2A is responsible for releasing the sister 
chromatids to allow cells to progress to anaphase (Edgerton et al. 2016). TOP2A is found in the 
centromere of kinetochores and facilitates the recruitment of the AURKB-CPC complex to the 
centromere. TOP2A is required for the phosphorylation of histone H3 at threonine 3 by Haspin 
kinases, a binding site for AURKB-CPC in the centromere during mitosis (Edgerton et al. 2016). 
In addition, in pancreatic cancer cells, TOP2A was associated with genes related to cell 
adhesion and cell cycle, which were regulated by β-catenin and correlated with migration (Pei et 
al., 2018)  
 CDK16 is a relative of the cyclin-dependent kinases, it has been reported to be involved 
in the spindle orientation in mitosis through an integrin-dependent mechanism (Iwano et al, 
2015). Phosphorylation of Ser119 leads to phosphorylation of lipoprotein receptor related 
proteins 6 (LRP6) and induction of Wnt-signaling in the G2/M phase of the cell cycle (Mikolcevic 
et al. 2011, Davidcon et al, 2009). Knockdown of CDK16 induced cell cycle arrest during 
mitosis, specifically in prometaphase, which results in cell death by apoptosis (Yanagi et al., 
2014, 2017). 
 PALLD is an actin-associated protein that is binding to proteins responsible for the 
organization and motility of the cytoskeleton (Parast et al., 2000, Mykkanen et al., 2001, Dixon 
et al., 2008). It is localized in focal adhesions, dense regions of actin fibers and membrane 
protrusions (Ronty et al., 2004). It binds directly to the Ena/VASP/WASP complex, which 
together with Arp2/3 is responsible for actin polimerizaton (Mykkanen et al., 2001). High 
expression of PALLD has been related to high indices of migration in breast cancer resulting in 
more aggressive and invasive tumor cells (Goicoecha et al., 2009).   
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 Phosphorylation of JNK2α2 at tyrosine 185 was increased, in a MKK7-independent 
pathway, in the presence of the interleukin IL-1 (Fleming et al. 2000). Studies have suggested 
that activation of JNK is important for the initiation of stress-induced apoptosis, playing a role in 
the release of cytochrome c and in the induction of the FasL (Lei et al., 2002, Kolbus et al, 
2000). Increase in JNK phosphorylation at Y183 and Y185 has been correlated with the 
induction of apoptosis (Takeuchi et al, 2009).  
 LYN is part of the SRC family of kinases, which has been shown to induce epithelial to 
mesenchymal transition (EMT) and transformation by regulating the focal adhesion (He et al., 
2014, Shibamoto et al., 1995). SRC family proteins, including LYN, have been shown to 
phosphorylate diverse sites of δ-catenin, a member of the p120ctn subfamily of armadillo 
proteins involved in E-cadherin-β-catenin-α-catenin complex formation in the cell-cell adhesion 
(Piedra et al., 2003). These phosphorylation events result in δ-catenin stabilization, increasing 
its binding to E-cadherin, decreasing its affinity to GSK3 and disrupting the binding of E-
cadherin to β-catenin, which then translocates to the nucleus (Jin et al., 2015, Shibamoto et al., 
1995, Piedra et al., 2003). δ-Catenin has also been shown to regulate the entry into mitosis.
 Finally, the non-receptor tyrosine kinase FER has a role in cell-cell adhesion, migration 
and proliferation. Activation of FER by c-SRC induces cell transformation by inducing its 
membrane localization and oligomerization (Oneyama et al., 2016). Overexpression of FER has 
been shown to decrease the association of E-cadherin with α-catenin and increase 
phosphorylation of β-catenin resulting in its dissociation from the E-cadherin complex (Rosato et 
al., 1998). This process is the result of FER phosphorylation of the tyrosine phosphatase PTP1B 
at Y152 (Xu et al., 2004). Immunohistochemistry of NSCLC patient samples showed 
overexpression of FER in 10% of lung adenocarcinoma cases and in 5.5% of squamous cell 
lung cancer cases. It was also associated with poor prognosis and low survival rate (Kawakami 
et al., 2013).  
 In summary, phosphoproteomics analysis suggested that foretinib regulates several 
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proteins involved in the cell cycle, cytoskeleton organization and focal adhesion. More 
importantly, several of these proteins were also detected as foretinib targets, such as FER, or 
were associated with the activity of or pathways involving other targets of foretinib, such as 
AURKB and LYN.  
 To complete the investigation in signaling changes, we further studied gene regulation, 
which is downstream of the regulated signaling pathways, upon treatment with foretinib in 
comparison to cabozantinib. This allows us to more thoroughly understand, which pathway is 
predominantly modulated by foretinib. In addition, the integration of all proteomics data plus 
changes in gene expression allows us to validate with high confidence the targets of foretinib 
involved in the modulated pathways. 
 RNA-seq was performed in H1155 cells after 4 hours of treatment with foretinib and 
cabozantinib. A total of 15,165 genes were detected and 231 genes passed the specific 
selection criteria (Appendix L). Interestingly, foretinib treatment resulted in a very different gene 
expression profile compared to DMSO and cabozantinib (Fig. 42).  
                         
Fig. 42: Heatmap representation of RNA-Seq analysis. Visual representation of the 231 genes that 
were differentially expressed between cabozantinib (CABO), DMSO and foretinib (FORE) treatment in 
H1155 cells. 
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 We performed integrated data analysis to identify global molecular differences in 
response to foretinib versus cabozantinib using Gene Set Enrichment Analysis (GSEA). We 
combined chemical proteomics, phosphoproteomics and RNA-Seq data to determine pathways 
modulated by foretinib (Fig. 43).  
                                            
Fig. 43: Systematic scheme of the integrated data analysis approach. Data comparing foretinib vs 
cabozantinib in the chemical proteomics, phosphoptoteomics and RNA-Seq were combined and analyzed 
using GSEA. Foretinib targeted kinases shared in regulated pathways were further validated.  
 
 From the chemical proteomics data set we selected direct foretinib kinase targets with 
NSAF > 0.005. Phosphotyrosine (p-value > 0.1 for FORE/CABO analysis) and global (+/- 2 
standard deviation for FORE/CABO analysis) phosphoprotemics provided proteins involved in 
signaling changes affected by these foretinib targets. Finally, differences in gene expression 
between foretinib and cabozantinib were selected from the RNA-Seq data comparing 
FORE/(DMSO+CABO).  
 Subsequently, GSEA analysis assigned several times mainly two pathways, “cell contact 
and cytoskeleton” and “cell cycle”, to be involved in the MoA of foretinib (Fig. 44a). To dissect 
which direct targets of foretinib were involved in the modulation of these pathways, we 
determined, using a Venn diagram, which kinases were shared between the cytoskeleton and 
the cell cycle pathways and were also present in foretinib’s pulldown (Fig.44b). ATM has no 
published Kd value and didn’t have a high NSAF based on our in vitro assay. It is possible that 
its detection by MS may be an artefact explained by its protein size (351 kDa) and often 
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observed stickiness. Foretinib is less potent for AURKA (IC50 = 105.3 nM) then AURKB (IC50 = 
73 nM). Therefore, we selected AURKB, MEK1, SRC and FER for further investigations. 
 
Fig. 44: A. Pathway analysis using GSEA: top 40 pathways assigned with GSEA after combining the 
specific data. Colors classify pathways into clusters. C. Venn diagram of the integrated data analysis: 
Displayed are the kinases targeted by foretinib and shared in the predominant differential pathways 
between foretinib and cabozantinib according to GSEA analysis.  
 
 Initially, we confirmed cellular regulation of these proteins by foretinib by investigating 
changes in downstream signaling. Foretinib, but not cabozantinib, decreased phosphorylation of 
pERK at T202/Y204, which are important phosphorylation sites downstream of MEK1/2, in both 
H1155 and A427 cells. In contrast, other MET and/or VEGFR inhibitors, including cabozantinib, 
had no effect on pERK (Fig. 45a). In addition, foretinib in a dose-dependent manner decreased 
the phosphorylation of histone H3 at S10, a downstream target of AURKB, which is required for 
the binding of HP1A to the chromatin (Fischle et al., 2005, Hirota et al., 2005) (Fig. 45b). Since 
antibodies for the FER phosphorylation site of interest were lacking, immunoprecipitation of 
tyrosine phosphorylated proteins was performed and subsequent blotting for FER indicated 
changes in its phosphorylation. This analysis showed that foretinib, but not cabozantinib, 
inhibited tyrosine phosphorylation of FER (Fig. 45c). Consistently, the potent FER inhibitor 
GSK1838705A, which was designed as an IGF1R/INSR inhibitor, also inhibited FER tyrosine 
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phosphorylation similar to foretinib. Surprisingly, saracatinib, a potent SRC family kinase (SFK) 
inhibitor, did not decrease phosphorylation of FER, which indicates that regulation of FER by 
SFK may be cell type-dependent.  
                    
Fig. 45: Representative western blot of downstream signaling of foretinib targets: A. 
Immunoblotting of pERK (T202/Y204) after 1 hour treatment of foretinib (FORE), cabozantinib (CABO), 
PF-04217903 (PF- METi) and motesanib (MOTE – VEGFR-i) in both H1155 and A427 cells. B. 
Immunoblotting of pH3 (S10) after 6 hours treatment with indicated doses of foretinib (FORE) and 
barasertib (AURKBi) in H1155 cells. C. Immunopreciptation blot of tyrosine phosphorylated FER in H1155 
after 3 hours treatment with 1 µM of foretinib (FORE), saracatinib (SARA – SRCi), GSK1838705A (GSK-
FERi) and cabozantinib (CABO).  
 
 Considering that AURKB is a major regulator of the cell cycle and mitosis we 
investigated the cell cycle changes after 6 hours of foretinib and cabozantinib treatment at 
varying concentrations in both H1155 and A427 cells. This analysis showed that foretinib, but 
not cabozantinib, caused a pronounced and dose-dependent accumulation of cells in G2 phase, 
which is consistent with inhibition of AURKB (Fig. 46). 
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Fig. 46: A, B. Cell cycle analysis by flow cytometry in H1155 and A427 cells: Quantification of cells in 
different phases of the cell cycle after 6 hours of treatment with foretinib (FORE) and cabozantinib 
(CABO) at indicated concentrations. Histograms show the quantification of the biological triplicates. 
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 Even though foretinib is a reasonably potent SRC, LYN and YES inhibitor, it 
unexpectedly did not decrease the SRC phosphorylation at Y419 in H1155 cells, the 
autophosphorylation site of SRC, responsible for its activation. We therefore focused in the 
following on MEK1/2, AURKB and FER.  
 In order to dissect the MoA underlying foretinib’s anticancer activity in NSCLC cells and 
evaluate the individual contributions of the identified foretinib-specific targets, we applied a 
combined functional validation approach using selective small molecule probes and RNAi. 
 The following tool compounds were utilized: GSK1838705A (FER inhibitor, Kd = 200 nM, 
Davis et al. 2011), barasertib (selective AURKB inhibitor, IC50 = 0.37 nM, Mortlock et al. 2007) 
and trametinib (selective MEK1/2 inhibitor, IC50 = 0.92 nM / 1.8 nM, Yamaguchi et al. 2011). 
 Whereas single agent treatment with these probe molecules showed no (H1155, Fig. 
47a) to only moderate (A427, Fig. 47c) effects, pairwise and particularly triple combinations 
markedly decreased cellular viability to similar extent as foretinib. This suggests that all three 
kinases contribute to foretinib’s MoA, a concept referred to as polypharmacology (Hopkins 
2008). Consistently, combined targeting of AURKB, FER and MEK1/2 using siRNA-mediated 
knockdown of AURKB and FER and the specific small molecule MEK inhibitor trametinib is 
more effective than each single treatment alone (Fig. 47b,d). However, single AURKB 
knockdown more predominately reduced cell viability than expected based on pharmacological 
inhibition. At the same time, FER knockdown in addition to AURKB and MEK targeting did not 
further enhance the effects obtained with dual targeting of AURKB and MEK alone, although 
knockdown did slightly enhance single MEK inhibition. The reduced effect of FER silencing 
could be maybe explained by the overly strong contribution of AURKB knockdown, which may 
mask the relatively small effects elicited by knocking down FER. Alternatively, this could be also 
the result of functional crosstalk between FER and AURKB as suggested by downregulation of 
AURKB upon knockdown of FER in H1155, but not A427 cells. 
 To verify that the effect on the cellular viability of the combination with GSK1838705A is 
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primarily due to inhibition of FER and not a reflection of inhibition of its other potent targets, 
namely IGF1R/INSR (Sabbatini et al. 2009.), H1155 cells were treated with linsitinib (Mulvihill et 
al. 2009), a different potent and selective IGF1R/INSR inhibitor with no potency against FER. 
Indeed, combination of linsitinib with barasertib and trametinib did not show any additional effect 
on cellular viability over the combination of barasertib with trametinib. This indicates that 
inhibition of IGF1R/INSR is not responsible for the decrease in cell viability observed upon the 
treatment with GSK1838795A (Fig. 48a). Interestingly, inhibition of IGF1R/INSR has been 
recently shown in several NSCLC cell lines, including H1155 cells, to reduce cell viability when 
combined with targeting of RSK1/2 and FAK (Kuenzi et al. 2017). This suggests that in the 
context of polypharmacology, the relevance of one individual target is dependent on what other 
proteins are targeted at the same time. 
 In addition, to confirm that mainly inhibition of AURKB, and not AURKA, is involved in 
the mechanism of action of foretinib, H1155 were treated with alisertib, a potent AURKA 
inhibitor. As observed in Fig. 48b, combination of a AURKA inhibitor with FER and MEK1/2 
inhibition did not result in synergistic effects or decrease in cell viability. Finally, FAK has also 
been reported to be a weak off-target of GSK1838705A. To confirm that its inhibition was not 
affected by GSK1838705A at the concentrations used in our studies, western blotting for the 
catalytic phosphorylation site of FAK was performed upon treatment with foretinib, cabozantinib 
and GSK1838705A; PF-573228, a potent inhibitor of FAK, was used as control (Fig. 48c). The 
western blot confirmed that neither foretinib, cabozantinib or even high concentrations of 
GSK1838705A were able to decrease phosphorylation of FAK, which was however observed 
upon treatment with the potent FAK inhibitor, as expected. 
 In summary, based on our detailed analysis of the drug combination, we have strong 
evidence that concomitant inhibition of FER, AURKB and MEK1/2 is important for the inhibition 
of proliferation of these cell lines. 
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 Fig. 47. Cell viability upon inhibition of FER, AURKB and MEK. A/C. Drug combination of 
GSK1838705A (1 µM and 2.5 µM) with barasertib (50 nM) and trametinib (35 nM) in H1155 and A427 
cells. Cell viability was determined using Cell-Titer-Glo after 72 hours of treatment and all treatments were 
normalized to DMSO (first black bar). B/D. RNA interference of FER and AURKB in combination with 
trametinib (35 mM) in H1155 and A427 cells. Cell viability was determined after 72 hours of treatment with 
trametinib by cell counting. 
 
 Furthermore, in A427 cells, combination of trametinib with barasertib was largely 
sufficient to mimic the effect of foretinib in this cell line. Because addition of cabozantinib at best 
slightly affected the viability of these cells, we conclude that MEK1/2 and AURKB are the major 
targets responsible for the differential efficacy between foretinib and cabozantinib in A427 cells 
(Fig. 48d).  
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 Thus, no single target is fully responsible for mediating foretinib’s anticancer effects in 
these cells. Rather, this represents a unique case of polypharmacology. In fact, it is possible 
that yet other kinases, such as the weak foretinib target INSR, further contribute to foretinib’s 
overall MoA in addition to the three targets we mechanistically validated here. 
 
Fig. 48. Evaluation of co-target impact of utilized probe molecules. A/B. Cell viability of H1155 cells 
after 72 hours treatment with drug combinations: A. linsitinib, an IGF1R/INSR inhibitor, (0 µM, 1.5 µM and 
2.5 µM) with barasertib (50 nM) and trametinib (35 nM) and B. GSK1838705A (0 µM, 1 µM and 2.5 µM) 
with the AURKA inhibitor alisertib (50 nM) and trametinib (35 nM). C. Representative western blot of 
pFAK (Y397) after 3 hours treatment with foretinib (FORE), cabozantinib (CABO), PF-573228 (PF), a FAK 
inhibitor, and GSK1838705A (GSK) in H1155 cells. The bar graph shows the densitometric quantification 
of the western blot signals. D. Cell viability of A427 cells after 72 hours treatment with various drug 
combinations: cabozantinib (CABO), barasertib (BARA) and trametinib (TRAME) compared to treatment 
with foretinib (FORE). 
 
 MEK1/2 is part of the central MAPK signaling pathway, which is important for cell 
proliferation and survival. MAPK signaling is activated by several growth factors, which results in 
the activation of RAS proteins, recruitment of the serine/threonine kinase RAF to the plasma 
membrane thereby inducing its activation. Finally, activated RAF phosphorylates MEK1/2, which 
then phosphorylates ERK resulting in the activation of several substrates and transcription of 
genes (Yamaguchi et al. 2011) However, MEK is not only a critical component of the MAPK 
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signaling pathway. MEK1 (MAP2K1) has been recently shown to also colocalize with α- and β-
tubulin in the centrosome independently of MAPK pathway signaling and regulation of ERK 
(Cao et al 2010). It shows statistically significant co-localization during metaphase, telophase 
and cytokinesis, resulting in defective mitotic spindle formation and leading to polyploid cells. In 
addition, staining with phalloidin has been shown that MEK1 affects organization of actin fibers 
and microtubule polymerization (Cao et al 2010). In another study, Mendoza et al., showed that 
inhibition of MEK also affects microtubule polymerization through regulation of ERK, which was 
independent of its effect on gene transcription. ERK phosphorylation of WAVE2 increased its 
ability to recruit Arp2/3 to the leading edge, which induced the formation of branched actin. 
  Interestingly, the BRAF/ERK pathway has been shown to regulate AURKB on the 
transcriptional level through activation of the transcription factor FOXM1 (Bonet et al. 2012). 
Consistently, BI-847325, a dual MEK/Aurora inhibitor, which is 8 and 5 times more potent for 
AURKB than AURKA and C, respectively, was shown to overcome BRAF inhibitor resistance of 
melanoma cells that express oncogenic BRAF V600E by decreasing ERK and histone H3 
phosphorylation, as well as expression of the anti-apoptotic protein MCL-1 (myeloid cell 
leukemia-1) (Phadke et al. 2015).  Similar mechanisms may also underlie the functional 
crosstalk and sensitivity towards dual targeting of MEK/AURKB by foretinib in lung cancer cells.  
 In addition, a study with S49076, another MET/AXL/FGFR inhibitor, also reported that 
cells sensitive to inhibition of MET signaling were arrested in the G1 phase of the cell cycle. 
However, resistant NSCLC cells accumulated in the G2 phase after high doses of the inhibitor. 
S49076 was also found to be a potent AURKB inhibitor (3 nM); and consistently a decrease in 
H3 phosphorylation was observed in these cells upon treatment with 1 µM of this inhibitor 
(Clemenson et al. 2017).  
 These reports support our data, which indicate that MET inhibitors in general can also 
target Aurora kinases albeit with different potency. In the case of the close structural analogues 
foretinib and cabozantinib, the slight change in their chemical structures by the addition of the 
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fluorine atom resulted in a more potent inhibition of AURKB by foretinib than what is seen with 
cabozantinib. This may be explained by differential conformational changes of the ATP binding 
site upon binding of these inhibitors. A recent study with an Aurora kinase A inhibitor has shown 
that induced-dipole forces along the Ala side chain of the ATP binding site of the kinase can 
alter the orientation of the DFG backbone from a DFG-in to a DFG-out conformation (Martin et 
al. 2012). In addition, in contrast to the data from Clemenson et al., foretinib (a less potent 
Aurora B inhibitor than S49076), also at 1 µM, was able to induce G2/M cell cycle arrest at 
earlier time point (6 hours). Foretinib also inhibited phosphorylation of histone H3 at S10 at 
lower concentrations (250 nM and 500 nM) than S49076 indicating that additional targets may 
be involved in foretinib’s mechanism of action in the cell cycle regulation, which would be 
supported by the inhibition of MEK.  
 This observation highlights the importance of the drug discovery design, since additional 
chemical groups may be important for the polypharmacology of compounds and their 
mechanism of action.  
 It is interesting to note that H1155 cells, the most sensitive NSCLC cell line to the 
treatment of foretinib, has a neuroendocrine origin, as do small cell lung cancer (SCLC) cells. 
This may indicate that also SCLC cells could exhibit sensitivity to foretinib, which as discussed 
is also an AURKB inhibitor. In addition, AURKB has been shown to be important for the 
proliferation of SCLC cells. A screen with 297 compounds in 44 SCLC cell lines, including 
established cell lines and primary tumor cells, had found that MYC-amplified SCLC cells were 
highly sensitive to AURKB inhibition, resulting in accumulation of cells in G2/M and induction of 
cell death within 24-48 hours (Sos et al. 2012).  
 Interestingly, in this study, expression of AURKB, but not AURKA, was correlated with 
the expression of MYC in SCLC cells, which was confirmed by reduction of cellular viability after 
RNAi-mediated knockdown of AURKB. In contrast, this effect was not observed upon 
knockdown of AURKA (Sos et al. 2012). An ABPP-based proteomics approach with a 
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desthiobiotin-ATP probe subsequently confirmed that specifically MYC-amplified SCLC cells are 
more sensitive to AURKB inhibitors than MYCL/N-amplified cells (Li et al. 2016). 
  Importantly, it has been shown that MYC regulates AURKA/B in vivo and in vitro as cells 
transfected with a tetracycline-off element regulated c-MYC, but upon removal of tetracycline 
the same cells showed high expression of c-MYC followed by increased AURKA/B expression 
(den Hollander et al. 2010). The regulation of AURKA/B by c-MYC was confirmed through a 
luciferase assay, which also showed that AURKB was 10 times more strongly expressed than 
AURKA. Whereas ChIP assay data showed that c-MYC regulated transcription of AURKA 
through its binding to the promoter, AURKB was regulated independently of promoter binding. 
However, only overexpression of AURKB was able to rescue cells from the apoptosis induced 
by AS703569, a pan-Aurora inhibitor, indicating that AURKB is the main functionally relevant 
target of c-MYC amplified cells. Additionally, CDK16, phosphorylation of which is also reduced 
by foretinib, is expressed to the highest level in the brain and knockdown of CDK16 has been 
shown to decrease the levels of c-MYC (Yanagi et al. 2014, 2017). 
 Cell death of MYC-amplified SCLC cells have been shown to be the result of the 
displacement of AURKB from the chromosomal passenger complex (CPC) (Yang et al. 2010). 
While AURKB inhibition arrests cells in the cytokinesis phase of the cell cycle inducing a G2/M 
cell cycle arrest, MYC still induces DNA replication eluding the G1/S and G2/M checkpoint, 
which leads to apoptosis (Yang et al. 2010). Since AURKB is an important target of foretinib in 
NSCLC cells and, in our phosphoproteomics dataset, we observed foretinib-induced regulation 
of important proteins with the CPC complex, such as HP1A and TOP2A, we hypothesized that 
c-MYC-amplified SCLC cells are more sensitive to foretinib treatment that non-MYC-amplified 
cells.  
 Indeed, interrogating a panel of MYC-amplified vs. non-MYC-amplified SCLC cell lines, 
foretinib showed significantly more potent inhibition of viability of c-MYC-amplified cells than 
non-MYC-amplified SCLC cells (Fig. 49a). In agreement, treatment with foretinib or the potent 
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and selective AURKB inhibitor barasertib confirmed inhibition of phosphorylation of histone H3 
(Ser10) in the MYC-amplified SCLC cell line 16HV (Fig. 49b). Consistently, foretinib also was 
markedly more potent than cabozantinib in these cells (Fig. 50). SCLC cells, similarly to NSCLC 
cells, were not sensitive to motesanib or PF-04217903, potent VEGFR and MET inhibitors, 
indicating that the effect on cell viability is the result of inhibition of foretinib’s off-targets, such as 
AURKB (Fig. 50). 
              
Fig. 49: A. IC50 comparison between c-MYC-amplified and non-MYC-amplified SCLC cells after 72 hours 
treatment with foretinib. IC50 values were determined using a dose-response curve. B. Representative 
western blot of pH3 in 16HV cells after 6 hours treatment with foretinib (FORE) and barasertib (BARA). 
 
 However, because foretinib is not a highly potent AURKB inhibitor, as it has not been 
optimized for this target, we investigated if the combination of barasertib, an AURKB inhibitor 
with subnanomolar potency, could result in increased cell death. Addition of barasertib at fixed 
concentrations to foretinib dose-response curves showed strong enhancement of foretinib 
efficacy in MYC-amplified SCLC. Interestingly, this was also apparent in H1155 cells, but not in 
A427 cells (Fig. 51a). Because SCLC cell sensitivity to AURKB inhibitors varies between cells, 
we also pursued the opposite approach and spiked in a fixed concentration of foretinib, which 
induces an average of 20% reduction of cell growth, to barasertib dose-response curves for 
better measurement of drug combination effects (Fig. 51b). Consistent with the previous 
approach, this analysis revealed that only the c-MYC-amplified SCLC cells, not the non-MYC-
amplified SCLC cells, showed enhanced effects with the drug combination. 
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 Fig. 50: Cellular viability of SCLC cells comparing foretinib and cabozantinib. Dose-
response curves of foretinib, cabozantinib, PF-04217903 (MET inhibitor) and motesanib (VEGFR-2 
inhibitor) after 72 hour treatment and their respective IC50 values [µM]. Experiments were done as 
biological triplicates, except for the H209, N417, DMS114, H69 and DMS79 cell lines, which were 
performed as duplicates. Each biological replicate contained three technical replicates. 
112 
 
 
Fig. 51: Dose-response curves for inhibition of viability by the combination of foretinib with 
barasertib. For H1155 and A427, barasertib (“BARA” or “B”) was spiked at 50 nM and 100 nM to the 
dose-response curve of foretinib (“FORE” or “F”). For SCLC cells, 250 nM of foretinib were spiked in the 
dose-response curve of barasertib. Cell viability was determined after 72 hours of treatment. 
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 Another important aspect is that combination of foretinib with barasertib decreased the 
concentration of foretinib needed to achieve sufficient inhibition of proliferation to a clinically 
relevant level. The plasma concentration reported for foretinib varies from 37 to 340 nM, with 
340 nM corresponding to the maximum tolerated dose (Shapiro et al. 2013, Katayama et al. 
2015). Peak plasma levels suggested for optimal efficacy of foretinib were 1 to 3 μM. However, 
prolonged biological effects were observed at 0.02 to 0.1 µM (Eder et al. 2010). 
 Formal statistical and synergy analysis using Student’s t-test and the Bliss model of 
independence, respectively, furthermore indicated significant drug synergy in multiple cell lines 
(Fig. 52).  
 
Fig. 52: Synergistic effects on cell viability upon combination of foretinib and barasertib. 
Combination analysis was performed with foretinib (200 nM) and barasertib (50 nM for H1155, 15 nM for 
16HV, 10 nM for 86M1, and 20 nM for H524). Synergy was determined using the Bliss model of 
independence. ΔBliss indicates the difference of observed inhibition of viability to the theoretically 
calculated additive effect. P-values for significance were determined using Student’s t-test. 
 
 Finally, we investigated, if the combination of foretinib with barasertib induces cell death 
of SCLC cells through apoptosis. For the combination, we used a barasertib concentration that 
is sufficient to induce approximately 20% reduction of cell viability. All concentrations used are 
below the plasma concentrations reported for the maximum tolerated dose of barasertib (218 
nM) and foretinib, which makes it clinically relevant (Schwartz et al. 2013). Immunoblotting 
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analysis of single drug and drug combination treatments of foretinib and barasertib showed 
strong increases of PARP1 and caspase-3 cleavage with the drug combination indicating strong 
induction of apoptosis (Fig. 53). Importantly, this effect was only observed in MYC-amplified, but 
not in non-MYC-amplified SCLC cells.  
 Transcription of MYC was shown previously to be regulated directly and indirectly by 
bromodomain proteins; and JQ1, a BET bromodomain protein inhibitor, has been shown to be 
more potent in MYC-amplified cells (Lenhart et al. 2015, Kaur et al. 2016). We therefore tested, 
if combination of foretinib with JQ1 would be synergistic in MYC-amplified SCLC. However, drug 
combination of JQ1 with foretinib did not result in significantly decreased viability of SCLC cells 
(Fig. 54). Since sensitivity to JQ1 depends of a specific localization of the super elongation 
complex during MYC transcription (Fowler et al., 2014), targeting a downstream target of MYC, 
such as AURKB, may be more clinically relevant.  
 
Fig. 53: The combination of foretinib and barasertib enhances apoptosis in MYC-amplified SCLC 
cells. Representative western blots of MYC-amplified and non-MYC-amplified SCLC cells for PARP1 and 
caspase-3 cleavage after 24 hours of treatment with single agent barasertib and foretinib or their 
combination at the indicated concentrations.  
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Fig. 54: Dose-response curves for inhibition of viability by the combination of foretinib with JQ1 in 
MYC-amplified and non-MYC-amplified SCLC cells. 250 nM of foretinib (“F”) were spiked in the dose-
response curve of JQ1. Cell viability was determined after 72 hours of treatment. 
  
 Conclusion 
 Our study showed that the clinical drug candidate foretinib displayed unexpected 
anticancer activity markedly more potent than its close structural analogue cabozantinib in lung 
cancer cells. Thus, foretinib, but not cabozatinib, reduced cell viability, induced G2/M cell cycle 
arrest and apoptosis. This also demonstrates that foretinib’s cellular activity in these cells is 
independent of its cognate targets MET and VEGFR that are shared with cabozantinib.  
 Using an integrated systems pharmacology analysis involving functional proteomics and 
RNA-seq, we defined not only the target profiles of foretinib and cabozantinib in two NSCLC cell 
lines, but we also elucidated the differential mechanism of action between these two close 
chemical analogs. To the best of our knowledge, this is the first time that these compounds 
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have been deeply analyzed side by side in the same study. 
 Specifically, we identified the kinases MEK1/2 and AURKB as important foretinib targets 
that are involved in the differential cellular activity of foretinib compared to cabozantinib in 
NSCLC. Our data also suggest that the kinase FER may also contribute to the overall cellular 
effect of foretinib. However further investigation with different techniques and a broader cell line 
panel may be necessary to confirm the functional relevance of FER for the MoA of foretinib. 
 Several studies have shown that MYC-amplified SCLC cells are more sensitive to 
AURKB inhibitors. Our studies confirmed these observations and used the fact that AURKB is 
one of the most important, but not most potent, targets involved in the MoA of foretinib to design 
a novel potent drug combination for MYC-amplified SCLC cells. Combination of foretinib with 
barasertib showed synergy in MYC-amplified cells resulting in markedly increased apoptosis at 
clinically relevant concentrations.  
 As preclinical studies have shown only a delay in tumor growth upon treatment with 
AURKB inhibitors; this enhanced induction of apoptosis might indicate an attractive novel 
opportunity for clinical translation, since foretinib is a multikinase inhibitor shown to inhibit also 
cell migration and metastasis, and SCLC is known to be an aggressive tumor, which rapidly 
spreads and recurs after initial response to chemotherapy. It would be important to investigate, 
if the combination of foretinib and barasertib would inhibit tumor cell migration and delay 
recurrence of SCLC.  
 In summary, we present a deep, systems-wide integrated analysis capable of 
differentiating the mechanisms of action of drugs that share cognate targets. In addition, the 
discovery of the differential targets allows us to repurpose and design new combination 
therapies for tumor types known to depend on the affected signaling pathways. The potent 
cellular synergy of the combination of foretinib with barasertib in SCLC resulted in the possibility 
to use foretinib at well tolerated doses, which may decrease its side effects, while eliciting 
potent antitumor activity.  
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Proteins Accession MW AMP1 AMP2 c-Palbo_PT1 c-Palbo_PT2 c-Palbo1 c-Palbo2 c-Ribo_PT1 c-Ribo_PT2 c-Ribo1 c-Ribo2
AP2-associated protein kinase 1 OS=Homo sapiens GN=AAK1 PE=1 SV=3AAK1_HUMAN 104 kDa 0 0 0 2 9 5 0 0 0 0
5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AAPK1_HUMAN 64 kDa 0 0 8 7 16 17 2 6 0 1
Serine-protein kinase ATM OS=Homo sapiens GN=ATM PE=1 SV=4ATM_HUMA 351 kDa 0 0 21 5 31 19 3 9 1 6
Aurora kinase A OS=Homo sapiens GN=AURKA PE=1 SV=2AURK _HUMAN 46 kDa 0 0 2 0 1 1 7 7 8 14
Aurora kinase B OS=Homo sapiens GN=AURKB PE=1 SV=3AURKB_HUMAN 39 kDa 0 0 0 0 2 1 0 0 1 2
Beclin-1 OS=Homo sapiens GN=BECN1 PE=1 SV=2BECN1_HUMAN 52 kDa 0 0 0 0 7 6 0 0 0 0
Cyclin-dependent kinase 11B OS=Homo sapiens GN=CDK11B PE=1 SV=3CD11B_HUMAN 93 kDa 0 0 0 1 10 12 0 0 0 0
Cyclin-dependent kinase 16 OS=Homo sapiens GN=CDK16 PE=1 SV=1CDK16_HUMA 56 kDa 0 0 0 0 3 1 0 0 0 0
Cyclin-dependent kinase 17 OS=Homo sapiens GN=CDK17 PE=1 SV=2CDK17_HUMA 60 kDa 0 0 0 0 6 6 0 0 0 2
Cyclin-dependent kinase 2 OS=Homo sapiens GN=CDK2 PE=1 SV=2CDK2_HUMAN 34 kDa 0 0 0 1 1 3 0 1 0 1
Cyclin-dependent kinase 4 OS=Homo sapiens GN=CDK4 PE=1 SV=2CDK4_HUMAN 34 kDa 0 0 3 2 10 15 0 1 5 6
Cyclin-dependent kinase 6 OS=Homo sapiens GN=CDK6 PE=1 SV=1CDK6_HUMAN 37 kDa 0 0 8 8 20 20 4 2 7 11
Cyclin-dependent kinase 9 OS=Homo sapiens GN=CDK9 PE=1 SV=3CDK9_HUMAN 43 kDa 0 0 1 2 8 9 1 3 5 10
Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1CSK21_HUMAN 45 kDa 1 0 9 9 29 28 2 2 1 3
Casein kinase II subunit alpha' OS=Homo sapiens GN=CSNK2A2 PE=1 SV=1CSK22_HUMAN 41 kDa 0 0 10 6 32 33 0 0 0 0
Casein kinase II subunit beta OS=Homo sapiens GN=CSNK2B PE=1 SV=1CSK2B_HUMAN 25 kDa 0 0 4 5 13 15 0 2 0 0
Death-associated protein kinase 3 OS=Homo sapiens GN=DAPK3 PE=1 SV=1DAPK3_HUMAN 53 k a 0 0 0 0 2 2 0 0 0 0
Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK1_HUMAN 119 kDa 0 0 31 29 38 36 13 20 6 20
Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER_HUMAN 95 kDa 0 0 6 8 15 21 2 0 12 5
Cyclin-G-associated kinase OS=Homo sapiens GN=GAK PE=1 SV=2GAK_HUMAN 143 kDa 0 0 0 0 0 0 0 0 8 13
Glycogen synthase kinase-3 alpha OS=Homo sapiens GN=GSK3A PE=1 SV=2G K3A_HUMAN 51 kDa 0 0 2 1 2 1 0 0 0 0
Glycogen synthase kinase-3 beta OS=Homo sapiens GN=GSK3B PE=1 SV=2GSK3B_HUMAN 47 kDa 0 0 3 3 7 7 0 0 0 0
Interleukin-1 receptor-associated kinase 1 OS=Homo sapiens GN=IRAK1 PE=1 SV=2IRAK _HUMAN 77 kDa 0 0 5 4 6 5 6 7 1 9
Calcium/calmodulin-dependent protein kinase type II subunit delta OS=Homo sapiens GN=CAMK2D PE=1 SV=3KCC2D_HUMAN 56 kDa 0 0 8 6 9 9 6 9 6 8
Calcium/calmodulin-dependent protein kinase type II subunit gamma OS=Homo sapiens GN=CAMK2G PE=1 SV=3KCC2G_HUMAN 63 kDa 0 0 10 8 8 9 5 8 2 11
Serine/threonine-protein kinase D2 OS=Homo sapiens GN=PRKD2 PE=1 SV=2KPCD2_HUMAN 97 kDa 0 0 6 6 26 22 9 11 3 12
Serine/threonine-protein kinase D3 OS=Homo sapiens GN=PRKD3 PE=1 SV=1KPCD3_HUMAN 100 kDa 0 0 1 0 13 10 2 3 0 3
Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2KS6A1_HUMAN 83 kDa 0 0 4 5 6 4 0 0 0 0
Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1KS6A3_HUMAN 84 kDa 0 0 1 3 4 3 0 1 0 1
Ribosomal protein S6 kinase alpha-4 OS=Homo sapiens GN=RPS6KA4 PE=1 SV=1KS6A4_HUMAN 86 kDa 0 0 5 3 5 3 0 0 0 0
Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=1 SV=2KT3K_HUMAN 34 kDa 0 0 1 1 1 4 0 0 0 0
Mitogen-activated protein kinase kinase kinase 1 OS=Homo sapiens GN=MAP3K1 PE=1 SV=4M3K1_HUMAN 164 kD 0 0 0 0 0 0 1 4 2 1
Mitogen-activated protein kinase kinase kinase 5 OS=Homo sapiens GN=MAP3K5 PE=1 SV=1M3K5_HUMAN 155 kD 0 0 3 2 2 0 2 1 0 0
Mitogen-activated protein kinase kinase kinase 6 OS=Homo sapiens GN=MAP3K6 PE=1 SV=3M3K6_HUMAN 143 kD 0 0 6 1 4 0 2 6 0 2
Maternal embryonic leucine zipper kinase OS=Homo sapiens GN=MELK PE=1 SV=3MELK_HUMAN 75 kDa 0 0 0 0 3 1 0 0 0 0
Mitogen-activated protein kinase 1 OS=Homo sapiens GN=MAPK1 PE=1 SV=3MK01_HUMAN 41 kDa 0 0 10 6 14 15 1 0 0 1
Mitogen-activated protein kinase 8 OS=Homo sapiens GN=MAPK8 PE=1 SV=2MK08_HUMAN 48 kDa 0 0 5 4 11 8 0 0 0 2
Mitogen-activated protein kinase 9 OS=Homo sapiens GN=MAPK9 PE=1 SV=2MK09_HUMAN 48 kDa 0 0 10 9 18 17 3 1 0 2
Phosphoinositide 3-kinase regulatory subunit 4 OS=Homo sapiens GN=PIK3R4 PE=1 SV=3PI3R4_HUMAN 153 kDa 0 0 4 9 41 32 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha OS=Homo sapiens GN=PIP4K2A PE=1 SV=2PI42A_HUMAN 46 kDa 0 0 0 0 2 4 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta OS=Homo sapiens GN=PIP4K2B PE=1 SV=1PI42B_HUMAN 47 kDa 0 0 0 0 2 3 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma OS=Homo sapiens GN=PIP4K2C PE=1 SV=3PI42C_HUMAN 47 kDa 0 0 1 1 10 13 0 0 0 0
Phosphatidylinositol 4-kinase alpha OS=Homo sapiens GN=PI4KA PE=1 SV=3PI4KA_HUMAN 231 kDa 0 0 3 0 3 1 0 0 0 0
Phosphatidylinositol 3-kinase catalytic subunit type 3 OS=Homo sapiens GN=PIK3C3 PE=1 SV=1PK3C3_HUMAN 102 kDa 0 0 6 5 33 34 0 0 0 0
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform OS=Homo sapiens GN=PIK3CD PE=1 SV=2PK CD_HUMAN 119 kDa 0 0 0 0 7 3 0 0 0 0
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3PRKDC_HUMAN 469 kDa 4 4 66 22 74 59 16 33 1 13
Receptor-interacting serine/threonine-protein kinase 2 OS=Homo sapiens GN=RIPK2 PE=1 SV=2RIPK2_HUMAN 61 kDa 0 0 0 0 0 0 4 4 0 6
Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1TBK1_ UMAN 84 kDa 0 0 6 1 17 9 15 15 1 13
Non-receptor tyrosine-protein kinase TNK1 OS=Homo sapiens GN=TNK1 PE=1 SV=3TNK1_HUMAN 72 kDa 0 0 4 3 3 2 0 0 4 6
Dual specificity protein kinase TTK OS=Homo sapiens GN=TTK PE=1 SV=2TTK_HUMAN 97 kDa 0 0 2 3 6 9 0 1 0 6
Non-receptor tyrosine-protein kinase TYK2 OS=Homo sapiens GN=TYK2 PE=1 SV=3TYK2_HUMAN 134 kDa 0 0 0 0 0 0 4 5 0 5
Tyrosine-protein kinase receptor UFO OS=Homo sapiens GN=AXL PE=1 SV=3UFO_HUMAN 98 kDa 0 0 1 2 3 3 0 1 0 0
UV radiation resistance-associated gene protein OS=Homo sapiens GN=UVRAG PE=1 SV=1UVRAG_HUMAN 78 kDa 0 0 2 1 8 5 0 0 0 0  
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Proteins Accession MW c-Palbo_PT1 c-Palbo_PT2 c-Palbo1 c-Palbo2 c-Ribo_PT1 c-Ribo_PT2 c-Ribo1 c-Ribo2
AP2-associated protein kinase 1 OS=Homo sapiens GN=AAK1 PE=1 SV=3AAK1_HUMA 104 kDa 1 1 5 5 0 0 0 0
5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AAPK1_HUMAN 64 kDa 2 2 1 1 4 0 0 0
Serine-protein kinase ATM OS=Homo sapiens GN=ATM PE=1 SV=4ATM_HUMAN 351 kDa 0 0 0 1 6 0 0 0
BMP-2-inducible protein kinase OS=Homo sapiens GN=BMP2K PE=1 SV=2BMP2K_HUMAN 129 kDa 1 2 3 4 1 0 0 0
Cyclin-dependent kinase 4 OS=Homo sapiens GN=CDK4 PE=1 SV=2CDK4_HUMAN 34 kDa 1 1 2 2 0 0 1 0
Cyclin-dependent kinase 6 OS=Homo sapiens GN=CDK6 PE=1 SV=1CDK6_HUMAN 37 kDa 1 2 3 4 0 0 0 0
Cyclin-dependent kinase 9 OS=Homo sapiens GN=CDK9 PE=1 SV=3CDK9_HUMAN 43 kDa 0 0 2 2 0 0 2 4
Cyclin-dependent kinase-like 1 OS=Homo sapiens GN=CDKL1 PE=1 SV=5CDKL1_HUMAN 42 kDa 0 0 0 0 0 0 0 0
Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1CSK21_HUMAN 45 kDa 0 0 3 5 1 0 0 0
Casein kinase II subunit alpha' OS=Homo sapiens GN=CSNK2A2 PE=1 SV=1CSK22_HUMAN 41 kDa 1 0 7 8 0 0 0 0
Casein kinase II subunit beta OS=Homo sapiens GN=CSNK2B PE=1 SV=1CSK2B_HUMAN 5 kDa 1 1 2 3 0 0 0 0
Death-associated protein kinase 3 OS=Homo sapiens GN=DAPK3 PE=1 SV=1DAPK3_HUMAN 53 kDa 0 0 3 4 0 0 0 0
Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK1_HUMAN 1 9 kDa 5 4 5 4 2 1 0 0
Protein-tyrosine kinase 2-beta OS=Homo sapiens GN=PTK2B PE=1 SV=2FAK2_HUMAN 116 kDa 4 3 5 8 0 0 0 0
Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER_HUMAN 95 kDa 3 2 5 7 0 0 0 1
Tyrosine-protein kinase Fes/Fps OS=Homo sapiens GN=FES PE=1 SV=3FES_HUMA 93 kDa 3 3 2 3 0 0 0 0
Cyclin-G-associated kinase OS=Homo sapiens GN=GAK PE=1 SV=2GAK_HUMAN 143 kDa 0 0 0 0 0 0 4 10
Glycogen synthase kinase-3 alpha OS=Homo sapiens GN=GSK3A PE=1 SV=2GSK3A_HUMAN 51 kDa 0 0 0 1 0 0 0 0
Glycogen synthase kinase-3 beta OS=Homo sapiens GN=GSK3B PE=1 SV=2GSK3B_HUMA 47 kDa 3 3 4 4 0 0 0 0
Inhibitor of nuclear factor kappa-B kinase subunit epsilon OS=Homo sapiens GN=IKBKE PE=1 SV=1IKKE_HUMAN 80 kDa 0 0 0 0 2 0 0 0
Calcium/calmodulin-dependent protein kinase type II subunit alpha OS=Homo sapiens GN=CAMK2A PE=1 SV=2KCC2A_HUMAN 54 kDa 0 0 0 0 0 0 0 0
Calcium/calmodulin-dependent protein kinase type II subunit beta OS=Homo sapiens GN=CAMK2B PE=1 SV=3KCC2B_HUMAN 73 kDa 0 0 0 0 0 0 0 0
Calcium/calmodulin-dependent protein kinase type II subunit delta OS=Homo sapiens GN=CAMK2D PE=1 SV=3KCC2D_HUMAN 56 kDa 9 6 6 5 9 5 5 8
Calcium/calmodulin-dependent protein kinase type II subunit gamma OS=Homo sapiens GN=CAMK2G PE=1 SV=3KCC2G_HUMAN 63 kDa 3 2 2 2 6 2 2 3
Mast/stem cell growth factor receptor Kit OS=Homo sapiens GN=KIT PE=1 SV=1KIT_HUMAN 110 kDa 0 0 0 0 0 0 0 0
Protein kinase C delta type OS=Homo sapiens GN=PRKCD PE=1 SV=2KPCD_HUMAN 78 kDa 0 0 0 0 3 0 0 0
Serine/threonine-protein kinase D2 OS=Homo sapiens GN=PRKD2 PE=1 SV=2KPCD2_HUMAN 97 kDa 0 0 1 2 0 0 0 0
Serine/threonine-protein kinase D3 OS=Homo sapiens GN=PRKD3 PE=1 SV=1KPCD3_HUMAN 100 k a 0 0 0 1 0 0 0 0
Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2KS6A1_HUMAN 83 kDa 0 0 0 1 0 0 0 0
Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1KS6A3_HUMAN 84 kDa 0 0 0 1 0 0 0 0
Mitogen-activated protein kinase kinase kinase 15 OS=Homo sapiens GN=MAP3K15 PE=1 SV=2M3K15_HUMAN 147 kDa 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase kinase kinase 5 OS=Homo sapiens GN=MAP3K5 PE=1 SV=1M3K5_HUMAN 155 kDa 0 2 0 2 9 0 0 0
Mitogen-activated protein kinase kinase kinase 6 OS=Homo sapiens GN=MAP3K6 PE=1 SV=3M3K6_HUMAN 143 kDa 1 0 0 1 8 0 0 0
Mitogen-activated protein kinase 1 OS=Homo sapiens GN=MAPK1 PE=1 SV=3MK01_HUMAN 41 kDa 5 8 4 6 2 1 0 0
Mitogen-activated protein kinase 3 OS=Homo sapiens GN=MAPK3 PE=1 SV=4MK03_HUMAN 43 kDa 2 2 1 3 0 0 0 0
Mitogen-activated protein kinase 4 OS=Homo sapiens GN=MAPK4 PE=1 SV=2MK04_HUMAN 66 kDa 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase 6 OS=Homo sapiens GN=MAPK6 PE=1 SV=1MK06_HUMAN 83 kDa 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase 8 OS=Homo sapiens GN=MAPK8 PE=1 SV=2MK08_HUMAN 48 kDa 3 3 4 4 0 0 0 0
Mitogen-activated protein kinase 9 OS=Homo sapiens GN=MAPK9 PE=1 SV=2MK09_HUMAN 48 kDa 3 5 3 4 1 0 0 0
Serine/threonine-protein kinase NLK OS=Homo sapiens GN=NLK PE=1 SV=2NLK_HUMAN 58 kDa 0 0 0 0 0 0 0 0
Platelet-derived growth factor receptor alpha OS=Homo sapiens GN=PDGFRA PE=1 SV=1PGFRA_ UMAN 123 kDa 0 0 0 0 0 0 0 0
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform OS=Homo sapiens GN=PHKG2 PE=1 SV=1PHKG2_HUMAN 46 kDa 0 0 0 0 2 0 0 0
Phosphoinositide 3-kinase regulatory subunit 4 OS=Homo sapiens GN=PIK3R4 PE=1 SV=3PI3R4_HUMAN 153 kDa 0 0 0 0 3 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha OS=Homo sapiens GN=PIP4K2A PE=1 SV=2PI42A_HUMAN 46 kDa 0 0 0 2 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta OS=Homo sapiens GN=PIP4K2B PE=1 SV=1PI42B_HUMAN 47 kDa 0 0 0 1 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma OS=Homo sapiens GN=PIP4K2C PE=1 SV=3PI42C_HUMAN 47 kDa 0 0 5 5 0 0 0 0
Phosphatidylinositol 4-kinase alpha OS=Homo sapiens GN=PI4KA PE=1 SV=3PI4KA_HUMAN 231 kDa 0 0 0 0 7 0 0 0
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3PRKDC_HUMAN 469 kDa 12 10 8 32 88 0 1 1
Serine/threonine-protein kinase 36 OS=Homo sapiens GN=STK36 PE=1 SV=2STK36_HUMAN 144 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 SV=1TAOK1_HUMAN 116 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase TAO2 OS=Homo sapiens GN=TAOK2 PE=1 SV=2TAOK2_HUMAN 138 kDa 0 0 1 1 0 0 0 0
Serine/threonine-protein kinase TAO3 OS=Homo sapiens GN=TAOK3 PE=1 SV=2TAOK3_HUMAN 105 kDa 1 1 3 1 0 0 0 0
Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1TBK1_HUMAN 84 kDa 0 0 1 2 9 0 0 0
Non-receptor tyrosine-protein kinase TNK1 OS=Homo sapiens GN=TNK1 PE=1 SV=3TNK1_HUMAN 72 kDa 0 1 2 2 1 0 1 1
Dual specificity protein kinase TTK OS=Homo sapiens GN=TTK PE=1 SV=2TTK_HUMAN 97 kDa 0 0 3 1 0 0 0 0
Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2VGFR1_HUMAN 151 kDa 0 0 0 0 0 0 0 0
Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2VGFR2_HUMAN 152 kDa 0 0 0 0 0 0 0 0
Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=3VGFR3_HUMAN 153 kDa 0 0 0 0 0 0 0 0  
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Proteins Accession MW c-Palbo_PT1 c-Palbo_PT2 c-Palbo1 c-Palbo2 c-Ribo_PT1 c-Ribo_PT2 c-Ribo1 c-Ribo2
AP2-associated protein kinase 1 OS=Homo sapiens GN=AAK1 PE=1 SV=3AAK1_HUMAN 104 kDa 1 0 3 6 0 0 0 0
5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AAPK1_HUMAN 64 kDa 2 1 4 2 0 0 0 0
BMP-2-inducible protein kinase OS=Homo sapiens GN=BMP2K PE=1 SV=2BMP2K_HUMAN 129 kDa 0 0 3 3 0 0 0 0
Cyclin-dependent kinase 4 OS=Homo sapiens GN=CDK4 PE=1 SV=2CDK4_HUMAN 34 kDa 0 0 3 3 0 0 1 0
Cyclin-dependent kinase 6 OS=Homo sapiens GN=CDK6 PE=1 SV=1CDK6_HUMAN 37 kDa 2 0 6 5 0 0 1 1
Cyclin-dependent kinase 9 OS=Homo sapiens GN=CDK9 PE=1 SV=3CDK9_HUMAN 43 kDa 0 0 1 2 0 0 0 2
Cyclin-dependent kinase-like 3 OS=Homo sapiens GN=CDKL3 PE=1 SV=1CDKL3_HUMAN 68 kDa 0 0 0 0 0 0 0 0
Cyclin-dependent kinase-like 5 OS=Homo sapiens GN=CDKL5 PE=1 SV=1CDKL5_HUMAN 116 kDa 0 0 0 0 0 0 0 0
Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1CSK21_HUMAN 45 kDa 0 0 7 4 0 0 0 0
Casein kinase II subunit alpha' OS=Homo sapiens GN=CSNK2A2 PE=1 SV=1CSK22_HUMAN 41 kDa 1 0 6 6 0 0 0 0
Casein kinase II subunit beta OS=Homo sapiens GN=CSNK2B PE=1 SV=1CSK2B_HUMA 25 kDa 0 0 2 3 0 0 0 0
Death-associated protein kinase 3 OS=Homo sapiens GN=DAPK3 PE=1 SV=1DAPK3_HUMAN 53 k a 0 0 1 4 0 0 0 0
Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK1_HUMAN 119 kDa 5 3 7 9 0 3 1 0
Protein-tyrosine kinase 2-beta OS=Homo sapiens GN=PTK2B PE=1 SV=2FAK2_HUMAN 116 kDa 1 1 7 7 0 0 0 0
Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER_HUMA 95 kDa 3 2 5 4 0 0 0 0
Tyrosine-protein kinase Fes/Fps OS=Homo sapiens GN=FES PE=1 SV=3FES_HUMAN 93 kDa 4 4 4 5 1 0 0 0
Receptor-type tyrosine-protein kinase FLT3 OS=Homo sapiens GN=FLT3 PE=1 SV=2FLT3_HUMAN 113 kDa 0 0 0 0 0 0 0 0
Cyclin-G-associated kinase OS=Homo sapiens GN=GAK PE=1 SV=2GAK_HUMA 143 kDa 0 0 0 0 0 0 5 3
Glycogen synthase kinase-3 beta OS=Homo sapiens GN=GSK3B PE=1 SV=2GSK3B_HUMAN 47 kDa 3 1 4 5 0 0 0 0
Calcium/calmodulin-dependent protein kinase type 1 OS=Homo sapiens GN=CAMK1 PE=1 SV=1KCC1A_HUMAN 41 kDa 0 0 0 0 0 0 0 0
Calcium/calmodulin-dependent protein kinase type 1D OS=Homo sapiens GN=CAMK1D PE=1 SV=1KCC1D_HUMAN 43 kDa 0 0 0 0 0 3 0 0
Calcium/calmodulin-dependent protein kinase type II subunit alpha OS=Homo sapiens GN=CAMK2A PE=1 SV=2KCC2A_HUMAN 54 kD 0 0 0 0 0 0 0 0
Calcium/calmodulin-dependent protein kinase type II subunit delta OS=Homo sapiens GN=CAMK2D PE=1 SV=3KCC2D_HUMAN 56 kDa 13 8 15 10 5 8 12 9
Calcium/calmodulin-dependent protein kinase type II subunit gamma OS=Homo sapiens GN=CAMK2G PE=1 SV=3KCC2G_HUMAN 63 kDa 6 4 6 5 0 5 6 2
Mast/stem cell growth factor receptor Kit OS=Homo sapiens GN=KIT PE=1 SV=1IT_HUMAN 110 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase D1 OS=Homo sapiens GN=PRKD1 PE=1 SV=2KPCD1_HUMAN 102 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase D2 OS=Homo sapiens GN=PRKD2 PE=1 SV=2KPCD2_HUMAN 97 kDa 0 0 3 3 0 0 0 0
Serine/threonine-protein kinase D3 OS=Homo sapiens GN=PRKD3 PE=1 SV=1KPCD3_HUMAN 100 kDa 0 0 0 1 0 0 0 0
Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2KS6A1_HUMAN 83 kDa 0 0 3 1 0 0 0 0
Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1KS6A3_HUMAN 84 kDa 0 0 1 1 0 0 0 0
Ribosomal protein S6 kinase alpha-4 OS=Homo sapiens GN=RPS6KA4 PE=1 SV=1KS6A4_HUMAN 86 kDa 1 0 2 2 0 0 0 0
Ribosomal protein S6 kinase alpha-5 OS=Homo sapiens GN=RPS6KA5 PE=1 SV=1KS6A5_HUMAN 90 kDa 0 0 1 2 0 0 0 0
Ribosomal protein S6 kinase alpha-6 OS=Homo sapiens GN=RPS6KA6 PE=1 SV=1KS6A6_HUMAN 84 kDa 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase kinase kinase 5 OS=Homo sapiens GN=MAP3K5 PE=1 SV=1M3K5_HUMAN 155 kD 4 1 4 3 0 10 0 0
Mitogen-activated protein kinase 1 OS=Homo sapiens GN=MAPK1 PE=1 SV=3MK01_HUMAN 41 kDa 6 4 6 5 0 2 0 0
Mitogen-activated protein kinase 3 OS=Homo sapiens GN=MAPK3 PE=1 SV=4MK03_HUMAN 43 kDa 3 0 2 0 0 0 0 0
Mitogen-activated protein kinase 8 OS=Homo sapiens GN=MAPK8 PE=1 SV=2MK08_HUMAN 48 kDa 1 0 0 2 0 0 0 0
Mitogen-activated protein kinase 9 OS=Homo sapiens GN=MAPK9 PE=1 SV=2MK09_HUMAN 48 kDa 4 3 5 4 0 2 0 0
Mitogen-activated protein kinase 10 OS=Homo sapiens GN=MAPK10 PE=1 SV=2MK10_HUMAN 53 kDa 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase 13 OS=Homo sapiens GN=MAPK13 PE=1 SV=1MK13_HUMAN 42 kDa 0 0 0 0 0 0 0 0
Platelet-derived growth factor receptor alpha OS=Homo sapiens GN=PDGFRA PE=1 SV=1PGFRA_HUMAN 123 kDa 0 0 0 0 0 0 0 0
Platelet-derived growth factor receptor beta OS=Homo sapiens GN=PDGFRB PE=1 SV=1PGFRB_HUMAN 124 kDa 0 0 0 0 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha OS=Homo sapiens GN=PIP4K2A PE=1 SV=2PI42A_HUMAN 46 kDa 1 0 1 3 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta OS=Homo sapiens GN=PIP4K2B PE=1 SV=1PI42B_HUMAN 47 kDa 0 0 1 1 0 0 0 0
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma OS=Homo sapiens GN=PIP4K2C PE=1 SV=3PI42C_HUMAN 47 kDa 0 0 8 6 0 0 0 0
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3PRKDC_HUMAN 469 kDa 1 0 1 2 0 17 0 0
Serine/threonine-protein kinase 36 OS=Homo sapiens GN=STK36 PE=1 SV=2TK36_HUMAN 144 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 SV=1TAOK1_HUMAN 116 kDa 0 0 0 0 0 0 0 0
Serine/threonine-protein kinase TAO2 OS=Homo sapiens GN=TAOK2 PE=1 SV=2TAOK2_HUMAN 138 kDa 0 0 0 1 0 0 0 0
Serine/threonine-protein kinase TAO3 OS=Homo sapiens GN=TAOK3 PE=1 SV=2TAOK3_HUMAN 105 kDa 1 0 1 1 0 0 0 0
Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1TBK1_HUMAN 84 kDa 0 0 0 0 0 2 0 0
Non-receptor tyrosine-protein kinase TNK1 OS=Homo sapiens GN=TNK1 PE=1 SV=3_HUMAN 72 kDa 0 0 3 1 0 0 0 0
Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2VGFR1_HUMAN 151 kDa 0 0 0 0 0 0 0 0
Vascular endothelial growth factor receptor 2 OS=Homo sapiens GN=KDR PE=1 SV=2VGFR2_HUMAN 152 kDa 0 0 0 0 0 0 0 0
Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=3VGFR3_HUMAN 153 kDa 0 0 0 0 0 0 0 0  
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Appendix E - Chemical synthesis  
All reagents were purchased from commercial suppliers and used without further 
purification. 1H NMR spectra were recorded on an Agilent-Varian Mercury 400 MHz 
spectrometer with CDCl3, CD3OD, or DMSO-d6 as the solvent. 13C NMR spectra were recorded 
at 100 MHz. All coupling constants are measured in Hertz, and the chemical shifts (δH and δC) 
are reported in parts per million. High-resolution mass spectrometry was carried out on an 
Agilent 6210 LC−MS (ESI-TOF) system. Microwave reactions were performed in Biotage 
Initiator 8 machines. HPLC analysis was performed using a JASCO HPLC system equipped 
with a PU-2089 Plus quaternary gradient pump and a UV-2075 Plus UV−vis detector, using an 
Alltech Kromasil C-18 column (150 × 4.6 mm, 5 μm) and an Agilent Eclipse XDB-C18 column 
(150 × 4.6 mm, 5 μm). The purities of the final compounds that underwent biological 
assessment were >97% as measured by HPLC. Melting points were recorded on an Optimelt 
automated melting point system (Stanford Research Systems). Thin-layer chromatography was 
performed using SiO2 60 F254 plates (Fisher), with observation under UV when necessary. 
Anhydrous solvents (dimethylformamide, dichloromethane, methanol, and tetrahydrofuran) were 
used as purchased from Aldrich. Burdick and Jackson HPLC-grade solvents (methanol and 
water) were purchased from VWR for HPLC and high-resolution mass analysis. HPLC-grade 
TFA was purchased from Fisher. The SiO2 column purification of compounds were carried out 
using Biotage automated Isolera purification system using a Biotage SiO2 prepacked columns. 
c-Cabozantinib  
tert-Butyl (3-((4-chloro-6-methoxyquinolin-7-yl)oxy)propyl)carbamate (8): In a 50 mL 
round bottom flask, 4-chloro-6-methoxyquinolin-7-ol (7) (1.17 g, 5.30 mmol) was dissolved in dry 
DMF (35.0 mL) and K2CO3 (7.32 g, 53 mmol) was added under argon atmosphere. The mixture 
was stirred at RT for 15 minutes followed by the addition of tert-butyl (3-bromopropyl)carbamate 
(1.30 g, 5.30 mmol). After stirring the reaction at RT. for 16 hours, crude NMR showed ~ 60% 
conversion to the product. Added more tert-butyl (3-bromopropyl)carbamate (0.5 equivalent,  
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650 mg, 2.65 mmol) and stirring was continued for an additional 8 hours. The reaction was 
repeated using the same procedure employing 1.0 g (4.77 mmol) of 4-chloro-6-methoxyquinolin-
7-ol. The combined crude mixture from both reactions was filtered and the solid was washed 
with ~ 30 mL of EtOAc. The filtrate was washed with water (2 x 50 mL) and concentrated. The 
crude solid was sonicated with methanol (3 mL) and solvent was decanted. The solid was 
further rinsed with methanol (2 x 1.5 mL) and dried under vacuum to give the title compound as 
beige solid (2.92 g, 80%).  Mp: 133-136 °C (dec.).  1H NMR (400 MHz, DMSO-d6): δ 8.60 (d, J = 
4.8 Hz, 1H), 7.57 (d, J = 4.8 Hz, 1H), 7.43 (s, 1H), 7.37 (s, 1H), 6.93 (t, J = 5.3 Hz, 1H, 
disappeared on D2O shake), 4.17 (t, J = 6.2 Hz, 2H), 3.97 (s, 3H), 3.13 (m, 2H), 1.92 (m, 2H), 
1.38 (s, 9H);  HPLC–MS (ESI+): m/z 367.2 [100%, (M35Cl+H)+], 369.2 [40%, (M37Cl+H)+]. 
tert-Butyl (3-((6-methoxy-4-(4-nitrophenoxy)quinolin-7-yl)oxy)propyl)carbamate (9): The 
tert-Butyl (3-((4-chloro-6-methoxyquinolin-7-yl)oxy)propyl)carbamate (8) (2.46 g, 6.71 mmol) 
and p-nitrophenol (1.03 g, 7.38 mmol, 1.10 equiv.) were dissolved in a 20 mL microwave vial 
and dry DIPEA (14.0 mL) was added. The microwave vial was capped and the reaction mixture 
was stirred at 130 °C (oil bath temp.) overnight. After completion of the reaction (monitored by 
HPLC-MS), the DIPEA was evaporated using a V-10 system and the resulting thick brown oil 
was triturated using EtOAc/hexane to give the title compound as a white solid (2.1 g, 67%).  Mp: 
212 °C (dec).  1H NMR (400 MHz, DMSO-d6): δ 8.61 (d, J = 5.1 Hz, 1H), 8.34 (d, J = 9.2 Hz, 
2H), 7.44 (d, J = 9.2 Hz, 2H), 7.43 (s, 1H), 7.37 (s, 1H), 6.94 (t, J = 6.2 Hz, 1H, peak intensity go 
down on D2O shake), 6.87 (d, J = 5.1 Hz, 1H), 4.17 (t, J = 6.4 Hz, 2H), 3.89 (s, 3H), 3.14 (m, 
2H), 1.89-1.90 (m, 2H), 1.38 (s, 9H);  HPLC–MS (ESI+): m/z 470.2 [100%, (M+H)+].  
tert-Butyl (3-((4-(4-aminophenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)carbamate (12): In 
a 50 mL round bottom flask, 10% Pd/C (455.61 mg, 0.2 equiv.) was added to dry MeOH (50 mL) 
and argon gas was bubbled through the mixture for 10 minutes. The tert-Butyl (3-((6-methoxy-4-
(4-nitrophenoxy)quinolin-7-yl)oxy)propyl)carbamate (9) (2.01 g, 4.28 mmol) was added to the  
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flask followed by hydrazine monohydrate (1.26 mL, 25.69 mmol, 6 equiv.). After stirring for 2 h 
at rt, HPLC-MS showed complete conversion of the starting material to the product. The 
reaction mixture was filtered through a short pad of celite and the filtrate was concentrated. The 
crude product was stirred in EtOAc/hexane (95:5,18 mL) at RT, filtered and dried under vacuum 
to give the title compound as a white solid (1.61 g, 86%).  Mp: 205 °C (dec).  1H NMR (400 MHz, 
DMSO-d6): δ 8.42 (d, J = 5.2 Hz, 1H), 7.50 (s, 1H), 7.34 (s, 1H), 6.94 (brs, partially overlapped, 
1H, 40% reduced on D2O shake), 6.92 (d, J = 8.6 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 6.36 (d, J = 
5.2 Hz, 1H), 5.17 (s, 2H), 4.15 (t, J = 6.2 Hz, 2H), 3.93 (s, 3H), 3.14 (m, 2H), 1.92 (m 2H), 1.38 
(s, 9H);  HPLC–MS (ESI+): m/z 440.2 [100%, (M+H)+]. 
1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid  (11): The Cyclopropane-
1,1-dicarboxylic acid (10) (2 g, 15.37 mmol) was dissolved in dry THF (20 mL) in a round bottom 
flask and the mixture was cooled to 0 °C (ice-water bath). Triethylamine (1.12 mL, 15.37 mmol) 
was slowly added (~over 2 min.) to the mixture and stirring was continued for 30 min. at the 
same temperature. Thionyl chloride (1.12 mL, 15. 37 mmol) was added and stirring was 
continued for another 30 min. The p-fluoroaniline (1.48 mL, 15.37 mmol) was dissolved in THF 
(20 mL) and added to the reaction mixture via a dropping funnel (over 20 min.). The reaction 
was stirred at 0 °C until the reaction went to completion (2 hours), diluted with EtOAc (~30 mL) 
and washed with brine (2 x 20 mL). The organic layer was separated and dried (Na2SO4). The 
crude solid product obtained was triturated using EtOAc/hexane (1:3) to give the title compound 
as an off-white solid (2.43 g, 67%).  Mp: 166-172 °C reported 167-170 °C (Literature (Exelixis, 
WO2005/30140, p=195).  1H NMR (400 MHz, DMSO-d6): δ 13.09 (s, 1H, disappeared on D2O 
shake), 10.57 (s, 1H), 7.66 – 7.57 (m, 2H), 7.17 – 7.11 (m, 2H), 1.40 (s, 4H);  19F NMR (400 
MHz, DMSO-d6): δ -119.02 – -119.22 (m);  HPLC–MS (ESI+): m/z 222.1 [100%, (M-H)+], 246.1 
[100%, (M+Na)+], 224.2 [80%, (M+H)+], 469.2 [35%, (2M+Na)+]. 
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tert-butyl (3-((4-(4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-
carboxamido)phenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)carbamate-bisTFA (13): The 1-((4-
fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid (11) (60 mg, 0.26 mmol) was dissolved 
in dry DMF (0.8 mL), cooled to 0 °C, followed by the addition of DIPEA (103.3 µL, 0.59 mmol, 
2.2 equiv.), HOBt (79.91 mg, 0.59 mmol, 2.2 eq.) and EDCI ( 113.37 mg, 0.59 mmol, 2.2 eq.). 
After stirring the reaction mixture for 40 minutes, tert-Butyl (3-((4-(4-aminophenoxy)-6-
methoxyquinolin-7-yl)oxy)propyl)carbamate (12) (118.15 mg, 0.26 mmol, 1 eq.) was added and 
the reaction was first warmed to RT and then heated at 70 °C (oil bath) for 12 h. The crude 
reaction mixture was diluted with water (~3 mL) and extracted with EtOAc (2 x 5 mL). The 
organic layer was dried (Na2SO4), evaporated and the crude product was purified using SiO2 
chromatography (eluents: MeOH:DCM , 5:95). The resulting material was further purified using 
preparative HPLC (Method: Gradient methanol-water with 0.1% TFA, 17 minutes run, flow rate 
20 mL/min). The title compound was obtained (in the form of bis-TFA salt) as a thick oil (39 mg, 
23%,) which partially solidified after drying under high-vacuum overnight.  1H NMR (400 MHz, 
DMSO-d6): δ 10.32 (s, 1H, disappeared on D2O shake), 10.02 (s, 1H, disappeared on D2O 
shake), 8.77 (d, J = 6.4 Hz, 1H), 7.85 (d, J = 9.0 Hz, 2H), 7.73 (s, 1H), 7.68 – 7.60 (m, 2H), 7.50 
(s, 1H), 7.37 (d, J = 9.0 Hz, 2H), 7.21–7.12 (m, 2H), 6.97 (t, J = 6.0 Hz, 1H, disappeared on D2O 
shake), 6.79 (d, J = 6.4 Hz, 1H), 4.23 (t, J = 6.0 Hz, 2H), 4.03 (s, 3H), 3.18–3.11 (m, 2H), 2.04–
1.92 (m, 2H), 1.55–1.44 (m, 4H), 1.38 (s, 9H); 19F NMR (400 MHz, DMSO-d6): δ -74.08 (s), -
118.95 – -119.07 (m);  HPLC–MS (ESI+): m/z 645.3 [100%, (M+H)+].   
N-(4-((7-(3-aminopropoxy)-6-methoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl) 
cyclopropane-1,1-dicarboxamide.bisTFA (14): The tert-butyl (3-((4-(4-(1-((4-
fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-6-methoxyquinolin-7-
yl)oxy)propyl)carbamate-bisTFA (13) (18 mg, 0.027 mmol) was dissolved in dry DCM (0.8 mL) 
and TFA (0.2 mL) was added. The reaction mixture was stirred at RT for 2 h at which point TLC  
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showed complete consumption of the starting material. The solvent was evaporated and the 
residual TFA was removed by evaporating the mixture with EtOAc (~ 4 mL) and DCM (~ 4 mL). 
Using a 4 mL vial, the crude compound was partitioned between 0.5 mL of 1N NaHCO3 (aq.) 
and EtOAc (2 x 2 mL). The aqueous layer was re-extracted with DCM (2 x 2 mL) and the 
combined organic layers were dried (Na2SO4), evaporated and lyophilized. The title compound 
was obtained as a white solid (11.7 mg, 77%) Mp: 203 °C (dec).  HPLC 99% [tR = 10.3 min, 
Gradient: MeOH-water (with 0.1% TFA) 40-95%, 1mL/min, 20 min];  1H NMR (400 MHz, DMSO-
d6) δ 10.27 (s, 1H, disappeared on D2O shake), 10.04 (s, 1H, disappeared on D2O shake), 8.61 
(s, 1H), 7.84 (brs, 2H, disappeared on D2O shake), 7.81 (d, J = 9.1 Hz, 2H), 7.64 (dd, J = 9.1, 
5.1 Hz, 3H), 7.50 (s, 1H), 7.28 (d, J = 9.0 Hz, 2H), 7.18–7.13 (m, 2H), 6.60 (s, 1H), 4.29 (t, J = 
5.9 Hz, 2H), 3.99 (s, 3H), 3.05-3.00 (m, 2H), 2.17–2.11 (m, 2H), 1.48 (d, J = 3.9 Hz, 4H);  19F 
NMR (400 MHz, DMSO-d6): δ -73.64 (brs), -118.97– -119.09 (m);  HPLC–MS (ESI+): m/z 545.3 
[95%, (M+H)+], 273.2 [100%, (M+2H)2+]; LC-MS 545.2 [100%, (M+H)+];  HRMS (ESI+) m/z 
calculated for C30H29FN4O5 (M+H)+ 545.2194, found 545.2193. 
c-Foretinib (10) 
N-(3-fluoro-4-hydroxyphenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (16): 
The 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid  (15), which was synthesized 
as described for the synthesis of c-cabozantinib, (100 mg, 0.45 mmol) was dissolved in dry THF 
(1 mL) and 1 drop of dry DMF was added at RT. The mixture was cooled to 0 °C and oxalyl 
chloride (38.4 µL, 0.45 mmol) was slowly added via a syringe. The mixture was stirred for 2 h at 
the same temperature and 3-fluoro-4-hydroxyaniline (56.9 mg, 68.3 mmol, 1.20 equiv.) and 
pyridine (0.5 ml, 500 mmol) were added in THF (1 mL). The reaction was stirred at 0 °C for 1 h, 
diluted with EtOAc (~5 mL) and the organic layer was washed with water (~5 mL). The organic 
layer was separated and stirred with 1M HCl (3 mL) for 30 minutes at rt. The organic layer was 
separated and the aqueous layer was extracted with EtOAc (5 mL). The combined organics  
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were dried (Na2SO4), evaporated and the solid obtained was triturated from EtOAc/hexane (1:3) 
to give the title compound as a beige solid (72 mg, 48%). Mp: 187 °C (dec).  1H NMR (400 MHz, 
DMSO-d6): δ 10.05 (s, 1H, disappeared on D2O shake), 9.90 (s, 1H, disappeared on D2O 
shake), 9.58 (s, 1H, disappeared on D2O shake), 7.61 (dd, J = 8.9, 5.1 Hz, 2H), 7.52 (dd, J = 
13.5, 2.0 Hz, 1H), 7.14 (t, J = 8.9 Hz, 3H), 6.93–6.80 (m, 1H), 1.43 (brs, 4H);  19F NMR (376 
MHz, DMSO-d6): δ -119.02 – -119.22 (m), -135.34 (dd, J = 13.3, 10.2 Hz, 1H);  HPLC–MS 
(ESI+): m/z 333.1 [90%, (M+H)+], 355.1 [100%, (M+Na) +], 687.2 [80%, (2M+Na)+].    
tert-Butyl 4-(3-chloropropyl)piperazine-1-carboxylate (18): In a 5 mL microwave reaction 
vial, 1-boc-piperazine (17) (186 mg, 1 mmol) and 1-bromo-3-chloropropane (197.8 µL, 2 mmol) 
were dissolved in dry DMF (1 mL) and K2CO3 (276 mg, 2 mmol) was added under argon.  The 
reaction mixture was heated at 80 °C (oil bath) for 1 h at which point TLC showed complete 
consumption of the starting material piperazine. The reaction mixture was filtered and 
concentrated to obtain a thick brown oil. The crude was rinsed with hexane (5 mL x 4) to give 
the title compound as a light yellow oil (217 mg, 87%) which partially solidified overnight at 4 °C. 
Reaction was repeated with 1-boc-piperazine (17) (1.86 g, 10 mmol) using the same procedure 
described here to obtain the title compound (2.2 g, 84%).  1H NMR (400 MHz, CDCl3): δ 3.60 (t, 
J = 6.5 Hz, 2H), 3.43 – 3.41 (t, J = 5.2 Hz, 4H), 2.48 (t, J = 7.0 Hz, 2H), 2.38 – 2.36 (J = 5.2 Hz, 
4H), 1.94 (p, J = 6.8 Hz, 2H), 1.46 (s, 9H);  HPLC–MS (ESI+): m/z 263.2 [100%, (M35Cl+H) +], 
265.2 [40%, (M37Cl+H) +]. 
tert-Butyl 4-(3-((4-chloro-6-methoxyquinolin-7-yl)oxy)propyl)piperazine-1-carboxylate 
(19): The 4-chloro-6-methoxyquinolin-7-ol (1.0 g, 4.77 mmol) was dissolved in dry DMF (10 mL) 
in a 20 ml microwave vial and K2CO3 (1.32 g, 9.54 mmol) was added at r.t. The mixture was 
stirred under argon for 10 minutes followed by the addition of tert-Butyl 4-(3-
chloropropyl)piperazine-1-carboxylate (18) (1.5 g, 5.72 mmol). The reaction mixture was heated 
at 80 °C (oil bath) for 6 h at which point HPLC-MS showed complete consumption of the starting  
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material. The crude mixture was filtered and the solid was washed with EtOAc (~ 5 mL). The 
organic filtrate was combined and evaporated. The crude solid was dissolved in EtOAc (~100 
mL) and the organic layer was washed with water (50 mL x 2) and brine (50 mL) and dried 
(Na2SO4). After evaporation of the organic layer, the crude mixture was triturated from 
EtOAc/hexane to give the title compound as light green solid (1.78 g, 86%). Mp: 116-119 °C.  1H 
NMR (400 MHz, MeOD): δ 8.51 (d, J = 4.0 Hz, 1H), 7.49 (d, J = 4.0 Hz, 1H), 7.46 (s, 1H), 7.38 
(s, 1H), 4.24 (t, J = 5.2 Hz, 2H), 4.01 (s, 3H), 3.45 (broad t, J = 3.6 Hz, 4H), 2.63 (t, J = 5.6 Hz, 
3H), 2.48 (t, J = 4.4 Hz, 4H), 2.14 – 2.09 (m, 2H), 1.45 (s, 9H);  HPLC–MS (ESI+): m/z 438.2 
[40%, (M37Cl+H) +], 436.2 [100%, (M35Cl+H) +]. 
tert-Butyl4-(3-((4-(2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-
carboxamido) phenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)piperazine-1-carboxylate (20): The 
N-(3-fluoro-4-hydroxyphenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (16) (381 mg, 
1.15 mmol) and tert-Butyl 4-(3-((4-chloro-6-methoxyquinolin-7-yl)oxy)propyl)piperazine-1-
carboxylate (19) (500 mg, 1.15 mmol) were dissolved in DIPEA (1.15 mL) in a 5 ml microwave 
vial and the reaction mixture was stirred at 130 °C (oil bath) for 3 h. The TLC showed ~50% 
conversion of the starting material to the product. However, undesired side products also started 
to form as indicated by TLC and HPLC-MS. At this stage, MeOH (1-2 mL) was added and the 
solvent mixture was evaporated using Biotage V-10 system. The crude compound was purified 
using SiO2 column chromatography (eluting with EtOAc: Hexane, 0:10 to 10:0 followed by 
MeOH:DCM, 0:10 to 1.2:8.8). The title compound was obtained as a gray solid (207 mg, 25%). 
Notably, doing the same reaction at elevated temperature or in a microwave reactor resulted in 
the formation of side products (indicated by TLC). Mp: 178 °C (dec).  1H NMR (400 MHz, 
DMSO-d6): δ 10.39 (s, 1H, disappeared on D2O shake), 10.01 (s, 1H, disappeared on on D2O 
shake), 8.46 (d, J = 5.1 Hz, 1H), 7.90 (dd, J = 13.2, 2.0 Hz, 1H), 7.64 (dd, J = 9.0, 5.1 Hz, 2H), 
7.52 (s, 2H), 7.43-7.38 (m, 2H), 7.15 (t, J = 9.0 Hz, 2H), 6.41 (d, J = 5.0 Hz, 1H), 4.19 (t, J = 6.0  
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Hz, 2H), 3.95 (s, 3H), 3.61 (brs, 2H), 3.17 – 3. 11 (m, 4H), 2.35 (brs, 4H), 1.99 – 1.96 (m, 2H), 
1.48 (brs, 4H), 1.40 (s, 9H); 19F NMR (376 MHz, DMSO-d6) δ -118.88 – -119.30 (m), -128.81 
(dd, J = 13.3, 10.2 Hz); HPLC–MS (ESI+): m/z 732.3 [100%, (M+H) +]. 
N-(3-Fluoro-4-((6-methoxy-7-(3-(piperazin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide (21): tert-Butyl4-(3-((4-(2-fluoro-4-(1-((4-
fluorophenyl)carbamoyl)cyclopropane-1-carboxamido) phenoxy)-6-methoxyquinolin-7-
yl)oxy)propyl)piperazine-1-carboxylate (20) (100 mg, 0.136 mmol) was dissolved in 20% TFA in 
DCM (1 mL) and stirred at RT for 2 h. The TLC and HPLC-MS showed complete consumption 
of the starting material. The solvent was evaporated and residual TFA was removed by 
evaporating the reaction mixture with DCM (2 mL x 4) and EtOAc (2 mL x 4). The crude product 
was rinsed with DCM (2 mL) and hexane (2 mL) and dried under high vacuum to give the title 
compound (tris TFA salt) as a gummy oil which (partly solidified after storage in a refrigerator 
overnight) (106 mg, 123%).  1H NMR (400 MHz, DMSO-d6): 10.47 (s, 1H, 50% disappeared on 
D2O shake), 9.98 (s, 1H, 40% disappeared on D2O shake), 8.96 (s, 1H, disappeared on D2O 
shake), 8.67 (d, J = 5.4 Hz, 1H), 7.95 (dd, J = 13.2, 1.7 Hz, 1H), 7.67 (s, 1H), 7.64 (dd, J = 8.9, 
5.1 Hz, 2H), 7.59 – 7.55 (m, 1H), 7.54 (s, 1H), 7.48 (t, J = 8.9 Hz, 1H), 7.16 (t, J = 8.9 Hz, 2H), 
6.71 (brs, 1H), 4.29 (t, J = 5.8 Hz, 2H), 4.01 (s, 3H), 3.66 – 3.56 (m, 2H), 3.30 (brs, 4H), 3.15-
3.12 (m, 2H), 2.18 (brs, 2H), 1.53 – 1.42 (m, 4H), 1.26 (t, J = 6.3 Hz, 4H);  19F NMR (376 MHz, 
DMSO-d6) δ -73.99 (s), -118.91 – -119.01 (m), -128.69 (dd, J = 11.4, 8.3 Hz);  HPLC–MS 
(ESI+): m/z 632.3 [100%, (M+H) +], 316.7 [100%, (M+2H)2+]. 
tert-Butyl(3-(4-(3-((4-(2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-
carboxamido)phenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)piperazin-1-yl)propyl)carbamate (22): 
The N-(3-Fluoro-4-((6-methoxy-7-(3-(piperazin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide (21) (104 mg, 0.13) was dissolved in dry DMF 
(0.2 mL) under inert conditions, powdered and dry K2CO3 (55.79 mg, 0.40 mmol) was added to  
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the mixture. After stirring at RT for 15 minutes, tert-butyl (3-bromopropyl)carbamate (41.66 mg, 
0.17 mmol, 1.3 equiv.) was added to the reaction mixture and heated at 80 °C for 12 h. The 
HPLC-MS and TLC showed complete consumption of the starting material. The crude mixture 
was concentrated, MeOH (5 mL) was added to the crude mixture before filtration. The filtrate 
was concentrated under reduced pressure and purified using Biotage Isolera purification system 
(SiO2, eluting with MeOH:DCM, 0:10 to 1.5: 8.5). The title compound (in the form of bis TFA 
salt) was obtained as a light yellow solid (67 mg, 63%). Mp: 188.2 °C (dec).  1H NMR (400 MHz, 
DMSO-d6): 10.39 (s, 1H, disappeared on D2O shake), 10.01 (s, 1H, disappeared on D2O 
shake), 8.47 (d, J = 5.0 Hz, 1H), 7.90 (d, J = 13.4 Hz, 1H), 7.64 (dd, J = 8.9, 5.0 Hz, 2H), 7.53–
7.49 (m, 2H), 7.43 – 7.39 (m, 2H), 7.16 (t, J = 8.8 Hz, 2H), 6.82 (brs, 1H, disappeared on D2O 
shake), 6.41 (d, J = 5.2 Hz, 1H), 4.19 (brt, J = 5.8 Hz, 2H), 3.95 (s, 3H), 3.108–3.03 (broad m, 
9H), 2.95–2.90 (m, 3H), 2.29 – 2.23 (m, 4H), 2.02–1.96 (m, 2H), 1.47 (broad s, 4H), 1.37 (s, 
9H); HPLC–MS (ESI+): m/z 789.4 [30%, (M+H)+], 395.2 [100%, (M+2H)2+].  
N-(4-((7-(3-(4-(3-aminopropyl)piperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3-
fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.TrisTFA (23): The tert-Butyl(3-
(4-(3-((4-(2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-6-
methoxyquinolin-7-yl)oxy)propyl)piperazin-1-yl)propyl)carbamate (22) (64 mg, 0.08 mmol) was 
dissolved in dry DCM (2 mL) and TFA (0.2 mL) was added to the mixture. After stirring the 
reaction mixture at RT for 2 h, TLC showed complete conversion of the starting material to the 
product. The solvent was evaporated and residual TFA was removed by evaporating the 
product with DCM (2 mL x 4) and MeOH (2 mL x 4). The crude product was loaded on a short 
plug of celite and low polar impurities were removed by eluting with DCM (10 mL). The product 
was eluted with MeOH:DCM (2:8), concentrated, and rinsed with DCM (~2 mL x 3) and 
lyophilized for 24 h. The title compound (tris TFA salt) was obtained as a light yellow gummy 
solid (20 mg, 36%).  Mp: 227 °C (dec). HPLC: 98% [tR = 14.5 min, gradient MeOH-water (with  
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0.1% TFA), 5-95% over 20 min.]; 1H NMR (400 MHz, CD3OD): δ 8.73 (dd, J = 6.7, 2.1 Hz, 1H), 
7.96 (dd, J = 12.7, 2.1 Hz, 1H), 7.87-7.85 (m, 1H), 7.59 – 7.54 (m, 3H), 7.51-7.47 (m, 2H), 7.07 
(t, J =, 8.4 Hz, 2H), 6.99 (d, J = 6.0 Hz, 1H), 4.52 – 4.32 (m, 3H), 4.22-4.14 (m, 1H), 4.11 (s, 
3H), 3.98 – 3.88 (m, 3H), 3.58 – 3.39 (m, 3H), 3.14 (t, J = 6.8 Hz, 2H), 3.06 (t, J = 7.2 Hz, 2H), 
2.78 (t, J = 6.8 Hz, 1H), 2.72-2.65 (m, 1H), 2.47-2.42 (m, 1H), 2.38 – 2.27 (m, 1H), 2.01-1.89 (m, 
1H), 1.66 (s, 4H);  19F NMR (376 MHz, DMSO-d6): δ -73.91 (s), -118.85 – -119.10 (m), -128.62 – 
-128.91 (m);  HPLC–MS (ESI+): m/z 689.3 [30%, (M+H) +], 345.3 [100%, (M+2H)2+];  LC-MS 
689.3 [100%, (M+H)+], 345.2 [55%, (M+2H)2+];  HRMS (ESI+) m/z calculated for C37H42F2N6O2 
(M+H)+ 689.3257, found 689.3255. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
Appendix F – CCCP in H1155 cells: kinases proteins and lipid kinases 
Appendix F - CCCP of H1155 cells: kinases proreins and lipid kinases 
Proteins Accession MW AMP1 AMP2 c-Cabo_PT1 c-Cabo_PT2 c-Cabo1 c-Cabo2 c-Fore_PT1 c-Fore_PT2 c-Fore1 c-Fore2
5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AAPK1_HUMAN 64 kDa 0 0 0 0 0 0 12 12 7 13
Abelson tyrosine-protein kinase 2 OS=Homo sapiens GN=ABL2 PE=1 SV=1ABL2_HUMA 1 8 kDa 0 0 31 28 38 38 9 10 31 34
Serine-protein kinase ATM OS=Homo sapiens GN=ATM PE=1 SV=4ATM_HUMAN 351 kDa 0 0 33 29 43 38 78 76 86 63
Serine/threonine-protein kinase ATR OS=Homo sapiens GN=ATR PE=1 SV=3ATR_HUMAN 301 kDa 0 0 18 21 22 30 44 45 46 47
Aurora kinase A OS=Homo sapiens GN=AURKA PE=1 SV=2AURKA_HUMAN 46 kDa 0 0 11 11 12 11 10 10 7 12
Aurora kinase B OS=Homo sapiens GN=AURKB PE=1 SV=3AURKB_HUMAN 39 kDa 0 0 5 5 8 10 1 2 5 6
Cyclin-dependent kinase 17 OS=Homo sapiens GN=CDK17 PE=1 SV=2CDK17_HUMAN 60 kDa 0 0 0 0 0 0 2 2 2 2
Cyclin-dependent kinase 7 OS=Homo sapiens GN=CDK7 PE=1 SV=1CDK7_HUMAN 39 kDa 0 0 0 0 0 1 0 0 0 3
Serine/threonine-protein kinase Chk2 OS=Homo sapiens GN=CHEK2 PE=1 SV=1CHK2_HUMAN 61 kDa 0 0 0 0 0 1 2 1 3 4
Tyrosine-protein kinase CSK OS=Homo sapiens GN=CSK PE=1 SV=1CSK_HUMAN 51 kDa 0 0 9 7 7 12 29 23 23 26
Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1CSK21_HUMAN 45 kDa 0 0 3 2 2 3 2 4 1 2
Epithelial discoidin domain-containing receptor 1 OS=Homo sapiens GN=DDR1 PE=1 SV=1DDR1_HUMAN 101 kDa 0 0 0 0 9 13 0 0 3 2
Discoidin domain-containing receptor 2 OS=Homo sapiens GN=DDR2 PE=1 SV=2DDR2_HUMAN 97 k a 0 0 0 0 28 26 0 0 20 21
Dual serine/threonine and tyrosine protein kinase OS=Homo sapiens GN=DSTYK PE=1 SV=2DUSTY_HUMAN 105 kDa 0 0 0 0 0 0 1 1 1 5
Eukaryotic translation initiation factor 2-alpha kinase 1 OS=Homo sapiens GN=EIF2AK1 PE=1 SV=2E2AK1_HUMAN 71 kDa 0 0 0 0 0 1 2 2 1 4
Eukaryotic translation initiation factor 2-alpha kinase 3 OS=Homo sapiens GN=EIF2AK3 PE=1 SV=3E2AK3_HUMAN 125 kDa 0 0 0 0 0 0 9 4 13 13
Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2EGFR_HUMA 134 kDa 0 0 0 0 0 0 0 1 4 4
Ephrin type-A receptor 2 OS=Homo sapiens GN=EPHA2 PE=1 SV=2EPHA2_HUM N 108 kDa 0 0 9 13 26 28 2 2 22 16
Ephrin type-A receptor 4 OS=Homo sapiens GN=EPHA4 PE=1 SV=1EPHA4_HUM N 110 kDa 0 0 1 1 1 2 2 2 2 2
Ephrin type-A receptor 5 OS=Homo sapiens GN=EPHA5 PE=1 SV=3EPHA5_HUM N 115 kDa 0 0 13 11 16 21 1 0 14 15
Ephrin type-B receptor 2 OS=Homo sapiens GN=EPHB2 PE=1 SV=5EPHB2_HUMAN 117 kDa 0 0 14 11 15 19 6 4 11 12
Ephrin type-B receptor 3 OS=Homo sapiens GN=EPHB3 PE=1 SV=2EPHB3_HUMAN 110 kDa 0 0 5 3 6 8 6 4 6 5
Ephrin type-B receptor 4 OS=Homo sapiens GN=EPHB4 PE=1 SV=2EPHB4_HUMAN 108 kDa 0 0 2 4 9 7 1 2 3 3
Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK1_HUMAN 119 kDa 0 0 27 27 36 39 58 51 56 57
Protein-tyrosine kinase 2-beta OS=Homo sapiens GN=PTK2B PE=1 SV=2FAK2_HUMAN 116 kDa 0 0 0 0 0 1 0 0 0 3
Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER_HUMAN 95 kDa 0 0 14 17 29 32 20 22 23 23
Tyrosine-protein kinase FRK OS=Homo sapiens GN=FRK PE=1 SV=1FRK_HUMAN 58 kDa 0 0 0 0 3 4 0 0 1 1
Tyrosine-protein kinase Fyn OS=Homo sapiens GN=FYN PE=1 SV=3FYN_HUMAN 61 kDa 0 0 5 5 10 7 5 6 1 7
Glycogen synthase kinase-3 alpha OS=Homo sapiens GN=GSK3A PE=1 SV=2GSK3A_HUMA 51 kDa 0 0 0 0 0 0 5 7 5 6
Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1IGF1R_HUMAN 155 kDa 0 0 0 0 0 0 5 7 6 9
Inhibitor of nuclear factor kappa-B kinase subunit alpha OS=Homo sapiens GN=CHUK PE=1 SV=2IKKA_HUMAN 85 kDa 0 0 0 0 0 0 1 2 0 0
Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=4INSR_HUMAN 156 kDa 0 0 0 0 0 0 7 4 11 9
Interleukin-1 receptor-associated kinase 1 OS=Homo sapiens GN=IRAK1 PE=1 SV=2IRAK1_HUMAN 77 kDa 0 0 2 0 0 0 2 3 1 2
Interleukin-1 receptor-associated kinase 3 OS=Homo sapiens GN=IRAK3 PE=1 SV=2IRAK3_HUMAN 68 kDa 0 0 0 0 1 1 11 14 11 13
Tyrosine-protein kinase JAK2 OS=Homo sapiens GN=JAK2 PE=1 SV=2JAK2_HUMAN 131 kDa 0 0 0 0 4 2 0 0 2 3
cAMP-dependent protein kinase catalytic subunit alpha OS=Homo sapiens GN=PRKACA PE=1 SV=2KAPCA_HUMAN 41 kDa 0 0 3 3 2 3 3 2 3 3
Tyrosine-protein kinase Lyn OS=Homo sapiens GN=LYN PE=1 SV=3LYN_HUMAN 59 kDa 0 0 13 15 22 23 17 12 12 16
Mitogen-activated protein kinase kinase kinase 1 OS=Homo sapiens GN=MAP3K1 PE=1 SV=4M3K1_HUMAN 164 kDa 0 0 3 7 5 11 1 1 2 3
Mitogen-activated protein kinase kinase kinase 11 OS=Homo sapiens GN=MAP3K11 PE=1 SV=1M3K11_HUMAN 93 kDa 0 0 0 0 0 0 5 3 3 3
Mitogen-activated protein kinase kinase kinase 12 OS=Homo sapiens GN=MAP3K12 PE=1 SV=2M3K12_HUMAN 93 kDa 0 0 7 8 5 6 1 1 2 3
Mitogen-activated protein kinase kinase kinase 13 OS=Homo sapiens GN=MAP3K13 PE=1 SV=1M3K13_HUMAN 108 kDa 0 0 2 1 1 0 0 0 0 0
Mitogen-activated protein kinase kinase kinase kinase 5 OS=Homo sapiens GN=MAP4K5 PE=1 SV=1M4K5_HUMAN 95 kDa 0 0 1 9 12 12 30 35 37 44
Maternal embryonic leucine zipper kinase OS=Homo sapiens GN=MELK PE=1 SV=3MELK_HUMAN 75 kDa 0 0 1 2 1 4 7 8 5 8
Tyrosine-protein kinase Mer OS=Homo sapiens GN=MERTK PE=1 SV=2MERTK_HU AN 110 kDa 0 0 0 0 13 9 0 0 2 1
Mitogen-activated protein kinase 8 OS=Homo sapiens GN=MAPK8 PE=1 SV=2MK08_HUMAN 48 kDa 0 0 0 0 0 0 0 1 1 0
Mitogen-activated protein kinase 9 OS=Homo sapiens GN=MAPK9 PE=1 SV=2MK09_HUMAN 48 kDa 0 0 3 1 3 6 7 6 7 9
Mitogen-activated protein kinase 12 OS=Homo sapiens GN=MAPK12 PE=1 SV=3MK12_HUMAN 42 kDa 0 0 0 0 0 0 2 1 2 4
Mitogen-activated protein kinase 13 OS=Homo sapiens GN=MAPK13 PE=1 SV=1MK13_HUMAN 42 kDa 0 0 5 2 5 7 12 15 16 12
Mitogen-activated protein kinase 14 OS=Homo sapiens GN=MAPK14 PE=1 SV=3MK14_HUMAN 41 kDa 0 0 12 9 11 17 10 11 12 15
MAP kinase-interacting serine/threonine-protein kinase 1 OS=Homo sapiens GN=MKNK1 PE=1 SV=1MKNK1_HUMAN 51 kDa 0 0 0 0 5 2 0 0 2 3
MAP kinase-interacting serine/threonine-protein kinase 2 OS=Homo sapiens GN=MKNK2 PE=1 SV=3MKNK2_HUMAN 52 kDa 0 0 0 0 3 3 2 1 2 1
Mitogen-activated protein kinase kinase kinase MLT OS=Homo sapiens GN=ZAK PE=1 SV=3MLTK_HUMAN 91 kDa 0 0 33 29 36 34 18 21 25 26
Dual specificity mitogen-activated protein kinase kinase 1 OS=Homo sapiens GN=MAP2K1 PE=1 SV=2MP2K1_HUMAN 43 kDa 0 0 9 8 12 11 10 15 11 14
Dual specificity mitogen-activated protein kinase kinase 2 OS=Homo sapiens GN=MAP2K2 PE=1 SV=1MP2K2_HUMAN 44 kDa 0 0 12 10 10 9 12 13 14 16
Dual specificity mitogen-activated protein kinase kinase 5 OS=Homo sapiens GN=MAP2K5 PE=1 SV=2MP2K5_HUMAN 50 kDa 0 0 7 5 9 8 4 4 3 5
Serine/threonine-protein kinase mTOR OS=Homo sapiens GN=MTOR PE=1 SV=1MTOR_HUMAN 289 kDa 0 0 59 49 73 86 125 132 126 121
High affinity nerve growth factor receptor OS=Homo sapiens GN=NTRK1 PE=1 SV=4NTRK1_HUMAN 87 kDa 0 0 2 1 7 7 0 0 0 0
Phosphoinositide 3-kinase regulatory subunit 4 OS=Homo sapiens GN=PIK3R4 PE=1 SV=3PI3R4_HUMAN 153 kDa 0 0 1 3 3 3 5 2 5 6
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta OS=Homo sapiens GN=PIP4K2B PE=1 SV=1PI42B_HUMAN 47 kDa 0 0 0 0 0 0 0 0 2 1
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma OS=Homo sapiens GN=PIP4K2C PE=1 SV=3PI42C_HUMAN 47 kDa 0 0 0 0 3 2 2 2 9 8
Phosphatidylinositol 4-kinase alpha OS=Homo sapiens GN=PI4KA PE=1 SV=3PI4KA_HUMAN 231 kDa 0 0 12 10 16 11 29 27 34 25
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform OS=Homo sapiens GN=PIK3CB PE=1 SV=1PK3CB_HUMAN 123 kDa 0 0 0 0 0 0 1 1 2 2
Serine/threonine-protein kinase PLK4 OS=Homo sapiens GN=PLK4 PE=1 SV=3PLK4_HUMAN 109 kDa 0 0 1 1 4 3 1 1 2 3
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3PRKDC_HUMAN 469 kDa 3 9 248 258 305 309 402 435 417 390
RAF proto-oncogene serine/threonine-protein kinase OS=Homo sapiens GN=RAF1 PE=1 SV=1RAF1_HUMAN 73 kDa 0 0 0 0 0 0 2 0 0 0
Proto-oncogene tyrosine-protein kinase receptor Ret OS=Homo sapiens GN=RET PE=1 SV=3RET_HUMAN 124 kDa 0 0 0 0 6 7 0 0 0 0
Receptor-interacting serine/threonine-protein kinase 2 OS=Homo sapiens GN=RIPK2 PE=1 SV=2RIPK2_HUMAN 61 kDa 0 0 12 9 29 24 2 1 13 18
Rho-associated protein kinase 2 OS=Homo sapiens GN=ROCK2 PE=1 SV=4ROCK2_HUMAN 161 kDa 0 0 0 0 0 0 0 2 1 0
Macrophage-stimulating protein receptor OS=Homo sapiens GN=MST1R PE=1 SV=2RON_HUMAN 152 kDa 0 0 7 7 13 11 0 0 5 10
Serine/threonine-protein kinase SIK2 OS=Homo sapiens GN=SIK2 PE=1 SV=1SIK2_HUMAN 104 kDa 0 0 0 0 0 0 1 2 2 2
STE20-like serine/threonine-protein kinase OS=Homo sapiens GN=SLK PE=1 SV=1SLK_ UMAN 143 kDa 0 0 0 1 2 3 7 6 5 6
Serine/threonine-protein kinase SMG1 OS=Homo sapiens GN=SMG1 PE=1 SV=3MG1_HUMAN 410 kDa 0 0 7 2 15 13 46 53 51 33
Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3SRC_HUMAN 60 kDa 0 0 22 23 25 29 18 20 19 21
Serine/threonine-protein kinase 10 OS=Homo sapiens GN=STK10 PE=1 SV=1STK10_HUMA 112 kDa 0 0 1 1 5 4 1 1 2 2
Serine/threonine-protein kinase 33 OS=Homo sapiens GN=STK33 PE=1 SV=1STK33_HUMA 58 kDa 0 0 0 0 0 0 7 6 7 8
Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1TBK1_HUMAN 84 kDa 0 0 4 4 8 8 15 19 17 23
Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=3VGFR3_HUMAN 153 kDa 0 0 0 0 23 22 0 0 6 3
Tyrosine-protein kinase Yes OS=Homo sapiens GN=YES1 PE=1 SV=3YES_HUMAN 61 kDa 0 0 14 8 13 16 18 18 14 17  
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Proteins Accession Number MW AMP1 AMP2 AMP3 c-CABO_PT1 c-CABO_PT2 c-CABO_PT3 c-CABO1 c-CABO2 c-CABO3 c-FORE_PT1 c-FORE_PT2 c-FORE_PT3 c-FORE1 c-FORE2 c-FORE3
5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AAPK1_HUMAN 64 kDa 0 0 0 0 0 0 0 0 1 4 1 2 8 7 2
Tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4ABL1_HUMAN 23 kDa 0 0 0 1 1 1 5 3 5 0 0 0 4 5 7
Abelson tyrosine-protein kinase 2 OS=Homo sapiens GN=ABL2 PE=1 SV=1ABL2_HUM N 128 kDa 0 0 0 4 4 4 5 6 5 1 1 2 4 5 6
Serine-protein kinase ATM OS=Homo sapiens GN=ATM PE=1 SV=4ATM_HUMAN 351 kDa 0 0 0 7 5 10 9 10 3 15 6 18 30 31 36
Serine/threonine-protein kinase ATR OS=Homo sapiens GN=ATR PE=1 SV=3ATR_HUMAN 301 kDa 0 0 0 1 0 3 2 2 0 5 0 4 9 12 10
Aurora kinase A OS=Homo sapiens GN=AURKA PE=1 SV=2AURKA_HUMAN 46 kDa 0 0 0 4 2 5 2 5 6 6 1 3 5 5 5
Aurora kinase B OS=Homo sapiens GN=AURKB PE=1 SV=3AURKB_HUMAN 39 kDa 0 0 0 2 1 5 5 8 8 1 0 1 7 9 13
Cyclin-dependent kinase 7 OS=Homo sapiens GN=CDK7 PE=1 SV=1CDK7_HUMAN 39 kDa 0 0 0 0 0 0 0 0 0 1 0 0 1 2 1
Serine/threonine-protein kinase Chk2 OS=Homo sapiens GN=CHEK2 PE=1 SV=1CHK2_HUMAN 61 kDa 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0
Tyrosine-protein kinase CSK OS=Homo sapiens GN=CSK PE=1 SV=1CSK_HUMAN 51 kDa 0 0 0 0 0 0 0 0 0 11 3 4 14 12 7
Epithelial discoidin domain-containing receptor 1 OS=Homo sapiens GN=DDR1 PE=1 SV=1DDR1_ UMAN 101 kDa 0 0 0 0 0 0 6 6 7 0 0 0 7 6 6
Eukaryotic translation initiation factor 2-alpha kinase 3 OS=Homo sapiens GN=EIF2AK3 PE=1 SV=3E2AK3_HUMAN 125 kDa 0 0 0 0 0 0 0 0 0 1 0 0 6 7 4
Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2EGFR_HUMAN 134 kDa 0 0 0 0 0 0 0 0 0 5 2 5 14 15 12
Ephrin type-A receptor 1 OS=Homo sapiens GN=EPHA1 PE=1 SV=4EPHA1_HUMAN 108 kDa 0 0 0 2 2 5 3 5 3 0 0 1 5 6 5
Ephrin type-A receptor 2 OS=Homo sapiens GN=EPHA2 PE=1 SV=2EPHA2_HUMAN 108 kDa 0 0 0 15 15 21 27 30 34 8 5 5 40 46 42
Ephrin type-A receptor 5 OS=Homo sapiens GN=EPHA5 PE=1 SV=3EPHA5_HUMAN 115 kDa 0 0 0 3 3 4 6 8 8 0 0 0 9 11 11
Ephrin type-A receptor 6 OS=Homo sapiens GN=EPHA6 PE=2 SV=3EPHA6_HUMAN 116 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Ephrin type-A receptor 7 OS=Homo sapiens GN=EPHA7 PE=1 SV=3EPHA7_HUMAN 112 kDa 0 0 0 3 3 3 11 12 12 1 0 0 13 14 10
Ephrin type-A receptor 8 OS=Homo sapiens GN=EPHA8 PE=1 SV=2EPHA8_HUMAN 111 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Ephrin type-B receptor 2 OS=Homo sapiens GN=EPHB2 PE=1 SV=5EPHB2_HUMAN 117 kDa 0 0 0 1 0 2 1 3 3 0 0 0 2 4 1
Ephrin type-B receptor 3 OS=Homo sapiens GN=EPHB3 PE=1 SV=2EPHB3_HUMAN 110 kDa 0 0 0 0 0 0 1 2 1 0 0 0 0 2 1
Ephrin type-B receptor 4 OS=Homo sapiens GN=EPHB4 PE=1 SV=2EPHB4_HUMAN 108 kDa 0 0 0 9 9 8 12 13 12 6 4 4 12 16 15
Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1ERBB2_HUMAN 138 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK1_HUMAN 119 kDa 0 0 0 0 0 0 0 0 0 6 1 3 15 13 10
Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER_HUMAN 95 kDa 0 0 0 0 0 0 1 2 3 3 1 1 4 4 4
Tyrosine-protein kinase Fes/Fps OS=Homo sapiens GN=FES PE=1 SV=3FES_HUMAN 93 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tyrosine-protein kinase Fyn OS=Homo sapiens GN=FYN PE=1 SV=3FYN_HUMAN 61 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tyrosine-protein kinase HCK OS=Homo sapiens GN=HCK PE=1 SV=5HCK_HUMAN 60 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Insulin-like growth factor 1 receptor OS=Homo sapiens GN=IGF1R PE=1 SV=1IGF1R_HUMAN 155 kDa 0 0 0 0 0 0 0 0 0 2 0 0 4 4 2
Inhibitor of nuclear factor kappa-B kinase subunit epsilon OS=Homo sapiens GN=IKBKE PE=1 SV=1IKKE_HUMAN 80 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=4INSR_HUMAN 156 kDa 0 0 0 0 0 1 0 0 0 7 2 4 13 12 14
Mast/stem cell growth factor receptor Kit OS=Homo sapiens GN=KIT PE=1 SV=1KIT_HUMAN 110 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tyrosine-protein kinase Lyn OS=Homo sapiens GN=LYN PE=1 SV=3LYN_HUMAN 59 kDa 0 0 0 3 4 3 4 8 8 3 2 4 11 7 11
Mitogen-activated protein kinase kinase kinase 1 OS=Homo sapiens GN=MAP3K1 PE=1 SV=4M3K1_HUMAN 164 kDa 0 0 0 0 2 2 0 2 2 1 0 1 2 0 2
Mitogen-activated protein kinase kinase kinase 11 OS=Homo sapiens GN=MAP3K11 PE=1 SV=1M3K11_HUMAN 93 kDa 0 0 0 0 0 0 0 0 0 1 0 1 4 3 2
Mitogen-activated protein kinase kinase kinase kinase 2 OS=Homo sapiens GN=MAP4K2 PE=1 SV=2M4K2_HUMAN 92 kDa 0 0 0 0 0 0 0 0 0 3 1 1 5 4 3
Mitogen-activated protein kinase kinase kinase kinase 3 OS=Homo sapiens GN=MAP4K3 PE=1 SV=1M4K3_HUMAN 101 kDa 0 0 0 0 0 0 0 0 0 1 1 1 4 6 2
Mitogen-activated protein kinase kinase kinase kinase 5 OS=Homo sapiens GN=MAP4K5 PE=1 SV=1M4K5_HUMAN 95 kDa 0 0 0 1 1 0 1 1 3 2 0 1 7 7 8
Tyrosine-protein kinase Mer OS=Homo sapiens GN=MERTK PE=1 SV=2MERTK_HUMAN 110 kDa 0 0 0 1 0 0 3 4 7 0 0 0 4 3 4
Hepatocyte growth factor receptor OS=Homo sapiens GN=MET PE=1 SV=4MET_HUMAN 156 kDa 0 0 0 0 0 0 4 7 6 0 0 0 6 5 6
Mitogen-activated protein kinase 3 OS=Homo sapiens GN=MAPK3 PE=1 SV=4MK03_HUMAN 43 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase 9 OS=Homo sapiens GN=MAPK9 PE=1 SV=2MK09_HUMAN 48 kDa 0 0 0 0 0 1 0 0 0 2 0 0 3 3 0
Mitogen-activated protein kinase 11 OS=Homo sapiens GN=MAPK11 PE=1 SV=2MK11_HUMAN 4  kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mitogen-activated protein kinase 13 OS=Homo sapiens GN=MAPK13 PE=1 SV=1MK13_HUMAN 42 kDa 0 0 0 0 0 0 0 0 0 2 2 2 4 7 2
Mitogen-activated protein kinase 14 OS=Homo sapiens GN=MAPK14 PE=1 SV=3MK14_HUMAN 4  kDa 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0
MAP kinase-interacting serine/threonine-protein kinase 1 OS=Homo sapiens GN=MKNK1 PE=1 SV=1MKNK1_HUMAN 51 kDa 0 0 0 0 0 0 0 1 2 0 0 0 1 0 2
Mitogen-activated protein kinase kinase kinase MLT OS=Homo sapiens GN=ZAK PE=1 SV=3MLTK_HUMAN 91 kDa 0 0 0 4 3 6 4 5 6 4 3 5 12 13 14
Dual specificity mitogen-activated protein kinase kinase 1 OS=Homo sapiens GN=MAP2K1 PE=1 SV=2MP2K1_HUMAN 43 kDa 0 0 0 1 1 0 5 5 5 4 0 3 8 10 10
Dual specificity mitogen-activated protein kinase kinase 2 OS=Homo sapiens GN=MAP2K2 PE=1 SV=1MP2K2_HUMAN 44 kDa 0 0 0 3 2 2 4 7 6 3 2 2 16 14 13
Dual specificity mitogen-activated protein kinase kinase 5 OS=Homo sapiens GN=MAP2K5 PE=1 SV=2MP2K5_HUMAN 50 kDa 0 0 0 0 0 0 1 3 1 0 0 0 1 2 2
Serine/threonine-protein kinase mTOR OS=Homo sapiens GN=MTOR PE=1 SV=1MTOR_HUMA 289 kDa 0 0 0 17 17 18 19 19 9 25 11 28 65 58 67
Phosphoinositide 3-kinase regulatory subunit 4 OS=Homo sapiens GN=PIK3R4 PE=1 SV=3PI3R4_HUMAN 153 kDa 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta OS=Homo sapiens GN=PIP4K2B PE=1 SV=1PI42B_HUMAN 47 kDa 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma OS=Homo sapiens GN=PIP4K2C PE=1 SV=3PI42C_HUMAN 47 kDa 0 0 0 0 0 0 5 5 6 2 1 1 18 19 16
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3PRKDC_HUMAN 469 kDa 0 0 0 148 158 207 166 192 164 191 151 240 306 306 334
Receptor-interacting serine/threonine-protein kinase 2 OS=Homo sapiens GN=RIPK2 PE=1 SV=2RIPK2_HUMAN 61 kDa 0 0 0 1 1 1 2 6 5 1 0 1 3 3 2
Rho-associated protein kinase 1 OS=Homo sapiens GN=ROCK1 PE=1 SV=1ROCK1_HUMAN 158 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rho-associated protein kinase 2 OS=Homo sapiens GN=ROCK2 PE=1 SV=4ROCK2_HUMAN 161 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Macrophage-stimulating protein receptor OS=Homo sapiens GN=MST1R PE=1 SV=2RON_HUMAN 152 kDa 0 0 0 2 3 8 6 11 11 0 0 0 13 12 10
STE20-like serine/threonine-protein kinase OS=Homo sapiens GN=SLK PE=1 SV=1SLK_HUMAN 143 kDa 0 0 0 0 0 0 0 1 1 3 1 3 4 4 3
Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1 SV=3RC_HUMAN 60 kDa 0 0 0 12 10 13 10.1 13 14 13 8 12 21 23 22
Serine/threonine-protein kinase 10 OS=Homo sapiens GN=STK10 PE=1 SV=1STK10_HUMAN 112 kDa 0 0 0 0 0 0 2 4 6 0 0 2 5 4 5
Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1TBK1_HUMA 84 kDa 0 0 0 0 0 0 0 0 0 2 0 1 17 17 6
Transformation/transcription domain-associated protein OS=Homo sapiens GN=TRRAP PE=1 SV=3TRRAP_HUMAN 438 kDa 0 0 0 3 1 2 3 6 2 2 1 7 14 23 19
Non-receptor tyrosine-protein kinase TYK2 OS=Homo sapiens GN=TYK2 PE=1 SV=3TYK2_HUMAN 134 kDa 0 0 0 0 0 0 0 1 0 0 0 0 0 3 2
Tyrosine-protein kinase receptor UFO OS=Homo sapiens GN=AXL PE=1 SV=3UFO_HUMAN 98 kDa 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
Serine/threonine-protein kinase ULK3 OS=Homo sapiens GN=ULK3 PE=1 SV=2ULK3_HUMA 53 kDa 0 0 0 0 0 0 0 0 0 4 0 2 4 5 3
Vascular endothelial growth factor receptor 1 OS=Homo sapiens GN=FLT1 PE=1 SV=2VGFR1_HUMAN 151 kDa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Vascular endothelial growth factor receptor 3 OS=Homo sapiens GN=FLT4 PE=1 SV=3VGFR3_HUMAN 153 kDa 0 0 0 0 0 0 5 10 8 0 0 0 6 4 6
Tyrosine-protein kinase Yes OS=Homo sapiens GN=YES1 PE=1 SV=3YES_HUMAN 61 kDa 0 0 0 5 3 6 5 8 9 15 9 15 26 28 26  
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Appendix H – ABPP in H1155: kinase proteins  Appendix H - ABPP of H1155 cells: kinases proreins 
Proteins Gene Names Amino Acid Position PEP Modified Sequence DMSO1-run1 DMSO1-run2 DMSO2-run1 DMSO2-run2 FORE1-run1 FORE1-run2 FORE2-run1 FORE2-run2 CABO1-run1 CABO1-run2 CABO2-run1 CABO2-run2
AAPK1_HUMAN 5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4AMPK1;PRKAA1 K 40 6.37E-06 _IGHYILGDTL VGTFGK(de)VK_ 0 0 0 0 0 0 6,461,933 0 4,409,420 0 0
AAPK1_HUMAN 5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4;>sp|P54646|AAPK2_HUMAN 5'-AMP-activated protein kinase catalytic subunit alpha-2 OS=Homo sapiens GN=PRKAA2 PE=1 SV=2AMPK1;PRKAA1;AMPK;AMPK2;PRKAA2K 152 6.47E-13 _DLK(de)PENVLLDAHMNAK_ 201,769,877 162,763,869 225,998,413 210,814,288 183,030,000 153,534,328 174,133,945 173,118,403 160,167,486 197,638,550 145,196,185 166,181,356
AAPK1_HUMAN 5'-AMP-activated protein kinase catalytic subunit alpha-1 OS=Homo sapiens GN=PRKAA1 PE=1 SV=4;>sp|P54646|AAPK2_HUMAN 5'-AMP-activated protein kinase catalytic subunit alpha-2 OS=Homo sapiens GN=PRKAA2 PE=1 SV=2AMPK1;PRKAA1;AMPK;AMPK2;PRKAA2K 56 3.77E-06 _VAVK(de)ILNR_ 111,425,654 133,827,344 89,962,844 108,467,803 82,719,000 86,107,853 78,362,449 76,417,618 95,337,640 35,969,047 86,942,417 124,164,084
ACK1_HUMAN Activated CDC42 kinase 1 OS=Homo sapiens GN=TNK2 PE=1 SV=3ACK1;TNK2 K 158 7.83E-26 _T SVAVK(de)CLKPDVLSQPEAMDDFIR_ 5,067,331 4,571,317 6,499,789 6,951,502 2,994,100 2,619,354 3,382,272 2,907,004 2,738,960 2,776,495 1,917,809 2,457,950
AKT1_HUMAN RAC-alpha serine/threonine-protein kinase OS=Homo sapiens GN=AKT1 PE=1 SV=2AKT1;PKB;RAC K 163 1.07E-05 _GTFGK(de)VILVK_ 9,503,220 7,729,159 11,522,450 9,982,278 9,720,300 8,084,010 8,904,468 9,597,310 8,455,649 10,093,438 7,401,076 8,082,905
AKT2_HUMAN RAC-beta serine/threonine-protein kinase OS=Homo sapiens GN=AKT2 PE=1 SV=2;>sp|Q9Y243|AKT3_HUMAN RAC-gamma serine/threonine-protein kinase OS=Homo sapiens GN=AKT3 PE=1 SV=1AKT2;AKT3;PKBG K 165 2.21E-04 _GTFGK(de)VIL R_ 9,880,906 16,127,072 21,850,605 21,659,242 10,6 8,000 8,987,242 10,037,195 20,157,763 7,935,011 0 0 62,337
ARAF_HUMAN Serine/threonine-protein kinase A-Raf OS=Homo sapiens GN=ARAF PE=1 SV=2ARAF;ARAF1;PKS;PKS2 K 431 2.39E-08 _DLK(de)SNNIFLHEGLTVK_ 34,784,918 30,372,998 41,566,631 32,129,918 35,354,000 30,881,326 35,187,558 28,500,171 23,796,581 28,638,469 16,057,165 23,183,791
ATR_HUMAN Serine/threonine-protein kinase ATR OS=Homo sapiens GN=ATR PE=1 SV=3ATR;FRP1 K 1961 2.00E-03 _AK(de)WLWSK_ 4,455,357 4,082,175 4,816,034 3,867,146 280,120 4,262,956 4,575,939 4,300,107 4,229,599 3,554,254 1,959,398 2,398,395
AURKA_HUMAN Aurora kinase A OS=Homo sapiens GN=AURKA PE=1 SV=2AURA; URKA K 258 2.01E-12 _DIK(de)PENLLLGSAGELK_ 72,086,257 78,565,664 75,500,013 65,448,148 32,157,000 35,448,409 32,081,469 33,993,244 51,664,137 53,195,394 53,861,105 46,026,572
AURKA_HUMAN Aurora kinase A OS=Homo sapiens GN=AURKA PE=1 SV=2;>sp|Q96GD4|AURKB_HUMAN Aurora kinase B OS=Homo sapiens GN=AURKB PE=1 SV=3;>sp|Q9UQB9|AURKC_HUMAN Aurora kinase C OS=Homo sapiens GN=AURKC PE=1 SV=1AURA; URKA;AURKB;AURKCK 143 3.65E-08 _GK(de)F NVYLAR_ 10,214,982 11,477,610 12,043,287 13,943,392 3,963,600 5,314,432 3,761,818 3,827,066 9,650,644 7,171,561 4,958,645 6,891,563
BRAF_HUMAN Serine/threonine-protein kinase B-raf OS=Homo sapiens GN=BRAF PE=1 SV=4BRAF;BRAF1;RAFB1 K 578 1.23E-34 _SIIHRDLK(de)SNNIFLHEDLTVK_ 241,162,672 170,502,074 199,529,650 194,028,521 178,970,000 176,138,700 235,221,222 206,576,757 10,648,612 13,055,607 193,728,580 124,200,621
CD11B_HUMAN Cyclin-dependent kinase 11B OS=Homo sapiens GN=CDK11B PE=1 SV=3;>sp|Q9UQ88|CD11A_HUMAN Cyclin-dependent kinase 11A OS=Homo sapiens GN=CDK11A PE=1 SV=4CDC2L1;CDK11;CDK11B;PITSLREA;PK58;CDC2L2;CDC2L3;CDK11A;PITSLREBK 564 4.35E-07 _ LK(de)TSNLLLSHAGILK_ 14,415,471 14,976,151 13,709,325 14,492,023 12,530,000 11,540,772 9,433,016 14,706,491 10,883,416 10,458,634 6,250,780 8,810,596
CDK1_HUMAN Cyclin-dependent kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=3CDC2 K 130 3.83E-18 _DLK(de)PQNLLIDDKGTIK_ 126,666,583 92,898,781 123,037,058 138,546,776 109,340,000 115,568,036 84,158,220 111,166,704 123,955,525 132,257,991 90,830,966 110,012,180
CDK1_HUMAN Cyclin-dependent kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=3CDC2 K 56 3.08E-04 _EISLLK(de)ELR_ 0 0 0 0 0 0 2,896,234 3,758,051 2,563,640 2,726,975 1,922,162 2,098,428
CDK1_HUMAN Cyclin-dependent kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=3CDC2 K 201 5.72E-34 _K(de)PLFHGDSEIDQLFR_ 6,516,888 5,117,024 7,712,656 5,574,906 2,481,900 2,830,969 4,333,137 4,092,122 0 1,692,082 0 245,758
CDK1_HUMAN Cyclin-dependent kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=3CDC2 K 33 4.03E-03 _TTGQVVAMK(de)K_ 0 0 0 0 3,499,400 0 0 0 0 0 0 0
CDK19_HUMAN Cyclin-dependent kinase 19 OS=Homo sapiens GN=CDK19 PE=1 SV=1;>sp|P49336|CDK8_HUMAN Cyclin-dependent kinase 8 OS=Homo sapiens GN=CDK8 PE=1 SV=1CDC2L6;CDK11;CDK19;KIAA1028;CDK8K 153 2.59E-12 _DLK(de)PANILVMGEGPER 40,792,291 28,248,806 37,504,530 34,710,818 23,605,000 23,575,691 25,153,840 26,177,195 17,775,168 18,560,205 17,734,489 17,438,995
CDK2_HUMAN Cyclin-dependent kinase 2 OS=Homo sapiens GN=CDK2 PE=1 SV=2CDK2 K 129 1.51E-08 _DLK(de)PQNLLINTEGAIK_ 121,916,308 83,653,261 111,435,628 119,181,278 118,380,000 111,654,471 89,800,991 114,519,364 98,547,669 117,914,663 90,931,789 97,528,787
CDK5_HUMAN Cyclin-dependent-like kinase 5 OS=Homo sapiens GN=CDK5 PE=1 SV=3CDK5 K 128 5.28E-13 _DLK(de)PQNLLINR_ 2,288,920,556 2,094,110,745 1,784,720,407 1,602,468,740 1,631,700,000 3,222,514,008 1,692,570,473 1,727,003,872 2,143,184,558 2,362,189,237 1,818,819,097 1,717,958,380
CDK5_HUMAN Cyclin-dependent-like kinase 5 OS=Homo sapiens GN=CDK5 PE=1 SV=3CDK5 K 33 3.77E-45 _NRETHEIVALK(de)R_ 85,233,505 106,133,291 84,325,424 88,113,602 98,754,000 93,577,574 103,058,156 93,021,390 89,841,145 84,282,174 59,518,635 57,527,126
CDK7_HUMAN Cyclin-dependent kinase 7 OS=Homo sapiens GN=CDK7 PE=1 SV=1CDK7;MO15 K 139 6.18E-06 _DLK(de)PNNLLLDENGVLK_ 22,797,982 13,852,476 22,390,653 12,550,804 17,308,000 22,272,426 16,331,088 17,984,932 15,779,858 14,830,324 15,424,732 18,281,776
CHK1_HUMAN Serine/threonine-protein kinase Chk1 OS=Homo sapiens GN=CHEK1 PE=1 SV=2CHEK1;CHK1 K 445 3.99E-17 _LSK(de)GDGLEFKR_ 176,238,539 193,400,620 165,216,313 179,437,278 163,510,000 173,403,920 198,066,388 156,167,422 177,929,088 176,097,927 155,965,886 167,435,785
CHK1_HUMAN Serine/threonine-protein kinase Chk1 OS=Homo sapiens GN=CHEK1 PE=1 SV=2CHEK1;CHK1 K 274 5.74E-03 _GAK(de)RPR_ 21,322,839 18,404,938 18,361,637 0 13,559,000 21,816,944 18,548,729 16,962,925 23,311,319 6,177,371 14,761,364 20,126,882
CHK2_HUMAN Serine/threonine-protein kinase Chk2 OS=Homo sapiens GN=CHEK2 PE=1 SV=1CHEK2;CHK2;RAD53 K 249 3.79E-04 _VAIK(de)IISK_ 9,699,350 10,396,659 9,461,516 9,081,590 3,314,800 2,782,780 2,347,083 2,738,944 4,681,048 4,608,525 5,128,898 4,917,361
CHK2_HUMAN Serine/threonine-protein kinase Chk2 OS=Homo sapiens GN=CHEK2 PE=1 SV=1CHEK2;CHK2;RAD53 K 349 5.03E-08 _DLK(de)PEN LLSSQEEDCLIK_ 11,097,955 13,547,307 12,332,523 10,990,592 4,843,400 4,274,933 4,782,577 4,653,799 6,140,067 5,797,616 6,408,201 7,925,919
CSK_HUMAN Tyrosine-protein kinase CSK OS=Homo sapiens GN=CSK PE=1 SV=1CSK K 337 1.10E-28 _VSDFGLTK(de)EASSTQDTGKLPVKWTAPEALR_ 518,625,455 514,743,189 610,457,201 526,125,226 339,340,000 471,428,941 389,491,153 326,496,207 520,356,486 450,671,668 606,574,737 510,796,061
CSK21_HUMAN Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1;>sp|Q8NEV1|CSK23_HUMAN Casein kinase II subunit alpha 3 OS=Homo sapiens GN=CSNK2A3 PE=1 SV=2CK2A1;CSNK2A1; CG_21984K 158 2.25E-08 _DVK(de)PHNVMIDHEHR_ 6,680,250 5,945,546 6,468,357 0 6,497,272 8,651,061 0 9,150,564 4,598,375 0 0
CSK22_HUMAN Casein kinase II subunit alpha' OS=Homo sapiens GN=CSNK2A2 PE=1 SV=1CK2A2;CSNK2A2 K 159 4.82E-05 _DVK(de)PHNVMIDHQQK_ 9,044,657 9,722,019 7,302,070 9,100,850 10,547,000 8,541,473 7,634,301 8,254,625 9,256,487 10,773,387 0 8,027,248
CSK22_HUMAN Casein kinase II subunit alpha' OS=Homo sapiens GN=CSNK2A2 PE=1 SV=1;>sp|P68400|CSK21_HUMAN Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1;>sp|Q8NEV1|CSK23_HUMAN Casein kinase II subunit alpha 3 OS=Homo sapiens GCK2A2;CSNK2A2;CK2A1;CSNK2A1;hCG_21984K 75 4.43E-03 _ILKPVKK(de)_ 0 0 0 0 0 0 0 5,968,332 0 0 0 0
E2AK2_HUMAN Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2EIF2AK2;PKR;PRKR K 296 4.63E-03 _TYVIK(de)R_ 8,632,039 10,757,521 7,489,593 8,296,698 9,348,400 8,659,163 9,969,388 8,854,265 10,509,817 11,166,060 10,879,001 10,407,130
E2AK2_HUMAN Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2EIF2AK2;PKR;PRKR K 416 2.72E-06 _DLK(de)PSNIFLVDTK_ 420,071,155 346,682,464 451,954,134 399,613,307 445,230,000 405,200,111 414,136,439 411,771,502 382,928,442 376,955,780 386,861,390 335,687,557
E2AK2_HUMAN Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2EIF2AK2;PKR;PRKR K 440 1.19E-34 _IGDFGLVTSLK(d )NDGKR_ 84,978,748 76,440,383 93,183,922 70,806,052 62,655,000 93,959,501 56,376,419 80,450,194 67,942,822 72,562,475 20,775,211 19,163,530
E2AK2_HUMAN Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2EIF2AK2;PKR;PRKR K 64 1.02E-02 _EAK(de)NAAAK_ 0 0 0 3,863,878 0 0 0 0 0 0 0 0
E2AK2_HUMAN Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2;>sp|P18848|ATF4_HUMAN Cyclic AMP-dependent transcription factor ATF-4 OS=Homo sapiens GN=ATF4 PE=1 SV=3EIF2AK2;PKR;PRKR;ATF4;CREB2;TXREBK 385 7.75E-03 _GEK(de)LDK_ 0 0 0 0 0 0 775,557 5,405,802 1,570,263 8,068,250 731,354 3,409,854
E2AK3_HUMAN Eukaryotic translation initiation factor 2-alpha kinase 3 OS=Homo sapiens GN=EIF2AK3 PE=1 SV=3EIF2AK3;PEK;PERK K 939 1.15E-05 _DLK(de)PS IFFTMDDVVK_ 9,100,392 7,762,945 8,202,542 11,702,177 7,430,400 8,139,366 7,589,183 8,314,341 4,810,660 3,201,361 2,985,269 3,423,981
E2AK4_HUMAN Eukaryotic translation initiation factor 2-alpha kinase 4 OS=Homo sapiens GN=EIF2AK4 PE=1 SV=3EIF2AK4;GCN2;KIAA1338K 619 3.83E-11 _LDGCCYAVK(de)R_ 4,347,336 4,976,646 4,767,793 4,887,016 5,558,400 118,095 6,040,225 4,972,857 5,586,556 6,388,471 7,614,178 6,561,393
E2AK4_HUMAN Eukaryotic translation initiation factor 2-alpha kinase 4 OS=Homo sapiens GN=EIF2AK4 PE=1 SV=3EIF2AK4;GCN2;KIAA1338K 850 .35E-07 _DLK(de)PV IFLDSDDHVK_ 11,874,575 9,856,075 13,385,937 13,390,092 12,828,000 12,530,951 10,575,305 12,568,637 10,856,283 11,980,113 7,179,151 10,397,387
EF2K_HUMAN Eukaryotic elongation factor 2 kinase OS=Homo sapiens GN=EEF2K PE=1 SV=2EEF2K K 238 3.20E-05 _YI (de)YN NSGFVR_ 436,947 5,410,422 5,037,176 5,056,625 5,800,000 0 0 4,769,052 377,982 0 4,599,006 4,090,534
EGFR_HUMAN Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2EGFR;ERBB1 K 875 1.23 -14 _EYHAEGGK(de)VPIKWMALESILHR_ 14,303,111 18,527,006 14,212,018 16,316,512 9,046,300 9,329,938 11,254,246 12,259,817 14,053,789 13,287,314 15,393,797 14,111,714
EGFR_HUMAN Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2EGFR;ERBB1 K 745 8.33 -07 _VKIPVAIK(de)ELR_ 16,650,437 16,845,308 19,226,141 18,891,575 16,267,000 16,131,431 13,801,360 17,957,633 21,448,543 17,676,434 10,909,134 13,400,465
ERN1_HUMAN Serine/threonine-protein kinase/endoribonuclease IRE1 OS=Homo sapiens GN=ERN1 PE=1 SV=2ERN1;IRE1 K 690 3.47E-06 _DLK(d )PH ILISMPNAHGK_ 6,272,922 6,013,130 10,344,911 5,754,203 7,178,000 7,625,699 7,155,913 7,596,207 6,042,075 6,673,697 4,827,232 4,940,866
FAK1_HUMAN Focal adhesion kinase 1 OS=Homo sapiens GN=PTK2 PE=1 SV=2FAK;FAK1;PTK2 K 581 1.93E-05 _ASK(de)GKLPIK_ 6,705,675 5,713,629 3,974,050 5,214,560 2,911,400 3,287,111 2,464,963 3,340,034 5,485,851 5,069,890 6,472,132 8,966,486
FER_HUMAN Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER;TYK3 K 591 1.46 -12 _TSVAVK(de)TCKEDLPQELK_ 11,890,150 12,123,914 10,620,485 10,511,298 890,180 849,904 1,319,737 3,568,704 4,114,864 4,237,877 4,948,051
FER_HUMAN Tyrosine-protein kinase Fer OS=Homo sapiens GN=FER PE=1 SV=2FER;TYK3 K 720 5.01 -20 _QEDGGVYSSSGLK(de)QIPIKWTAPEALNYGR_ 18,908,764 15,865,499 19,096,999 16,512,619 1,718,900 1,969,230 1,410,475 1,489,161 4,721,226 7,058,476 5,888,047 5,447,387
GSK3A_HUMAN Glycogen synthase kinase-3 alpha OS=Homo sapiens GN=GSK3A PE=1 SV=2GSK3A K 246 5.79E-06 _DIK(de)PQNLLVDPDTAVLK_ 80,261,848 74,858,955 64,086,426 69,794,004 59,884,000 94,387,635 70,103,018 59,333,554 61,340,140 66,243,824 73,742,660 61,760,519
GSK3B_HUMAN Glycogen synthase kinase-3 beta OS=Homo sapiens GN=GSK3B PE=1 SV=2GSK3B K 183 2.37E-08 _DIK(de)PQNLLLDPDTAVLK_ 59,098,093 52,544,589 46,279,779 44,686,559 59,840,000 49,764,511 56,990,160 48,337,170 50,967,031 64,784,885 72,213,133 63,139,172
IKKA_HUMAN Inhibitor of nuclear factor kappa-B kinase subunit alpha OS=Homo sapiens GN=CHUK PE=1 SV=2CHUK;IKKA;TCF16 K 146 2.03E-08 _DLK(de)PENIVLQDVGGK_ 6,556,714 7,827,030 5,189,585 4,647,486 5,634,000 7,391,922 6,567,556 5,596,724 5,129,784 5,006,836 5,003,786 4,862,677
IKKB_HUMAN Inhibitor of nuclear factor kappa-B kinase subunit beta OS=Homo sapiens GN=IKBKB PE=1 SV=1IKBKB;IKKB K 147 7.44E-12 _DLK(de)PENIVLQQG QR_ 624,233 0 0 0 0 0 0 0 0 0 0
ILK_HUMAN Integrin-linked protein kinase OS=Homo sapiens GN=ILK PE=1 SV=2ILK;ILK1;ILK2 K 341 2.15E-34 _ISMADVK(de)FSFQCPGR_ 500,870,329 415,149,227 623,873,022 585,692,519 510,620,000 408,793,046 488,559,119 429,695,011 234,480,274 248,040,122 198,918,659 274,123,119
IRAK1_HUMAN Interleukin-1 receptor-associated kinase 1 OS=Homo sapiens GN=IRAK1 PE=1 SV=2IRAK;IRAK1 K 342 1.33E-04 _AIQFLHQDSPSLIHGDIK(de)SSNVLLDER_ 0 0 12,125,469 0 6,470,300 0 5,298,693 5,065,161 0 0 0 0
IRAK4_HUMAN Interleukin-1 receptor-associated kinase 4 OS=Homo sapiens GN=IRAK4 PE=1 SV=1IRAK4 K 313 3.47E-25 _DIK(de)SANILLDEAFTAK_ 42,279,672 33,344,033 23,111,073 36,647,367 28,032,000 29,237,629 26,662,984 27,647,930 28,689,891 16,441,001 19,741,778 15,944,641
JAK1_HUMAN Tyrosine-protein kinase JAK1 OS=Homo sapiens GN=JAK1 PE=1 SV=2JAK1;JAK1A;JAK1B K 718 1.94E-56 _QLASALSYLEDKDLVHGNVCTK(de)NLLLAR_ 34,466,749 24,901,760 51,704,808 43,899,799 19,806,000 22,494,038 22,896,210 30,516,032 982,221 1,091,077 0 0
KAPCA_HUMAN cAMP-dependent protein kinase catalytic subunit alpha OS=Homo sapiens GN=PRKACA PE=1 SV=2;>sp|P22694|KAPCB_HUMAN cAMP-dependent protein kinase catalytic subunit beta OS=Homo sapiens GN=PRKACB PE=1 SV=2PKACA;PRKACA;PRKACBK 280 1.44E-02 _NLLQVDLTK(de) _ 2,640,797 0 2,684,552 0 0 0 0 0 0 0 0 0
KC1A_HUMAN Casein kinase I isoform alpha OS=Homo sapiens GN=CSNK1A1 PE=1 SV=2CSNK1A1 K 138 2.46E-06 _DIK(de)PDNFLMGIGR_ 6,492,302 4,727,716 3,873,725 5,118,608 4,742,100 4,778,981 4,478,922 4,531,551 3,809,561 4,714,536 3,196,997 3,139,969
KC1E_HUMAN Casein kinase I isoform epsilon OS=Homo sapiens GN=CSNK1E PE=1 SV=1;>sp|P48730|KC1D_HUMAN Casein kinase I isoform delta OS=Homo sapiens GN=CSNK1D PE=1 SV=2CSNK1E;CSNK1D K 130 1.49E-08 _DVK(de)PDNFLMGLGKK_ 10,030,756 8,711,257 9,905,508 5,642,959 8,707,200 9,383,219 10,221,491 9,792,668 4,191,195 4,567,207 4,638,418 7,578,454
KCC1A_HUMAN Calcium/calmodulin-dependent protein kinase type 1 OS=Homo sapiens GN=CAMK1 PE=1 SV=1CAMK1 K 49 1.48E-04 _LVAIK(de)CIAK_ 10,960,787 10,520,907 10,691,032 11,041,369 14,889,000 12,778,967 10,621,380 12,470,531 16,759,772 13,411,370 13,042,795 14,539,194
KCC1D_HUMAN Calcium/calmodulin-dependent protein kinase type 1D OS=Homo sapiens GN=CAMK1D PE=1 SV=1CAMK1D K 52 4.03E-05 _LFAVK(de)CIPK_ 45,276,684 43,283,811 57,120,232 70,455,863 84,499,000 50,584,002 38,226,708 53,736,403 37,278,492 60,745,378 45,105,568 52,504,540
KCC2B_HUMAN Calcium/calmodulin-dependent protein kinase type II subunit beta OS=Homo sapiens GN=CAMK2B PE=1 SV=3CAM2;CAMK2B;CAMKB K 43 7.51E-13 _LCTG EYAAK(d )IINTK_ 12,039,222 11,895,037 11,251,359 11,310,899 10,728,000 11,640,733 12,739,049 9,121,283 9,500,787 11,160,934 10,164,535 10,913,408
KCC2B_HUMAN Calcium/calmodulin-dependent protein kinase type II subunit beta OS=Homo sapiens GN=CAMK2B PE=1 SV=3;>sp|Q9UQM7|KCC2A_HUMAN Calcium/calmodulin-dependent protein kinase type II subunit alpha OS=Homo sapiens GN=CAMK2A PE=1 SV=2;>sp|Q13CAM2;CAMK2B;CAMKB;CAMK2A;CAMKA;KIAA0968;CAMK2G;CAMKG;CAMK2D;CAMKDK 57 1.95E-03 _DHQ (de)LER_ 0 0 0 141,033 5,573,100 0 4,016,877 0 0 0 185,262 0
KCC2D_HUMAN Calcium/calmodulin-dependent protein kinase type II subunit delta OS=Homo sapiens GN=CAMK2D PE=1 SV=3CAMK2D;CAMKD K 43 3.11E-39 _IPTGQEYAAK(de)IINTKK_ 173,690,968 159,189,037 198,206,211 205,736,535 180,620,000 202,609,486 199,648,554 203,701,830 168,317,786 166,368,250 163,298,448 184,060,010
KCC2G_HUMAN Calcium/calmodulin-dependent protein kinase type II subunit gamma OS=Homo sapiens GN=CAMK2G PE=1 SV=3CAMK2G;CAMKG K 43 4.02E-18 _TSTQEYAAK(de)IINTKK_ 75,971,025 66,388,346 45,943,583 82,744,024 51,396,000 63,381,830 49,188,862 42,784,380 83,764,423 66,886,660 67,226,991 76,387,401
KCC4_HUMAN Calcium/calmodulin-dependent protein kinase type IV OS=Homo sapiens GN=CAMK4 PE=1 SV=1CAMK4 K 166 5.90E-07 _DLK(de)PENLLYATPAPDAPLK_ 9,315,768 8,716,379 7,151,476 8,644,553 7,847,300 13,032,642 8,993,139 7,646,113 7,523,531 8,637,780 9,227,113 7,903,753
KPCD2_HUMAN Serine/threonine-protein kinase D2 OS=Homo sapiens GN=PRKD2 PE=1 SV=2HSPC187;PKD2;PRKD2 K 580 8.32E-04 _DVAVK(de)VIDKLR_ 1,517,641 1,700,879 2,649,118 2,322,693 1,556,300 0 1,732,646 1,817,773 0 0 0 0
KPCD2_HUMAN Serine/threonine-protein kinase D2 OS=Homo sapiens GN=PRKD2 PE=1 SV=2;>sp|Q15139|KPCD1_HUMAN Serine/threonine-protein kinase D1 OS=Homo sapiens GN=PRKD1 PE=1 SV=2HSPC187;PKD2;PRKD2;PKD;PKD1;PRKCM;PRKD1676 7.32E-08 _NIVHCDLK(de)PENVLLASADPFPQVK_ 2,980,770 3,044,275 3,103,996 3,314,430 3,124,300 2,627,746 4,083,815 2,882,776 3,272,121 2,325,280 1,584,521 1,856,676
KS6A1_HUMAN Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2MAPKAPK1A;RPS6KA1;RSK1K 537 2.61E-19 _DLK(de)PSNILYVDESGNPECLR_ 13,626,726 8,048,387 11,641,987 12,725,899 13,233,000 10,750,515 9,124,407 10,796,760 10,461,813 12,110,321 9,509,646 10,033,481
KS6A1_HUMAN Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2MAPKAPK1A;RPS6KA1;RSK1K 210 4.70E-26 _LTDFGLSK(de)EAIDHEKK_ 192,235,952 137,740,042 161,342,055 149,087,491 128,720,000 141,058,072 124,817,292 131,495,938 117,892,370 146,427,026 82,073,138 116,234,390
KS6A1_HUMAN Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2;>sp|Q9UK32|KS6A6_HUMAN Ribosomal protein S6 kinase alpha-6 OS=Homo sapiens GN=RPS6KA6 PE=1 SV=1MAPKAPK1A;RPS6KA1;RSK1;RPS6KA6;RSK4K 75 1.21E-02 _VLGQGSFGK(de)_ 48,109,050 36,094,910 49,162,526 46,388,482 53,782,000 50,161,526 53,583,286 44,845,455 58,799,041 48,979,543 44,618,640 49,446,413
KS6A2_HUMAN Ribosomal protein S6 kinase alpha-2 OS=Homo sapiens GN=RPS6KA2 PE=1 SV=2MAPKAPK1C;RPS6KA2;RSK3K 186 3.25E-09 _DLK(de)PENILLDEEGHIK_ 2,176,115,431 1,742,948,841 1,714,706,259 1,573,402,983 2,010,500,000 1,794,958,786 1,888,689,578 1,710,709,773 1,834,078,424 2,175,900,268 1,159,346,800 1,514,570,425
KS6A2_HUMAN Ribosomal protein S6 kinase alpha-2 OS=Homo sapiens GN=RPS6KA2 PE=1 SV=2MAPKAPK1C;RPS6KA2;RSK3K 72 1.98E-04 _VLGQGSYGK(de)VFLVR_ 26,295,609 22,509,456 21,602,994 25,095,772 20,875,000 18,898,274 16,777,051 15,577,500 16,492,618 12,637,302 9,974,347 14,790,080
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1ISPK1;MAPKAPK1B;RPS6KA3;RSK2K 541 2.34E-26 _DLK(de)PSNILYVDESGNPESIR_ 5,896,237 4,788,096 6,647,395 5,428,526 5,474,300 5,684,288 5,762,737 5,183,571 5,003,512 5,389,975 6,206,326 6,618,512
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1ISPK1;MAPKAPK1B;RPS6KA3;RSK2K 81 3.30E-18 _VLGQGSFGK(de)VFLVK_ 56,533,835 43,327,406 60,175,880 54,860,741 60,834,000 58,645,002 60,992,520 53,878,016 64,565,822 55,295,118 48,897,877 53,841,785
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1ISPK1;MAPKAPK1B;RPS6KA3;RSK2K 16 5.51E-35 _LTDFGLSK(de)ESIDHEKK_ 283,748,276 312,133,016 251,431,906 288,194,571 253,570,000 244,838,263 233,847,692 238,294,799 259,202,503 117,043,196 141,014,334 188,712,357
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1ISPK1;MAPKAPK1B;RPS6KA3;RSK2K 100 2.10E-02 _QLYAMK(de)VLK_ 0 0 0 0 0 0 0 2,764,964 0 0 0 0
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV=1;>sp|Q15418|KS6A1_HUMAN Ribosomal protein S6 kinase alpha-1 OS=Homo sapiens GN=RPS6KA1 PE=1 SV=2ISPK1;MAPKAPK1B;RPS6KA3;RSK2;MAPKAPK1A; 1;RSK1K 195 9.74E-23 _DLK(de)PENILLDEEGHIKLTDFGLSK_ 2,264,891,062 1,825,998,305 1,809,374,779 1,650,561,479 2,042,200,000 1,833,245,707 1,927,200,555 1,749,866,796 1,835,330,711 2,179,078,561 1,159,346,800 1,514,570,425
KS6A4_HUMAN Ribosomal protein S6 kinase alpha-4 OS=Homo sapiens GN=RPS6KA4 PE=1 SV=1MSK2;RPS6KA4 K 65 9.49E-05 _LYAMK(de)VLR_ 6,736,379 5,626,765 10,472,345 8,508,796 7,322,100 8,659,917 6,208,526 6,558,247 9,006,969 6,876,083 5,760,300 6,250,830
KS6A5_HUMAN Ribosomal protein S6 kinase alpha-5 OS=Homo sapiens GN=RPS6KA5 PE=1 SV=1MSK1;RPS6KA5 K 179 2.22E-38 _DIK(de)LENILLDSNGHVVLTDFGLSK_ 28,761,969 31,995,841 39,183,375 45,942,573 16,698,000 17,941,101 22,569,345 30,100,575 0 0 0 0
KS6A5_HUMAN Ribosomal protein S6 kinase alpha-5 OS=Homo sapiens GN=RPS6KA5 PE=1 SV=1;>sp|O75676|KS6A4_HUMAN Ribosomal protein S6 kinase alpha-4 OS=Homo sapiens GN=RPS6KA4 PE=1 SV=1MSK1;RPS6KA5;MSK2;RPS6KA4K 62 2.48E-08 _VLGTGAYGK(de)VFLVRK_ 205,296,427 190,926,575 186,572,763 166,141,736 136,880,000 166,897,029 142,099,419 167,615,946 105,557,344 105,211,745 65,716,941 65,064,659
KS6C1_HUMAN Ribosomal protein S6 kinase delta-1 OS=Homo sapiens GN=RPS6KC1 PE=1 SV=2RPK118;RPS6KC1 K 348 3.55E-13 _VLGVIDK(de)VLLVMDTR_ 18,729,656 10,470,118 28,681,253 17,434,785 2,080,300 2,363,416 3,203,974 4,842,589 115,847 0 0 0
KSYK_HUMAN Tyrosine-protein kinase SYK OS=Homo sapiens GN=SYK PE=1 SV=1SYK K 517 7.61E-09 _I DFGLSK(de)ALR_ 37,122,231 27,615,581 34,520,390 24,718,734 26,833,000 30,921,876 29,970,755 29,262,837 31,530,495 31,116,512 24,727,920 27,385,518
KSYK_HUMAN Tyrosine-protein kinase SYK OS=Homo sapiens GN=SYK PE=1 SV=1SYK K 533 1.31E-12 _AQTHGK(de)WPVK_ 81,286,438 87,532,173 66,819,753 75,877,969 93,976,000 89,307,545 97,842,222 110,049,150 78,973,382 100,931,302 79,028,979 66,470,107
LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens GN=LATS1 PE=1 SV=1LATS1;WARTS K 734 5.79E-07 _ALYATK(de)TLR_ 74,448,045 52,095,555 55,559,855 55,661,509 46,491,000 53,579,058 45,236,054 52,483,207 54,222,976 67,400,313 44,579,686 73,072,299
LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens GN=LATS1 PE=1 SV=1LATS1;WARTS K 830 4.38E-09 _DIK(de) DNILIDRDGHIK_ 54,068,587 47,902,756 50,902,207 53,367,765 56,627,000 54,344,796 50,301,595 56,186,489 71,458,617 43,838,910 46,246,698 21,604,185
LYN_HUMAN Tyrosine-protein kinase Lyn OS=Homo sapiens GN=LYN PE=1 SV=3LYN K 275 2.12 - 7 _VAVK(de)TLKPGTMSVQAFLEEANLMK_ 7,908,596 5,366,608 5,201,005 5,781,868 948,070 963,869 888,708 1,129,923 247,118 313,390 0 0
LYN_HUMAN Tyrosine-protein kinase Lyn OS=Homo sapiens GN=LYN PE=1 SV=3;>sp|P08631|HCK_HUMAN Tyrosine-protein kinase HCK OS=Homo sapiens GN=HCK PE=1 SV=5;>sp|P06239|LCK_HUMAN Tyrosine-protein kinase Lck OS=Homo sapiens GN=LCK PE=1 SV=6LYN;HCK;LCK K 404 1.19 -03 _EGAK(de)FPIK_ 21,840,140 19,107,916 20,477,004 17,841,005 1,492,500 0 0 0 21,532,029 28,843,520 3,538,992 14,116,586
M3K11_HUMAN Mitogen-activated protein kinase kinase kinase 11 OS=Homo sapiens GN=MAP3K11 PE=1 SV=1MAP3K11;MLK3;PTK1;SPRKK 243 6.88E-21 _DLK(de)SNNILLLQPIESDDMEHK_ 21,303,926 18,873,590 24,702,400 22,986,462 15,518,000 17,197,995 18,865,163 17,765,686 15,911,348 21,572,406 15,436,189 13,742,693
M3K12_HUMAN Mitogen-activated protein kinase kinase kinase 12 OS=Homo sapiens GN=MAP3K12 PE=1 SV=2MAP3K12;ZPK K 238 1.89E-04 _DLK(de)SPNMLITYDDVVK_ 0 4,179,502 0 0 0 141,416 0 0 0 3,074,742 0 0
M3K2_HUMAN Mitogen-activated protein kinase kinase kinase 2 OS=Homo sapiens GN=MAP3K2 PE=1 SV=2MAP3K2;MAPKKK2;MEKK2K 446 1.26E-05 _TLSIFMEYMPGGSIK(de)DQLK_ 3,778,304 5,155,432 11,178,410 7,350,700 1,830,358 2,056,213 0 0 0 0
M3K2_HUMAN Mitogen-activated protein kinase kinase kinase 2 OS=Homo sapiens GN=MAP3K2 PE=1 SV=2;>sp|Q99759|M3K3_HUMAN Mitogen-activated protein kinase kinase kinase 3 OS=Homo sapiens GN=MAP3K3 PE=1 SV=2MAP3K2;MAPKKK2;MEKK2;MAP3K3;MAPKKK3;MEKK3K 485 2.81E-11 _DIK(de)GANILR_ 383,504,050 317,211,894 378,151,111 401,294,219 304,480,000 397,212,667 360,177,606 353,189,524 530,510,445 388,869,252 373,135,750 373,308,240
M3K4_HUMAN Mitogen-activated protein kinase kinase kinase 4 OS=Homo sapiens GN=MAP3K4 PE=1 SV=2KIAA0213;MAP3K4;MAPKKK4;MEKK4;MTK11 65 4.94E-18 _DIK(de)GANIFLTSSGLIK_ 125,086,866 83,867,969 72,781,628 131,216,136 111,130,000 125,017,173 104,892,426 131,538,593 80,099,397 78,024,013 62,020,872 100,946,192
M3K4_HUMAN Mitogen-activated protein kinase kinase kinase 4 OS=Homo sapiens GN=MAP3K4 PE=1 SV=2KIAA0213;MAP3K4;MAPKKK4;MEKK4;MTK11372 1.47E-18 _VYTCISVDTGELMAMK(de)EIR_ 6,833,944 7,330,033 9,922,746 13,342,898 10,320,594 6,933,096 281,932 253,248 643,238 598,375
M3K5_HUMAN Mitogen-activated protein kinase kinase kinase 5 OS=Homo sapiens GN=MAP3K5 PE=1 SV=1ASK1;MAP3K5;MAPKKK5;MEKK5K 1262 1.14E-02 _LLEELVRK(de)_ 0 0 2,770,255 2,766,733 2,331,100 2,326,166 2,305,443 2,246,538 0 0 0 0
M3K5_HUMAN Mitogen-activated protein kinase kinase kinase 5 OS=Homo sapiens GN=MAP3K5 PE=1 SV=1ASK1;MAP3K5;MAPKKK5;MEKK5K 805 7.21E-03 _DIK(de)GDNVLINTYSGVLK_ 1,501,510 0 0 0 0 0 0 0 0 0 0 0
M3K6_HUMAN Mitogen-activated protein kinase kinase kinase 6 OS=Homo sapiens GN=MAP3K6 PE=1 SV=3ASK2;MAP3K6;MAPKKK6;MEKK6K 773 8.08E-05 _DIK(de)GDNVLINTFSGLLK_ 4,958,642 6,067,297 3,610,211 4,837,873 4,268,200 3,045,791 4,926,102 5,456,220 2,382,371 1,104,508 787,884 1,238,596
M3K6_HUMAN Mitogen-activated protein kinase kinase kinase 6 OS=Homo sapiens GN=MAP3K6 PE=1 SV=3;>sp|Q6ZN16|M3K15_HUMAN Mitogen-activated protein kinase kinase kinase 15 OS=Homo sapiens GN=MAP3K15 PE=1 SV=2;>sp|Q99683|M3K5_HUMAN Mitogen-activatedASK2;MAP3K6;MAPKKK6;MEKK6;MAP3K15;ASK1;MAP3K5; APK K5;MEKK5K 827 9.71E-03 _ISDFGTSK(de)R_ 0 1,771,940 0 0 0 1,393,040 1,790,891 1,484, 55 2,102,381 0 0 0
M3K6_HUMAN Mitogen-activated protein kinase kinase kinase 6 OS=Homo sapiens GN=MAP3K6 PE=1 SV=3;>sp|Q6ZN16|M3K15_HUMAN Mitogen-activated protein kinase kinase kinase 15 OS=Homo sapiens GN=MAP3K15 PE=1 SV=2;>sp|Q99683|M3K5_HUMAN Mitogen-activatedASK2;MAP3K6;MAPKKK6;MEKK6;MAP3K15;ASK1;MAP3K5; APK K5;MEKK5K 709 .52E-09 _I IK(de)EIPERDSR_ 11,587,556 14,026,858 11,305,791 11,217,631 10,805,000 11,437,982 12,233,972 10,493,059 15,935,350 11,250,131 12,701,372 12,826,838
M4K2_HUMAN Mitogen-activated protein kinase kinase kinase kinase 2 OS=Homo sapiens GN=MAP4K2 PE=1 SV=2GCK;MAP4K2;RAB8IP K 138 3.14E-25 _DIK(de)GANLLLTLQGDVK_ 13,863,683 12,950,049 9,025,421 12,869,477 5,975,400 6,822,993 5,359,459 7,545,362 6,199,237 4,402,448 3,073,833 2,663,286
M4K3_HUMAN Mitogen-activated protein kinase kinase kinase kinase 3 OS=Homo sapiens GN=MAP4K3 PE=1 SV=1MAP4K3;RAB8IPL1 K 138 1.68E-04 _DIK(de)GANILLTDNGHVK_ 23,127,276 19,765,118 25,143,191 28,243,978 15,828,000 21,412,385 20,070,913 18,725,417 29,516,401 27,810,062 18,746,153 19,662,865
M4K5_HUMAN Mitogen-activated protein kinase kinase kinase kinase 5 OS=Homo sapiens GN=MAP4K5 PE=1 SV=1MAP4K5 K 49 2.65E-08 _NVHTGELAAVK(de)II _ 19,317,043 23,154,670 18,959,319 18,759,670 1,057,400 890,228 950,169 1,681,619 10,788,451 10,015,723 8,867,130 10,094,985
M4K5_HUMAN Mitogen-activated protein kinase kinase kinase kinase 5 OS=Homo sapiens GN=MAP4K5 PE=1 SV=1MAP4K5 K 142 .19E-09 _DIK(de)GANILLTDHGDVK_ 161,320,228 147,723,415 188,664,649 190,164,760 16,345,000 19,975,211 16,255,457 16,207,083 145,776,623 118,109,462 83,611,830 90,212,910
MARK1_HUMAN Serine/threonine-protein kinase MARK1 OS=Homo sapiens GN=MARK1 PE=1 SV=2KIAA1477;MARK;MARK1 K 89 6.09E-07 _EVAVK(de)IIDKTQLNPTSLQK_ 3,570,049 4,335,901 5,960,275 4,465,154 2,826,800 3,899,608 3,333,938 4,183,574 4,342,826 2,409,556 1,814,122 3,114,393
MARK2_HUMAN Serine/threonine-protein kinase MARK2 OS=Homo sapiens GN=MARK2 PE=1 SV=2EMK1;MARK2 K 82 6.69E-10 _EVAVK(de)IIDKTQLNSSSLQK_ 19,507,277 20,889,883 19,854,774 21,219,170 24,332,000 27,356,288 23,719,458 23,083,023 24,982,079 18,987,736 18,814,896 12,767,161  
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Appendix H (Continued) Appendix H (Continued)
Proteins Gene Names Amino Acid Position PEP Modified Sequence DMSO1-run1 DMSO1-run2 DMSO2-run1 DMSO2-run2 FORE1-run1 FORE1-run2 FORE2-run1 FORE2-run2 CABO1-run1 CABO1-run2 CABO2-run1 CABO2-run2
MARK3_HUMAN MAP/microtubule affinity-regulating kinase 3 OS=Homo sapiens GN=MARK3 PE=1 SV=4CTAK1;EMK2;MARK3 K 85 3.50E-21 _EVAIK(de)IIDKTQLNPTSLQK_ 12,884,704 10,424,451 14,731,788 13,069,085 12,490,000 14,679,168 11,629,793 11,806,824 13,066,570 10,572,437 6,560,466 6,745,538
MARK3_HUMAN MAP/microtubule affinity-regulating kinase 3 OS=Homo sapiens GN=MARK3 PE=1 SV=4;>sp|Q7KZI7|MARK2_HUMAN Serine/threonine-protein kinase MARK2 OS=Homo sapiens GN=MARK2 PE=1 SV=2CTAK1;EMK2;MARK3;EMK1;MARK2180 1.04E-25 _DLK(de)AENLLLDADMNIK_ 18,927,676 16,422,432 11,295,118 17,419,610 14,705,000 15,779,681 12,391,320 15,030,666 6,831,016 6,085,098 7,329,125 9,517,704
MARK3_HUMAN MAP/microtubule affinity-regulating kinase 3 OS=Homo sapiens GN=MARK3 PE=1 SV=4;>sp|Q96L34|MARK4_HUMAN MAP/microtubule affinity-regulating kinase 4 OS=Homo sapiens GN=MARK4 PE=1 SV=1;>sp|Q7KZI7|MARK2_HUMAN Serine/threonine-protein kiCTAK1;EMK2;MARK3;KIAA1860;MARK4;MARKL1;EMK1;MARK2;KIAA1477;MARK;MARK1K 64 9.53E-05 _TIGK(de)GNFAK_ 5,714,792 5,924,086 4,402,246 4,900,790 4,468,500 4,885,166 5,644,944 5,118,053 4,929,940 5,767,269 6,423,897 7,345,228
MAST2_HUMAN Microtubule-associated serine/threonine-protein kinase 2 OS=Homo sapiens GN=MAST2 PE=1 SV=2;>sp|Q9Y2H9|MAST1_HUMAN Microtubule-associated serine/threonine-protein kinase 1 OS=Homo sapiens GN=MAST1 PE=1 SV=2KIAA0807;MAST2;MAST205;KIAA0973;MAST1K 637 1.47E-08 _DLK(de)PDNLLITSMGHIK_ 134,353,796 118,459,923 105,449,205 104,037,902 91,366,000 101,667,808 99,467,855 109,912,655 70,880,478 87,194,925 51,563,951 63,146,480
MAST3_HUMAN Microtubule-associated serine/threonine-protein kinase 3 OS=Homo sapiens GN=MAST3 PE=1 SV=2KIAA0561;MAST3 K 492 6.15E-06 _DLK(de)PDNLLITSLGHIK_ 43,070,643 37,246,921 44,426,965 36,802,618 31,534,000 38,302,010 41,306,717 42,646,178 24,384,112 35,151,918 12,577,635 13,228,742
MK01_HUMAN Mitogen-activated protein kinase 1 OS=Homo sapiens GN=MAPK1 PE=1 SV=3ERK2;MAPK1;PRKM1;PRKM2 151 2.01E-12 _DLK(de)P NLLLNTTCDLK_ 4,166,447,273 3,924,577,591 4,310,993,103 3,342,211,900 3,876,200,000 4,948,631,776 3,938,029,913 5,336,530,687 4,231,164,137 4,127,269,527 3,956,031,787 4,251,417,208
MK10_HUMAN Mitogen-activated protein kinase 10 OS=Homo sapiens GN=MAPK10 PE=1 SV=2;>sp|P45983|MK08_HUMAN Mitogen-activated protein kinase 8 OS=Homo sapiens GN=MAPK8 PE=1 SV=2;>sp|P45984|MK09_HUMAN Mitogen-activated protein kinase 9 OS=Homo sapieJNK3;JNK3A;MAPK10;PRKM10;JNK1;MAPK8;PRKM8;SAPK1;JNK2;MAPK9;PRKM9191 8.63E-04 _DLK(de)PSNI VK_ 100,835,989 40,769,439 48,190,226 43,512,256 51,576,000 52,071,156 44,970,911 42,710,160 54,120,706 43,379,596 43,755,918 42,237,711
MLKL_HUMAN Mixed lineage kinase domain-like protein OS=Homo sapiens GN=MLKL PE=1 SV=1MLKL K 230 4.03E-05 _APVAIK(de)VFK_ 11,697,691 14,253,555 12,952,617 13,790,476 7,675,900 10,693,933 9,892,018 9,359,296 16,387,217 0 10,575,731 13,111,825
MLKL_HUMAN Mixed lineage kinase domain-like protein OS=Homo sapiens GN=MLKL PE=1 SV=1MLKL K 367 2.84E-03 _EK(de)TDRVK_ 8,556,502 8,836,812 7,924,086 10,673,436 0 0 4,782,142 0 7,269,629 10,570,387 6,116,502 456,222
MP2K2_HUMAN Dual specificity mitogen-activated protein kinase kinase 2 OS=Homo sapiens GN=MAP2K2 PE=1 SV=1;>sp|Q02750|MP2K1_HUMAN Dual specificity mitogen-activated protein kinase kinase 1 OS=Homo sapiens GN=MAP2K1 PE=1 SV=2MAP2K2;MEK2;MKK2;PRKMK2;MAP2K1;MEK1;PRKMK1101 2.61E-23 _K(de)LIHLEIKPAIR_ 276,761,923 322,236,277 196,455,858 227,273,211 46,924,000 58,133,881 59,806,765 58,411,359 64,350,846 83,464,020 7,739,176 9,399,325
MP2K2_HUMAN Dual specificity mitogen-activated protein kinase kinase 2 OS=Homo sapiens GN=MAP2K2 PE=1 SV=1;>sp|Q02750|MP2K1_HUMAN Dual specificity mitogen-activated protein kinase kinase 1 OS=Homo sapiens GN=MAP2K1 PE=1 SV=2MAP2K2;MEK2;MKK2;PRKMK2;MAP2K1;MEK1;PRKMK1196 2.54E-10 _DVK(de)PSNILVNSR_ 819,650,492 636,832,440 772,226,171 891,956,886 275,280,000 240,453,184 225,24 ,402 233,440,693 658,828,103 558,774,634 507,436,207 588,071,305
MP2K3_HUMAN Dual specificity mitogen-activated protein kinase kinase 3 OS=Homo sapiens GN=MAP2K3 PE=1 SV=2MAP2K3;MEK3;MKK3;PRKMK3 192 9.40E-13 _DVK(de)PSNVLINKEGHVK_ 168,362,205 162,742,072 149,986,101 144,768,483 169,040,000 178,760,317 154,756,752 180,096,714 262,103,634 155,449,276 192,537,039 165,730,736
MP2K3_HUMAN Dual specificity mitogen-activated protein kinase kinase 3 OS=Homo sapiens GN=MAP2K3 PE=1 SV=2MAP2K3;MEK3;MKK3;PRKMK3 228 5.04E-47 _TMDAGCK(de)PY ER_ 4,877,097 5,037,135 5,119,464 5,764,008 5,529,600 4,782,282 4,966,004 5,495,206 5,677,451 5,399,099 6,134,719 5,188,463
MP2K3_HUMAN Dual specificity mitogen-activated protein kinase kinase 3 OS=Homo sapiens GN=MAP2K3 PE=1 SV=2MAP2K3;MEK3;MKK3;PRKMK3 221 5.04E-47 _MCDFGISGYLVDSVAK(de)TMDAGCKPYMAPER_ 10,961,565 10,134,541 8,141,813 10,588,690 4,588,900 4,707,405 4,969,742 6,877,133 0 0 0 0
MP2K3_HUMAN Dual specificity mitogen-activated protein kinase kinase 3 OS=Homo sapiens GN=MAP2K3 PE=1 SV=2MAP2K3;MEK3;MKK3;PRKMK3 93 3.35E-36 _HAQSGTIMAVK(de)R_ 37,452,636 51,609,465 36,562,114 45,829,345 51,516,000 56,878,711 46,290,542 51,772,580 39,052,565 55,864,135 50,300,230 44,755,093
MP2K4_HUMAN Dual specificity mitogen-activated protein kinase kinase 4 OS=Homo sapiens GN=MAP2K4 PE=1 SV=1JNKK1;MAP2K4;MEK4;MKK4;PRKMK4;SERK1K 231 1.89E-08 _IIHRDIK(de)PS ILLDR_ 969,834,830 751,390,564 869,157,344 870,513,595 838,420,000 862,559,080 1,033,276,458 963,740,503 963,373,825 1,038,891,646 878,796,102 893,786,542
MP2K4_HUMAN Dual specificity mitogen-activated protein kinase kinase 4 OS=Homo sapiens GN=MAP2K4 PE=1 SV=1JNKK1;MAP2K4;MEK4;MKK4;PRKMK4;SERK1K 131 9.09E-09 _MVHKPSGQIMAVK(de)R_ 30,794,464 33,603,426 32,970,687 36,147,763 30,529,000 40,256,906 28,724,147 26,496,252 36,963,333 35,548,692 15,252,875 19,429,030
MP2K4_HUMAN Dual specificity mitogen-activated protein kinase kinase 4 OS=Homo sapiens GN=MAP2K4 PE=1 SV=1JNKK1;MAP2K4;MEK4;MKK4;PRKMK4;SERK1K 260 2.7 E-26 _LCDFGISGQLVDSIAK(de)TR_ 12,080,383 8,992,884 13,074,288 11,785,056 11,134,000 15,030,917 11,663,697 13,495,950 0 0 0 0
MP2K5_HUMAN Dual specificity mitogen-activated protein kinase kinase 5 OS=Homo sapiens GN=MAP2K5 PE=1 SV=2MAP2K5;MEK5;MKK5;PRKMK5 285 6.43E-06 _DVK(de)PSNMLVNTR_ 6,106,424 8,928,725 7,114,223 0 0 0 0 0 0 0 0
MP2K6_HUMAN Dual specificity mitogen-activated protein kinase kinase 6 OS=Homo sapiens GN=MAP2K6 PE=1 SV=1MAP2K6;MEK6;MKK6;PRKMK6 181 7.32E-09 _DVK(de)PSNVLINALGQVK_ 19,446,091 14,747,274 18,275,187 17,405,603 13,968,000 24,484,769 23,249,155 25,123,624 19,877,966 21,075,157 16,884,370 17,216,121
MP2K7_HUMAN Dual specificity mitogen-activated protein kinase kinase 7 OS=Homo sapiens GN=MAP2K7 PE=1 SV=2JNKK2;MAP2K7;MEK7;MKK7;PRKMK7K 245 2.83E-09 _DVK(de)PSNILLDER_ 8,366,046 7,498,974 7,430,678 6,610,534 6,965,800 7,246,979 7,811,991 7,008,681 8,752,128 9,356,997 8,366,568 8,799,269
MTOR_HUMAN Serine/threonine-protein kinase mTOR OS=Homo sapiens GN=MTOR PE=1 SV=1FRAP;FRAP1;FRAP2;M K 2166 1.21E-18 _IQSIAPSLQVITSK(de)QRPR_ 11,247,138 7,733,082 11,844,772 10,575,850 8,169,100 10,540,220 8,692,093 7,695,763 11,327,978 8,730,360 6,756,956 7,264,117
NEK1_HUMAN Serine/threonine-protein kinase Nek1 OS=Homo sapiens GN=NEK1 PE=1 SV=2KIAA1901;NEK1 K 130 1.46E-08 _DIK(de)SQNIFLTK_ 9,834,293 8,694,363 9,814,681 7,388,656 10,456,000 8,848,805 10,069,360 10,373,625 10,070,473 12,793,141 10,754,233 9,567,150
NEK2_HUMAN Serine/threonine-protein kinase Nek2 OS=Homo sapiens GN=NEK2 PE=1 SV=1NEK2;NEK2A;NLK1 K 143 8.48E-06 _DLK(de)PANVFLDGK_ 11,523,032 9,498,483 9,016,883 8,449,731 9,206,200 9,432,162 8,610,637 9,695,415 10,550,517 11,154,783 9,335,955 12,213,020
NEK3_HUMAN Serine/threonine-protein kinase Nek3 OS=Homo sapiens GN=NEK3 PE=1 SV=2NEK3 K 131 8.46E-24 _SK(de)NIFLTQNGK_ 9,315,100 6,876,866 8,552,933 7,921,178 8,231,800 9,398,025 7,573,536 8,815,022 9,773,577 9,240,425 8,707,761 8,573,472
NEK4_HUMAN Serine/threonine-protein kinase Nek4 OS=Homo sapiens GN=NEK4 PE=1 SV=2NEK4;STK2 K 133 1.30E-12 _DLK(de)TQNVFLTR_ 16,040,800 15,858,960 18,070,267 15,078,008 16,602,000 19,143,461 18,965,135 19,622,019 18,734,211 21,133,597 18,766,776 22,711,249
NEK7_HUMAN Serine/threonine-protein kinase Nek7 OS=Homo sapiens GN=NEK7 PE=1 SV=1;>sp|Q9HC98|NEK6_HUMAN Serine/threonine-protein kinase Nek6 OS=Homo sapiens GN=NEK6 PE=1 SV=2NEK7;NEK6 K 163 1.16E-05 _DIK(de)PANVFITATGVVK_ 109,978,322 94, 53,501 102,254,810 102,075,671 143,620,000 91,812,227 106,100,784 115,577,200 83,797,817 88,224,282 85,823,056 96,314,549
NEK8_HUMAN Serine/threonine-protein kinase Nek8 OS=Homo sapiens GN=NEK8 PE=1 SV=1JCK;NEK12A;NEK8 K 130 6.01E-16 _DLK(de)TQNILLDK_ 7,878,448 6,592,187 7,547,226 6,778,975 6,581,200 11,123,954 8,407,129 7,651,914 8,471,512 10,385,841 8,567,640 8,755,425
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2KIAA1995;NEK8;NEK9;NERCCK 199 3.62E-04 _LGDYGLAK(de)K_ 0 0 0 0 0 0 0 0 0 0 58,746,425 395,973
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2KIAA1995;NEK8;NEK9;NERCCK 81 7.71E-04 _RTEDDSLVVWK(de)EVDLTR_ 0 0 0 6,972,163 0 0 0 0 0 529,329 0 0
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2KIAA1995;NEK8;NEK9;NERCCK 200 3.62E-04 _LGDYGLAK(de)K_ 666,952 67,611,200 0 75,172,920 56,593,000 52,526,639 0 321,907 57,404,828 0 1,051,661 0
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2KIAA1995;NEK8;NEK9;NERCCK 178 1.07E-08 _DIK(de)TLNIFLTK_ 17,058,716 14,596,870 13,652,759 17,839,838 15,970,000 16,185,183 15,474,806 17,181,317 7,758,752 10,864,635 7,244,800 8,037,478
NUAK2_HUMAN NUAK family SNF1-like kinase 2 OS=Homo sapiens GN=NUAK2 PE=1 SV=1NUAK2;SNARK K 81 2.54E-03 _LVAIK(de)SIR_ 2,976,765 2,651,261 3,698,049 3,433,145 3,792,100 3,207,614 2,851,290 1,364,354 0 0 2,976,218 3,105,503
OXSR1_HUMAN Serine/threonine-protein kinase OSR1 OS=Homo sapiens GN=OXSR1 PE=1 SV=1KIAA1101;OSR1;OXSR1 K 148 4.36E-22 _DVK(de)AGNILLGEDGSVQIADFGVSAFLATGGDITR_ 1,975,313 8,939,184 12,598,663 1,239,233 0 0 0 0 0 0
PAK2_HUMAN Serine/threonine-protein kinase PAK 2 OS=Homo sapiens GN=PAK2 PE=1 SV=3PAK2 K 62 2.13E-04 _IISIFSGTEK(de)GSK_ 0 0 0 0 0 0 0 0 0 0 0 3,609,710
PAK2_HUMAN Serine/threonine-protein kinase PAK 2 OS=Homo sapiens GN=PAK2 PE=1 SV=3PAK2 K 38 1.54E-03 _MSSTIFSTGGKDPLSANHSLK(de)PLPSVPEEK_ 4,466,037 5,062,203 6,823,178 5,801,945 4,078,500 4,127,255 4,287,758 5,134,433 4,766,830 5,456,206 2,498,341 0
PAK2_HUMAN Serine/threonine-protein kinase PAK 2 OS=Homo sapiens GN=PAK2 PE=1 SV=3PAK2 K 191 6.68E-23 _GTEAPAVVTEEEDDDEETAPPVIAPRPDHTK(de)SIYTR_ 6,835,056 7,380,394 7,473,477 6,412,093 7,357,000 8,811,933 8,320,892 6,876,024 6,607,483 6,650,731 7,177,318 6,594,398
PASK_HUMAN PAS domain-containing serine/threonine-protein kinase OS=Homo sapiens GN=PASK PE=1 SV=3KIAA0135;PASK K 314 4.70E-03 _DGTTFPLSLK(de)L _ 0 0 0 0 126,790 0 0 228,365 6,287,837 6,951,747 5,974,434 5,931,377
PDPK1_HUMAN 3-phosphoinositide-dependent protein kinase 1 OS=Homo sapiens GN=PDPK1 PE=1 SV=1PDK1;PDPK1 K 465 1.38E-02 _MGPVDK(de)R_ 2,685,073 3,215,496 2,573,767 3,305,325 2,715,600 2,919,614 4,017,747 3,147,064 2,409,713 3,444,039 4,671,300 3,292,571
PHKG2_HUMAN Phosphorylase b kinase gamma catalytic chain, liver/testis isoform OS=Homo sapiens GN=PHKG2 PE=1 SV=1PHKG2 K 364 7.60E-04 _K(de)GEQQNR_ 25,974,103 24,250,007 16,079,774 0 20,468,000 20,378,827 18,831,259 17,055,912 23,098,431 26,108,138 17,860,517 31,990,368
PHKG2_HUMAN Phosphorylase b kinase gamma catalytic chain, liver/testis isoform OS=Homo sapiens GN=PHKG2 PE=1 SV=1PHKG2 K 53 5.27E-18 _ATGHEFAVK(de)IMEVTAERLSPEQLEEVR_ 86,012,239 93,626,826 99,089,231 81,408,634 49,328,000 45,752,871 53,637,184 77,039,524 23,024,337 21,964,054 2,911,256 4,086,515
PLK1_HUMAN Serine/threonine-protein kinase PLK1 OS=Homo sapiens GN=PLK1 PE=1 SV=1PLK;PLK1 K 82 3.48E-10 _EVFAGK(de)IVPK_ 249,628,619 275,807,050 239,574,327 343,477,875 312,350,000 231,881,063 299,377,206 313,136,752 398,728,128 314,927,807 285,179,377 307,030,560
PLK1_HUMAN Serine/threonine-protein kinase PLK1 OS=Homo sapiens GN=PLK1 PE=1 SV=1PLK;PLK1 K 178 1.19E-25 _DLK(de)LGNLFLNEDLEVK_ 3,731,135 22,474,580 23,488,893 31,417,866 20,365,000 25,816,324 16,418,021 15,237,968 0 0 776,083 693,870
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 2908 9.29E-03 _LLPAELPAK(de)R_ 2,121,048 0 0 0 0 0 0 0 0 2,713,442 2,433,379 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 1147 1.98E-03 _HVSL K(de)AK_ 0 1,948,720 0 0 0 162,267 0 0 3,480,314 0 0 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 963 7.84E-03 _ATQMPEGGQGAPPMYQLYK(de)R_ 0 0 0 0 0 0 0 1,609,447 0 2,392,024 0 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 4019 7.23E-04 _NFEQK(de)MLK_ 11,978,035 9,792,643 12,865,100 13,224,336 12,676,000 12,226,353 8,452,334 8,134,082 12,318,328 12,652,681 11,877,605 8,029,927
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 1057 7.87E-08 _SPVNTK(de)SLFK_ 5,693,544 4,387,780 7,412,855 4,558,421 5,193,800 3,676,770 6,416,902 4,421,502 7,803,312 3,739,518 3,214,183 4,481,599
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 4023 6.48E-62 _K(de)GGSWIQEINVAEKNWYPR_ 75,884,252 75,043,146 84,399,067 55,812,091 68,018,000 60,274,554 64,618,463 72,645,235 62,829,318 72,411,763 57,617,898 62,269,597
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 3753 1.25E-09 _GHDEREHPFLVK(de)GGEDLRQDQR_ 14,266,400 15,424,095 26,907,419 26,980,960 10,962,000 22,464,804 16,133,752 25,180,781 10,839,586 25,474,529 16,463,893 16,232,064
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 2683 4.47E-14 _SSFDWLTGSSTDPLVDHTSPSSDSLLFAHK(de)R_ 5,608,996 3,519,466 8,068,277 6,091,552 2,851,200 3,521,925 3,686,622 3,747,643 384,995 610,509 0 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 4070 9.36E-05 _LAGA PAVITCDELLLGHEK(de)APAFR_ 2,500,069 1,189,068 0 0 1,800,000 1,733,285 1,533,745 1,755,924 0 0 0 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 310 5.04E-07 _K(de)AALSALESFLK_ 0 0 0 2,222,655 0 0 0 2,089,484 0 0 0 0
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3HYRC;HYRC1;PRKDC K 471 1.25E-02 _VFLALAAK(de)GPVLR_ 0 0 585,579 0 0 0 0 0 0 0 0 0
PRPK_HUMAN TP53-regulating kinase OS=Homo sapiens GN=TP53RK PE=1 SV=2C20orf64;PRPK;TP53RK K 40 2.92E-08 _FLSGLELVK(de)QGAEAR_ 14,036,117 120,029,362 149,388,420 120,838,843 113,530,000 124,724,834 141,942,941 6,516,701 56,663,892 9,142,000 3,961,187 3,200,742
ROCK1_HUMAN Rho-associated protein kinase 1 OS=Homo sapiens GN=ROCK1 PE=1 SV=1ROCK1 K 333 2.92E-02 _NGVEEIK(de)RHLFFK_ 0 0 0 5,757,121 6,657,800 232,013 0 220,909 8,366,215 0 6,211,482 7,002,270
ROCK2_HUMAN Rho-associated protein kinase 2 OS=Homo sapiens GN=ROCK2 PE=1 SV=4KIAA0619;ROCK2 K 1065 3.75E-03 _K(de)LHMELK_ 6,302,180 6,429,467 4,925,431 5,495,062 6,494,700 13,175,982 16,229,378 6,529,668 6,839,782 13,873,761 4,813,483 9,233,813
SLK_HUMAN STE20-like serine/threonine-protein kinase OS=Homo sapiens GN=SLK PE=1 SV=1KIAA0204;SLK;STK2 K 63 3.94E-05 _ETSVLAAAK(de)VIDTK_ 5,652,271 5,152,772 7,170,260 4,357,179 5,306,900 4,247,679 5,001,385 5,818,529 4,238,574 6,598,136 5,193,172 2,167,604
SLK_HUMAN STE20-like serine/threonine-protein kinase OS=Homo sapiens GN=SLK PE=1 SV=1KIAA0204;SLK;STK2 K 157 3.72E-25 _IIHRDLK(de)AGNILFTLDGDIK_ 649,486,075 533,641,847 445,625,112 715,823,066 589,500,000 502,529,992 588,713,739 589,709,888 134,485,170 92,297,623 139,261,393 155,792,738
SMG1_HUMAN Serine/threonine-protein kinase SMG1 OS=Homo sapiens GN=SMG1 PE=1 SV=3ATX;KIAA0421;LIP;SMG1 K 2134 3.43E-37 _DTVTIHSVGGTITILPTK(de)TKPKK_ 44,009,573 61,609,187 64,061,396 64,712,442 61,095,100 99,487,844 188,396,118 59,921,072 34,599,381 39,931,023
SRPK1_HUMAN SRSF protein kinase 1 OS=Homo sapiens GN=SRPK1 PE=1 SV=2SRPK1 K 109 5.97E-03 _KFVAMK(de)VVK_ 14,898,286 17,070,915 16,950,681 13,561,685 15,604,000 27,036,602 12,842,498 14,913,793 17,351,478 14,803,668 16,105,285 12,593,003
SRPK1_HUMAN SRSF protein kinase 1 OS=Homo sapiens GN=SRPK1 PE=1 SV=2SRPK1 K 215 1.04E-12 _IIHTDIK(de)PENILLSVNEQYIR_ 6,717,134 4,030,733 7,836,889 5,703,659 4,372,200 5,095,084 4,917,669 4,953,577 0 1,977,001 0 0
SRPK1_HUMAN SRSF protein kinase 1 OS=Homo sapiens GN=SRPK1 PE=1 SV=2SRPK1 K 4 2.52E-02 _K(de)VLALQAR_ 2,385,372 0 0 0 0 0 0 0 0 0 0 0
SRPK2_HUMAN SRSF protein kinase 2 OS=Homo sapiens GN=SRPK2 PE=1 SV=3SRPK2 K 110 5.97E-03 _FVAMK(de)VVK_ 12,426,363 13,828,499 14,369,977 13,561,685 12,675,000 24,453,649 12,842,498 12,215,456 14,616,274 12,636,277 14,399,319 12,593,003
SRPK2_HUMAN SRSF protein kinase 2 OS=Homo sapiens GN=SRPK2 PE=1 SV=3;>sp|Q9UPE1|SRPK3_HUMAN SRSF protein kinase 3 OS=Homo sapiens GN=SRPK3 PE=1 SV=2;>sp|Q96SB4|SRPK1_HUMAN SRSF protein kinase 1 OS=Homo sapiens GN=SRPK1 PE=1 SV=2SRPK2;MSSK1;SRPK3;STK23;SRPK1K 506 8.95E-03 _IADLGNACWVHK(de)HFTEDIQTR_ 0 0 0 0 0 1,755,352 1,799,671 0 0 0 0 0
ST32C_HUMAN Serine/threonine-protein kinase 32C OS=Homo sapiens GN=STK32C PE=1 SV=1STK32C K 218 6.70E-06 _DVK(de)PDNILLDER_ 6,016,051 4,843,462 2,612,723 5,991,865 2,887,900 2,945,547 7,122,879 4,886,950 3,260,120 4,417,827 3,342,617 4,300,985
ST38L_HUMAN Serine/threonine-protein kinase 38-like OS=Homo sapiens GN=STK38L PE=1 SV=3KIAA0965;NDR2;STK38L K 119 3.39E-07 _DTGHIYAMK(de)ILR_ 10,938,871 10,359,276 12,519,298 12,031,356 12,548,000 12,839,321 10,480,549 12,535,366 7,136,157 9,352,280 3,927,045 4,363,707
STK10_HUMAN Serine/threonine-protein kinase 10 OS=Homo sapiens GN=STK10 PE=1 SV=1LOK;STK10 K 159 2.03E-45 _DLK(de)AGNVLMTLEGDIR_ 160,318,999 139,854,424 116,078,335 173,752,529 101,130,000 137,682,034 105,970,386 119,501,434 85,460,228 31,920,312 18,407,022 18,706,820
STK11_HUMAN Serine/threonine-protein kinase STK11 OS=Homo sapiens GN=STK11 PE=1 SV=1LKB1;PJS;STK11 K 178 1.15E-05 _DIK(de) GNLLLTTGGTLK_ 39,308,247 28,014,480 47,371,615 40,271,832 38,770,000 39,414,783 34,907,636 44,089,614 39,526,347 38,083,125 35,216,921 38,465,899
STK24_HUMAN Serine/threonine-protein kinase 24 OS=Homo sapiens GN=STK24 PE=1 SV=1MST3;STK24;STK3 K 158 6.03E-18 _DIK(de)AANVLLSEHGEVK_ 261,231,750 203,558,376 280,024,574 264,078,164 255,860,000 226,807,575 214,314,021 204,947,347 283,277,717 233,225,177 181,251,768 218,660,320
STK25_HUMAN Serine/threonine-protein kinase 25 OS=Homo sapiens GN=STK25 PE=1 SV=1;>sp|Q9P289|STK26_HUMAN Serine/threonine-protein kinase 26 OS=Homo sapiens GN=STK26 PE=1 SV=2SOK1;STK25;YSK1;MASK;MST4K 142 8.74E-26 _DIK(de)AANVLLSE GDVK_ 105,948,932 92,966,354 117,657,922 9 ,400,261 100,040,000 117,293,776 108,004,600 108,377,086 107,143,574 130,904,654 124,264,012 122,568,646
STK3_HUMAN Serine/threonine-protein kinase 3 OS=Homo sapiens GN=STK3 PE=1 SV=2MST2;STK3 K 56 4.25E-21 _ESGQVVAIK(de)QVPVESDLQEIIK_ 67,617,439 49,132,150 48,158,207 37,176,154 35,358,000 45,811,339 43,207,925 39,975,994 33,990,195 29,777,528 29,922,582 42,009,965
STK38_HUMAN Serine/threonine-protein kinase 38 OS=Homo sapiens GN=STK38 PE=1 SV=1NDR1;STK38 K 118 9.12E-08 _DTGHVYAMK(de)ILR_ 46,943,174 37,746,090 50,671,673 47,791,576 34,776,000 45,568,038 42,810,645 37,852,642 42,011,093 33,674,525 18,081,640 13,152,015
STK38_HUMAN Serine/threonine-protein kinase 38 OS=Homo sapiens GN=STK38 PE=1 SV=1;>sp|Q9Y2H1|ST38L_HUMAN Serine/threonine-protein kinase 38-like OS=Homo sapiens GN=STK38L PE=1 SV=3NDR1;STK38;KIAA0965;NDR2;STK38LK 239 4.76E-13 _LSDFGLCTGLK(de)K_ 53,843,866 46,055,396 53,406,067 50,157,692 49,986,000 51,597,757 50,048,622 53,850,421 72,818,789 62,533,006 0
STK38_HUMAN Serine/threonine-protein kinase 38 OS=Homo sapiens GN=STK38 PE=1 SV=1;>sp|Q9Y2H1|ST38L_HUMAN Serine/threonine-protein kinase 38-like OS=Homo sapiens GN=STK38L PE=1 SV=3NDR1;STK38;KIAA0965;NDR2;STK38LK 240 4.76E-13 _LSDFGLCTGLK(de)K_ 0 0 3,637,772 57,944 5,232,016 232,886 0 0 0 0
STK4_HUMAN Serine/threonine-protein kinase 4 OS=Homo sapiens GN=STK4 PE=1 SV=2MST1;STK4 K 59 8.68E-16 _ETGQI AIK(de)QVPVESDLQEIIK_ 25,747,158 27,415,042 26,017,300 35,608,471 44,921,000 25,807,837 23,181,348 27,264,890 22,705,004 24,683,032 15,955,197 120,668,734
STK4_HUMAN Serine/threonine-protein kinase 4 OS=Homo sapiens GN=STK4 PE=1 SV=2;>sp|Q13188|STK3_HUMAN Serine/threonine-protein kinase 3 OS=Homo sapiens GN=STK3 PE=1 SV=2MST1;STK4;MST2;STK3 K 148 3.19E-45 _DIK(de)AGNILLNTEGHAK_ 1,580,050,481 1,572,817,329 1,823,142,805 1,787,252,249 1,662,000,000 1,556,372,796 1,772,548,122 1,470,393,141 2,020,147,376 1,426,745,895 1,450,930,712 1,416,164,756
STRAA_HUMAN STE20-related kinase adapter protein alpha OS=Homo sapiens GN=STRADA PE=1 SV=1LYK5;STRAD;STRADA K 239 1.97E-22 _YSVK(de)VLPWLSPEVLQQNLQGYDAK_ 7,919,053 9,121,926 5,574,556 12,612,671 6,591,800 7,148,527 11,538,515 9,163,938 575,374 2,413,452 955,673 1,444,785
TAOK1_HUMAN Serine/threonine-protein kinase TAO1 OS=Homo sapiens GN=TAOK1 PE=1 SV=1;>sp|Q9H2K8|TAOK3_HUMAN Serine/threonine-protein kinase TAO3 OS=Homo sapiens GN=TAOK3 PE=1 SV=2KIAA1361;MAP3K16;TAOK1;DPK;JIK;KDS;MAP3K18;TAOK3K 153 5.86E-18 _DIK(de)AGNILLTEPGQVK_ 33,838,200 26,648,851 28,666,311 29,561,860 27,882,000 28,988,669 32,956,877 31,444,199 34,824,010 35,605,082 30,290,355 33,160,762
TAOK2_HUMAN Serine/threonine-protein kinase TAO2 OS=Homo sapiens GN=TAOK2 PE=1 SV=2KIAA0881;MAP3K17;PSK;PSK1;TAOK2;UNQ2971/PRO7431K 153 8.58E-18 _DVK(de)AGNILLSEPGLVK_ 16,859,583 13,770,734 17,366,924 17,304,048 14,103,000 14,732,921 16,704,897 15,731,910 16,537,491 16,084,212 13,462,126 18,169,730
TBK1_HUMAN Serine/threonine-protein kinase TBK1 OS=Homo sapiens GN=TBK1 PE=1 SV=1;>sp|Q14164|IKKE_HUMAN Inhibitor of nuclear factor kappa-B kinase subunit epsilon OS=Homo sapiens GN=IKBKE PE=1 SV=1NAK;TBK1;IKBKE;IKKE;IKKI;KIAA0151137 7.02E-03 _DIK(de)PGNIMR_ 0 0 222,434 0 4,487,800 5,542,173 0 6,052,789 6,332,606 5,782,442 6,489,317 5,646,878
TLK1_HUMAN Serine/threonine-protein kinase tousled-like 1 OS=Homo sapiens GN=TLK1 PE=1 SV=2KIAA0137;TLK1 K 485 1.25E-16 _YAAVK(de)IHQLNK_ 10,507,786 11,934,273 8,884,859 17,944,895 12,192,000 13,326,866 11,332,485 4,496,148 9,731,938 5,057,997 15,070,706 10,300,443
TLK1_HUMAN Serine/threonine-protein kinase tousled-like 1 OS=Homo sapiens GN=TLK1 PE=1 SV=2KIAA0137;TLK1 K 588 1.32E-20 _YLNEI PPIIHYDLK(de)PGNILLVDGTACGEIK_ 4,475,938 3,775,917 40,512,150 33,938,065 27,968,000 26,037,936 5,842,193 27,520,818 0 0 0 0
TLK2_HUMAN Serine/threonine-protein kinase tousled-like 2 OS=Homo sapiens GN=TLK2 PE=1 SV=2TLK2 K 491 8.00E-07 _YVAVK(de)IHQLNK_ 5,517,328 7,379,087 5,062,044 5,506,035 6,797,800 6,265,570 8,346,276 6,542,123 5,475,729 6,324,803 6,683,172 5,338,629
TLK2_HUMAN Serine/threonine-protein kinase tousled-like 2 OS=Homo sapiens GN=TLK2 PE=1 SV=2TLK2 K 594 1.81E-20 _YLNEI PPIIHYDLK(de)PGNILLVNGTACGEIK_ 35,375,643 33,240,493 39,366,949 30,829,547 30,253,000 26,805,560 23,295,229 27,180,434 0 0 0 0
TNIK_HUMAN TRAF2 and NCK-interacting protein kinase OS=Homo sapiens GN=TNIK PE=1 SV=1;>sp|Q8N4C8|MINK1_HUMAN Misshapen-like kinase 1 OS=Homo sapiens GN=MINK1 PE=1 SV=2;>sp|O95819|M4K4_HUMAN Mitogen-activated protein kinase kinase kinase kinase 4KIAA0551;TNIK;MAP4K6;MINK;MINK1;HGK;KIAA0687;MAP4K4;NIKK 155 1.94E-34 _DIK(de)GQ VLLTENAEVK_ 647,060,876 528,279,598 575,225,996 496,312,397 547,470,000 352,409,424 390,403,941 374,934,895 419,182,146 519,220,267 489,207,916 500,443,980
TNK1_HUMAN Non-receptor tyrosine-protein kinase TNK1 OS=Homo sapiens GN=TNK1 PE=1 SV=3TNK1 K 148 2.07E-03 _SVPVAVK(de)SLR_ 6,875,439 6,943,567 6,663,511 7,440,951 0 911,238 0 0 0 0 0 0
TOPK_HUMAN Lymphokine-activated killer T-cell-originated protein kinase OS=Homo sapiens GN=PBK PE=1 SV=3PBK;TOPK K 90 5.88E-03 _ILK(de)SLHHP IVGYR_ 0 0 0 2,221,955 0 0 0 2,561,757 0 0 0 0
ULK1_HUMAN Serine/threonine-protein kinase ULK1 OS=Homo sapiens GN=ULK1 PE=1 SV=2KIAA0722;ULK1 K 140 7.60E-05 _DLK(de)PQNILLSNPAGR_ 4,166,225 4,016,237 4,231,694 4,462,236 4,008,900 3,798,327 2,928,138 4,423,976 3,758,008 4,142,136 4,159,052 4,533,846
ULK3_HUMAN Serine/threonine-protein kinase ULK3 OS=Homo sapiens GN=ULK3 PE=1 SV=2ULK3 K 44 2.27E-12 _EVVAIK(de)CVAKK_ 25,196,482 21,779,231 23,671,399 24,376,715 25,933,000 23,126,810 25,692,820 25,591,119 42,430,609 49,424,504 54,146,388 64,618,911
ULK3_HUMAN Serine/threonine-protein kinase ULK3 OS=Homo sapiens GN=ULK3 PE=1 SV=2ULK3 K 139 4.10E-22 _NISHLDLK(de)PQNILLSSLEKPHLK_ 826,492,223 666,281,213 850,928,050 773,230,855 308,890,000 250,288,963 421,204,029 436,570,950 118,309,799 96,565,763 858,517 2,547,830
WNK1_HUMAN Serine/threonine-protein kinase WNK1 OS=Homo sapiens GN=WNK1 PE=1 SV=2;>sp|Q9Y3S1|WNK2_HUMAN Serine/threonine-protein kinase WNK2 OS=Homo sapiens GN=WNK2 PE=1 SV=4;>sp|Q96J92|WNK4_HUMAN Serine/threonine-protein kinase WNK4 OS=Homo sapKDP;KIAA0344;PRKWNK1;WNK1;KIAA1760;P/OKcl.13;PRKWNK2;SDCCAG43;WNK2;PRKWNK4;WNK4375 5.09E-15 _IGDLGLATLK(de)R_ 63,981,865 43,506,148 59,454,392 44,684,2 4 48,733,000 31,384,902 55,588,813 53,421,611 72,383,223 76,715,786 51,277,523 45,080,270
YES_HUMAN Tyrosine-protein kinase Yes OS=Homo sapiens GN=YES1 PE=1 SV=3;>sp|P06241|FYN_HUMAN Tyrosine-protein kinase Fyn OS=Homo sapiens GN=FYN PE=1 SV=3;>sp|P12931|SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src OS=Homo sapiens GN=SRC PE=1YES;YES1;F N;SRC;SRC1K 433 2.71E-06 _QGAK(de)FPIKWTAPEAALYGR_ 9,661,303 38,065,427 8,662,010 0,811,528 17,846,000 4,533,228 15,739,949 4,263,253 3,454,851 3,557,330 22,321,923 24,712,245  
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Appendix I – Tyrosine phosphoproteomics in H1155 cells: peptides with PEP score < 0.05 ppendix I - Tyrosine phosphoproteomics of H1155 cells: peptides with PEP score < 0.05
Proteins Gene Name Amino Acid Position PEP ModifiedSequence DMSO1-run1 DMSO1-run2 DMSO2-run1 DMSO2-run2 CABO1-run1 CABO1-run2 CABO2-run1 CABO2-run2 FORE1-run1 FORE1-run2 FORE2-run1 FORE2-run2
1433E_HUMAN14-3-3proteinepsilonOS=HomosapiensGN=YWHAEPE=1SV=1YWHAE Y 131 4.77E-08 _Y(ph)LAEFATGNDRK_ 285,047 410,494 398,434 397,811 591,015 465,700 572,772 492,649 500,690 637,612 608,881 617,452
41_HUMANProtein4.1OS=HomosapiensGN=EPB41PE=1SV=4E41P;EPB41 Y 660 1.06E-25 _LDGENIY(ph)IR_ 12,066,633 13,968,420 12,279,110 12,298,514 8,234,556 8,911,600 9,412,239 9,434,806 5,510,819 6,267,068 6,208,613 5,456,314
ABI2_HUMANAblinteractor2OS=HomosapiensGN=ABI2PE=1SV=1ABI2;ARGBPIA Y 213 1.38E-24 _TLEPVRPPVVPNDY(ph)VPSPTR_ 4,415,917 3,766,916 3,887,426 3,010,359 3,677,615 1,925,000 1,613,871 1,570,929 1,558,397 2,098,346 1,540,136 1,616,006
ABL1_HUMANTyrosine-proteinkinaseABL1OS=HomosapiensGN=ABL1PE=1SV=4;>spABL;ABL1;JTK7;ABL2;ABLL;ARGY 393 2.47E-12 _LM(ox)TGDTY(ph)TAHAGAK_ 1,753,833 2,895,273 1,491,681 2,259,296 1,153,777 1,913,500 2,647,459 2,648,669 348,703 967,631 1,129,513 1,360,666
ACK1_HUMANActivatedCDC42kinase1OS=HomosapiensGN=TNK2PE=1SV=3ACK1;TNK2 Y 859 6.49E-27 _VSSTHY(ph)YLLPERPSYLER_ 810,747 5,021,464 2,820,093 2,616,486 4,903,409 4,693,100 2,544,853 2,172,686 5,312,792 4,809,019 3,551,788 3,379,793
ACK1_HUMANActivatedCDC42kinase1OS=HomosapiensGN=TNK2PE=1SV=3ACK1;TNK2 Y 84 8.91E-20 _ALPQNDDHY(ph)VMQEHR_ 1,569,944 3,409,895 1,649,046 2,035,610 2,084,116 2,165,900 1,631,642 4,440,873 1,281,684 2,144,560 3,338,240 2,662,311
ACK1_HUMANActivatedCDC42kinase1OS=HomosapiensGN=TNK2PE=1SV=3ACK1;TNK2 Y 827 2.40E-10 _Y(ph)ATPQVIQAPGPR_ 17,824,404 24,225,381 16,123,570 19,540,468 21,185,091 20,369,000 17,732,987 14,623,121 17,803,666 16,645,902 21,392,521 17,821,350
ACTB_HUMANActin,cytoplasmic1OS=HomosapiensGN=ACTBPE=1SV=1;>spACTB;ACTB;ACTG;ACTG1Y 198 5.86E-04 _GY(ph)SFTTTAER_ 1,534,162 1,656,658 1,869,551 4,147,218 2,347,603 2,053,300 4,031,595 4,645,904 1,833,864 4,233,481 2,310,392 1,962,364
ACTB_HUMANActin,cytoplasmic1OS=HomosapiensGN=ACTBPE=1SV=1;>spACTB;ACTB;ACTG;ACTG1;A26C1A;POTE2;POTEE;A26C1B;POTEF;ACTBL3;FKSG30;POTEKP;ACTC;ACTC1;ACTA;ACTA1Y 91 2.09 -04 _IWHHTFY(ph)NELR_ 4,158,358 4,953,623 5,449,121 6,205,508 7,084,587 8,189,600 6,109,696 5,527,216 7,020,707 3,772,463 6,399,762 5,409,675
ACTB_HUMANActin,cytoplasmic1OS=HomosapiensGN=ACTBPE=1SV=1;>spACTB;ACTB;ACTG;ACTG1Y 294 5.63E-25 _KDLY(ph)ANTVLSGGTTM(ox)YPGIADR_ 184,434 994,663 0 834,722 1,241,375 0 0 0 0 1,301,978 0 553,269
ACTB_HUMANActin,cytoplasmic1OS=HomosapiensGN=ACTBPE=1SV=1;>spACTB;ACTB;ACTG;ACTG1;ACTC;ACTC ;ACTA;ACTA1;ACTA2;ACTSA;ACTVS;GIG46;ACTA3;ACTG2;ACTL3;ACTSGY 53 1.95E-19 _DSY(ph)VGDEAQSKR_ 541,114 686,342 898,984 620,551 938,591 770,510 798,922 0 729,044 764,708 772,836 926,092
ACTB_HUMANActin,cytoplasmic1OS=HomosapiensGN=ACTBPE=1SV=1;>spACTB;ACTB;ACTG;ACTG1Y 169 2.26E-07 _TTGIVMDSGDGVTHTVPIYEGY(ph)ALPHAILR_ 1,012,346 809,368 0 900,367 643,516 1,434,800 336,589 216,221 2,106,462 834,585 562,749 654,835
ADAM9_HUMANDisintegrinandmetalloproteinasedomain-containingprotein9OS=HomosapiensGN=ADAM9PE=1SV=1ADAM9;KIAA0021;MCMP;MDC9;MLTNGT 761 1.62E-03 _HVSPVT(ph)PPREVPIY(ph)ANR_ 1,307,697 788,076 1,152,815 655,977 0 968,870 0 227,512 414,870 713,326 0 300,388
ADAM9_HUMANDisintegrinandmetalloproteinasedomain-containingprotein9OS=HomosapiensGN=ADAM9PE=1SV=1ADAM9;KIAA0021;MCMP;MDC9;MLTNGY 769 3.53E-02 _HVSPVT(ph)PPREVPIY(ph)ANR_ 3,425,003 3,278,247 3,564,252 2,885,352 0 3,218,800 3,264,991 3,513,585 2,420,211 713,326 2,753,973 300,388
AGRL2_HUMANAdhesionGprotein-coupledreceptorL2OS=HomosapiensGN=ADGRL2PE=1SV=2KIAA0786;LEC1;LPHH1;LPHN2Y 1372 2.91E-05 _DSLY(ph)TSMPNLR_ 0 0 585,187 575,562 0 0 0 0 0 0 0 0
AGRL2_HUMANAdhesionGprotein-coupledreceptorL2OS=HomosapiensGN=ADGRL2PE=1SV=2KIAA0786;LEC1;LPHH1;LPHN2Y 1406 3.75E-02 _SENEDIY(ph)YK_ 2,268,761 3,137,206 3,364,146 2,202,028 1,667,708 2,057,000 3,165,040 3,595,057 927,232 1,962,646 1,457,460 1,842,332
AKA11_HUMANA-kinaseanchorprotein11OS=HomosapiensGN=AKAP11PE=1SV=1AKAP11;AKAP220;KIAA0629Y 424 2.23E-32 _KPESPY(ph)GNLCDAPDSPRPVK_ 1,407,583 2,024,464 1,057,171 747,593 0 0 674,449 833,105 0 859,010 663,860 762,340
ALDOA_HUMANFructose-bisphosphatealdolaseAOS=HomosapiensGN=ALDOAPE=1SV=2ALDA;ALDOA Y 3 2.50E-03 _PY(ph)QYPALTPEQKK_ 267,624 922,785 542,065 692,360 1,256,379 1,183,400 1,137,787 937,058 700,549 591,915 886,191 1,234,036
ALDOA_HUMANFructose-bisphosphatealdolaseAOS=HomosapiensGN=ALDOAPE=1SV=2ALDA;ALDOA Y 364 1.82E- 7 _YTPSGQAGAAASESLFVSNHAY(ph)_ 604,882 541,780 602,179 599,427 588,845 510,480 0 0 761,977 733,281 640,693 522,167
ANXA2_HUMANAnnexinA2OS=HomosapiensGN=ANXA2PE=1SV=2;>spANX2;ANX2L4;ANXA2;CAL1H;LPC D;ANX2L2;ANX2P2;ANXA2P2;LPC2BY 4 9.46E-86 _LSLEGDHSTPPSAY(ph)GSVK_ 35,140,769 32,158,330 25,670,087 30,108,381 22,296,512 19,184,000 18,775,736 19,690,073 22,100,887 23,032,658 21,475,575 19,178,039
AP3D1_HUMANAP-3complexsubunitdelta-1OS=HomosapiensGN=AP3D1PE=1SV=1AP3D1;PR 0039 Y 682 .48E-02 _KQEQANNPFY(ph)IK_ 348,528 442,258 578,761 55,261 214,932 0 740,962 669,621 332,293 268,017 0 438,027
ARAP2_HUMANArf-GAPwithRho-GAPdomain,ANKrepeatandPHdomain-containingprotein2OS=HomosapiensGN=ARAP2PE=1SV=3ARAP2;CENTD1; IAA0580Y 473 1.01E-38 _HSYPLSSTSGNADSSAVSSQAISPY(ph)ACFYGASAK_ 1,157,295 1,221,567 1,482,266 1,389,627 0 0 0 827,798 1,695,320 1,512,066 1,478,852 0
ARAP2_HUMANArf-GAPwithRho-GAPdomain,ANKrepeatandPHdomain-containingprotein2OS=HomosapiensGN=ARAP2PE=1SV=3ARAP2;CENTD1; IAA0580Y 77 1.10E-02 _MQDIPIY(ph)ANVHK_ 1,149,449 1,576,709 1,640,751 0 1,376,754 1,129,800 0 0 1,187,136 1,187,661 0 1,073,421
AT1A1_HUMANSodium/potassium-transportingATPasesubunitalpha-1OS=HomosapiensGN=ATP1A1PE=1SV=1ATP1A1 Y 55 4.58E-02 _Y(ph)GTDLSR_ 863,388 2,405,491 3,123,615 3,430,383 2,075,691 1,472,900 0 1,891,762 1,376,208 1,797,149 2,756,867 4,197,783
AT1A1_HUMANSodium/potassium-transportingATPasesubunitalpha-1OS=HomosapiensGN=ATP1A1PE=1SV=1ATP1A1 Y 260 2.86E-11 _GIVVY(ph)TGDRTVMGR_ 7,129,953 8,047,758 11,912,971 10,006,606 8,316,499 12,834,000 7,999,275 7,275,304 7,906,713 12,367,120 8,201,012 9,198,553
BACH_HUMANCytosolicacylcoenzymeAthioesterhydrolaseOS=HomosapiensGN=ACOT7PE=1SV=3ACOT7;BACH Y 194 2.98E-04 _Y(ph)EAQKLER_ 690,244 1,261,020 1,236,803 1,361,262 1,129,091 977,940 1,173,917 1,717,156 1,307,622 1,502,540 1,561,780 1,780,870
BCAR1_HUMANBreastcanceranti-estrogenresistanceprotein1OS=HomosapiensGN=BCAR1PE=1SV=2BCAR1;CAS;CASS1;CRKASY 128 8.31E-11 _AQQGLY(ph)QVPGPSPQFQSPPAK_ 3,056,459 2,713,735 3,037,012 3,246,492 2,347,833 1,977,500 1,452,774 1,224,963 1,934,373 2,167,160 1,087,394 1,313,937
BCR_HUMANBreakpointclusterregionproteinOS=HomosapiensGN=BCRPE=1SV=2BCR;BCR1;D22S11 Y 177 3.76E-25 _KGHGQPGADAEKPFY(ph)VNVEFHHER_ 2,919,260 3,253,546 1,218,197 855,247 0 0 0 0 0 0 0 0
BI2L1_HUMANBrain-specificangiogenesisinhibitor1-associatedprotein2-likeprotein1OS=HomosapiensGN=BAIAP2L1PE=1SV=2BAIAP2L1;IRTKS Y 274 3.10E-05 _SNVVRKDY(ph)DTLSK_ 909,628 1,235,344 931,488 622,466 359,256 744,310 944,315 265,813 173,473 306,609 415,946 294,721
CALM_HUMANCalmodulinOS=HomosapiensGN=CALM1PE=1SV=2CALM;CALM1;CALM2;CALM3;CALML2;CAM;CAM1;CAM2;CAM3;CAMB;CAMC;CAMIIIY 100 2.26E-50 _VFDKDGNGY(ph)ISAAELR_ 2,787,897 3,153,975 3,357,271 3,217,050 3,127,790 3,684,700 2,713,081 2,545,224 2,604,894 4,074,370 2,337,196 2,793,190
CDCP1_HUMANCUBdomain-containingprotein1OS=HomosapiensGN=CDCP1PE=1SV=3CDCP1;TRASK;UNQ2486/PRO5773Y 806 2.42E-59 _LATEEPPPRSPPESESEPY(ph)TFSHPNNGDVSSK_ 4,309,430 4,313,058 3,838,632 3,754,422 0 0 7,761,442 6,462,786 0 0 5,859,537 0
CDK1_HUMANCyclin-dependentkinase1OS=HomosapiensGN=CDK1PE=1SV=3CDC2 Y 5 1.09E-18 _IGEGT(ph)Y(ph)GVVYKGR_ 4,889,416,697 5,566,424,140 5,936,011,414 5,189,168,820 6,774,705,077 6,446,900,000 7,446,606,769 6,939,445,155 6,521,900,328 7,024,722,624 8,034,779,353 6,400,031,183
CDK1_HUMANCyclin-dependentkinase1OS=HomosapiensGN=CDK1PE=1SV=3CDC2 T 4 1.09E-18 _IGEGT(ph)Y(ph)GVVYKGR_ 15,028,757 19,017,230 11,400,376 17,874,495 21,445,923 12,514,000 62,942,347 33,327,254 22,097,146 45,613,318 28,434,436 30,769,103
CDK16_HUMANCyclin-dependentkinase16OS=HomosapiensGN=CDK16PE=1SV=1CDK16;PCTK1 Y 176 2.86E-10 _LGEGTY(ph)ATVYK_ 12,352,704 131,515,372 200,771,252 68,876,947 200,032,689 184,470,000 165,176,484 183,919,383 19,666,709 193,082,328 275,372,086 197,673,542
CDK17_HUMANCyclin-dependentkinase17OS=HomosapiensGN=CDK17PE=1SV=2CDK17;PCTK2 Y 203 3.72E-14 _LGEGTY(ph)ATVYK_ 20,128,277 149,425,566 200,771,252 68,876,947 200,032,689 184,470,000 188,252,374 183,919,383 29,321,117 193,082,328 275,372,086 197,673,542
CDK2_HUMANCyclin-dependentkinase2OS=HomosapiensGN=CDK2PE=1SV=2;>spCDK2;CDK3 Y 15 1.09E-18 _VEKIGEGTY(ph)GVVYK_ 4,424,910,630 5,000,590,054 5,531,465,074 4,726,598,188 6,212,646,921 5,867,800,000 7,284,258,110 6,775,826,037 5,797,133,890 6,262,507,535 7,286,796,135 6,379,061,699
CDK5_HUMANCyclin-dependent-likekinase5OS=HomosapiensGN=CDK5PE=1SV=3CDK5 Y 15 1.74E-03 _IGEGTY(ph)GTVFK_ 117,174 40,663,237 265,376 0 43,921,325 226,750 39,500,415 40,057,949 271,126 188,714 47,559,350 44,502,307
CDKL5_HUMANCyclin-dependentkinase-like5OS=HomosapiensGN=CDKL5PE=1SV=1CDKL5;STK9 Y 171 1.61E-32 _NLSEGNNANYTEY(ph)VATR_ 1,022,583 1,447,288 1,225,968 945,248 1,223,371 1,396,300 998,198 1,029,398 624,718 868,191 644,267 782,171
CDV3_HUMANProteinCDV3homologOS=HomosapiensGN=CDV3PE=1SV=1CDV3;H41 Y 190 2.36E-25 _KTPQGPPEIY(ph)SDTQFPSLQSTAK_ 10,605,664 9,238,988 8,743,999 6,880,514 4,766,184 4,776,000 3,226,300 3,296,046 2,789,578 3,137,943 2,479,897 2,780,355
CEP89_HUMANCentrosomalproteinof89kDaOS=HomosapiensGN=CEP89PE=1SV=3CCDC123 Y 157 1.20E-05 _GGHSDDLY(ph)AVPHR_ 0 577,259 704,242 573,067 0 414,930 0 0 0 208,173 0 0
CLAP2_HUMANCLIP-associatingprotein2OS=HomosapiensGN=CLASP2PE=1SV=2CLASP2;KIAA0627 Y 1022 .94E-07 _DYNPY(ph)NYSDSISPFNK_ 941,890 1,024,583 893,230 788,644 810,806 678,320 334,522 340,034 831,823 738,004 473,316 602,592
CLD3_HUMANClaudin-3OS=HomosapiensGN=CLDN3PE=1SV=1C7orf1;CLDN3; PETR2Y 219 6.74E-20 _STGPGASLGTGYDRKDY(ph)V_ 0 1,268,395 774,272 0 772,559 842,030 0 0 0 359,633 0 423,141
CNN3_HUMANCalponin-3OS=HomosapiensGN=CNN3PE=1SV=1CNN3 Y 261 3.51E-02 _GM(ox)SVY(ph)GLGR_ 2,377,257 3,056,283 1,839,214 3,271,864 3,050,118 2,636,400 2,837,877 1,820,601 502,785 657,161 954,081 1,170,495
COE1_HUMANTranscriptionfactorCOE1OS=HomosapiensGN=EBF1PE=1SV=2;>spCOE1;EBF;EBF1;COE3;EBF3;COE2;EBF2Y 412 4.15E-07 _AADIAEALY(ph)SVPR_ 1,476,660 1,335,054 912,807 795,346 701,903 679,690 696,923 691,358 81,105 1,242,590 396,554 0
COF1_HUMANCofilin-1OS=HomosapiensGN=CFL1PE=1SV=3CFL;CFL1 Y 68 3.72E-11 _NIILEEGKEILVGDVGQTVDDPY(ph)ATFVK_ 1,158,347 549,357 796,988 1,365,152 595,609 879,070 0 0 683,365 1,106,180 294,588 448,874
COF1_HUMANCofilin-1OS=HomosapiensGN=CFL1PE=1SV=3CFL;CFL1 Y 140 1.68E-05 _HELQANCY(ph)EEVKDR_ 0 447,163 0 437,336 0 325,950 0 0 0 0 0 0
COF1_HUMANCofilin-1OS=HomosapiensGN=CFL1PE=1SV=3;>spCFL;CFL1;CFL2 Y 89 1.27E-04 _YALYDATY(ph)ETKESK_ 0 4,454,378 0 0 4,233,787 0 0 0 7,589,971 5,370,976 6,476,397 6,017,700
CPNE3_HUMANCopine-3OS=HomosapiensGN=CPNE3PE=1SV=1CPN3;CPNE3;KIAA0636Y 392 5.13E-52 _LY(ph)GPTNFSPIINHVAR_ 1,321,092 1,204,589 1,421,591 1,579,023 1,776,312 1,232,200 1,082,065 1,071,925 2,726,104 2,620,982 2,414,964 1,339,787
CSKI2_HUMANCaskin-2OS=HomosapiensGN=CASKIN2PE=1SV=2CASKIN2;KIAA1139Y 53 2.11E-109 _NTY(ph)NQTALDIVNQFTTSQASR_ 993,498 748,485 1,220,962 1,010,893 1,116,949 855,190 364,450 416,434 1,078,321 1,110,031 906,779 810,344
CTND1_HUMANCatenindelta-1OS=HomosapiensGN=CTNND1PE=1SV=1CTNND1;KIAA0384 Y 257 2.19E-02 _QDVY(ph)GPQPQVR_ 465,807 782,927 753,275 772,786 0 0 0 0 361,959 0 325,619 235,012
CTND1_HUMANCatenindelta-1OS=HomosapiensGN=CTNND1PE=1SV=1CTNND1;KIAA0384 Y 904 2.73E-04 _SLDNNY(ph)STPNER_ 598,366 845,829 681,557 743,285 0 1,299,500 0 0 0 239,022 228,611 0
CTND1_HUMANCatenindelta-1OS=HomosapiensGN=CTNND1PE=1SV=1CTNND1;KIAA0384 Y 228 1.09E-39 _HYEDGYPGGSDNY(ph)GSLSR_ 0 0 0 1,179,824 0 744,260 1,120,642 783,377 412,202 566,842 0 456,547
CTND1_HUMANCatenindelta-1OS=HomosapiensGN=CTNND1PE=1SV=1CTNND1;KIAA0384 Y 96 3.38E-12 _LNGPQDHSHLLY(ph)STIPR_ 456,211 638,268 1,958,769 406,488 0 902,010 929,275 1,077,165 950,950 220,486 603,470 774,705
CYBP_HUMANCalcyclin-bindingproteinOS=HomosapiensGN=CACYBPPE=1SV=2CACYBP;PNAS-107;S100A6BP;SIPY 199 9.30E-03 _KIY(ph)EDGDDDMKR_ 545,343 544,180 674,473 398,224 328,417 600,570 472,973 252,021 236,622 268,594 220,267 315,076
DBNL_HUMANDrebrin-likeproteinOS=HomosapiensGN=DBNLPE=1SV=1CMAP;DBNL;PP5423;SH3P7Y 62 8.69E-05 _FQDVGPQAPVGSVY(ph)QK_ 777,022 1,071,759 707,022 715,159 625,650 677,560 643,572 624,559 534,634 412,383 519,234 423,484
DCBD2_HUMANDiscoidin,CUBandLCCLdomain-containingprotein2OS=HomosapiensGN=DCBLD2PE=1SV=1CLCP1;DCBLD2;ESDNY 750 1.31E-03 _AGKPGLPAPDELVY(ph)QVPQSTQEVSGAGR_ 368,208 0 583,006 0 0 0 0 0 0 0 0 0
DCTN2_HUMANDynactinsubunit2OS=HomosapiensGN=DCTN2PE=1SV=4DCTN2;DCTN50 Y 6 7.12E-04 _Y(ph)ADLPGIAR_ 1,700,446 1,780,026 1,552,355 1,397,227 1,331,743 1,524,900 1,837,764 1,644,017 0 0 0 975,081
DDX3X_HUMANATP-dependentRNAhelicaseDDX3XOS=HomosapiensGN=DDX3XPE=1SV=3;>spDBX;DDX3;D X3X;DBY;DDX3YY 266 2.5 E-08 _RKQY(ph)PISLVLAPTR_ 2,106,494 2,178,517 2,441,176 3,089,349 3,043,539 2,822,600 1,518,794 1,698,393 3,268,432 3,180,001 3,281,864 2,729,106
DOK1_HUMANDockingprotein1OS=HomosapiensGN=DOK1PE=1SV=1DOK1 Y 449 3.62E-50 _SHNSALY(ph)SQVQK_ 1,073,100 1,397,190 1,157,000 1,269,825 1,060,697 995,140 1,209,156 847,929 541,093 410,437 394,843 0
DPYL1_HUMANDihydropyrimidinase-relatedprotein1OS=HomosapiensGN=CRMP1PE=1SV=1CRMP1;DPYSL1;ULIP3Y 504 6.96E-07 _GMYDGPVY(ph)EVPATPK_ 6,431,519 6,990,124 5,717,524 5,343,319 4,222,823 4,521,000 5,358,644 4,063,603 2,731,467 4,086,632 3,247,762 1,996,078
DPYL1_HUMANDihydropyrimidinase-relatedprotein1OS=HomosapiensGN=CRMP1PE=1SV=1CRMP1;DPYSL1;ULIP3Y 512 4.06E-02 _Y(ph)ATPAPSAK_ 501,791 1,002,247 777,261 621,089 0 439,180 355,365 942,500 374,330 386,408 611,751 749,153
DYL1_HUMANDyneinlightchain1,cytoplasmicOS=HomosapiensGN=DYNLL1PE=1SV=1;>spDLC1;DNCL1;DNCLC1;DYNLL1;HDLC1;DLC2;DYNLL2Y 65 7.60E-04 _NFGSY(ph)VTHETK_ 1,321,474 1,573,369 1,563,563 1,604,157 2,197,682 2,095,900 2,920,948 2,161,023 1,921,155 1,984,637 2,628,889 2,012,528
DYR1A_HUMANDualspecificitytyrosine-phosphorylation-regulatedkinase1AOS=HomosapiensGN=DYRK1APE=1SV=2;>spDYRK;DYRK1A;MNB;MNBH;DYRK1B;MIRKY 321 3.29E-39 _IYQY(ph)IQSR_ 502,738,122 638,003,678 671,028,352 38,158,188 834,223,564 754,580,000 927,435,680 939,221,068 713,867,507 32,908,720 961,216,321 791,299,754
DYRK2_HUMANDualspecificitytyrosine-phosphorylation-regulatedkinase2OS=HomosapiensGN=DYRK2PE=1SV=3;>spDYRK2;DYRK4 Y 382 4.95E-05 _VYTY(ph)IQSR_ 10,773,096 14,323,980 14,032,094 15,294,751 19,564,702 18,621,000 22,470,875 40,387,554 18,568,087 20,336,884 24,738,563 1,086,707
DYRK3_HUMANDualspecificitytyrosine-phosphorylation-regulatedkinase3OS=HomosapiensGN=DYRK3PE=2SV=3DYRK3 T 368 2.17E-04 _LYT(ph) IQSR_ 0 0 0 0 0 0 5,018,015 0 3,129,140 0 5,651,904 4,684,059
E41L2_HUMANBand4.1-likeprotein2OS=HomosapiensGN=EPB41L2PE=1SV=1EPB41L2 Y 623 1.05E-43 _VEGDNIY(ph)VR_ 6,172,812 6,490,114 5,356,989 5,171,755 1,740,765 1,601,800 1,578,082 1,638,693 1,227,489 1,443,658 1,115,406 1,012,591
EF1A1_HUMANElongationfactor1-alpha1OS=HomosapiensGN=EEF1A1PE=1SV=1;>spEEF1A;EEF1A1;EF1A;LEN 7;E F1AL3;EEF1A2;EEF1AL;STNY 29 .15 -02 _STTTGHLIY(ph)K_ 5,888,655 5,993,235 6,895,072 6,177,382 8,259,831 8,816,100 10,628,147 10,326,598 7,515,150 7,934,192 9,905,744 9,289,843
EF1A1_HUMANElongationfactor1-alpha1OS=HomosapiensGN=EEF1A1PE=1SV=1;>spEEF1A;EEF1A1;EF1A;LEN 7;E F1AL3;EEF1A2;EEF1AL;STNY 41 5.59 -51 _EHALLAY(ph)TLGVK_ 6,967,591 6,544,666 7,060,656 6,229,444 8,013,657 7,830,800 7,069,374 8,508,025 8,078,677 9,772,893 9,063,885 8,671,424
EF2_HUMANElongationfactor2OS=HomosapiensGN=EEF2PE=1SV=4EEF2;EF2 Y 443 8.80E-11 _EDLY(ph)LKPIQR_ 494,223 774,021 812,605 1,046,559 895,115 772,000 954,538 1,097,228 607,746 655,215 561,189 591,430
EFNB1_HUMANEphrin-B1OS=HomosapiensGN=EFNB1PE=1SV=1EFL3;EFNB1;EPLG2;LERK2Y 317 1.19E-03 _TTENNYCPHY(ph)EK_ 487,621 839,566 650,121 574,946 0 0 0 0 0 0 0 0
EFS_HUMANEmbryonalFyn-associatedsubstrateOS=HomosapiensGN=EFSPE=1SV=1CASS3;EFS Y 163 9.86E-49 _VPSSGPY(ph)DCPASFSHPLTR_ 3,059,617 3,959,934 3,070,786 1,249,599 3,465,140 3,481,900 3,846,487 1,511,009 2,317,207 2,310,259 5,103,752 1,758,906
EGFR_HUMANEpidermalgrowthfactorreceptorOS=HomosapiensGN=EGFRPE=1SV=2EGFR;ERBB1 Y 869 4. 0E-19 _EY(ph)HAEGGKVPIK_ 668,544 823,493 723,625 824,489 687,154 545,990 1,023,764 740,833 410,493 409,251 452,628 363,486
EIFCL_HUMANEukaryotictranslationinitiationfactor3subunitC-likeproteinOS=HomosapiensGN=EIF3CLPE=3SV=1;>spEIF3CL;EIF3C;EIF3CL;EIF3S8Y 882 4.31E-02 _QGTY(ph)GGYFR_ 560,651 630,614 708,808 768,478 714,414 707,740 960,038 966,164 479,715 568,160 744,309 581,307
ENOA_HUMANAlpha-enolaseOS=HomosapiensGN=ENO1PE=1SV=2ENO1;ENO1L1;MBPB1;MPB1Y 44 1.80E-32 _AAVPSGASTGIY(ph)EALELRDNDKTR_ 5,988,923 5,084,505 5,686,439 5,732,525 5,757,922 4,886,800 823,123 813,904 5,431,883 8,581,279 3,993,732 5,372,075
ENOG_HUMANGamma-enolaseOS=HomosapiensGN=ENO2PE=1SV=3;>spENO2;ENO3 Y 44 1.80E-32 _AAVPSGASTGIY(ph)EALELR_ 3,958,013 3,248,397 4,945,418 4,493,996 4,292,416 4,281,400 823,123 813,904 4,862,494 5,568,295 3,404,809 3,556,135
ENPL_HUMANEndoplasminOS=HomosapiensGN=HSP90B1PE=1SV=1GRP94;HSP90B1;TRA1Y 94 3.37E-02 _LIINSLY(ph)K_ 430,292 392,006 466,962 345,133 646,552 598,230 581,307 341,639 609,729 695,479 528,332 684,889
ENSA_HUMANAlpha-endosulfineOS=HomosapiensGN=ENSAPE=1SV=1;>spEN A;ARPP19 Y 64 7.17E-03 _Y(ph)FDSGDYNMAK_ 344,596 855,153 786,751 821,736 576,831 1,020,400 649,679 548,800 0 968,239 508,488 1,020,455
EPHA2_HUMANEphrintype-Areceptor2OS=HomosapiensGN=EPHA2PE=1SV=2ECK;EPHA2 Y 772 4.54E-42 _VLEDDPEATY(ph)TTSGGKIPIR_ 7,862,447 967,944 12,262,671 4,837,783 5,253,224 3,608,700 5,887,604 5,133,550 4,157,181 6,833,890 2,632,790 2,931,751
EPHA3_HUMANEphrintype-Areceptor3OS=HomosapiensGN=EPHA3PE=1SV=2;>spEPHA ;ETK;ETK1;HEK;TYRO4;EPHA4;HEK8;SEK;TYRO1;EHK1;EPHA5;HEK7Y 779 3.30E-10 _VLEDDPEAAY(ph)TTR_ 0 0 0 0 0 15,318,000 24,048,843 0 5,950,392 0 0 0
EPHA5_HUMANEphrintype-Areceptor5OS=HomosapiensGN=EPHA5PE=1SV=3EHK1;EPHA5;HEK7Y 6 0 1.13E-06 _TY(ph)IDPHTYEDPNQAVHEFAK_ 0 791,277 0 508,122 0 0 0 0 0 0 0 0
EPHB4_HUMANEphrintype-Breceptor4OS=HomosapiensGN=EPHB4PE=1SV=2EPHB ;HTK;TYRO11Y 574 2. 1E-03 _EAEY(ph)SDKHGQYLIGHGTK_ 547,160 1,026,809 0 0 0 0 0 0 0 0 0 0
ESYT1_HUMANExtendedsynaptotagmin-1OS=HomosapiensGN=ESYT1PE=1SV=1ESYT1;FAM62A;KIAA0747;MBC2Y 1009 5.88E-40 _QNGRDPPDPY(ph)VSLLLLPDKNR_ 0 0 0 309,982 0 0 0 0 0 901,868 378,622 329,935
ESYT1_HUMANExtendedsynaptotagmin-1OS=HomosapiensGN=ESYT1PE=1SV=1ESYT1;FAM62A;KIAA0747;MBC2Y 822 2.25E-07 _HLSPY(ph)ATLTVGDSSHK_ 1,697,385 2,360,611 2,120,543 2,011,135 2,226,651 2,376,500 1,171,585 2,642,077 2,710,018 2,753,643 3,176,286 1,526,615
F171B_HUMANProteinFAM171BOS=HomosapiensGN=FAM171BPE=2SV=3FAM171B;KIAA1946; PD019Y 463 9.35E-26 _TRDDFKIY(ph)NEDVSFLSVNQNNYSR_ 810,240 925,082 1,086,835 1,302,977 796,576 791,400 0 589,739 0 0 492,280 375,254
FAF2_HUMANFAS-associatedfactor2OS=HomosapiensGN=FAF2PE=1SV=2ETEA;FAF2;KIAA0887;UBXD8;UBXN3BY 79 8.54E-19 _IY(ph)SYVVSRPQPR_ 654,796 1,654,988 518,475 1,041,472 944,004 628,040 0 1,020,642 0 0 469,553 524,273
FAK1_HUMANFocaladhesionkinase1OS=HomosapiensGN=PTK2PE=1SV=2FAK;FAK1;PTK2 Y 861 3.54E-13 _GSIDREDGSLQGPIGNQHIY(ph)QPVGKPDPAAPPK_ 1,439,251 2,019,246 1,926,191 2,729,107 0 745,090 0 0 2,609,758 3,925,697 0 445,638
FAK1_HUMANFocaladhesionkinase1OS=HomosapiensGN=PTK2PE=1SV=2FAK;FAK1;PTK2 Y 576 1.03E-08 _YM(ox)EDSTY(ph)YKASK_ 42,073,438 58,411,306 57,846,988 21,020,933 60,503,772 81,516,000 78,405,299 96,217,507 53,600,543 62,513,596 60,090,334 74,230,166
FAK1_HUMANFocaladhesionkinase1OS=HomosapiensGN=PTK2PE=1SV=2FAK;FAK1;PTK2 Y 925 2.67E-154 _SNDKVY(ph)ENVTGLVK_ 4,835,934 5,964,568 8,142,485 8,024,075 7,211,772 6,604,800 6,170,577 5,860,032 4,759,117 4,756,522 5,160,631 4,702,859
FER_HUMANTyrosine-proteinkinaseFerOS=HomosapiensGN=FERPE=1SV=2FER;TYK3 Y 402 1.01E-32 _VQENDGKEPPPVVNY(ph)EEDAR_ 2,462,600 2,791,110 2,559,163 1,771,771 975,165 2,047,100 2,046,238 1,663,979 1,282,433 1,430,382 0 1,162,360
FER_HUMANTyrosine-proteinkinaseFerOS=HomosapiensGN=FERPE=1SV=2FER;TYK3 Y 714 1.10E-04 _QEDGGVY(ph)SSSGLK_ 2,191,550 2,739,759 2,508,426 0 1,482,818 1,817,400 0 0 0 0 0 0
FGFR1_HUMANFibroblastgrowthfactorreceptor1OS=HomosapiensGN=FGFR1PE=1SV=3FGFBR;FGFR1;FLG;FLT2Y 653 9.37E-16 _DIHHIDY(ph)YKK_ 1,083,816 1,551,312 1,109,401 1,041,053 2,009,560 1,588,600 1,719,853 1,615,299 3,341,632 3,706,792 4,576,867 1,847,303
FRK_HUMANTyrosine-proteinkinaseFRKOS=HomosapiensGN=FRKPE=1SV=1FRK;PTK5;RAK Y 46 8.94E-03 _HGHY(ph)FVALFDYQAR_ 994,933 737,839 1,098,716 940,461 0 0 0 0 0 0 0 0
FUBP3_HUMANFarupstreamelement-bindingprotein3OS=HomosapiensGN=FUBP3PE=1SV=2FBP3;FUBP3 Y 51 1.55E-04 _IDSIPHLNNSTPLVDPSVY(ph)GYGVQK_ 852,357 0 650,338 0 0 245,760 0 0 0 0 366,932 368,611
GAGE1_HUMANGantigen1OS=HomosapiensGN=GAGE1PE=1SV=2;>spGAGE1;GAGE3;GAGE12C;GAGE12D;GAGE12E;GAGE12H;GAGE12J;GAGE12I;GAGE7;GAGE7B;GAGE4;GAGE5;GAGE6Y 10 .23E-09 _STY(ph)YWPRPR_ 1,511,391 0 0 0 2,188,218 0 2,814,170 2,397,324 0 0 0 0
GAGE1_HUMANGantigen1OS=HomosapiensGN=GAGE1PE=1SV=2;>spGAGE1;GAGE3;GAGE12C;GAGE12D;GAGE12E;GAGE12H;GAGE12J;GAGE12I;GAGE7;GAGE7B;GAGE4;GAGE5;GAGE6Y 9 .23E-09 _STY(ph)YWPRPR_ 0 0 1,827,034 2,064,453 0 2,594,100 213,955 0 1,843,590 2,080,003 0 0
GAREM_HUMANGRB2-associatedandregulatorofMAPKproteinOS=HomosapiensGN=GAREMPE=1SV=2C18orf11;FAM59A Y 74 3.63E-02 _QWTTITAHSLEEGHY(ph)VIGPK_ 729,222 753,355 587,444 380,720 378,783 0 0 0 588,829 0 0 0
GIT1_HUMANARFGTPase-activatingproteinGIT1OS=HomosapiensGN=GIT1PE=1SV=2GIT1 Y 545 4.55E-09 _LQPFHSTELEDDAIY(ph)SVHVPAGLYR_ 0 0 0 4,152,005 2,433,123 2,619,500 528,866 941,418 0 0 1,107,944 1,104,152  
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Proteins Gene Name Amino Acid Position PEP ModifiedSequence DMSO1-run1 DMSO1-run2 DMSO2-run1 DMSO2-run2 CABO1-run1 CABO1-run2 CABO2-run1 CABO2-run2 FORE1-run1 FORE1-run2 FORE2-run1 FORE2-run2
GPC5C_HUMANG-proteincoupledreceptorfamilyCgroup5memberCOS=HomosapiensGN=GPRC5CPE=1SV=2GPRC5C;PSEC0087;RAIG3Y 387 1.23E-21 _VPSEGAY(ph)DIILPR_ 7,044,514 8,034,538 6,299,386 8,505,794 5,346,593 5,972,100 4,407,690 4,499,864 5,795,637 5,548,431 4,821,245 852,744
GPC5C_HUMANG-proteincoupledreceptorfamilyCgroup5memberCOS=HomosapiensGN=GPRC5CPE=1SV=2GPRC5C;PSEC0087;RAIG3T 423 3.88E-10 _AEDMY(ph)SAQSHQAAT(ph)PPKDGK_ 0 0 1,583,215 0 1,312,008 0 2,205,552 1,638,507 955,988 1,267,521 1,209,332 1,258,802
GPC5C_HUMANG-proteincoupledreceptorfamilyCgroup5memberCOS=HomosapiensGN=GPRC5CPE=1SV=2GPRC5C;PSEC0087;RAIG3Y 414 3.88E-10 _AEDMY(ph)SAQSHQAAT(ph)PPKDGK_ 1,808,560 2,282,680 3,198,487 3,298,314 0 1,790,400 2,590,371 0 0 1,369,575 0 0
GPC5C_HUMANG-proteincoupledreceptorfamilyCgroup5memberCOS=HomosapiensGN=GPRC5CPE=1SV=2GPRC5C;PSEC0087;RAIG3Y 324 5.53E-05 _GVGY(ph)ETILKEQK_ 5,638,750 6,316,022 5,332,779 4,544,682 5,327,780 5,938,800 6,909,870 5,809,662 3,290,380 2,866,338 4,896,748 4,059,403
GPC5C_HUMANG-proteincoupledreceptorfamilyCgroup5memberCOS=HomosapiensGN=GPRC5CPE=1SV=2GPRC5C;PSEC0087;RAIG3Y 438 1.33E-04 _NSQVFRNPY(ph)VWD_ 20,569,343 20,897,313 15,350,942 14,237,362 11,882,856 15,634,000 18,182,670 18,329,398 13,163,514 17,333,020 13,479,805 14,816,025
GSK3A_HUMANGlycogensynthasekinase-3alphaOS=HomosapiensGN=GSK3APE=1SV=2;>spGSK3A;GSK3B Y 279 1.29E-08 _QLVRGEPNVSY(ph)ICSR_ 2,531,773 1,829,776 2,026,991 1,055,475 1,464,813,575 3,158,100 1,631,376,430 1,424,145,540 1,332,063,849 1,435,449,343 2,811,103 4,738,380
H2B1J_HUMANHistoneH2Btype1-JOS=HomosapiensGN=HIST1H2BJPE=1SV=3;>spH2BFR; IST1H2BJ;H2BF ;H2BFN;HIST1H2BO;H2BFF;HIST1H2BB;H2BFQ;HIST2H2BE;HIST3H2BB;HIST2H2BC;HIST2H2BDS 37 2.99E-04 _KE (ph)YSIYVYK_ 0 0 0 1,089,824 0 796,700 0 0 0 1,258,501 1,986,359 1,037,989
H2B1J_HUMANHistoneH2Btype1-JOS=HomosapiensGN=HIST1H2BJPE=1SV=3;>spH2BFR; IST1H2BJ;H2BF ;H2BFN;HIST1H2BO;H2BFF;HIST1H2BB;H2BFQ;HIST2H2BE;HIST3H2BB;HIST2H2BC;HIST2H2BDS 39 2.99E-04 _KE (ph)YSIYVYK_ 0 0 0 1,089,824 0 796,700 0 0 0 1,258,501 1,986,359 1,037,989
H2B1K_HUMANHistoneH2Btype1-KOS=HomosapiensGN=HIST1H2BKPE=1SV=3;>spH2BFT;HIRIP1;HIST1H2BK;H2BFB;HIRIP2;HIST1H2BD;H2BFA;H2BFG;H2BFH;H2BFK;H2BFL;HIST1H2BC;HIST1H2BE;HIST1H2BF;HIST1H2BG;HIST1H2BI;HIST2H2BF;H2BFJ;HIST1H2BH;H2BFD;HIST1H2BN;H2BFE;HIST1H2BM;H2BFC;HIST1H2BL;H2BFSY 41 4.12E-32 _KESYSVY(ph)VYK_ 9,607,765 11,219,964 12,212,607 13,389,415 13,795,238 14,903,000 14,712,278 13,898,160 14,702,334 17,695,835 17,321,650 14,236,653
H4_HUMANHistoneH4OS=HomosapiensGN=HIST1H4APE=1SV=2H4/A;H4/B;H4/C;H4/D;H4/ ;H4/G;H4/H;H4/I;H4/J;H4/K;H4/M;H4/N;H4/O;H4F2;H4FA;H4FB;H4FC;H4FD;H4FE;H4FG;H4FH;H4FI;H4FJ;H4FK;H4FM;H4FN;H4FO;HIST1H4A;HIST1H4B;HIST1H4C;HIST1H4D;HIST1H4E;HIST1H4F;HIST1H4H;HIST1H4I;HIST1H4J;HIST1H4K;HIST1H4L;HIST2H4;HIST2H4A;HIST2H4B;HIST4H4Y 89 9.10E-16 _TVTAMDVVY(ph)ALKR_ 1,764,166 1,980,767 1,676,095 1,983,907 2,461,745 2,478,100 ,987,443 1,969,683 3,129,889 3,740,742 3,261,101 2,944,676
HIPK1_HUMANHomeodomain-interactingproteinkinase1OS=HomosapiensGN=HIPK1PE=1SV=1;>spHIPK1;KIAA0630;HIPK2Y 352 4.92E-07 _AVCSTY(ph)LQSR_ 45,638,319 0 0 69,283,865 85,632,503 79,502,000 0 87,095,065 69,637,185 0 0 83,751,397
HIPK3_HUMANHomeodomain-interactingproteinkinase3OS=HomosapiensGN=HIPK3PE=1SV=1DYRK6;FIST3;HIPK3;PKYY 359 1.72E-04 _TVCSTY(ph)LQSR_ 12,977,467 8,545,959 9,066,800 9,542,838 12,266,025 11,039,000 29,937,775 25,409,981 20,115,636 12,058,018 15,298,170 26,161,239
HNRH1_HUMANHeterogeneousnuclearribonucleoproteinHOS=HomosapiensGN=HNRNPH1PE=1SV=4;>spHNRNPH1;HNRPH;HNRPH1;FTP3;HNRNPH2;HNRPH2Y 266 .52E-12 _DLNY(ph)CFSGM(ox)SDHR_ 3,423,568 4,054,704 3,000,099 2,412,608 2,553,729 3,176,600 4,305,843 3,722,673 3,391,388 3,332,423 4,552,454 4,024,966
HNRL1_HUMANHeterogeneousnuclearribonucleoproteinU-likeprotein1OS=HomosapiensGN=HNRNPUL1PE=1SV=2E1BAP5;HNRNPUL1;HNRPUL1Y 5 0 8.42E-20 _NYILDQTNVY(ph)GSAQR_ 771,865 1,387,449 816,191 849,622 886,367 796,150 681,390 562,779 1,133,190 1,405,654 937,307 872,629
HNRPK_HUMANHeterogeneousnuclearribonucleoproteinKOS=HomosapiensGN=HNRNPKPE=1SV=1HNRNPK;HNRPK Y 380 3.90E-30 _GSY(ph)GDLGGPIITTQVTIPK_ 1,148,875 1,148,020 1,012,636 0 785,104 787,690 0 0 938,667 1,072,635 0 662,907
HS71A_HUMANHeatshock70kDaprotein1AOS=HomosapiensGN=HSPA1APE=1SV=1;>spHSC70;HSP73; SPA10;HSPA8;HSPA2;HSP70B';HSPA6;HSP70B;HSPA7Y 41 1.28E-03 _TTPSY(ph)VAFTDTER_ 715,607 810,760 621,936 621,149 0 627,750 494,006 464,827 822,969 731,629 572,917 539,115
HS90A_HUMANHeatshockproteinHSP90-alphaOS=HomosapiensGN=HSP90AA1PE=1SV=5;>spHSP90A;HSP90AA1;HSPC1;HSPCA; 2;HSPCAL3;HSP90AB1;HSP90B;HSPC2;HSPCB;HSP90AB2P;HSP90BBY 284 6.63E-1 _Y(ph)IDQEELNKTK IWTR_ 2,711,165 1,973,392 505,720 509,588 3,181,111 2,604,700 620,149 432,779 2,827,238 808,976 2,180,527 3,904,663
HS90A_HUMANHeatshockproteinHSP90-alphaOS=HomosapiensGN=HSP90AA1PE=1SV=5;>spHSP90A;HSP90AA1;HSPC1;HSPCA; 2;HSPCAL3;HSP90AB1;HSP90B;HSPC2;HSPCB;HSP90AB3P;HSP90BC;HSP90AB2P;HSP90BBY 61 2.92E-25 _Y(ph)ESLTDPSKLDSGK_ 1,370,460 1,235,622 1,543,463 1,652,149 1,654,782 1,814,900 1,518,207 1,649,409 1,647,435 1,656,483 1,729,019 1,787,377
HS90A_HUMANHeatshockproteinHSP90-alphaOS=HomosapiensGN=HSP90AA1PE=1SV=5;>spHSP90A;HSP90AA1;HSPC1;HSPCA; 5 ;HSP90AEY 492 9.70E-03 _HIY(ph)YITGETK_ 0 909,843 0 0 1,255,571 0 0 0 968,247 1,053,987 1,533,466 1,172,393
HS90B_HUMANHeatshockproteinHSP90-betaOS=HomosapiensGN=HSP90AB1PE=1SV=4;>spHSP90AB1;HSP90B;HSPC2;HSPCB;HSP90AB2P;HSP90BBY 484 4.54 -02 _SIY(ph)YITGESK_ 1,130,792 994,315 982,149 978,041 1,128,410 1,958,400 1,300,496 1,239,415 1,114,821 1,868,395 1,286,446 1,373,863
IF4A3_HUMANEukaryoticinitiationfactor4A-IIIOS=HomosapiensGN=EIF4A3PE=1SV=4;>spDDX48;EIF4A3;KIAA0111;DDX2A;EIF4A;EIF4A ;DDX2B;EIF4A2;EIF4FY 54 1.20E-0 _GIY(ph)AYGFEKPSAIQQR_ 353,675 268,848 0 388,069 322,127 419,390 0 0 846,488 424,362 692,929 459,783
IF4H_HUMANEukaryotictranslationinitiationfactor4HOS=HomosapiensGN=EIF4HPE=1SV=5EIF4H;KIAA0038;WB CR1;WSCR1Y 12 2.96 -02 _AY(ph)SSFGGGR_ 0 776,943 504,099 1,476,157 398,242 0 0 704,188 152,523 298,258 0 759,511
ITSN2_HUMANIntersectin-2OS=HomosapiensGN=ITSN2PE=1SV=3ITSN2;KIAA1256;SH3D1B;SWAPY 553 2.98E-02 _LIY(ph)LVPEK_ 0 2,257,352 2,730,576 2,444,204 1,952,662 2,161,000 2,287,675 2,832,402 1,407,384 147,578 1,786,150 1,318,727
ITSN2_HUMANIntersectin-2OS=HomosapiensGN=ITSN2PE=1SV=3ITSN2;KIAA1256;SH3D1B;SWAPY 968 8.57E-07 _REEPEALY(ph)AAVNK_ 0 1,493,560 1,568,121 1,350,611 1,146,264 1,149,300 1,578,670 892,181 891,804 908,932 854,770 877,338
JAK2_HUMANTyrosine-proteinkinaseJAK2OS=HomosapiensGN=JAK2PE=1SV=2JAK2 Y 570 4.54E-51 _REVGDY(ph)GQLHETEVLLK_ 11,179,719 12,425,110 12,275,374 12,096,252 11,333,378 12,231,000 10,891,774 11,697,246 14,553,939 17,390,787 13,306,148 13,424,085
K1C18_HUMANKeratin,typeIcytoskeletal18OS=HomosapiensGN=KRT18PE=1SV=2CYK18;KRT18;PIG46Y 13 3.32E-02 _STFSTNY(ph)R_ 1,472,164 1,802,222 1,170,524 1,248,402 1,166,934 1,312,900 1,973,598 0 750,792 1,066,554 1,382,586 0
KI26B_HUMANKinesin-likeproteinKIF26BOS=HomosapiensGN=KIF26BPE=2SV=1KIF26B Y 1677 2.18E-03 _ATVSHY(ph)ECLSLER_ 0 747,789 0 406,661 0 0 0 0 0 0 0 0
KIRR1_HUMANKinofIRRE-likeprotein1OS=HomosapiensGN=KIRRELPE=1SV=2KIRREL;KIRREL1;NEPH1Y 721 5.53E-03 _TPY(ph)EAYDPIGK_ 846,473 860,650 894,500 676,083 447,615 0 780,848 768,537 528,910 483,192 411,038 489,538
KPCD_HUMANProteinkinaseCdeltatypeOS=HomosapiensGN=PRKCDPE=1SV=2PRKCD Y 313 5.79E-84 _SDSASSEPVGIY(ph)QGFEKK_ 29,201,215 31,450,690 20,919,245 15,784,250 22,751,237 21,440,000 48,583,215 47,162,197 32,837,706 32,847,913 27,636,621 23,920,578
KSYK_HUMANTyrosine-proteinkinaseSYKOS=HomosapiensGN=SYKPE=1SV=1SYK Y 323 2.55E-13 _QESTVSFNPY(ph)EPELAPWAADKGPQR_ 274,982 274,539 343,670 432,136 11,036,768 696,850 0 0 0 638,838 0 472,636
KSYK_HUMANTyrosine-proteinkinaseSYKOS=HomosapiensGN=SYKPE=1SV=1SYK Y 131 4.28E-03 _EY(ph)VKQTWNLQGQALEQAIISQKPQLEK_ 737,326 499,739 646,153 598,829 858,275 749,310 0 0 804,950 1,099,896 547,611 569,321
LAP2_HUMANProteinLAP2OS=HomosapiensGN=ERBB2IPPE=1SV=2ERBB2IP;ERBI ;KIAA1225;LAP2Y 884 1.26E-32 _SHSITNMEIGGLKIY(ph)DILSDNGPQQPSTTVK_ 0 1,133,060 1,053,509 1,132,610 1,139,582 1,584,500 0 379,688 474,365 498,191 725,861 0
LARP1_HUMANLa-relatedprotein1OS=HomosapiensGN=LARP1PE=1SV=2KIAA0731;LARP;LARP1Y 361 4.54E-02 _THFDY(ph)QFGYR_ 691,392 782,510 484,992 449,807 718,373 0 691,973 714,481 529,883 587,496 805,026 714,571
LDHA_HUMANL-lactatedehydrogenaseAchainOS=HomosapiensGN=LDHAPE=1SV=2LDHA;PIG19 Y 239 9.69E-03 _QVVESAY(ph)EVIKLK_ 2,817,270 2,952,677 3,329,624 2,765,550 3,368,771 3,801,800 3,587,412 3,449,017 3,482,919 4,613,220 3,646,041 3,837,687
LDHB_HUMANL-lactatedehydrogenaseBchainOS=HomosapiensGN=LDHBPE=1SV=2LDHB Y 240 2.14E-02 _MVVESAY(ph)EVIK_ 1,035,978 1,129,650 1,240,688 1,214,353 0 1,357,000 0 1,125,389 1,615,511 1,653,848 1,215,020 1,440,839
LSR_HUMANLipolysis-stimulatedlipoproteinreceptorOS=HomosapiensGN=LSRPE=1SV=4LISCH;LSR Y 372 8.80E-05 _SSSAGGQGSY(ph)VPLLR_ 1,928,346 2,128,836 2,241,817 1,644,430 1,330,820 1,442,900 0 1,242,001 1,267,842 965,868 1,082,701 915,336
LSR_HUMANLipolysis-stimulatedlipoproteinreceptorOS=HomosapiensGN=LSRPE=1SV=4LISCH;LSR Y 551 1.11E-10 _SRDPHY(ph)DDFR_ 2,026,796 2,769,818 1,968,110 2,039,380 2,043,376 2,111,700 2,886,051 2,762,256 1,473,102 1,548,246 1,896,007 1,666,893
LYN_HUMANTyrosine-proteinkinaseLynOS=HomosapiensGN=LYNPE=1SV=3LYN Y 194 1.23E-05 _SLDNGGY(ph)YISPR_ 2,840,998 2,788,048 3,759,128 2,972,660 3,426,362 3,238,800 4,330,309 3,995,822 3,349,488 3,483,225 3,679,388 595,615
LYN_HUMANTyrosine-proteinkinaseLynOS=HomosapiensGN=LYNPE=1SV=3LYN Y 193 1.23E-05 _SLDNGGY(ph)YISPR_ 0 426,052 0 498,308 0 596,000 0 0 0 0 0 0
LYN_HUMANTyrosine-proteinkinaseLynOS=HomosapiensGN=LYNPE=1SV=3;>spLYN;HCK Y 397 4.02E-71 _VIEDNEY(ph)TAREGAK_ 19,654,682 21,830,397 29,994,264 26,846,451 1,170,050 34,492,000 47,560,950 46,655,113 24,162,207 26,780,393 29,452,468 32,255,044
MAGI1_HUMANMembrane-associatedguanylatekinase,WWandPDZdomain-containingprotein1OS=HomosapiensGN=MAGI1PE=1SV=3AIP3;BAIAP1;BAP1;MAGI1;TNRC19Y 373 1.31E-11 _IEDPVY(ph)GIYYVDHINRK_ 843,363 754,608 0 592,222 650,729 775,920 0 381,361 807,506 762,235 656,574 510,797
MAP1B_HUMANMicrotubule-associatedprotein1BOS=HomosapiensGN=MAP1BPE=1SV=2MAP1B Y 2042 9.06 -26 _TPDTSTY(ph)CYETAEK_ 1,572,336 1,795,751 1,490,410 1,349,593 1,071,973 1,051,900 1,062,929 952,794 1,024,337 708,148 784,841 0
MAP1B_HUMANMicrotubule-associatedprotein1BOS=HomosapiensGN=MAP1BPE=1SV=2MAP1B Y 1062 2.51 -29 _AAEAGGAEEQY(ph)GFLTTPTK_ 12,943,981 15,781,706 12,453,213 8,824,148 6,908,237 10,165,000 10,448,729 10,045,166 5,891,533 7,150,593 4,946,077 5,348,755
MAP1B_HUMANMicrotubule-associatedprotein1BOS=HomosapiensGN=MAP1BPE=1SV=2MAP1B Y 1904 3.02 -25 _TSDVGGY(ph)YYEKIER_ 569,290 524,099 449,096 423,674 571,695 494,330 628,608 416,367 654,834 659,451 845,432 529,823
MAP1B_HUMANMicrotubule-associatedprotein1BOS=HomosapiensGN=MAP1BPE=1SV=2MAP1B Y 1938 .33 -34 _TTKTPEDGDY(ph)SYEIIEK_ 2,771,824 1,648,030 982,897 3,755,260 2,258,389 2,976,400 4,295,412 959,048 976,265 3,236,551 2,085,267 4,095,376
MK01_HUMANMitogen-activatedproteinkinase1OS=HomosapiensGN=MAPK1PE=1SV=3ERK2;MAPK1;PRKM1;PRKM2Y 187 6.70E-40 _VADPDHDHTGFLTEY(ph)VATR_ 17,150,846 15,531,213 24,032,175 19,131,754 12,028,275 2,974,200 21,609,820 0 13,708,461 20,614,569 9,370,176 12,121,627
MK03_HUMANMitogen-activatedproteinkinase3OS=HomosapiensGN=MAPK3PE=1SV=4ERK1;MAPK3;PRKM3Y 204 6.09E-40 _IADPEHDHTGFLTEY(ph)VATR_ 2,081,906 15,658,547 16,539,026 14,314,556 12,059,437 12,891,000 11,730,639 13,180,128 14,206,021 11,576,629 8,941,445 7,387,224
MK09_HUMANMitogen-activatedproteinkinase9OS=HomosapiensGN=MAPK9PE=1SV=2JNK2;MAPK9;PRKM9Y 185 6.42E-03 _TACTNFMM(ox)TPY(ph)VVTR_ 605,437 822,658 0 644,308 553,656 473,340 244,168 386,854 1,030,622 0 945,877 1,760,894
MK10_HUMANMitogen-activatedproteinkinase10OS=HomosapiensGN=MAPK10PE=1SV=2;>spJNK3;JNK3A;MAPK10;PRKM10;JNK1; 8;PRKM8;SAPK1Y 223 .21 -06 _TAGTSFM(ox)M(ox)TPY(ph)VVTR_ 2,716,141 2,202,731 2,214,095 1,561,430 1,645,549 1,792,800 847,342 832,987 3,970,254 555,299 3,296,336 2,896,952
MK11_HUMANMitogen-activatedproteinkinase11OS=HomosapiensGN=MAPK11PE=1SV=2MAPK11;PRKM11;SAPK2Y 182 2.33 -30 _QADEEMTGY(ph)VATR_ 21,810,258 6,958,813 4,868,454 16,586,718 18,228,227 19,031,000 19,419,251 18,890,571 18,179,018 21,253,042 21,470,541 21,336,450
MK12_HUMANMitogen-activatedproteinkinase12OS=HomosapiensGN=MAPK12PE=1SV=3ERK6;MAPK12;SAPK3Y 185 2.37 -44 _QADSEMTGY(ph)VVTR_ 96,833,489 31,611,422 85,280,520 16,405,998 28,749,217 115,170,000 119,752,998 94,283,827 35,111,018 141,740,995 48,056,412 41,656,061
MK13_HUMANMitogen-activatedproteinkinase13OS=HomosapiensGN=MAPK13PE=1SV=1MAPK13;PRKM13;SAPK4Y 182 3.54 -70 _HADAEMTGY(ph)VVTR_ 13,629,019 14,156,289 1,879,265 23,035,180 3,293,522 11,628,000 26,501,143 8,644,093 4,930,831 9,587,229 36,420,138 14,569,272
MK14_HUMANMitogen-activatedproteinkinase14OS=HomosapiensGN=MAPK14PE=1SV=3CSBP;CSBP1;CSBP2;CSPB1;MAPK14;MXI2Y 182 3.52 -70 _HTDDEMTGY(ph)VATR_ 294,518,852 119,366,500 99,746,751 327,371,948 393,071,389 99,414,000 71,674,278 484,434,291 90,150,620 96,313,138 481,432,402 485,506,828
MPP5_HUMANMAGUKp55subfamilymember5OS=HomosapiensGN=MPP5PE=1SV=3MPP5 Y 243 3. 8E-19 _VY(ph)ESIGQYGGETVK_ 1,652,034 2,282,262 2,108,139 2,438,280 1,590,728 1,518,400 1,390,376 1,579,550 1,329,071 1,708,777 1,170,423 1,068,721
MPZL1_HUMANMyelinproteinzero-likeprotein1OS=HomosapiensGN=MPZL1PE=1SV=1MPZL1;PZR;UNQ849/PRO1787Y 241 1.73E-32 _SLPSGSHQGPVIY(ph)AQLDHSGGHHSDKINKSESVVYADIR_16,784,408 21,568,772 20,385,728 11,896,383 15,584,130 12,746,000 10,851,187 7,811,292 10,504,375 8,914,096 12,146,422 9,185,899
MTMRA_HUMANMyotubularin-relatedprotein10OS=HomosapiensGN=MTMR10PE=1SV=3MTMR10 Y 708 3.65E-04 _SGPLEACY(ph)GELGQSR_ 680,886 810,481 799,603 489,762 841,610 639,340 542,237 671,988 0 476,990 0 392,229
MYPT1_HUMANProteinphosphatase1regulatorysubunit12AOS=HomosapiensGN=PPP1R12APE=1SV=1MBS;MYPT1;PPP1R12AY 911 2.98E-04 _SGSY(ph) YLEER_ 1,042,101 1,392,110 985,437 0 0 1,074,800 0 982,695 352,806 396,522 450,715 0
P85B_HUMANPhosphatidylinositol3-kinaseregulatorysubunitbetaOS=HomosapiensGN=PIK3R2PE=1SV=2PIK3R2 Y 464 1.19E-38 _SREYDQLY(ph)EEYTR_ 2,323,774 3,211,589 3,261,552 2,603,740 2,154,172 3,627,600 2,625,838 2,687,038 3,166,177 4,727,740 2,535,014 3,492,865
PABP1_HUMANPolyadenylate-bindingprotein1OS=HomosapiensGN=PABPC1PE=1SV=2;>spPAB1;PABP1;PABPC1;PABPC2;PABP3; AB C3;PABPL3Y 364 3.52E-05 _IVATKPLY(ph)VALAQR_ 1,082,189 975,528 1,700,380 1,148,707 910,834 875,260 724,215 611,459 1,084,818 884,062 1,110,461 625,912
PAIRB_HUMANPlasminogenactivatorinhibitor1RNA-bindingproteinOS=HomosapiensGN=SERBP1PE=1SV=2CGI-55;PAIRBP1;SERBP1Y 207 1.11E-10 _ SFSHY(ph)SGLKHEDKR_ 394,079 2,031,561 534,608 540,950 733,746 472,710 765,827 451,457 1,332,189 853,588 1,606,578 403,690
PAPS1_HUMANBifunctional3'-phosphoadenosine5'-phosphosulfatesynthase1OS=HomosapiensGN=PAPSS1PE=1SV=2ATPSK1;PAPSS;PAPSS1Y 30 5.25E-22 _ATNVTY(ph)QAHHVSR_ 638,282 0 649,157 688,889 804,574 458,900 718,089 645,552 234,177 0 304,340 238,103
PAXI_HUMANPaxillinOS=HomosapiensGN=PXNPE=1SV=3PXN Y 88 5.01E-21 _FIHQQPQSSSPVY(ph)GSSAK_ 1,982,977 4,378,534 1,968,110 6,738,092 0 1,917,800 2,251,829 0 4,597,628 3,027,983 6,111,969 1,723,294
PAXI_HUMANPaxillinOS=HomosapiensGN=PXNPE=1SV=3PXN Y 118 3.80E-82 _VGEEEHVY(ph)SFPNKQK_ 9,255,678 12,622,025 10,161,481 10,476,357 6,723,808 5,704,700 13,702,910 15,363,463 13,168,502 12,958,974 14,496,579 11,941,760
PCM1_HUMANPericentriolarmaterial1proteinOS=HomosapiensGN=PCM1PE=1SV=4PCM Y 1176 1.57E-58 _TEY(ph)M(ox)AFPKPFESSSSIGAEKPR_ 3,034,550 2,882,191 1,935,830 1,723,120 3,165,184 1,993,500 1,196,449 1,008,827 2,597,163 2,740,975 2,557,413 2,176,759
PER3_HUMANPeriodcircadianproteinhomolog3OS=HomosapiensGN=PER3PE=1SV=4GIG13;PER3 Y 719 7.24E-08 _Y(ph)SYFQGDSTSK_ 0 1,791,089 0 0 1,959,702 2,088,200 1,551,890 0 0 1,180,972 0 0
PGAM1_HUMANPhosphoglyceratemutase1OS=HomosapiensGN=PGAM1PE=1SV=2;>spCDABP0006;PGAM1;PGAMA;PGAM2;PGAMM;PGAM3;PGAM4Y 92 3.81E-108 _HY(ph)GGLTGLNKAETAAK_ 4,300,341 5,183,797 6,123,788 6,388,023 7,830,959 7,276,800 6,456,014 6,505,212 6,994,769 7,216,265 8,546,941 7,502,737
PHAG1_HUMANPhosphoproteinassociatedwithglycosphingolipid-enrichedmicrodomains1OS=HomosapiensGN=PAG1PE=1SV=2CBP;PAG;PAG1 Y 227 1.00E-07 _ELPGPQTEGKAEFAEY(ph)ASVDR_ 3,101,714 3,683,418 3,885,334 3,144,403 2,506,064 3,936,600 2,126,274 2,515,475 3,699,027 4,721,964 2,947,889 3,810,119
PHAG1_HUMANPhosphoproteinassociatedwithglycosphingolipid-enrichedmicrodomains1OS=HomosapiensGN=PAG1PE=1SV=2CBP;PAG;PAG1 Y 359 6.93E-30 _SPSSCNDLY(ph)ATVKDFEK_ 3,711,360 2,892,211 3,998,463 3,690,332 2,886,694 3,464,100 3,982,853 3,692,924 3,698,154 3,660,173 2,703,763 2,709,402
PHAG1_HUMANPhosphoproteinassociatedwithglycosphingolipid-enrichedmicrodomains1OS=HomosapiensGN=PAG1PE=1SV=2CBP;PAG;PAG1 Y 417 1.35E-14 _ENDY(ph)ESISDLQQGR_ 1,936,957 2,288,664 2,301,296 2,051,647 1,872,450 2,019,400 2,271,933 2,475,077 1,929,385 2,543,859 1,501,503 1,732,875
PI4KA_HUMANPhosphatidylinositol4-kinasealphaOS=HomosapiensGN=PI4KAPE=1SV=3PI4KA;PIK4;PIK4CAY 1096 2.18E-02 _YAGEVY(ph)GM(ox)IR_ 1,877,351 1,522,366 1,515,666 1,496,802 1,497,360 984,470 1,599,836 999,936 1,491,931 1,878,428 1,648,231 1,121,687
PKP4_HUMANPlakophilin-4OS=HomosapiensGN=PKP4PE=1SV=2PKP4 Y 415 5.16E-12 _SAVSPDLHITPIY(ph)EGR_ 649,486 549,427 674,615 574,395 369,077 269,800 0 236,250 0 333,516 0 0
PKP4_HUMANPlakophilin-4OS=HomosapiensGN=PKP4PE=1SV=2PKP4 Y 1168 4.20E-03 _STTNY(ph)VDFYSTK_ 1,579,895 1,552,147 1,161,035 0 0 0 0 0 0 0 0 0
PLCG1_HUMAN1-phosphatidylinositol4,5-bisphosphatephosphodiesterasegamma-1OS=HomosapiensGN=PLCG1PE=1SV=1PLC1;PLCG1 Y 771 1.74E-06 _IGTAEPDY(ph)GA YEGR_ 3,609,083 3,855,980 4,203,725 3,434,333 2,228,497 2,392,100 3,213,214 2,420,650 2,952,438 3,490,116 1,635,018 1,860,861
PP14B_HUMANProteinphosphatase1regulatorysubunit14BOS=HomosapiensGN=PPP1R14BPE=1SV=3PLCB3N;PNG;PPP1RY 29 2.25E-13 _VY(ph)FQSPPGAAGEGPGGADDEGPVRR_ 291,562 505,535 413,670 433,626 0 433,540 0 0 0 526,720 0 440,657
PP1A_HUMANSerine/threonine-proteinphosphatasePP1-alphacatalyticsubunitOS=HomosapiensGN=PPP1CAPE=1SV=1PPP1A;PPP1CA Y 306 7.13E-39 _Y(ph)GQFSGLNPGGRPITPPR_ 12,562,234 13,532,146 21,209,915 11,940,067 9,063,101 11,738,000 11,389,252 6,775,150 11,096,084 11,185,438 9,872,019 8,603,002
PP1B_HUMANSerine/threonine-proteinphosphatasePP1-betacatalyticsubunitOS=HomosapiensGN=PPP1CBPE=1SV=3PPP1CB Y 306 1.92E-75 _Y(ph)QYGGLNSGRPVT(ph)PPR_ 11,262,000 6,824,660 12,820,846 7,164,758 15,199,807 8,108,600 23,612,626 14,861,281 3,716,735 3,326,343 0 4,066,272
PPIA_HUMANPeptidyl-prolylcis-transisomeraseAOS=HomosapiensGN=PPIAPE=1SV=2CYPA;PPIA Y 79 4.36E-26 _SIY(ph)GEKFEDENFILK_ 691,286 565,834 789,366 604,513 560,027 712,200 146,476 210,575 826,947 979,782 596,121 574,582
PRC2C_HUMANProteinPRRC2COS=HomosapiensGN=PRRC2CPE=1SV=4BAT2D1;BAT2L2;KIAA1096;XTP2Y 17 8.72E-05 _Y(ph)ATLSLFNTYK_ 820,123 649,081 617,707 521,771 681,764 768,580 403,349 385,451 485,289 419,365 454,188 442,700
PRP4B_HUMANSerine/threonine-proteinkinasePRP4homologOS=HomosapiensGN=PRPF4BPE=1SV=3KIAA0536;PRP4;PRP4H;PRP4K;PRPF4BY 849 0.00E+00 _LCDFGSASHVADNDITPY(ph)LVSR_ 693,362,610 574,928,346 724,230,604 675,245,410 546,604,441 658,650,000 412,775,258 368,058,503 939,091,296 993,859,155 816,187,610 717,084,050
PSA6_HUMANProteasomesubunitalphatype-6OS=HomosapiensGN=PSMA6PE=1SV=1PROS27;PSMA6 Y 103 1.62E-08 _Y(ph)KYGYEIPVDMLCKR_ 2,128,787 1,996,701 2,445,137 2,750,949 2,246,617 2,164,800 748,871 751,059 3,269,305 3,463,868 2,667,270 1,330,478
PTBP1_HUMANPolypyrimidinetract-bindingprotein1OS=HomosapiensGN=PTBP1PE=1SV=1PTB;PTBP1 Y 127 1.91E-19 _GQPIY(ph)IQFSNHK_ 1,336,208 1,443,392 1,361,514 1,695,474 1,573,070 1,296,500 1,228,312 1,267,524 1,745,699 1,655,165 1,613,248 1,245,696
PTN11_HUMANTyrosine-proteinphosphatasenon-receptortype11OS=HomosapiensGN=PTPN11PE=1SV=2PTP2C;PTPN11;SHPTP2Y 584 5.15E-35 _VY(ph)ENVGLMQQQK_ 1,944,707 5,339,659 3,843,713 4,565,566 2,599,663 2,270,400 3,205,058 3,340,501 2,022,537 1,682,528 1,649,741 1,688,676
PTN11_HUMANTyrosine-proteinphosphatasenon-receptortype11OS=HomosapiensGN=PTPN11PE=1SV=2PTP2C;PTPN11;SHPTP2Y 62 1.10E-09 _IQNTGDY(ph)YDLYGGEK_ 1,118,546 1,041,143 1,572,829 1,130,635 1,145,837 1,390,600 1,029,264 868,195 1,520,987 2,071,287 1,319,667 1,363,830
PTPRA_HUMANReceptor-typetyrosine-proteinphosphatasealphaOS=HomosapiensGN=PTPRAPE=1SV=2PTPA;PTPRA;PTPRL2Y 798 2.09E-32 _VVQEYIDAFSDY(ph)ANFK_ 7,160,665 7,651,841 9,048,119 8,077,333 9,879,297 11,176,000 4,688,197 5,044,979 1,600,796 12,236,385 1,783,885 11,552,197
PTTG_HUMANPituitarytumor-transforminggene1protein-interactingproteinOS=HomosapiensGN=PTTG1IPPE=1SV=1C21orf1;C21orf3;PTTG1IPY 174 5.76E-26 _YGLFKEENPY(ph)AR_ 26,844,719 41,494,732 28,139,658 33,842,457 29,873,333 27,324,000 44,346,219 41,854,717 27,495,484 28,770,807 35,681,467 32,860,628
PUR9_HUMANBifunctionalpurinebiosynthesisproteinPURHOS=HomosapiensGN=ATICPE=1SV=3ATIC;OK/SW-cl.86;PURHY 208 1.69E-06 _Y(ph)GMNPHQTPAQLYTLQPK_ 395,371 579,222 542,020 776,377 776,113 639,090 0 0 785,933 936,812 589,339 574,898
RAPH1_HUMANRas-associatedandpleckstrinhomologydomains-containingprotein1OS=HomosapiensGN=RAPH1PE=1SV=3ALS2CR18;ALS2CR9;KIAA1681;LPD;PREL2;RAPH1;RMO1Y 524 8.98E- 7 _TESAY(ph)DWTSLSSSSIK_ 968,909 950,131 763,363 606,368 534,613 595,740 370,785 366,706 420,582 455,231 307,285 332,647
RBM14_HUMANRNA-bindingprotein14OS=HomosapiensGN=RBM14PE=1SV=2RBM14; IP Y 6 8 7.15E-03 _Y(ph)SGSYNDYLR_ 934,035 1,233,465 676,080 615,823 979,701 1,184,400 2,388,763 1,517,483 862,288 1,160,197 1,345,212 1,554,905
RBM14_HUMANRNA-bindingprotein14OS=HomosapiensGN=RBM14PE=1SV=2RBM14; IP Y 226 7.55E-10 _ASY(ph)VAPLTAQPATYR_ 773,836 1,303,603 925,585 709,833 720,993 956,730 824,583 1,015,402 1,056,835 1,011,807 1,087,973 956,371
RBM4_HUMANRNA-bindingprotein4OS=HomosapiensGN=RBM4PE=1SV=1RBM4;RBM4A Y 194 3.85E-03 _VADLTEQYNEQY(ph)GAVR_ 484,034 523,125 424,086 330,567 289,627 65,493 343,682 0 309,098 0 0 0
RBMX_HUMANRNA-bindingmotifprotein,XchromosomeOS=HomosapiensGN=RBMXPE=1SV=3;>spHNRPG;RBMX;RBMXP1;CCBL2;DKFZp547N1117;hCG_23341;RBMXL1;RP4-531M19.2-001Y 255 .4 E-10 _DYGHSSSRDDY(ph)PSR_ 685,297 1,989,743 1,086,835 1,108,195 1,422,226 1,070,300 1,463,376 1,073,734 1,003,325 825,657 3,018,485 1,358,497
RED_HUMANProteinRedOS=HomosapiensGN=IKPE=1SV=3IK;RED;RER Y 114 7.97E-24 _DGVNKDY(ph)EETELISTTANYR_ 921,521 991,462 1,075,253 783,318 845,615 881,700 0 242,234 0 685,021 201,945 544,122  
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RHG35_HUMANRhoGTPase-activatingprotein35OS=HomosapiensGN=ARHGAP35PE=1SV=3ARHGAP35;GRF1;GRLF1;KIAA1722Y 1105 4.40E-77 _NEEENIY(ph)SVPHDSTQGK_ 12,744,975 14,610,654 15,686,445 8,225,140 7,156,605 13,906,000 10,077,945 21,228,228 4,638,655 10,091,318 10,338,628 9,476,941
RHG39_HUMANRhoGTPase-activatingprotein39OS=HomosapiensGN=ARHGAP39PE=1SV=2ARHGAP39;KIAA1688Y 448 1.20E-05 _ GDY(ph)STM(ox)EGPELR_ 3,870,756 3,607,923 2,331,932 1,489,920 410,914 1,135,200 480,389 528,601 0 0 202,726 0
RL27_HUMAN60SribosomalproteinL27OS=HomosapiensGN=RPL27PE=1SV=2RP Y 49 1.16E-04 _NIDDGTSDRPYSHALVAGIDRY(ph)PR_ 0 628,527 0 734,787 531,670 591,880 0 0 1,090,105 897,085 880,265 0
RL38_HUMAN60SribosomalproteinL38OS=HomosapiensGN=RPL38PE=1SV=2RP Y 43 1.51E-05 _YLY(ph)TLVITDKEK_ 545,821 952,636 617,079 685,179 484,686 647,510 580,529 475,053 625,953 673,032 508,563 682,647
ROA0_HUMANHeterogeneousnuclearribonucleoproteinA0OS=HomosapiensGN=HNRNPA0PE=1SV=1HNRNPA0;HNRPA0Y 180 3.87E-07 _KAVPKEDIY(ph)SGGGGGGSR_ 2,024,500 2,511,811 1,938,296 344,361 2,344,948 698,300 3,876,074 3,505,979 1,176,611 1,233,773 913,775 781,511
ROA1_HUMANHeterogeneousnuclearribonucleoproteinA1OS=HomosapiensGN=HNRNPA1PE=1SV=5HNRNPA1;HNRPA1Y 347 6.19E-25 _SSGPYGGGGQY(ph)FAKPR_ 0 21,645,311 17,762,977 10,083,800 27,807,452 0 43,075,499 41,981,488 36,066,234 23,010,362 17,536,834 19,001,787
ROA2_HUMANHeterogeneousnuclearribonucleoproteinsA2/B1OS=HomosapiensGN=HNRNPA2B1PE=1SV=2HNRNPA2B1;HNRPA2B1Y 174 2.54E-03 _Y(ph)HTINGHNAEVR_ 285,420 355,268 492,001 406,936 575,838 653,910 526,287 541,008 482,521 673,934 850,239 850,367
ROA2_HUMANHeterogeneousnuclearribonucleoproteinsA2/B1OS=HomosapiensGN=HNRNPA2B1PE=1SV=2HNRNPA2B1;HNRPA2B1Y 336 5.93E-63 _NM(ox)GGPYGGGNY(ph)GPGGSGGSGGYGGR_ 3,047,179 2,837,033 2,097,753 2,425,534 1,997,326 2,995,700 1,488,733 570,402 3,021,648 2,952,076 1,097,285 2,794,274
ROA3_HUMANHeterogeneousnuclearribonucleoproteinA3OS=HomosapiensGN=HNRNPA3PE=1SV=2HNRNPA3;HNRPA3Y 360 7.36E-35 _SSGSPY(ph)GGGYGSGGGSGGYGSR_ 0 0 0 0 1,251,416 1,341,700 0 0 0 0 1,600,790 1,342,047
ROBO1_HUMANRoundabouthomolog1OS=HomosapiensGN=ROBO1PE=1SV=1DUTT ;ROBO1 Y 1587 5.51E-17 _THLIQEDILPY(ph)CRPTFPTSNNPR_ 614,621 748,763 810,363 826,404 477,669 388,940 0 0 394,020 693,534 677,023 493,714
ROBO1_HUMANRoundabouthomolog1OS=HomosapiensGN=ROBO1PE=1SV=1DUTT ;ROBO1 Y 1038 2.06E-27 _QTNLMLPESTVY(ph)GDVDLSNKINEMK_ 0 1,461,135 2,275,667 969,244 0 0 782,631 815,983 681,981 748,959 667,661 604,129
ROBO1_HUMANRoundabouthomolog1OS=HomosapiensGN=ROBO1PE=1SV=1DUTT ;ROBO1 Y 932 4.81E-02 _NGLTSTY(ph)AGIR_ 0 5,929,986 4,810,171 6,060,094 4,563,404 4,505,300 6,626,139 5,662,608 5,000,040 3,047,137 3,455,270 5,569,658
ROCK2_HUMANRho-associatedproteinkinase2OS=HomosapiensGN=ROCK2PE=1SV=4KIAA0619;ROCK2 Y 722 6.75E-14 _LADKNKIY(ph)ESIEEAK_ 606,307 641,058 574,891 535,523 632,229 606,870 395,725 505,766 364,266 262,899 290,095 350,480
ROR2_HUMANTyrosine-proteinkinasetransmembranereceptorROR2OS=HomosapiensGN=ROR2PE=1SV=2NTRKR2;ROR2 Y 873 2.22E-53 _PSSHHSGSGSTSTGY(ph)VTTAPSNTSMADR_ 1,705,900 2,425,113 1,676,917 2,307,647 1,930,156 4,161,200 0 0 1,247,516 1,662,158 1,859,136 1,817,205
RS10_HUMAN40SribosomalproteinS10OS=HomosapiensGN=RPS10PE=1SV=1RPS10 Y 2 3.23E-02 _IAIY(ph)ELLFK_ 447,342 484,758 12,600 483,892 384,577 379,000 221,333 292,841 692,618 840,879 564,674 486,167
RS17_HUMAN40SribosomalproteinS17OS=HomosapiensGN=RPS17PE=1SV=2;>spRPS17 Y 53 1.01E-03 _IAGY(ph)VTHLMK_ 665,234 1,868,672 2,023,778 2,119,447 2,412,003 2,447,300 2,866,895 2,428,256 2,192,381 1,926,263 2,684,887 2,289,651
RS29_HUMAN40SribosomalproteinS29OS=HomosapiensGN=RPS29PE=1SV=2RPS29 Y 7 1.65E-02 _GHQQLY(ph)WSHPR_ 1,359,553 0 2,133,395 2,271,982 2,374,032 2,604,400 2,859,499 2,936,693 2,882,106 0 0 2,555,746
RS8_HUMAN40SribosomalproteinS8OS=HomosapiensGN=RPS8PE=1SV=2OK/SW-cl.83;RPS8 Y 117 3.93E-07 _QWYESHY(ph)ALPLGR_ 621,558 601,599 798,258 593,527 670,569 674,440 521,317 557,961 815,400 1,117,125 777,467 627,313
RSSA_HUMAN40SribosomalproteinSAOS=HomosapiensGN=RPSAPE=1SV=4LAMBR;LAMR1;RPSAY 139 4.01E-29 _ADHQPLTEASY(ph)VNLPTIALCNTDSPLR_ 332,760 508,311 565,961 555,683 620,018 607,230 0 189,717 893,076 823,194 814,514 662,482
RU17_HUMANU1smallnuclearribonucleoprotein70kDaOS=HomosapiensGN=SNRNP70PE=1SV=2RNPU1Z;RPU1;SNRNP70;SNRP70;U1AP1Y 126 4.77E-11 _REFEVY(ph)GPIKR_ 15,135,913 15,931,305 18,549,055 18,427,426 19,946,717 21,063,000 25,869,576 28,225,988 22,436,335 23,121,842 23,229,761 29,225,315
RU17_HUMANU1smallnuclearribonucleoprotein70kDaOS=HomosapiensGN=SNRNP70PE=1SV=2RNPU1Z;RPU1;SNRNP70;SNRP70;U1AP1Y 146 2.94E-19 _GY(ph)AFIEYEHER_ 599,964 851,882 940,305 936,571 1,046,386 867,640 0 0 1,154,102 1,206,106 876,615 853,304
S38A2_HUMANSodium-coupledneutralaminoacidtransporter2OS=HomosapiensGN=SLC38A2PE=1SV=2ATA2;KIAA1382;SAT2;SLC38A2;SNAT2Y 41 3.82E-11 _SHY(ph)AD DPENQNFLLESNLGKK_ 724,295 601,501 559,797 658,550 0 0 0 0 0 0 0 0
SC16A_HUMANProteintransportproteinSec16AOS=HomosapiensGN=SEC16APE=1SV=3KIAA0310;SEC16;SEC16A;SEC16LY 1113 3.30E-50 _Y(ph)WCDAEYDAYRR_ 798,042 1,115,595 613,223 351,458 1,048,302 1,567,900 1,343,644 1,146,213 1,120,320 1,688,305 1,645,588 2,206,406
SC16A_HUMANProteintransportproteinSec16AOS=HomosapiensGN=SEC16APE=1SV=3KIAA0310;SEC16;SEC16A;SEC16LY 813 6.46E-49 _ANHSSHQEDTY(ph)GALDFTLSR_ 3,680,361 4,896,357 4,665,210 3,968,413 3,499,533 3,530,800 3,428,477 0 4,642,521 4,086,734 3,057,872 2,643,963
SCAM3_HUMANSecretorycarrier-associatedmembraneprotein3OS=HomosapiensGN=SCAMP3PE=1SV=3C1orf3;PROPIN1;SCAMP3Y 83 5.93E-58 _NY(ph)GSYSTQASAAAATAELLK_ 1,028,419 939,067 855,420 812,521 424,521 526,110 167,913 252,241 617,473 692,642 326,840 549,410
SEPT2_HUMANSeptin-2OS=HomosapiensGN=SEPT2PE=1SV=1DIFF6;KIAA0158;NEDD5;SEPT2Y 17 1.04E-06 _QQPTQFINPETPGY(ph)VGFANLPNQVHRK_ 0 1,276,188 0 1,188,741 1,195,210 0 539,847 555,832 0 0 0 1,208,276
SG223_HUMANTyrosine-proteinkinaseSgK223OS=HomosapiensGN=SGK223PE=1SV=4SGK223 Y 413 4.93E-04 _EATQPEPIY(ph)AESTKR_ 4,374,394 5,861,796 5,170,482 4,890,323 5,175,436 4,936,100 10,957,207 3,454,764 4,091,838 3,086,966 6,090,703 6,487,525
SHPS1_HUMANTyrosine-proteinphosphatasenon-receptortypesubstrate1OS=HomosapiensGN=SIRPAPE=1SV=2BIT;MFR;MYD1;PTPNS1;SHPS1;SIRP;SIRPAY 496 1.57E-03 _QPAPKPE SFSEY(ph)ASVQVPR_ 1,000,195 1,051,580 951,439 1,076,958 734,923 0 0 240,611 705,425 895,727 446,940 590,544
SHRM2_HUMANProteinShroom2OS=HomosapiensGN=SHROOM2PE=1SV=1APXL;SHROOM2 Y 10 2.15E-57 _DSAY(ph)GSFSTSSSTPDHTLSK_ 655,848 647,822 463,951 537,629 281,952 384,380 0 0 0 307,521 0 176,596
SPN1_HUMANSnurportin-1OS=HomosapiensGN=SNUPNPE=1SV=1RNUT1;SNUPN;SP 1Y 334 5.53E-20 _ASENGHY(ph)ELEHLSTPK_ 1,254,406 1,167,850 949,944 973,612 846,827 764,940 0 500,881 0 0 0 0
SRC8_HUMANSrcsubstratecortactinOS=HomosapiensGN=CTTNPE=1SV=2CTTN;EMS1 Y 334 6.20E-17 _NASTFEDVTQVSSAY(ph)QK_ 601,141 581,921 495,386 398,547 552,767 498,860 363,881 310,572 486,025 436,249 436,319 387,059
SRCN1_HUMANSRCkinasesignalinginhibitor1OS=HomosapiensGN=SRCIN1PE=1SV=3KIAA1684;P 40;SRCIN1Y 268 7.77E-26 _GEGLY(ph)ADPYGLLHEGR_ 1,106,491 1,008,649 1,059,113 905,513 468,009 469,720 445,795 487,409 459,863 466,328 334,353 286,731
SRP14_HUMANSignalrecognitionparticle14kDaproteinOS=HomosapiensGN=SRP14PE=1SV=2SRP14 Y 27 2.87E-02 _TSGSVY(ph)ITLK_ 1,144,857 1,050,328 1,237,998 1,024,298 1,097,525 1,063,000 566,969 329,926 2,056,830 1,555,138 1,397,938 943,175
SRSF3_HUMANSerine/arginine-richsplicingfactor3OS=HomosapiensGN=SRSF3PE=1SV=1SFRS3;SRP20 Y 32 1.42E-05 _AFGY(ph)YGPLR_ 1,047,841 1,215,583 1,106,487 1,096,107 1,406,069 1,482,500 1,086,389 1,234,327 1,346,155 1,836,066 1,682,207 1,401,430
STAM2_HUMANSignaltransducingadaptermolecule2OS=HomosapiensGN=STAM2PE=1SV=1HBP;STAM2 Y 371 1.44E-04 _L NEAPVY(ph)SVYSK_ 2,647,732 3,011,334 2,384,836 0 2,088,617 629,390 569,984 673,306 623,646 2,032,776 2,074,949 413,704
STAT3_HUMANSignaltransducerandactivatoroftranscription3OS=HomosapiensGN=STAT3PE=1SV=2APRF;STAT3 Y 705 6.63E-68 _YCRPESQEHPEADPGSAAPY(ph)LK_ 41,653,422 52,355,657 43,759,600 50,386,688 70,663,521 61,945,000 53,504,883 51,369,304 90,643,191 104,476,471 87,895,578 80,590,608
SYNEM_HUMANSyneminOS=HomosapiensGN=SYNMPE=1SV=2DMN;KIAA0353;SYN;SYNMY 432 2.56E-14 _TFSPTY(ph)GLLR_ 0 0 407,886 428,647 0 0 0 0 0 0 0 0
SYWC_HUMANTryptophan--tRNAligase,cytoplasmicOS=HomosapiensGN=WARSPE=1SV=2IFI53;WARS;WRS Y 329 1.33E-03 _IGY(ph)PKPALLHSTFFPALQGAQTK_ 336,980 332,466 383,788 499,822 0 354,710 0 0 491,425 437,111 589,792 474,715
TAGL2_HUMANTransgelin-2OS=HomosapiensGN=TAGLN2PE=1SV=3;>spCDABP0035;KIAA0120;TAGLN2;NP25;TAGLN3Y 192 2.82E-14 _GASQAGMTGY(ph)GMPR_ 4,092,437 6,299,740 4,647,874 3,579,208 6,193,950 6,214,100 8,033,983 4,763,886 4,231,379 4,283,039 6,689,945 6,347,336
TBA1B_HUMANTubulinalpha-1BchainOS=HomosapiensGN=TUBA1BPE=1SV=1;>ENSEMBL:ENSBTAP00000016242(Bostaurus)similartoalpha-tubulinIisoform1;>spTUBA1B;TUBA1;TUBA4A;TUBA1A;TUBA3;TUBA2;TUBA3C;TUBA3D;TUBA1C;TUBA6;TUBA8;TUBAL2Y 03 1.40E-32 _QLFHPEQLITGKEDAANNY(ph)AR_ 10,702,296 10,917,982 7,247,537 5,846,641 5,103,765 4,693,100 2,647,269 2,868,405 3,854,406 3,996,233 3,604,388 3,670,654
TBA1B_HUMANTubulinalpha-1BchainOS=HomosapiensGN=TUBA1BPE=1SV=1;>ENSEMBL:ENSBTAP00000016242(Bostaurus)similartoalpha-tubulinIisoform1;>spTUBA1B;TUBA1;TUBA4A;TUBA1A;TUBA3;TUBA2;TUBA3C;TUBA3D;TUBA3E;TUBA1C;TUBA6;TUBA8;TUBAL2Y 357 5.07E-04 _VGINY(ph)QPPTVVPGGDLAK_ 1,928,155 1,724,221 1,676,618 1,407,220 1,393,950 1,463,100 654,914 626,976 1,548,671 1,644,017 1,270,464 1,142,747
TBAL3_HUMANTubulinalphachain-like3OS=HomosapiensGN=TUBAL3PE=1SV=2;>spTUBAL3;TUBA1B;TUBA1;TUBA4A;TUBA1A;TUBA3;TUBA2;TUBA3C;TUBA3D;TUBA1C;TUBA6;TUBA8;TUBAL2Y 406 3.88E-02 _LDHKFDLMY(ph)AK_ 637,603 1,451,394 1,221,858 732,932 1,062,036 1,176,700 0 0 0 0 90,247 523,794
TBAL3_HUMANTubulinalphachain-like3OS=HomosapiensGN=TUBAL3PE=1SV=2;>spTUBAL3;TUBA1B;TUBA1;TUBA4A;TUBA1A;TUBA3;TUBA1C;TUBA6Y 326 1.03E-07 _YM(ox)ACCLLY(ph)R_ 3,159,885 1,005,657 1,186,067 918,319 911,942 1,418,500 923,832 739,464 2,140,131 3,024,132 1,012,118 1,275,704
TBB4A_HUMANTubulinbeta-4AchainOS=HomosapiensGN=TUBB4APE=1SV=2;>spTUBB4;TUBB5;OK/SW-cl.56;TU B;TUBB5;TUBB2C;TUBB3;TUBB4;TUBB2;TUBB2A;TUBB2B;TUBB6Y 340 6.03E-09 _NSSY(ph)FVEWIPNNVK_ 1,887,588 1,432,746 1,568,943 1,344,148 1,550,911 1,540,600 732,029 707,433 1,692,452 1,746,072 1,570,211 1,486,303
TCOF_HUMANTreacleproteinOS=HomosapiensGN=TCOF1PE=1SV=3TCOF1 S 381 2.79E-04 _TSQVGAASAPAKES(ph)PR_ 366,295 319,698 421,247 372,253 558,977 410,500 0 583,451 448,028 437,516 650,786 672,723
TLN1_HUMANTalin-1OS=HomosapiensGN=TLN1PE=1SV=3KIAA1027;TLN;TLN1Y 70 3.61E-02 _ALDY(ph)YMLR_ 800,577 727,193 413,498 480,990 790,471 855,300 767,097 821,087 940,625 931,106 1,044,521 826,306
TM192_HUMANTransmembraneprotein192OS=HomosapiensGN=TMEM192PE=1SV=1TMEM192 Y 213 1.90E-09 _AKPEPDILEEEKIY(ph)AYPSNITSETGFR_ 1,733,072 1,812,033 2,263,860 1,970,144 1,683,174 1,583,000 1,138,185 947,909 1,248,888 1,025,306 1,454,440 924,736
TNS2_HUMANTensin-2OS=HomosapiensGN=TNS2PE=1SV=2KIAA1075;TENC1;TNS2Y 483 1.26E-24 _GPLDGSPY(ph)AQVQRPPR_ 1,314,777 1,205,146 862,519 0 1,145,041 1,207,400 978,056 1,309,697 627,237 823,590 527,426 546,797
TPX2_HUMANTargetingproteinforXklp2OS=HomosapiensGN=TPX2PE=1SV=2C20orf1;C20orf2;DIL2;HCA519;TPX2Y 519 1.49E-05 _AQPVPHY(ph)GVPFKPQIPEAR_ 2,102,189 1,872,847 1,533,749 1,521,576 1,444,155 1,130,700 1,595,322 1,521,438 2,075,536 1,424,605 2,132,079 1,468,587
TYK2_HUMANNon-receptortyrosine-proteinkinaseTYK2OS=HomosapiensGN=TYK2PE=1SV=3TYK2 Y 292 8.53E-05 _LLAQAEGEPCY(ph)IR_ 11,053,427 11,091,935 11,908,487 10,046,699 10,140,706 10,577,000 12,143,528 12,839,537 13,506,444 13,768,720 13,455,896 11,883,009
UBP15_HUMANUbiquitincarboxyl-terminalhydrolase15OS=HomosapiensGN=USP15PE=1SV=3KIAA0529;USP15 Y 274 1.09E-06 _NSNYCLPSYTAYKNY(ph)DYSEPGR_ 1,335,730 1,414,307 1,310,031 0 771,289 822,810 0 0 0 0 0 0
UBP2L_HUMANUbiquitin-associatedprotein2-likeOS=HomosapiensGN=UBAP2LPE=1SV=2KIAA0144;NICE4;UBAP2LY 858 1.39 -04 _DGSLASNPY(ph)SGDLTK_ 646,491 673,720 0 475,933 0 569,650 868,110 956,175 0 541,233 619,842 832,624
UNG_HUMANUracil-DNAglycosylaseOS=HomosapiensGN=UNGPE=1SV=2DGU;UNG;UNG1;UNG15Y 8 4.39E-13 _TLY(ph)SFFSPSPAR_ 1,780,144 1,397,538 1,158,120 1,205,855 997,244 927,340 687,308 788,279 639,171 623,129 528,811 383,778
VASP_HUMANVasodilator-stimulatedphosphoproteinOS=HomosapiensGN=VASPPE=1SV=3VASP Y 39 2.46E-10 _ QIY(ph)HNPTANSFR_ 0 666,769 634,952 979,357 672,462 536,090 596,385 674,675 713,207 745,807 741,893 597,675
VTA1_HUMANVacuolarproteinsorting-associatedproteinVTA1homologOS=HomosapiensGN=VTA1PE=1SV=1C6orf55;HSPC228;My012;VTA1Y 278 2.06E-108 _Y(ph)AGSALQYEDVSTAVQNLQK_ 2,419,641 2,557,665 3,349,500 2,966,077 2,627,131 2,620,100 1,221,105 1,015,402 3,492,272 3,206,350 2,806,825 2,656,526
WASL_HUMANNeuralWiskott-AldrichsyndromeproteinOS=HomosapiensGN=WASLPE=1SV=2WASL Y 256 9.38E-34 _VIY(ph)DFIEK_ 34,461,471 27,589,630 27,600,910 23,361,911 29,899,878 44,636,000 25,831,644 18,839,863 16,354,632 19,993,324 18,406,377 20,672,115
YES_HUMANTyrosine-proteinkinaseYesOS=HomosapiensGN=YES1PE=1SV=3;>spYES;YES1;FYN;SRC;SRC1Y 446 2.20E-02 _WTAPEAALY(ph)GR_ 1,462,309 1,566,829 1,458,280 1,449,767 1,581,842 1,687,900 1,739,729 1,714,113 1,108,087 1,494,837 1,106,975 1,080,561
YES_HUMANTyrosine-proteinkinaseYesOS=HomosapiensGN=YES1PE=1SV=3;>spYES;YES1;FYN;SRC;SRC1;LCKY 426 3.07E-07 _LIEDNEY(ph)TAR_ 68,151,794 83,887,060 95,622,082 81,557,246 81,174,124 94,455,000 158,528,914 142,035,931 65,270,131 1,032,198 90,682,898 91,144,948
YES_HUMANTyrosine-proteinkinaseYesOS=HomosapiensGN=YES1PE=1SV=3;>spYES;YES1;FYN;FGR;SRC2Y 194 1.19E-32 _GAY(ph)SLSIRDWDEIRGDNVK_ 3,418,018 5,875,852 4,665,658 6,078,645 7,267,977 5,208,800 7,143,531 6,067,430 5,348,582 4,412,253 5,061,974 4,372,499
ZN326_HUMANDBIRDcomplexsubunitZNF326OS=HomosapiensGN=ZNF326PE=1SV=2ZNF326 Y 93 4.94E-04 _SGY(ph)GFNEPEQSR_ 0 416,207 0 275,448 684,961 595,230 923,718 671,413 471,846 550,972 925,000 823,161
ZO2_HUMANTightjunctionproteinZO-2OS=HomosapiensGN=TJP2PE=1SV=2TJP2;X104;ZO2 Y 1118 2.30E-31 _IEIAQKHPDIY(ph)AVPIK_ 8,431,909 7,745,080 17,886,268 20,779,774 9,767,694 2,108,400 12,071,078 8,617,048 4,820,844 2,243,270 12,591,386 1,882,463  
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Appendix J – Global phosphoproteomics in H1155 cells: peptides with PEP score < 0.05 and 2 +/- St. dev. for foretinib vs 
DMSO Appendix I - Global phosphoproteomics in H1155 cells: peptides with PEP score < 0.05 and 2+/- St. Dev for comparion of foretinib vs DMSO
Proteins Positions Amino acid Number PEP Phospho (STY) Probabilities DMSO1 DMSO2 FORE1 FORE2 CABO1 CABO2
1A03_HUMAN;sp 350;350;350;350;350S 3 0.003852 PHOSPHOSITEPLUS 4,772 3,446 5,988 6,258 4,519 4,660
3BP2_HUMAN 427 S 1 0.001717 S(0.001)FS(0.999)FEKPR 16,350 14,783 21,373 18,818 17,185 19,150
41_HUMAN 85 S 1 0.00548 LFS(0.023)S(0.977)FLK 12,292 8,182 13,743 12,119 7,489 24,997
4ET_HUMAN 5 S 1 0.004485 S(0.743)MGET(0.236)ES(0.021)GDAFLDLKKPPASK 65,427 61,239 45,980 48,498 53,191 61,979
ACACA_HUMAN 1259 S 2 2.18E-07 IFDEVMGCFS(0.142)DS(0.837)PPQS(0.777)PT(0.241)FPEAGHT(0.001)S(0.001)LY(0.001)DEDKVPR 5,414 4,426 4,441 3,290 5,032 5,350
ACACA_HUMAN 1263 S 2 2.18E-07 IFDEVMGCFS(0.142)DS(0.837)PPQS(0.777)PT(0.241)FPEAGHT(0.001)S(0.001)LY(0.001)DEDKVPR 5,414 4,426 4,441 3,290 5,032 5,350
ACINU_HUMAN 243 S 2 6.51E-26 AAKLS(1)EGS(1)QPAEEEEDQETPSR 94,859 79,044 61,024 59,436 74,250 88,626
ACINU_HUMAN 240 S 1;2 3.57E-32 AAKLS(1)EGS(1)QPAEEEEDQETPSR 176,789 161,715 129,735 121,826 151,380 168,131
ACK1_HUMAN 517 T 1 1.32E-08 KPT(0.565)Y(0.435)DPVSEDQDPLSSDFKR 36,105 30,514 22,545 26,701 28,247 29,161
ACOD_HUMAN 198 S 1 3.80E-09 EKGS(0.827)T(0.173)LDLSDLEAEK 77,578 89,726 63,877 59,359 76,312 77,559
ACTB_HUMAN;sp 233;233;933 S 1 1.01E-38 LCYVALDFEQEMATAAS(0.171)S(0.711)S(0.103)S(0.015)LEK 67,882 71,411 55,295 57,195 61,319 56,792
AFAD_HUMAN 1799 S 1 4.33E-07 LFS(1)QGQDVSNKVK 216,454 204,132 166,140 146,706 173,500 252,903
AFF3_HUMAN 878 S 2 0.004339 MLRS(0.998)PIS(0.945)PLS(0.054)DAS(0.002)K 7,591 7,758 5,811 6,190 6,865 6,484
AHNK_HUMAN 5077 S 1 0.036076 VDVKS(1)PK 13,244 16,157 11,150 11,601 13,622 13,124
AHNK_HUMAN 135 S 1 8.69E-27 LKS(1)EDGVEGDLGETQSR 143,593 135,481 110,560 107,827 131,150 146,956
AIM1_HUMAN 410 S 1 0.000107 LLEKEDS(1)EAADSK 17,994 15,083 23,612 19,283 20,360 20,764
AKAP1_HUMAN 151 S 1 9.72E-05 SIPLECPLS(0.163)S(0.837)PK 16,369 16,074 11,084 11,359 14,798 14,400
ALMS1_HUMAN 92 S 1 0.000167 ILPPLS(1)PPQHR 8,978 9,237 8,332 6,495 9,605 8,300
AMPD2_HUMAN 192 S 1 0.000169 AKQDFLKT(0.092)DS(0.33)DS(0.576)DLQLY(0.002)K 24,902 26,530 30,451 33,116 31,774 22,569
ANLN_HUMAN 72 S 1 6.93E-20 RCS(0.996)DNT(0.004)EVEVSNLENKQPVESTSAK 90,524 93,351 59,649 61,554 81,576 85,931
ANO6_HUMAN 909 S 1 6.31E-06 MIEAVDNNLRPKS(1)E 41,958 41,072 25,757 27,734 31,085 33,057
ARHG2_HUMAN 782 S 1 0.003865 ANS(1)RDGEAGR 6,090 5,548 7,499 9,770 8,303 15,024
ASAP1_HUMAN 1041 S 1 1.65E-09 QAS(0.979)EDS(0.021)NDLTPTLPETPVPLPR 12,805 12,868 17,431 16,292 12,321 14,654
ATG2B_HUMAN 255 S 1 3.67E-06 LS(1)PSWNPK 146,504 145,786 121,546 115,255 138,260 130,751
ATX2L_HUMAN 31 T 1 1.74E-12 RPPGGT(0.54)S(0.459)PPNGGLPGPLATSAAPPGPPAAASPCLGPVAAAGSGLR 7,086 6,420 7,060 10,054 7,004 6,934
AUTS2_HUMAN 1233 S 1 9.79E-06 TPPTAALS(0.001)APPPLIS(0.062)T(0.263)LGGRPVS(0.674)PR 373 1,404 1,320 743 799 1,371
AZI2_HUMAN 318 S 1 0.000299 AILQS(0.712)WT(0.288)DNER 17,556 15,766 19,799 23,799 22,583 16,465
BABA1_HUMAN 27 T 1 3.46E-21 T(0.541)RS(0.459)NPEGAEDR 43,951 50,544 35,132 35,408 48,354 39,430
BCLF1_HUMAN 450 S 1 0.001855 GNRES(1)DGFREEK 108,667 108,460 85,358 88,067 93,845 89,097
BD1L1_HUMAN 2779 S 2 8.98E-05 QHY(0.001)LS(1)S(1)EDEPDDNPDVLDSR 24,272 23,784 32,064 29,223 25,717 31,319
BD1L1_HUMAN 2780 S 2 8.98E-05 QHY(0.001)LS(1)S(1)EDEPDDNPDVLDSR 24,272 23,784 32,064 29,223 25,717 31,319
BMT2_HUMAN 21 T 1 0.015529 AGS(0.422)PNT(0.578)PPPREQER 7,210 6,901 8,352 9,345 8,310 8,110
BORG2_HUMAN 100 S 2 2.88E-13 ANS(0.701)T(0.21)S(0.086)DS(0.003)VFT(0.01)ETPS(0.989)PVLK 30,904 28,123 19,221 19,947 26,984 28,181
BORG4_HUMAN 140 S 2 0.000296 S(0.043)LS(0.854)S(0.594)S(0.509)PVKK 151,271 154,289 113,057 126,275 155,380 131,643
BORG4_HUMAN 174 S 1 5.26E-43 RNGAAGPHS(1)PDPLLDEQAFGDLTDLPVVPK 74,438 76,646 45,650 46,536 66,042 69,244
BRSK2_HUMAN 481 S 2 0.003382 LNS(0.739)IKNS(0.261)FLGS(1)PR 7,019 6,892 10,210 10,383 6,330 12,028
BTF3_HUMAN 158 S 1 2.95E-26 QLTEMLPSILNQLGADS(0.962)LT(0.037)S(0.001)LRR 10,152 10,902 13,860 15,267 9,539 14,617
C170B_HUMAN 224 S 1 8.98E-05 REPS(0.999)Y(0.001)FEIPTK 22,577 16,407 27,025 22,422 16,853 24,793
CBX3_HUMAN 93 S 1;2 1.43E-66 S(1)LS(0.992)DS(0.006)ES(0.002)DDSKSKK 908,806 1,057,318 566,855 571,432 903,510 767,648
CBX5_HUMAN 92 S 1 0.008269 RKS(0.978)NFS(0.019)NS(0.002)ADDIK 48,106 42,837 23,724 27,325 39,012 48,581
CCNL1_HUMAN 338 S 3 2.24E-09 GLNPDGTPALS(0.091)T(0.056)LGGFS(0.923)PAS(0.897)KPS(0.598)S(0.434)PR 28,075 28,716 36,504 34,376 31,599 31,314
CDCA3_HUMAN 199 S 2 2.50E-09 VLGRS(0.997)PLT(0.005)ILQDDNS(0.966)PGT(0.03)LT(0.002)LR 16,608 19,773 20,621 24,187 15,280 19,582
CDCA3_HUMAN 209 S 2 2.50E-09 VLGRS(0.997)PLT(0.005)ILQDDNS(0.966)PGT(0.03)LT(0.002)LR 16,608 19,773 20,621 24,187 15,280 19,582
CDK16_HUMAN 138 S 1 0.001416 LT(0.004)LNS(0.984)PIFDKPLS(0.012)R 17,705 17,037 9,349 10,386 14,597 17,022
CDK16_HUMAN 111 T 1 0.000112 KIS(0.343)T(0.657)EDINK 43,333 41,022 30,285 29,425 38,975 44,303
CDK16_HUMAN 153 S 1 1.63E-06 RVS(1)LSEIGFGK 170,330 182,323 137,198 134,025 156,440 157,072
CDK16_HUMAN 119 S 1 8.20E-45 RLS(1)LPADIRLPEGYLEK 499,502 403,838 273,661 289,918 399,830 538,574
CDK17_HUMAN 9 S 1 0.011273 RLS(0.942)LT(0.058)LR 15,648 13,453 10,650 11,043 12,352 15,516
CDK17_HUMAN 180 S 1 6.07E-05 RAS(0.999)LS(0.001)EIGFGK 129,427 131,984 97,183 111,064 129,910 156,723
CDK17_HUMAN 137 S 1 4.06E-06 RIS(1)MEDLNKR 194,987 165,278 126,725 124,592 157,470 191,007
CDK17_HUMAN 146 S 1 1.95E-10 RLS(1)LPADIRIPDGYLEK 143,303 118,455 85,806 86,713 113,000 156,026
CE170_HUMAN 122 S 1 0.000282 FTIQLQLS(1)QK 2,628 1,778 2,989 2,580 3,087 2,933
CHD7_HUMAN 2567 T 1 0.001828 NIPS(0.131)PGQLDPDT(0.77)RIPVINLEDGT(0.099)RLVGEDAPK 14,500 13,782 16,041 19,722 16,912 16,879
CHMP7_HUMAN 439 S 2 1.81E-13 IS(1)DAELEAELEKLSLS(0.001)EGGLVPS(0.174)S(0.519)KS(0.306)PK 21,914 22,283 13,697 10,395 20,925 17,788
CHMP7_HUMAN 417 S 2 4.63E-17 IS(1)DAELEAELEKLSLSEGGLVPS(0.419)S(0.366)KS(0.214)PK 28,023 29,162 17,824 13,202 26,576 22,462
CHRD1_HUMAN 199 T 1 2.80E-07 RKT(0.742)S(0.191)DFNT(0.067)FLAQEGCTK 84,113 80,621 62,405 64,842 72,350 75,353
CHRD1_HUMAN 47 T 1 1.03E-09 RRT(0.731)T(0.192)DFS(0.077)DFLSIVGCTK 26,706 22,781 16,479 14,811 20,597 19,134
CIR1_HUMAN 365 S 1 0.007634 T(0.001)HKHS(0.999)PEKR 21,783 18,406 23,632 25,932 22,639 40,891
CK084_HUMAN 310 S 1 0.000106 AES(0.432)PS(0.568)PAPPPGLR 6,020 5,151 7,401 6,449 6,105 5,354
CK084_HUMAN 49 T 1 5.15E-09 VT(0.001)QQEKT(0.976)PPPRPS(0.016)PLEAGS(0.008)DGCEEPK 26,052 25,487 19,219 21,487 25,492 21,244
COBL1_HUMAN 404 S 1 0.012632 KAPS(0.5)PPS(0.5)K 38,439 28,875 39,196 60,565 35,866 157,881
COBL1_HUMAN 407 S 1 0.012632 KAPS(0.5)PPS(0.5)K 38,439 28,875 39,196 60,565 35,866 157,881
CR025_HUMAN 66 S 1 1.24E-89 RDS(0.906)S(0.092)ES(0.002)QLASTESDKPTTGR 238,916 242,704 183,660 182,777 212,150 200,939
CT2NL_HUMAN 481 S 1 8.99E-07 HKFQSQADQDQQAS(0.213)GLQS(0.644)PPS(0.06)RDLS(0.06)PT(0.021)LIDNSAAK 12,540 12,758 16,045 15,169 14,071 15,057
CWC27_HUMAN 206 S 1 2.10E-25 NFS(0.004)LLS(0.996)FGEEAEEEEEEVNR 8,906 7,717 12,647 8,797 8,010 8,358
DBR1_HUMAN 514 S 1 3.29E-05 RLS(1)DEHEPEQR 43,953 47,627 30,532 30,842 40,614 35,466
DC1L2_HUMAN 446 S 2 2.56E-05 KT(0.574)GS(0.428)PGS(0.998)PGAGGVQSTAK 32,949 36,750 41,426 44,186 30,209 34,118
DC1L2_HUMAN 441 T 2 2.56E-05 KT(0.574)GS(0.428)PGS(0.998)PGAGGVQSTAK 32,949 36,750 41,426 44,186 30,209 34,118
DCP1A_HUMAN 321 T 2 6.41E-06 HAPT(0.006)Y(0.002)T(0.018)IPLS(0.65)PVLS(0.659)PT(0.663)LPAEAPT(0.002)AQVPPSLPR 5,542 5,338 3,922 3,976 5,027 4,416
DDX20_HUMAN 767 S 1 2.17E-31 LS(0.212)FS(0.677)DT(0.11)YQDYEEYWR 23,210 26,112 20,076 16,666 27,021 20,984
DDX3X_HUMAN;sp 594;592 S 1 0.011202 FS(1)GGFGAR 25,206 29,623 13,532 12,274 18,751 20,693
DDX5_HUMAN 498 S 1 0.024888 DRY(0.001)S(0.999)AGKR 66,068 72,480 41,169 50,783 61,738 62,873
DKC1_HUMAN 21 S 1 9.54E-68 S(1)LPEEDVAEIQHAEEFLIKPESK 233,085 260,556 86,156 85,079 204,530 191,018
DLG5_HUMAN 1795 S 1 2.19E-05 S(1)GHFDVTTVASIK 22,892 24,911 16,665 16,098 24,327 21,011
DMD_HUMAN 3490 S 1 5.87E-05 S(1)PAQILISLESEERGELER 12,235 11,679 10,502 8,709 9,625 9,523
DNLI1_HUMAN 233 T 1 0.000267 TLSSFFT(1)PR 31,422 38,752 28,747 27,592 30,841 30,685
DOCK7_HUMAN 434 S 1 0.007223 KGS(0.219)WS(0.781)ER 30,729 33,893 24,830 25,156 32,708 29,151  
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DOS_HUMAN 561 S 1 5.27E-16 RDYS(1)IDEKTDALFHEFLR 12,394 7,828 12,661 15,079 10,561 16,196
DPYL2_HUMAN 509 T 1 2.03E-11 GLYDGPVCEVS(0.003)VT(0.997)PK 222,381 203,522 265,704 266,260 218,500 233,542
DPYL3_HUMAN 509 T 1 7.71E-07 GMYDGPVFDLTT(0.012)T(0.988)PK 54,818 51,412 65,501 65,832 56,817 48,645
DSG2_HUMAN 680 S 1 3.51E-10 VVPSFLPVDQGGS(1)LVGR 4,194 5,173 5,907 5,826 5,288 5,680
E41L3_HUMAN 760 S 2 0.000943 RLS(0.846)T(0.584)S(0.571)PVR 78,731 75,950 59,161 59,940 72,286 75,360
E41L3_HUMAN 761 T 2 0.000943 RLS(0.846)T(0.584)S(0.571)PVR 78,731 75,950 59,161 59,940 72,286 75,360
EEPD1_HUMAN 31 S 2 1.06E-07 KFS(1)AACNFS(1)NILVNQER 18,449 12,513 20,166 20,576 12,587 19,648
EF2_HUMAN 59 T 2 0.002624 FT(1)DT(1)RKDEQER 143,980 108,320 238,331 123,188 108,100 160,557
EHBP1_HUMAN 1058 S 1 2.04E-36 KPS(1)EDEVLNK 334,326 304,679 228,574 212,256 299,100 265,223
EHMT2_HUMAN 246 S 1 0.015166 S(1)GEVTLTK 66,102 66,957 34,060 31,201 49,315 54,710
EMAL1_HUMAN 140 S 2 0.034119 T(0.355)S(0.047)S(0.469)S(0.175)ERVS(0.953)PGGRR 6,351 6,306 8,053 7,554 6,596 8,117
EPHA3_HUMAN;sp 779;779;833 Y 1 3.00E-21 VLEDDPEAAY(0.972)T(0.023)T(0.005)R 95,178 85,883 69,496 67,226 69,048 84,171
ERC6L_HUMAN 949 Y 1 5.34E-17 LEEEPS(0.001)AS(0.074)S(0.417)PQY(0.508)ACDFNLFLEDSADNR 5,540 5,574 3,600 2,893 5,298 3,573
ERF_HUMAN 21 S 1 5.10E-09 TPADTGFAFPDWAYKPES(0.199)S(0.747)PGS(0.054)R 57,010 57,183 45,193 39,572 53,990 60,056
ERRFI_HUMAN 337 S 1 2.67E-19 S(0.884)LPS(0.113)Y(0.003)LNGVMPPTQSFAPDPK 12,362 13,505 10,024 10,502 10,652 13,054
EXO1_HUMAN 610 S 1 1.78E-31 SCFS(0.908)WS(0.092)GGLGDFSR 52,388 37,097 62,857 59,631 46,738 66,118
EXOC2_HUMAN 432 S 1 0.000679 GS(0.168)S(0.815)FQS(0.013)GRDDT(0.004)WR 9,417 11,449 12,723 12,993 10,617 11,760
F117B_HUMAN 220 S 1 2.26E-11 T(0.17)S(0.17)S(0.657)LDT(0.002)LAAPYLAGHWPR 4,824 3,912 5,409 5,895 3,761 5,171
FA13A_HUMAN 727 S 1 0.00078 LKIS(0.998)EEDLT(0.002)PR 32,332 31,472 23,761 23,853 27,570 28,292
FA21A_HUMAN;sp 352;352 S 1 2.53E-17 LT(0.001)DEDFS(0.998)PFGSGGGLFSGGK 38,709 37,359 30,066 26,253 33,202 30,709
FA83H_HUMAN 892 S 1 0.000116 RGS(0.991)PT(0.007)T(0.001)GFIEQK 115,300 110,729 79,500 78,691 97,851 95,036
FA83H_HUMAN 894 T 1 9.33E-05 RGS(0.205)PT(0.78)T(0.015)GFIEQK 36,682 34,510 18,165 17,396 32,892 31,446
GAREM_HUMAN 700 S 1 0.011144 S(0.055)AS(0.858)Y(0.02)S(0.062)LES(0.003)T(0.003)DVK 14,112 47,150 47,025 43,891 49,619 47,745
GRDN_HUMAN 1717 S 1 3.51E-09 SLS(0.003)VS(0.96)S(0.037)DFLGKDKPVSCGLAR 211,048 194,343 163,953 159,537 177,350 217,205
GRIN1_HUMAN 895 S 1 9.45E-05 VRPGS(1)ALAAAVAPPEPAEPVRDVSWDEK 26,190 26,143 20,616 20,512 28,031 26,835
GYS1_HUMAN 653 S 2 3.87E-06 HS(0.148)S(0.852)PHQS(1)EDEEDPR 10,284 13,660 10,288 9,019 13,082 10,076
GYS1_HUMAN 657 S 2 3.87E-06 HS(0.148)S(0.852)PHQS(1)EDEEDPR 10,284 13,660 10,288 9,019 13,082 10,076
H12_HUMAN 146 T 1 0.004791 KAAGGAT(1)PK 19,050 15,936 20,131 34,578 20,777 38,355
H14_HUMAN 187 S 1 0.000114 KAPKS(1)PAK 404,063 244,476 380,340 638,953 369,980 2,014,720
HACE1_HUMAN 385 S 1 7.41E-07 NKRDS(0.96)T(0.04)EITSILLK 108,599 98,344 75,385 68,637 90,925 90,461
HNRPK_HUMAN 118 T 1 1.94E-60 IIPTLEEGLQLPS(0.158)PT(0.645)AT(0.158)S(0.039)QLPLESDAVECLNYQHYK 17,637 16,685 13,178 12,778 14,173 12,898
HNRPK_HUMAN 116 S 1 1.47E-84 IIPTLEEGLQLPS(0.821)PT(0.174)AT(0.005)SQLPLESDAVECLNYQHYK 28,433 32,737 19,796 20,412 24,162 24,743
HSPB1_HUMAN 15 S 1 4.20E-06 GPS(1)WDPFR 65,407 51,906 49,834 42,992 49,387 36,667
HUWE1_HUMAN 1905 T 2 4.10E-21 IALPAPRGS(0.99)GT(0.912)AS(0.098)DDEFENLR 45,217 45,354 37,048 33,691 45,788 46,295
IASPP_HUMAN 282 S 1 4.95E-11 LDVFARPAS(0.397)PS(0.603)LQLLPWR 9,090 10,107 8,351 5,918 9,532 8,110
ICAL_HUMAN 366 S 1 1.86E-31 S(0.001)ES(0.999)ELIDELSEDFDRSECK 75,387 66,160 48,217 40,245 63,925 56,271
IF16_HUMAN 779 T 1 6.83E-07 DILNPDS(0.055)S(0.297)MET(0.565)S(0.084)PDFFF 4,201 4,448 6,030 4,872 4,421 5,721
IF4B_HUMAN 425 S 3 1.53E-07 S(0.412)RT(0.583)GS(0.452)ES(0.614)S(0.925)QT(0.013)GT(0.001)S(0.001)TTSSR 37,855 38,913 30,284 29,087 40,021 32,920
IF4B_HUMAN 420 T 2;3 9.94E-11 S(0.215)RT(0.83)GS(0.844)ES(0.313)S(0.727)QT(0.062)GT(0.007)S(0.002)T(0.001)TSSR 81,571 82,645 64,532 65,535 89,332 72,016
IF4B_HUMAN 418 S 2 9.94E-11 ERS(0.832)RT(0.55)GS(0.55)ES(0.056)S(0.007)QT(0.003)GT(0.001)STTSSR 15,689 15,392 12,801 12,228 16,655 12,993
IF4G1_HUMAN 1145 S 2 0.00535 VVQRS(0.202)S(0.802)LS(0.996)RER 34,148 34,137 24,773 26,481 27,552 32,851
IF4G1_HUMAN 1185 S 1 4.43E-05 S(1)FSKEVEER 274,413 290,221 124,779 122,094 154,090 149,415
IF4G1_HUMAN 1209 S 1 1.27E-06 KAAS(0.982)LT(0.018)EDRDR 253,508 256,749 169,760 174,909 188,330 177,406
IF4G1_HUMAN 1211 T 1 1.68E-10 AAS(0.001)LT(0.999)EDRDR 329,114 342,510 222,272 234,927 254,550 235,285
IF4G1_HUMAN 1231 S 1 2.99E-12 EAALPPVS(1)PLK 161,975 151,842 124,770 127,926 155,310 150,881
IF4G1_HUMAN 1092 S 1 2.01E-19 ITKPGSIDSNNQLFAPGGRLS(1)WGK 320,711 323,477 212,409 199,210 240,120 238,319
K0100_HUMAN 937 S 2 0.007789 KIEELY(1)AS(1)LER 6,542 7,641 5,471 5,602 6,555 6,010
K0100_HUMAN 935 Y 2 0.007789 KIEELY(1)AS(1)LER 6,542 7,641 5,471 5,602 6,555 6,010
K0754_HUMAN 442 S 1 0.009354 DTSTVSKEECEKVPFS(0.999)PR 27,639 26,755 20,220 20,838 25,768 25,673
K0907_HUMAN 571 S 2 1.39E-38 GFGLVAYAADS(1)S(1)DEEEEHGGHK 41,479 35,893 25,796 31,352 33,752 29,371
K0907_HUMAN 572 S 1;2 1.39E-38 GFGLVAYAADS(1)S(1)DEEEEHGGHK 47,516 41,019 31,939 36,975 39,748 34,516
K0930_HUMAN 358 S 2 0.00057 S(1)LVGS(1)WLK 23,616 24,464 27,875 32,084 21,381 32,933
K1614_HUMAN 1107 S 1 9.83E-08 RALS(1)VEDVGAPSLAR 76,803 131,534 136,608 129,212 132,290 132,371
K1671_HUMAN 508 S 1 0.000174 TFQARPLS(0.998)ADLT(0.001)K 55,183 48,479 42,339 35,555 49,251 45,238
KAPCA_HUMAN;sp 202;202;202 T 1 2.42E-05 T(0.016)WT(0.083)LCGT(0.694)PEY(0.207)LAPEIILSK 23,637 21,359 27,814 28,235 21,556 36,270
KCC2D_HUMAN;sp 287;286 T 1 0.006372 QET(1)VDCLKK 34,363 25,271 34,755 38,185 23,796 43,852
KI67_HUMAN 2002 S 1 0.00679 LKIS(1)LGK 79,709 70,403 6,684 2,445 47,049 52,846
KI67_HUMAN 1636 S 1 0.002088 LKT(0.054)S(0.946)LGK 133,024 134,309 37,879 35,971 100,780 122,542
KI67_HUMAN 1193 T 1 0.000179 AFMGT(1)PVQK 32,069 36,725 25,403 30,650 24,576 35,451
KI67_HUMAN 1937 S 1 0.00013 LDLLGNLPGS(1)KR 9,072 9,196 5,850 9,142 8,237 10,420
KI67_HUMAN 1764 T 1 9.91E-17 KADT(1)EEEFLAFRK 102,101 73,138 134,236 144,016 81,105 161,366
KIF4A_HUMAN 810 S 1 0.000245 GQVS(0.991)ES(0.009)EDSITK 38,862 37,411 31,807 28,154 41,107 28,401
KPCD3_HUMAN;sp 735;742 S 1 2.40E-07 S(0.999)VVGT(0.001)PAYLAPEVLR 51,096 61,014 41,316 44,731 54,124 56,498
KS6A4_HUMAN 687 T 2 7.48E-05 S(0.484)S(0.526)PPLRT(0.826)PDVLES(0.126)S(0.037)GPAVR 26,894 30,554 22,564 22,004 25,896 24,902
KS6B1_HUMAN 427 S 1 0.005497 EKFS(1)FEPK 63,424 57,702 43,506 46,818 56,848 64,441
LAP2A_HUMAN 433 S 1 0.012341 KVPRLS(1)EK 51,438 53,086 26,961 27,323 39,949 48,209
LAP2A_HUMAN 272 S 1 1.73E-07 LAS(1)ERNLFISCK 44,442 23,167 44,038 50,472 27,256 93,046
LAP2A_HUMAN;sp 156;156 S 1;2 1.14E-05 LREQGTES(1)R 110,301 103,932 125,118 147,414 101,000 148,032
LARP1_HUMAN 1056 S 1 1.22E-11 CPS(0.782)QS(0.073)S(0.073)S(0.073)RPAAMISQPPTPPTGQPVREDAK 73,841 75,920 56,969 60,358 67,322 94,481
LIMA1_HUMAN 225 S 1 1.92E-34 KIS(0.995)ENS(0.005)YSLDDLEIGPGQLSSSTFDSEKNESR 30,395 33,917 22,468 21,440 28,050 31,966
LIMD1_HUMAN 233 S 1 0.003451 QLS(0.99)LS(0.01)SSR 22,120 18,883 25,278 26,674 20,202 28,343
LMO7_HUMAN 926 S 1 0.006915 GIS(0.079)S(0.921)LPR 22,795 22,319 26,712 30,066 21,884 27,798
LR16A_HUMAN 1331 S 1 9.73E-08 S(1)WGQQAQEYQEQK 60,903 61,439 42,670 39,210 53,534 55,326
LR16A_HUMAN 967 S 1 2.09E-22 S(0.5)S(0.5)GFISELPSEEGK 48,374 43,119 27,789 28,886 44,084 45,203
LR16A_HUMAN 968 S 1 1.53E-112 S(0.205)S(0.795)GFISELPSEEGK 101,386 95,071 65,093 57,551 97,768 94,504
LRC45_HUMAN 337 S 1 3.06E-08 AQDLGELLATAEQEQLS(0.014)LS(0.986)QR 5,151 3,985 7,113 4,901 5,719 2,990  
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MAP1B_HUMAN 1276 S 2 1.36E-06 S(1)VNFS(0.003)LT(0.997)PNEIK 58,793 57,273 70,572 89,260 54,712 63,907
MAP1B_HUMAN 1282 T 1;2 1.05E-06 SVNFS(0.001)LT(0.999)PNEIK 78,379 79,672 91,840 109,788 74,998 82,147
MAP1B_HUMAN 1797 S 1;2 2.89E-46 ES(0.164)S(0.836)PLYS(1)PTFSDSTSAVK 1,650,308 1,646,217 1,272,865 1,296,837 1,535,100 1,517,113
MAP1B_HUMAN 1396 S 1;2 1.82E-112 VLS(1)PLRS(1)PPLIGSESAYESFLSADDKASGR 1,624,104 1,677,720 1,313,325 1,293,407 1,598,800 1,368,292
MAP1B_HUMAN 1400 S 1;2 1.82E-112 VLS(1)PLRS(1)PPLIGSESAYESFLSADDKASGR 1,962,346 2,029,691 1,628,299 1,589,371 1,949,800 1,698,014
MAP4_HUMAN 643 S 1 1.32E-06 KCS(0.255)LPAEEDS(0.745)VLEK 20,397 21,487 16,482 16,670 20,612 16,434
MARCS_HUMAN 163 S 2 0.002152 S(1)FKLS(0.999)GFS(0.001)FK 13,790 9,405 17,464 18,650 8,785 21,080
MATR3_HUMAN 195 S 2 0.00101 RDS(0.273)FDDRGPS(0.727)LNPVLDY(0.001)DHGS(0.999)R 7,618 8,244 7,386 5,433 7,877 7,024
MAZ_HUMAN 302 S 1 9.08E-13 LS(0.001)HS(0.999)DEKPYQCPVCQQR 42,873 47,884 56,024 55,559 46,524 46,059
MBD3_HUMAN 56 S 1 4.51E-08 YLGGS(0.808)MDLS(0.19)T(0.003)FDFR 26,561 15,632 27,436 30,297 19,376 37,476
MCM4_HUMAN 31 S 2 0.000922 SEDARS(0.984)S(0.602)PS(0.413)QR 4,952 4,694 5,388 6,743 6,863 10,887
MCM4_HUMAN 32 S 2 0.000922 SEDARS(0.984)S(0.602)PS(0.413)QR 4,952 4,694 5,388 6,743 6,863 10,887
MCM4_HUMAN 34 S 2 0.000922 S(0.006)EDARS(0.895)S(0.549)PS(0.549)QR 1,499 1,618 1,770 2,456 2,275 3,361
MDC1_HUMAN 1797 S 1 0.005972 S(0.5)RFT(0.5)PELQPK 19,967 16,725 22,410 23,816 17,167 22,475
MDC1_HUMAN 1800 T 1 0.005972 S(0.5)RFT(0.5)PELQPK 19,967 16,725 22,410 23,816 17,167 22,475
MIMIT_HUMAN 134 S 1 8.07E-14 GHAS(1)APYFGKEEPSVAPSSTGK 18,654 21,492 26,321 28,246 20,984 23,928
MKRN2_HUMAN 139 S 1 9.85E-06 KTQPSMVSNPGS(0.003)CS(0.003)DPQPS(0.924)PEMKPHS(0.059)Y(0.01)LDAIR 24,309 26,679 20,832 19,220 25,909 23,416
MOES_HUMAN 384 S 1 0.000256 AQS(1)EAEKLAK 42,695 40,884 30,220 28,674 40,442 43,886
MON2_HUMAN 205 S 1 0.001047 S(0.978)VS(0.008)T(0.014)LKPCAK 68,130 66,666 20,248 18,054 55,392 49,581
MORC2_HUMAN 739 S 2 9.89E-05 KRS(1)VAVS(1)DEEEVEEEAER 62,354 47,464 46,385 37,607 57,909 59,930
MPIP3_HUMAN 168 S 1 0.014598 YLGS(0.635)PIT(0.293)T(0.071)VPK 7,540 8,289 5,585 6,676 5,594 6,786
MPZL1_HUMAN 221 S 1 0.000184 KS(0.016)PS(0.969)DT(0.015)EGLVK 86,645 81,362 64,979 68,391 78,551 79,541
MPZL1_HUMAN 263 Y 1 7.28E-05 SESVVY(1)ADIR 38,209 36,569 31,392 28,751 33,276 30,723
MTCL1_HUMAN 1514 S 1 0.02472 VLHS(1)PPAVR 89,027 97,265 58,809 61,387 84,798 76,154
MTMRE_HUMAN 529 S 1 0.001685 MGS(0.5)S(0.5)PLEVPKPR 18,062 17,020 12,015 14,213 14,749 16,247
MTMRE_HUMAN 530 S 1 0.001685 MGS(0.5)S(0.5)PLEVPKPR 18,062 17,020 12,015 14,213 14,749 16,247
MTUS1_HUMAN 1224 S 1 7.88E-05 RLS(1)MENEELLWK 8,090 8,432 4,796 6,172 5,686 6,179
MYCB2_HUMAN 2645 T 1 0.000941 HEDEQALLDQNS(0.212)QT(0.738)PPPS(0.019)PFS(0.03)VQAFNK 13,990 13,114 10,217 11,090 13,017 12,901
NAA30_HUMAN 199 S 1 2.35E-21 LLSSSLTADCS(0.033)LRS(0.858)PS(0.109)GR 48,010 49,469 37,883 37,414 47,393 46,610
NAMPT_HUMAN 472 S 1 1.10E-07 S(0.001)YS(0.999)FDEIRK 142,491 154,233 134,023 105,940 168,240 99,074
NCBP1_HUMAN 27 T 1 0.000258 RKT(0.15)S(0.114)DANET(0.736)EDHLESLICK 45,164 32,464 41,078 22,857 34,935 39,446
NCBP1_HUMAN 7 S 1 4.68E-05 RRHS(1)DENDGGQPHK 61,880 58,535 34,969 37,142 52,092 56,065
NCBP1_HUMAN 21 T 1 5.41E-27 KT(0.5)S(0.5)DANETEDHLESLICK 8,701 8,712 5,318 4,174 7,914 9,420
NCBP1_HUMAN 22 S 1 5.41E-27 KT(0.229)S(0.767)DANET(0.004)EDHLESLICK 73,173 67,872 50,765 45,122 65,567 68,166
NCOA1_HUMAN 698 S 1 4.95E-08 LLQEGS(0.959)PS(0.041)DITTLSVEPDKK 7,605 7,680 6,191 6,027 5,742 6,653
NEB1_HUMAN 338 S 1 4.92E-26 S(0.003)EIPS(0.994)PQS(0.003)QLLEDAEANLVGR 7,250 9,660 6,283 7,372 8,693 6,706
NELFB_HUMAN 557 S 1 3.99E-29 KPS(1)PAQAAETPALELPLPSVPAPAPL 8,018 11,255 7,144 8,018 8,523 7,712
NFIL3_HUMAN 301 S 1 8.39E-05 GPIHS(1)PVELK 39,097 32,246 28,735 28,194 33,942 31,952
NIBL1_HUMAN 692 S 2 4.28E-17 AAPEAS(0.149)S(0.851)PPAS(1)PLQHLLPGK 131,168 133,681 102,662 102,668 124,430 125,473
NIBL1_HUMAN 696 S 2 4.28E-17 AAPEAS(0.149)S(0.851)PPAS(1)PLQHLLPGK 131,168 133,681 102,662 102,668 124,430 125,473
NONO_HUMAN 118 T 1 0.004147 LET(0.5)RT(0.5)LAEIAK 10,883 9,064 7,031 7,329 10,628 9,963
NONO_HUMAN 120 T 1 0.004147 LET(0.5)RT(0.5)LAEIAK 10,883 9,064 7,031 7,329 10,628 9,963
NOP9_HUMAN 7 S 1 0.002436 GQGPRS(1)PHK 41,204 35,824 44,726 55,302 45,161 61,726
NU153_HUMAN 192 S 1 0.00111 AS(1)DKDITVSK 48,047 59,284 46,191 38,595 50,322 33,277
NU214_HUMAN 433 S 2 0.001391 S(0.16)PGS(0.541)T(0.252)PT(0.06)T(0.831)PT(0.111)S(0.032)S(0.012)QAPQK 10,698 11,425 9,342 8,560 11,384 9,963
NU214_HUMAN 430 S 2 0.00115 S(0.594)PGS(0.289)T(0.114)PT(0.052)T(0.905)PT(0.03)S(0.011)S(0.005)QAPQK 14,108 13,522 10,451 11,390 14,026 10,991
NU214_HUMAN 437 T 2 0.00115 S(0.594)PGS(0.289)T(0.114)PT(0.052)T(0.905)PT(0.03)S(0.011)S(0.005)QAPQK 24,807 24,946 19,794 19,950 25,411 20,954
NUCKS_HUMAN 50 S 1;2;3 1.12E-13 S(1)GKNSQEDSEDSEDKDVK 311,428 352,739 194,598 189,434 300,930 271,967
NUCL_HUMAN 99 T 1 0.014189 KT(0.002)VT(0.998)PAK 52,362 44,899 53,441 79,709 48,523 92,041
NUCL_HUMAN 105 T 1 0.003994 AVT(0.892)T(0.108)PGKK 46,622 41,218 44,373 65,987 37,131 64,657
NUCL_HUMAN 106 T 1 0.001627 AVT(0.028)T(0.972)PGKK 50,114 44,179 47,450 76,601 41,560 78,936
NUFP2_HUMAN 629 S 1 3.22E-59 ADTSSQGALVFLSKDYEIESQNPLAS(0.991)PT(0.009)NT(0.001)LLGSAK 59,939 58,628 43,797 44,396 51,036 57,482
NUMB_HUMAN 194 S 1 0.000941 EGS(0.993)FRVT(0.002)T(0.002)AT(0.002)EQAEREEIMK 98,243 84,789 114,442 114,033 95,325 124,632
NUP50_HUMAN 246 T 1 3.72E-30 LQQESTFLFHGNKT(0.043)EDT(0.957)PDKK 16,583 21,976 25,378 25,595 20,041 19,823
ODPA_HUMAN;sp 295;293 S 2 3.64E-11 YHGHS(0.325)MS(0.675)DPGVS(1)YR 46,510 37,119 57,598 49,309 39,707 54,139
P3C2A_HUMAN 259 S 1 7.33E-05 VSNLQVS(1)PK 17,773 18,262 12,473 12,320 16,288 15,319
PAK1_HUMAN 144 S 1 8.21E-13 YMS(0.956)FT(0.043)DKS(0.001)AEDYNSSNALNVK 237,205 192,871 165,424 158,755 192,930 236,996
PAK1_HUMAN 146 T 1 3.68E-17 YMS(0.194)FT(0.806)DK 90,308 69,223 64,691 56,083 81,877 84,163
PAK2_HUMAN 141 S 1 1.40E-38 YLS(0.99)FT(0.01)PPEKDGFPSGTPALNAK 1,123,896 961,122 725,562 662,150 923,620 1,076,697
PALLD_HUMAN 893 S 1 1.41E-17 IAS(1)DEEIQGTKDAVIQDLER 43,267 33,940 20,704 23,964 35,522 37,559
PAR10_HUMAN 431 S 1 0.003328 AGPVS(1)PGCVK 111,577 102,310 90,303 81,287 96,373 93,072
PAWR_HUMAN 162 S 1 9.82E-14 S(0.812)T(0.188)GVVNIPAAECLDEYEDDEAGQKER 38,724 35,397 29,822 30,389 31,647 33,408
PB1_HUMAN 681 S 1 0.00173 RLS(1)AIFLR 8,849 10,107 9,080 6,248 9,600 7,758
PCM1_HUMAN 1435 S 1 4.97E-07 HIS(0.982)ES(0.018)HEKGENVK 45,490 43,906 32,766 29,370 44,652 50,127
PDE4A_HUMAN 13 S 1 0.000702 S(0.009)LS(0.983)LS(0.009)LPGPR 11,280 9,005 12,836 13,319 8,422 14,639
PERQ2_HUMAN 201 S 1 0.006105 S(0.002)ES(0.998)ENWR 180,937 145,870 199,593 204,109 150,760 193,641
PHF2_HUMAN 705 S 1 4.37E-05 RDLS(1)FLLDKK 86,221 59,708 88,971 102,327 69,795 120,717
PHIP_HUMAN 1315 S 1 5.04E-05 AQS(1)YDIQAWKK 109,266 90,093 71,200 70,083 88,131 94,437
PJA1_HUMAN 265 S 1 9.12E-06 NLAS(1)PNCVKPK 170,059 165,137 128,729 141,111 161,730 180,451
PJA2_HUMAN 323 S 1 2.23E-06 KLIS(0.762)S(0.19)S(0.048)QVDQETGFNRHEAK 5,357 4,487 6,530 5,758 4,824 7,855
PLCL2_HUMAN 1113 S 1 1.88E-07 S(1)LEVIPEKANDETGE 96,532 91,954 77,027 73,368 95,490 91,211
PLXA4_HUMAN 426 T 1 0.005153 GIPVFT(1)EDRDR 57,189 57,021 40,051 42,096 48,157 42,501
PP12C_HUMAN 427 S 1 0.009643 T(0.086)GS(0.828)S(0.086)GALGPPER 19,006 14,560 22,855 20,585 14,564 24,468
PPR3F_HUMAN 14 S 2 0.001168 T(0.011)APVEPPLRHS(0.99)APPS(1)PAAGEPR 6,242 4,604 3,547 4,964 4,102 4,296
PPR3F_HUMAN 18 S 2 0.001168 T(0.011)APVEPPLRHS(0.99)APPS(1)PAAGEPR 6,242 4,604 3,547 4,964 4,102 4,296
PRDX2_HUMAN 112 S 1 2.86E-06 RLS(1)EDYGVLK 77,482 90,278 71,982 55,561 93,336 58,759
PRR36_HUMAN 1310 S 1 3.51E-15 WAELLS(1)PLDESR 24,607 25,260 14,768 15,867 19,164 20,190  
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PRS6B_HUMAN 28 S 1 7.71E-06 AQDEIPALS(0.011)VS(0.009)RPQT(0.136)GLS(0.843)FLGPEPEDLEDLY(0.001)SR 9,593 7,996 11,001 11,144 9,970 10,474
PSD11_HUMAN 14 S 1 9.80E-07 AQS(0.987)LLS(0.005)T(0.005)DREAS(0.002)IDILHSIVKR 33,764 25,561 38,544 34,844 33,105 43,208
PTN12_HUMAN 573 T 2 7.21E-07 KT(0.003)VS(0.009)LT(0.082)PS(0.344)PT(0.507)T(0.054)QVET(0.001)PDLVDHDNT(0.571)S(0.428)PLFR5,923 6,219 4,758 3,865 5,531 6,417
PTN12_HUMAN 454 T 1 4.10E-17 KVPLQEGPKS(0.155)FDGNT(0.845)LLNR 17,840 14,032 19,835 22,769 16,576 22,704
PTTG_HUMAN 174 Y 1 0.000138 YGLFKEENPY(1)AR 56,010 41,543 35,204 34,881 39,191 43,598
RAB8A_HUMAN 181 S 2 3.84E-05 KLEGNS(1)PQGS(1)NQGVK 27,526 26,446 32,369 35,690 27,060 22,154
RADIL_HUMAN 216 S 1 5.35E-09 RT(0.194)VS(0.618)ET(0.063)S(0.063)LS(0.063)PVNALPAAAQGPEEPGPDAMR 13,901 15,871 11,405 12,272 13,769 14,610
RBBP6_HUMAN 1500 S 1 0.029606 RKDS(0.992)PS(0.008)R 2,449 2,098 3,295 3,845 2,994 7,248
RBM12_HUMAN 413 S 1 0.020036 S(0.022)KS(0.805)PS(0.173)GQKR 30,323 18,558 33,255 37,599 35,872 80,622
RBM3_HUMAN 147 S 1 6.75E-17 NQGGYDRYS(1)GGNYRDNYDN 88,297 86,376 56,840 57,292 74,822 77,616
RBP2_HUMAN 1128 S 1 1.42E-07 S(1)DDMFTFHGPGK 21,715 25,059 17,017 16,671 22,292 18,163
RD23B_HUMAN 160 S 1 3.30E-30 QEKPAEKPAETPVAT(0.015)S(0.981)PT(0.004)ATDSTSGDSSR 163,426 180,458 128,893 131,624 152,850 143,563
RFA1_HUMAN 384 S 1 0.014576 VS(1)DFGGR 25,307 27,634 11,126 12,013 17,788 16,911
RFC1_HUMAN 552 S 1 1.01E-07 ET(0.003)DVFWKS(0.997)LDFKEQVAEETSGDSK 46,711 33,389 47,572 49,973 37,399 70,941
RHG05_HUMAN 1195 S 1 5.79E-11 HRGS(1)EEDPLLSPVETWK 123,848 130,456 100,106 98,323 117,140 118,749
RHG21_HUMAN 924 S 1 1.73E-05 KDS(0.22)S(0.587)S(0.193)EVFSDAAK 33,779 28,512 26,287 21,638 28,883 29,801
RHGBA_HUMAN 1004 S 1 0.007211 AWYKGS(1)PK 28,493 26,545 33,858 38,256 27,814 36,715
RIF1_HUMAN 1542 S 1 1.03E-06 RAS(0.999)QGLLS(0.001)SIENSESDSSEAKEEGSR 17,260 16,727 24,333 19,995 19,234 20,306
RL13_HUMAN 77 S 1 0.001848 GFS(1)LEELR 13,026 12,111 9,370 8,724 11,916 8,842
RL34_HUMAN 12 S 1 7.02E-05 RLS(0.953)Y(0.001)NT(0.038)AS(0.008)NK 80,272 65,987 46,804 60,963 67,965 53,053
RMXL1_HUMAN 161 S 1 0.019801 S(0.001)GGPS(0.999)PKR 28,971 23,431 31,644 33,519 31,839 46,004
RPA43_HUMAN 316 S 1;2 2.84E-10 KHS(1)EEAEFT(0.039)PPLKCS(0.961)PK 286,297 277,292 229,396 215,482 242,650 257,382
RPB1_HUMAN 1843 S 3 1.66E-07 YT(0.028)PT(0.15)S(0.561)PS(0.275)Y(0.005)S(0.06)PS(0.22)S(0.696)PEY(0.004)T(0.011)PT(0.634)S(0.356)PK13,950 11,880 8,659 10,643 11,088 10,654
RPB1_HUMAN 1850 S 3 1.66E-07 YT(0.028)PT(0.15)S(0.561)PS(0.275)Y(0.005)S(0.06)PS(0.22)S(0.696)PEY(0.004)T(0.011)PT(0.634)S(0.356)PK13,950 11,880 8,659 10,643 11,088 10,654
RPB1_HUMAN 1856 T 3 1.66E-07 YT(0.028)PT(0.15)S(0.561)PS(0.275)Y(0.005)S(0.06)PS(0.22)S(0.696)PEY(0.004)T(0.011)PT(0.634)S(0.356)PK13,950 11,880 8,659 10,643 11,088 10,654
RPP30_HUMAN 251 S 1 1.78E-07 KPRPS(1)EGDEDCLPASK 106,298 101,906 80,234 80,303 95,921 101,261
RTF1_HUMAN 697 S 1 1.09E-05 S(1)LNLEDYKK 346,819 400,406 98,925 99,649 274,520 281,950
RTN3_HUMAN 560 S 1 1.28E-26 NFEELVS(0.986)DS(0.014)ELHQDQPDILGR 22,415 21,641 27,308 28,160 25,817 25,568
RU17_HUMAN 268 S 1 0.003487 S(1)RDKEER 50,711 40,835 53,533 71,134 62,749 115,213
S39AE_HUMAN 311 S 1 1.27E-13 VIVGS(0.028)LS(0.972)VQDLQASQSACYWLK 14,008 14,455 10,528 12,325 12,838 12,968
SASH1_HUMAN 813 S 1 0.001952 S(1)LPVSICR 34,531 33,352 23,456 23,642 31,755 30,937
SCG2_HUMAN 259 S 2 0.000476 IES(0.966)QT(0.053)QEEVRDS(0.981)KENIEK 61,311 70,020 95,601 83,861 77,015 62,983
SCG2_HUMAN 227 T 2 9.91E-05 ERMDEEQKLY(0.062)T(1)DDEDDIY(0.938)K 38,580 37,414 47,765 50,624 43,967 40,867
SCRIB_HUMAN 1298 S 3 0.001026 MAES(0.075)PCS(0.562)PS(0.562)GQQPPS(0.848)PPS(0.954)PDELPANVK 6,366 6,014 4,198 4,525 4,410 3,771
SCRIB_HUMAN 1300 S 3 0.001026 MAES(0.075)PCS(0.562)PS(0.562)GQQPPS(0.848)PPS(0.954)PDELPANVK 6,366 6,014 4,198 4,525 4,410 3,771
SCRIB_HUMAN 1306 S 3 0.001026 MAES(0.075)PCS(0.562)PS(0.562)GQQPPS(0.848)PPS(0.954)PDELPANVK 6,366 6,014 4,198 4,525 4,410 3,771
SCRIB_HUMAN 1309 S 3 0.001026 MAES(0.075)PCS(0.562)PS(0.562)GQQPPS(0.848)PPS(0.954)PDELPANVK 6,366 6,014 4,198 4,525 4,410 3,771
SCRIB_HUMAN 1508 S 1 0.000595 MKS(1)LEQDALR 50,358 49,357 40,054 38,888 47,636 51,326
SF3B1_HUMAN 229 S 2 4.39E-06 KLSSWDQAET(1)PGHT(0.256)PS(0.744)LR 9,894 11,324 12,510 13,574 10,231 13,434
SFPQ_HUMAN 496 S 1 5.37E-05 WKS(1)LDEMEK 52,579 55,708 44,276 38,556 56,454 36,392
SGTA_HUMAN 305 S 1;2 7.63E-15 SRT(0.005)PS(0.99)AS(0.005)NDDQQE 215,922 206,241 150,808 159,902 219,980 199,279
SH3K1_HUMAN 230 S 1 1.29E-15 S(1)IEVENDFLPVEK 130,278 115,323 90,317 82,213 116,660 108,602
SHRM3_HUMAN 1490 S 2 1.79E-13 IS(0.796)ES(0.277)VLRDS(0.927)PPPHEDYEDEVFVRDPHPK 13,703 10,665 10,964 8,830 10,097 12,609
SLK_HUMAN 347 S 1 7.87E-22 ASSDLSIAS(0.5)S(0.5)EEDKLSQNACILESVSEKTER 23,335 27,516 31,117 31,190 28,029 28,366
SLK_HUMAN 348 S 1 7.87E-22 ASSDLSIAS(0.5)S(0.5)EEDKLSQNACILESVSEKTER 23,335 27,516 31,117 31,190 28,029 28,366
SMCA4_HUMAN 1417 S 1 7.78E-10 KRDS(1)DAGSSTPTTSTR 43,819 42,932 26,461 28,641 37,975 39,725
SMCR8_HUMAN 400 S 1 0.000232 QES(0.001)IPS(0.011)KPS(0.031)QDRPPS(0.781)S(0.088)S(0.088)LEECPIPK 20,544 21,520 16,517 15,680 18,574 17,616
SMRCD_HUMAN 79 S 1 0.000578 KAS(0.998)IS(0.002)YFK 44,483 41,966 57,644 58,718 45,409 53,773
SMRCD_HUMAN 81 S 1 0.000486 KAS(0.297)IS(0.703)YFK 21,919 17,896 27,145 25,555 24,972 25,995
SNX17_HUMAN 440 S 1 0.000128 LSSKLS(0.058)AVS(0.942)LR 70,167 52,009 70,445 81,160 55,901 71,097
SPB1_HUMAN 639 S 1 0.000602 S(0.572)RGPKS(0.428)DDDGFEIVPIEDPAK 15,906 13,137 20,995 16,092 14,812 15,758
SPIR2_HUMAN 371 S 1 0.000168 GFGS(1)LPCILNACSGDAK 7,734 7,879 10,572 9,869 8,417 10,833
SQSTM_HUMAN 249 S 1 2.89E-22 NVGESVAAALS(1)PLGIEVDIDVEHGGKR 11,350 11,404 7,414 9,086 7,343 7,649
SRBS1_HUMAN 484 S 1 0.000141 S(0.018)KS(0.127)EMS(0.852)Y(0.003)IDGEK 32,361 27,584 21,680 22,472 25,049 26,132
SRBS1_HUMAN 481 S 1 0.000133 S(0.254)KS(0.745)EMSYIDGEK 30,311 31,963 24,525 21,547 23,272 26,018
SRC8_HUMAN 261 S 1 0.00047 LQLHES(1)QKDYK 76,723 71,050 94,743 88,394 76,968 94,445
SRC8_HUMAN 399 T 2;3 1.11E-10 AKT(0.535)QT(0.535)PPVS(0.93)PAPQPT(0.208)EERLPS(0.413)S(0.377)PVY(0.003)EDAASFK 53,204 52,376 44,765 41,163 52,564 50,246
SRC8_HUMAN 411 T 1;3 2.10E-13 T(0.067)QT(0.907)PPVS(0.134)PAPQPT(0.883)EERLPS(0.481)S(0.439)PVY(0.087)EDAAS(0.002)FK 69,808 62,842 49,356 50,512 63,908 60,618
SRC8_HUMAN 447 S 1 8.89E-17 GPVSGTEPEPVYS(1)MEAADYR 49,360 55,966 68,947 61,352 56,881 51,928
SRC8_HUMAN 417 S 1;2;3 4.22E-43 TQTPPVSPAPQPT(0.005)EERLPS(0.773)S(0.222)PVYEDAASFKAELSYR 509,336 500,719 383,437 388,044 462,330 462,401
SRC8_HUMAN 405 S 2;3 4.22E-43 AKT(0.211)QT(0.789)PPVS(1)PAPQPT(0.002)EERLPS(0.607)S(0.39)PVYEDAASFK 731,640 711,226 588,741 579,289 676,190 674,706
SRP54_HUMAN 16 S 1 2.70E-08 S(0.548)LS(0.451)NAT(0.001)IINEEVLNAMLK 9,199 5,741 9,455 10,209 6,343 8,777
SRRM1_HUMAN 541 S 1 0.008783 QKET(0.01)S(0.99)PR 104,248 95,071 114,132 156,354 130,170 277,594
SRRM2_HUMAN 1093 S 1 0.017986 S(0.016)QT(0.054)S(0.93)PKGGR 21,382 15,041 20,029 25,257 20,966 52,805
SRRM2_HUMAN 2729 S 2 0.000343 GDS(0.786)RS(0.607)PS(0.607)HKR 55,121 41,034 58,701 63,085 64,429 133,898
SRRM2_HUMAN 2727 S 2 0.000343 GDS(0.981)RS(0.407)PS(0.612)HKR 129,398 92,735 132,697 150,201 142,720 306,877
SRRM2_HUMAN 2731 S 2 0.000343 GDS(0.942)RS(0.071)PS(0.988)HKR 129,398 92,735 132,697 150,201 142,720 306,877
SRRM2_HUMAN 2272 S 1 9.15E-07 TPAAAAAMNLAS(1)PR 5,471 6,170 4,942 4,182 4,671 5,832
SRRM2_HUMAN 1008 S 2 2.57E-07 VKAQT(0.398)PPGPS(0.602)LS(0.01)GS(0.543)KS(0.447)PCPQEK 8,399 9,349 7,229 6,743 7,661 8,261
SSFA2_HUMAN 737 S 2 6.39E-06 S(0.998)QS(0.95)LPT(0.041)T(0.011)LLSPVR 32,814 28,526 37,331 37,881 31,717 37,570
STAU2_HUMAN 440 S 1 6.36E-05 VISGTTLGY(0.106)LS(0.894)PK 6,498 6,334 4,528 5,575 5,604 4,576
STMN1_HUMAN 63 S 1 1.88E-13 S(1)HEAEVLK 1,836,738 1,992,281 1,275,284 1,381,843 1,595,500 1,447,007
STMN1_HUMAN 25 S 1;2 3.91E-40 RAS(1)GQAFELILS(1)PR 1,668,100 1,579,273 957,969 1,038,488 1,355,900 1,392,993
STMN1_HUMAN 16 S 1;2 1.33E-52 RAS(1)GQAFELILS(1)PR 2,811,529 2,449,918 1,938,916 1,766,027 2,397,900 2,291,556  
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STMN1_HUMAN;sp 46;80 S 1 4.41E-09 DLS(1)LEEIQKK 422,261 394,987 265,908 253,954 325,470 321,379
SUN2_HUMAN 12 S 1;2 2.95E-30 LT(0.014)RYS(0.986)QGDDDGSSSSGGSSVAGSQSTLFK 133,015 131,947 106,969 108,148 133,600 147,745
SYNE1_HUMAN 8223 S 1 0.001483 LPLPDDEHDLS(0.929)DRELELEDS(0.062)AALS(0.01)DLHWHDR 7,853 7,976 5,670 6,871 5,433 7,370
SYNPO_HUMAN 263 S 1 7.05E-05 HLEKVAS(1)EEEEVPLVVYLK 8,335 8,576 11,561 10,827 9,019 9,945
TAB2_HUMAN 582 S 1 0.00014 S(0.197)NS(0.71)IS(0.093)QIPSLEEMQQLR 5,414 5,445 6,257 7,323 5,613 5,570
TANC2_HUMAN 1722 S 1 5.21E-05 S(0.204)QS(0.738)AS(0.057)YYPVCHSK 17,598 14,803 18,910 21,562 19,780 27,879
TB182_HUMAN 983 S 1 7.73E-15 S(0.001)FGT(0.003)RPLS(0.761)S(0.216)GFS(0.018)PEEAQQQDEEFEK 44,825 38,844 34,259 33,215 37,581 38,603
TBB4A_HUMAN;sp 172;172;172;172 S 1 0.000864 IMNT(0.002)FS(0.136)VVPS(0.863)PK 4,894 3,357 2,779 3,134 3,170 2,379
TDRD3_HUMAN 256 S 1 5.15E-47 IRS(1)EDEEDLGNARPSAPSTLFDFLESK 38,615 30,629 27,013 24,465 31,945 31,528
TF3C1_HUMAN 1632 S 1 0.000288 S(0.999)MEVKPAQASHTNYLLMR 39,569 42,131 24,725 26,813 35,032 35,703
TIF1A_HUMAN 1042 S 1 0.001733 LKS(1)IEER 91,778 97,284 67,979 57,958 86,650 86,730
TIF1B_HUMAN 489 S 1 6.44E-07 VS(0.999)LERLDLDLT(0.001)ADSQPPVFK 31,781 33,964 21,920 22,472 30,459 25,748
TIF1B_HUMAN 498 T 1 2.48E-20 VS(0.273)LERLDLDLT(0.727)ADSQPPVFK 34,240 36,888 25,841 24,661 30,808 24,245
TMF1_HUMAN 399 S 1 2.10E-13 S(0.534)AT(0.466)PVNCEQPDILVSSTPINEGQTVLDK 11,337 12,685 8,744 9,785 12,263 10,725
TNK1_HUMAN 514 T 2 7.38E-10 S(0.991)LES(0.009)VLS(0.001)LGPRPT(0.671)GGGS(0.177)S(0.151)PPEIR 1,420 1,359 1,661 677 1,204 1,493
TOB1_HUMAN 204 T 1 1.05E-11 T(0.5)S(0.5)PINLGLNVNDLLK 18,394 16,832 13,071 12,799 15,367 15,137
TOB1_HUMAN 205 S 1 1.05E-11 T(0.44)S(0.56)PINLGLNVNDLLK 50,924 42,839 39,340 35,735 41,321 41,911
TOP2A_HUMAN 29 S 1 0.029771 KRLS(1)VER 41,907 43,963 19,160 23,510 38,377 52,613
TOPB1_HUMAN 864 S 2 0.0065 KPS(0.462)T(0.539)PLS(1)EVIVK 8,575 7,247 8,720 12,366 7,483 11,861
TOPB1_HUMAN 861 T 2 0.0065 KPS(0.462)T(0.539)PLS(1)EVIVK 8,575 7,247 8,720 12,366 7,483 11,861
TOPK_HUMAN 59 S 1 1.16E-06 GLSHS(1)PWAVK 69,724 65,528 81,240 96,985 57,397 83,777
TP53B_HUMAN 782 S 2 4.18E-19 VDVSCEPLEGVEKCS(0.667)DS(0.667)QS(0.667)WEDIAPEIEPCAENR 4,361 4,124 2,591 4,462 2,790 4,661
TP53B_HUMAN 784 S 2 4.18E-19 VDVSCEPLEGVEKCS(0.667)DS(0.667)QS(0.667)WEDIAPEIEPCAENR 4,361 4,124 2,591 4,462 2,790 4,661
TP53B_HUMAN 786 S 2 4.18E-19 VDVSCEPLEGVEKCS(0.667)DS(0.667)QS(0.667)WEDIAPEIEPCAENR 4,361 4,124 2,591 4,462 2,790 4,661
TPPP_HUMAN 32 S 1 3.57E-47 RLS(1)LESEGAGEGAAASPELSALEEAFRR 52,944 51,853 42,897 40,485 48,453 51,527
TPX2_HUMAN 121 S 2 0.035208 S(1)LRLS(1)AQK 13,242 13,682 7,468 8,329 11,641 11,906
TPX2_HUMAN 125 S 1;2 0.003955 S(1)LRLS(1)AQK 22,636 23,060 12,705 16,055 18,048 21,127
TRAF4_HUMAN 422 T 1 1.57E-05 NFQKPGT(0.53)WRGS(0.409)LDES(0.056)S(0.005)LGFGYPK 26,584 24,100 19,986 19,976 24,143 25,112
TRAF4_HUMAN 426 S 1 2.91E-10 NFQKPGT(0.045)WRGS(0.954)LDES(0.001)SLGFGYPK 25,443 23,003 19,542 19,054 26,770 23,131
TRI33_HUMAN 1119 S 1 7.58E-05 LKS(1)DERPVHIK 292,379 275,482 202,603 185,553 263,630 262,456
UBAP1_HUMAN 146 S 1 0.000956 VLS(1)PPHIK 131,777 130,587 90,825 93,877 120,920 112,784
UBP10_HUMAN 215 S 2 7.00E-07 T(0.214)CNS(0.741)PQNS(0.737)T(0.255)DS(0.038)VS(0.016)DIVPDSPFPGALGSDTR 8,871 8,702 11,020 10,653 12,584 8,917
UBP14_HUMAN 143 S 1 5.85E-33 AS(1)GEMASAQYITAALR 192,289 191,784 153,034 142,365 173,340 163,560
UBP2L_HUMAN 992 S 1 0.002746 TQQS(1)FEK 67,009 65,352 84,443 79,556 77,580 77,846
UBR4_HUMAN 362 S 1;2 5.31E-21 T(0.158)GS(0.785)T(0.039)S(0.008)S(0.01)KEDDYESDAATIVQK 188,431 150,445 125,680 115,974 168,610 164,298
UBR4_HUMAN 360 T 1;2 1.70E-74 T(0.515)GS(0.378)T(0.084)S(0.019)S(0.004)KEDDYESDAATIVQK 63,001 59,495 34,681 39,396 53,808 60,045
UH1BL_HUMAN 935 S 1 5.62E-08 S(0.155)MS(0.843)VDLS(0.001)HIPLKDPLLFK 6,748 4,933 6,507 8,001 5,879 10,947
UN45A_HUMAN 472 S 1 0.0004 RAS(0.968)FIT(0.032)ANGVSLLK 3,287 2,841 2,250 2,613 3,507 3,469
VP13C_HUMAN 736 S 1 0.000522 T(0.046)T(0.046)NS(0.505)S(0.404)LEEIMDKAYDKFDVEIK 27,397 25,854 20,986 22,129 23,302 24,704
WDFY3_HUMAN 3335 S 1 0.000358 RWS(1)DQLSLDEK 9,742 9,344 7,284 6,637 9,701 7,827
WDR43_HUMAN 431 S 1 0.000231 S(1)GGNEVSIEER 56,605 68,231 43,865 36,619 57,863 50,579
WDR48_HUMAN 335 S 1 2.59E-11 GIHNFRAS(0.996)GDYDNDCT(0.003)NPITPLCTQPDQVIK 19,803 21,650 16,145 13,556 19,936 21,577
WEE1_HUMAN 642 S 1 0.013224 S(0.011)VS(0.973)LT(0.016)IY 3,684 3,920 3,237 2,738 3,492 3,124
YM012_HUMAN 154 S 1 0.004683 AWAT(0.083)RS(0.692)PS(0.142)T(0.066)AS(0.015)LT(0.001)R 9,551 9,877 11,323 13,187 9,999 11,978
YTDC2_HUMAN 1202 S 1 1.46E-20 KS(0.076)S(0.922)ADT(0.002)EFSDECTTAER 71,274 63,944 56,950 51,105 71,862 66,460
ZC3HD_HUMAN 1014 S 2 6.59E-20 S(0.214)KGDS(0.79)DIS(0.996)DEEAAQQSK 51,213 56,865 76,629 81,776 58,125 50,651
ZC3HD_HUMAN 1017 S 2 6.59E-20 S(0.249)KGDS(0.751)DIS(1)DEEAAQQSK 51,213 56,865 76,629 81,776 58,125 50,651
ZCHC8_HUMAN 695 S 1 0.043825 S(0.001)LLKNS(0.999)PR 11,809 13,520 14,483 17,391 11,583 14,624
ZEP1_HUMAN 804 S 2 0.02179 RT(0.536)S(0.536)S(0.536)S(0.218)S(0.17)DIPKS(0.003)PFTPTEK 12,346 10,471 9,367 8,503 11,255 10,507
ZEP1_HUMAN 805 S 2 0.02179 RT(0.536)S(0.536)S(0.536)S(0.218)S(0.17)DIPKS(0.003)PFTPTEK 12,346 10,471 9,367 8,503 11,255 10,507
ZEP1_HUMAN 803 T 2 0.02179 RT(0.536)S(0.536)S(0.536)S(0.218)S(0.17)DIPKS(0.003)PFTPTEK 12,346 10,471 9,367 8,503 11,255 10,507
ZFR_HUMAN 1054 S 1 1.23E-23 RRDS(1)DGVDGFEAEGK 310,104 319,399 226,889 229,332 283,330 246,047
ZN217_HUMAN;sp 492;113;121;242;300;257;339;326;340;64;378;246;208;329;396;399;271;445;401;326;334;417;375;376;472;320;261;218;513;480;486;351;269;271;133;286;515;161;384;272;582;418;424;322;274;247;415;243;345;586;661;199;924T 1 0.000639 T(0.524)HT(0.476)GEKPYK 54,521 57,789 70,713 83,909 52,685 56,362
ZN217_HUMAN;sp 494;115;123;244;302;259;341;328;342;66;380;248;210;331;398;401;273;447;403;328;336;419;377;378;474;322;263;220;515;482;488;353;271;273;135;288;517;163;386;274;584;420;426;324;276;249;417;245;347;588;663;201;926T 1 7.99E-05 THT( )GEKPYK 104,1 2 11 , 7 132,601 153,074 111,81 112,928
ZN219_HUMAN 611 S 1 0.011342 RKPAS(1)PGR 13,141 10,667 13,905 18,162 13,289 18,881
ZN318_HUMAN;sp 305;590;250;134 S 2 0.023072 RRS(1)PS(1)PR 17,779 14,447 19,378 21,536 19,279 39,664
ZN318_HUMAN;sp 307;592;252;136 S 2 0.023072 RRS(1)PS(1)PR 17,779 14,447 19,378 21,536 19,279 39,664
ZN787_HUMAN 89 T 1 0.000262 T(0.004)HT(0.996)GERPNACADCGK 12,779 13,212 16,157 18,527 12,561 14,723
ZN813_HUMAN;sp 350;169;478;386;1651T 1 0.000208 LHT(1)GEKPFK 17,438 15,061 20,039 26,371 13,013 21,900
ZN860_HUMAN;sp 447;684;483;591;283;491;421;466T 1 0.000639 T(0.524)HT(0.476)GEKPYK 54,521 57,789 70,713 83,909 52,685 56,362
ZN860_HUMAN;sp 449;686;485;593;285;493;423;468T 1 7.99E-05 THT(1)GEKPYK 68,233 80,132 87,715 109,124 71,660 75,574
ZN860_HUMAN;sp 309;574;294;113;12;405;328;268;378;294;499;250;422;308;630;293;540;472;422;1101;350;411T 1 1.63E-05 LHT(1)GEKPYK 33,121 33,634 39,596 50,410 29,463 45,897
ZO2_HUMAN 1118 Y 1 1.29E-10 IEIAQKHPDIY(1)AVPIK 94,385 78,592 57,363 59,819 70,642 89,844
ZO2_HUMAN 925 T 2 3.82E-49 LIS(0.004)DFEDT(0.995)DGEGGAY(0.745)T(0.256)DNELDEPAEEPLVSSITR 10,564 11,969 10,135 8,022 10,063 11,967
ZO2_HUMAN 932 Y 2 3.82E-49 LIS(0.004)DFEDT(0.995)DGEGGAY(0.745)T(0.256)DNELDEPAEEPLVSSITR 10,564 11,969 10,135 8,022 10,063 11,967  
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Appendix K – EIC for pepetides selected from tyrosine phosphoproteomics data set and annotated on figure 41 
Appendix J - EIC for peptides selected from tyrosine phosphoproteomics data set  and annotated on figure 41
Proteins Peptide Modified Sequence Precursor Mz Precursor Charge DMSO2-run2 DMSO2-run1 DMSO1-run2 DMSO1-run1 CABO2-run2 CABO2-run1 CABO1-run2 CABO1-run1 FORE2-run2 FORE2-run1 FORE1-run2 FORE1-run1 
MK09_HUMAN TAC[+57]TNFMM[+16]TPY[+80]VVTR944.395591 2 13,864,872 11,069,158 9,217,662 7,642,895 1,126,587 1,545,210 4,368,173 5,429,118 10,092,179 10,464,676 15,291,233 11,066,122
GSK3A_HUMAN QLVRGEPNVSY[+80]IC[+57]SR 929.437493 2 1,624,648 3,298,522 11,405,812 5,948,875 1,268,311 5,738,540 2,812,842 1,687,452 9,048,056 7,260,063 2,209,858 3,955,758
CTND1_HUMAN SLDNNY[+80]STPNER 745.301385 2 7,042,896 4,417,786 6,437,714 3,611,873 1,160,813 773,489 2,469,271 621,775 982,399 691,131 1,087,596 192,153
FER_HUMAN QEDGGVY[+80]SSSGLK 703.795404 2 26,480,320 22,849,220 26,232,706 14,531,910 9,868,715 8,429,486 11,069,656 7,432,006 3,465,864 2,233,864 2,782,426 1,815,517
LYN_HUMAN SLDNGGY[+80]YISPR 711.308481 2 57,803,320 46,285,976 44,061,776 25,021,524 22,616,102 20,063,108 34,767,068 28,765,372 38,076,896 28,186,826 32,101,144 24,790,674  
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Appendix L – RNA seq in H1155 cells: genes that passed our cut off Appendix K - RNA-Seq of H1155 cells: genes that passed our cut off
ProbeID Symbol Description DMSO1 DMSO2 DMSO3 CABO1 CABO2 CABO3 FORE1 FORE2 FORE3
ELL ELL elongation factor RNA polymerase II (ELL), mRNA9.45710531 8.44945877 8.67315507 5.44971235 4.853006 5.318079 10.2703022 10.6609751
LZTS2 LZTS2 leucine zipper, putative tumor suppressor 2 (LZTS2), transcript variant 1, mRNA8.56084627 7.00651527 7.894064 9.39542219 8.2238437 9.0128163 11.0429386 11.5171256 10.366924
ADAM19 ADAM19 ADAM metallopeptidase domain 19 (ADAM19), mRNA7.670 3572 7.34429093 6.97896542 6.518587 6.8528557 9.65132377 9.5400188
PHACTR1 PHACTR1 phosphatase and actin regulator 1 (PHACTR1), transcript variant 1, mRNA ||| phosphatase and actin regulator 1 (PHACTR1), transcript variant 2, mRNA8.5287 365 10.3977589 9.7423907 7.39967167 8.5028197 8.1 48258 10.2490146 10.491371 10.965152
ZNF304 ZNF304 zinc finger protein 304 (ZNF304), transcript variant 2, mRNA9.01738614 7.54567408 7.724139 7.27568295 7.6532365 7.0326767 9.89131025 9.70147451
C17orf69 CRHR1-IT1 CRHR1 intronic transcript 1 (non-protein coding) (CRHR1-IT1), transcript variant 1, long non-coding RNA ||| CRHR1 intronic transcript 1 (non-protein coding) (CRHR1-IT1), transcript variant 2, long non-coding RNA7.8840449 7.55340973 7.46909739 8.25237557 8.5912148 8.7469223 9.91607816 10.1077494
TRAPPC2 TRAPPC2 trafficking protein particle complex 2 (TRAPPC2), transcript variant 1, mRNA ||| trafficking protein particle complex 2 (TRAPPC2), transcript variant 2, mRNA ||| trafficking protein particle complex 2 (TRAPPC2), transcript variant 3, mRNA7.10933721 7.07260446 6.82723249 5.71820118 8.6989286 7.9455661 9.34698974 9.2639577
CXorf40A CXorf40A chromosome X open reading frame 40A (CXorf40A), transcript variant 1, mRNA ||| chromosome X open reading frame 40A (CXorf40A), transcript variant 2, mRNA ||| chromosome X open reading frame 40A (CXorf40A), transcript variant 3, mRNA ||| chromosome X open reading frame 40A (CXorf40A), transcript variant 4, mRNA7.963116 7 6.25444279 8.29568099 7.28490148 7.4868781 9.53141431 9.76813481
GPR108 GPR108 G-protein-coupled receptor 108 (GPR108), mRNA6.07414779 6.29117959 5.38259815 6.7605972 8.39005846 8.2688565
ZSWIM4 ZSWIM4 zinc finger, SWIM-type containing 4 (ZSWIM4), mRNA6.5156575 8.42436779 8.65575203 8.50991698 8.5949192 9.97737638 10.3467278 10.024287
CHCHD7 CHCHD7 coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 1, mRNA ||| coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 2, mRNA ||| coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 3, mRNA ||| coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 4, mRNA ||| coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 5, mRNA ||| coiled-coil-helix-coiled-coil-helix domain containing 7 (CHCHD7), transcript variant 6, mRNA10.4519742 7.83940529 8.07777595 9.66976083 9.9680048 9.4859474 10.7358333 11.4349414 10.894801
CTSL1 CTSL cathepsin L (CTSL), transcript variant 1, mRNA ||| cathepsin L (CTSL), transcript variant 2, mRNA8.52546067 8.54954709 8.06200864 9.53331255 8.0118333 8.4589415 10.6272112 10.477913
EFHA2 MICU3 mitochondrial calcium uptake family, member 3 (MICU3), mRNA8.11367615 8.54179065 8.65224608 8.68376769 8.7127014 8.5404714 10.6661002 10.456603
FAM54A MTFR2 mitochondrial fission regulator 2 (MTFR2), transcript variant 1, mRNA ||| mitochondrial fission regulator 2 (MTFR2), transcript variant 2, mRNA7.29191749 7.48495134 7.79763565 7.7763847 8.1671031 9.41326154 9.356607
ZNF839 ZNF839 zinc finger protein 839 (ZNF839), transcript variant 1, mRNA6.39250927 7.3815547 8.81787444 7.86064545 7.3613472 7.5640582 9.28368715 9.66268551 9.463029
SHOC2 SHOC2 soc-2 suppressor of clear homolog (C. elegans) (SHOC2), transcript variant 1, mRNA10.1038951 10.4369678 9.40596304 11.0029053 10.429653 10.796719 11.8323515 12.1889205 11.724281
PMS2 PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) (PMS2), transcript variant 1, mRNA ||| PMS2 postmeiotic segregation increased 2 (S. cerevisiae) (PMS2), transcript variant 2, non-coding RNA9.43820136 8.15117352 9.10110846 9.391 6017 9.1035495 9.6729217 10.7722374 10.987346 10.685421
MCCC1 MCCC1 methylcrotonoyl-CoA carboxylase 1 (alpha) (MCCC1), transcript variant 1, mRNA8.0197 9.98092986 9.21004283 9.50005573 9.0771741 8.5164925 10.9173055 10.4710169 11.255345
SLC4A3 SLC4A3 solute carrier family 4 (anion exchanger), member 3 (SLC4A3), transcript variant 1, mRNA ||| solute carrier family 4 (anion exchanger), member 3 (SLC4A3), transcript variant 2, mRNA8.0517104 8.40312005 8.1092218 7.4707585 7.6473866 9.49899283 9.67967858
IGF2R IGF2R insulin like growth factor 2 receptor (IGF2R), mRNA7.88911589 9.88456619 10.7014189 9.54486958 9.5667777 9.6473866 11.3142888 11.3922821 11.296706
OTUD4 OTUD4 OTU deubiquitinase 4 (OTUD4), transcript variant 2, mRNA ||| OTU deubiquitinase 4 (OTUD4), transcript variant 3, mRNA10.3969662 9.69476558 9.94796196 9.39754849 10.181139 9.3478263 11.1600583 11.9921152 11.183875
RCL1 RCL1 RNA terminal phosphate cyclase-like 1 (RCL1), transcript variant 1, mRNA9.20190333 8.06179771 7.35295579 9.01542029 9.028448 8.5325226 9.79444871 10.305721 9.8489202
GIPC1 GIPC1 GIPC PDZ domain containing family member 1 ||| GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 1, mRNA ||| GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 3, mRNA ||| GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 4, mRNA ||| GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 5, mRNA ||| GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 6, mRNA9.97270252 7.65037146 9.58212 9.31671022 9.6115739 9.8335766 10.8767514 10.737594
IPO13 IPO13 importin 13 (IPO13), mRNA 9.06297271 9.68247231 9.92199275 9.2453093 9.7482418 9.1094923 11.0718825 10.6315843 11.434973
SCO2 SCO2 SCO2 cytochrome c oxidase assembly protein (SCO2), transcript variant 1, mRNA ||| SCO2 cytochrome c oxidase assembly protein (SCO2), transcript variant 2, mRNA ||| SCO2 cytochrome c oxidase assembly protein (SCO2), transcript variant 3, mRNA ||| SCO2 cytochrome c oxidase assembly protein (SCO2), transcript variant 4, mRNA7.68266501 8.14094159 8.25002227 7.1092218 7.5724539 8.3946205 9.18115749 9.4196364
LEPREL2 P3H3 prolyl 3-hydroxylase 3 (P3H3), mRNA 9.8687241 7.7746996 8.93503578 8.88206443 9.0006496 9.0241986 10.3477913 10.425132
DENND4A DENND4A DENN domain containing 4A (DENND4A), transcript variant 1, mRNA ||| DENN domain containing 4A (DENND4A), transcript variant 2, mRNA10.6928505 10.310296 9.79738798 10.0237037 9.9680048 10.017095 11.555261 11.4928139 11.312806
MYBL1 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 (MYBL1), transcript variant 1, mRNA ||| v-myb avian myeloblastosis viral oncogene homolog-like 1 (MYBL1), transcript variant 2, mRNA9.98103838 10.2697845 0.3849933 9.52555611 10.764863 10.484918 11.8196088 11.284772 11.804066
KIF15 KIF15 kinesin family member 15 (KIF15), mRNA11.1266152 10.8298825 10.2604222 10.335686 9.8514506 10.400091 11.5485444 11.3413983 11.945782
ISG20L2 ISG20L2 interferon stimulated exonuclease gene 20kDa like 210.1341097 9.70174356 9.51034811 9.60682957 9.9922045 9.863984 11.1433735 11.0343435 11.221
JAGN1 JAGN1 jagunal homolog 1 (Drosophila) (JAGN1), mRNA7.70584134 9.82029646 8.911766 8.18010529 8.8467741 8.6325896 9.79978216 10.1077494 9.766458
TCF19 TCF19 transcription factor 19 (TCF19), transcript variant 1, mRNA ||| transcription factor 19 (TCF19), transcript variant 2, mRNA10.0907498 8.09397811 9.48495134 9.50598057 9.4233852 9.56 1073 10.4675025 10.4284213 10.691819
WDR18 WDR18 WD repeat domain 18 (WDR18), mRNA8.5156575 7.93132778 8.54668033 8.83263107 9.3613472 8.4077162 9.24315393 9.77921426 9.8291569
ERI3 ERI3 ERI1 exoribonuclease family member 3 (ERI3), transcript variant 1, mRNA9.83758559 9.40312005 9.95224507 9.47611004 9.7565763 9.6006328 10.8084072 10.969672
CLDN12 CLDN12 claudin 12 (CLDN12), transcript variant 1, mRNA ||| claudin 12 (CLDN12), transcript variant 2, mRNA ||| claudin 12 (CLDN12), transcript variant 3, mRNA9. 1367615 9.30572329 8.54 89869 8.18995307 8.3393209 8.6473866 9.81829546 9.29473315 9.5460848
RDBP NELFE negative elongation factor complex member E (NELFE), mRNA9.9029699 10.3045778 9.74074097 10.5667651 9.1087672 10.581499 11.1211778 11.383493 10.807437
C14orf118 GPATCH2L G patch domain containing 2-like (GPATCH2L), transcript variant 1, mRNA ||| G patch domain containing 2-like (GPATCH2L), transcript variant 2, mRNA10.3434765 10.4390572 11.1652388 10.0922564 10.442108 10.401183 11.319868 11.513339 11.411353
RALB RALB v-ral simian leukemia viral oncogene homolog B (RALB), mRNA9.28119224 9.50636116 9.73246386 9.84359028 9.8055967 9.8319584 10.6002762 10.6618306 10.464097
LRPAP1 LRPAP1 low density lipoprotein receptor-related protein associated protein 1 (LRPAP1), transcript variant 1, mRNA10.169968 11.2999869 10.821781 11.0056958 10.845993 10.726164 11.6372414 11.987346 11.869626
RALY RALY RALY heterogeneous nuclear ribonucleoprotein (RALY), transcript variant 1, mRNA ||| RALY heterogeneous nuclear ribonucleoprotein (RALY), transcript variant 2, mRNA11.2588395 11.2425295 11.2040689 11.0737601 11.386806 11.653813 12.2477956 12.4030658 12.191957
RANBP10 RANBP10 RAN binding protein 10 (RANBP10), transcript variant 1, mRNA10.5758621 10.3988327 10.8843839 10.6314293 10.3927 10.385824 11.3360186 11.4223765 11.781533
PTGES3 PTGES3 prostaglandin E synthase 3 (cytosolic) (PTGES3), transcript variant 1, mRNA10.8954297 11.2574058 11.4017934 11.5089339 11.40971 11.287705 11.9301295 12.2575849 12.356607
AUH AUH AU RNA binding protein/enoyl-CoA hydratase (AUH), mRNA9.7566656 9.82669424 10.0881926 9.60682957 9.2141935 9.2590889 10.4284396 10.251637
MGRN1 MGRN1 mahogunin ring finger 1, E3 ubiquitin protein ligase (MGRN1), transcript variant 1, mRNA ||| mahogunin ring finger 1, E3 ubiquitin protein ligase (MGRN1), transcript variant 2, mRNA ||| mahogunin ring finger 1, E3 ubiquitin protein ligase (MGRN1), transcript variant 3, mRNA ||| mahogunin ring finger 1, E3 ubiquitin protein ligase (MGRN1), transcript variant 4, mRNA11.6310086 11.297686 11.1817479 11.7254136 11.507272 11.492 08 12.4679214 12.4216191 12.142436
IDH2 IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2), transcript variant 1, mRNA11.577041 11.4036551 11.3722635 11.2352391 11.317517 11.686865 12.4495885 12.3920244 12.175421
LYSMD3 LYSMD3 LysM, putative peptidoglycan-binding, domain containing 3 (LYSMD3), transcript variant 1, mRNA10.4502598 10.1714222 10.8318889 10.2570673 10.34043 9.9766567 11.1201123 10.8454682 11.12768
ATG2B ATG2B autophagy related 2B (ATG2B), mRNA11.0685711 10.4597859 10.8693636 10.6150762 10.416038 10.37919 11.3510825 11.2229368 11.085959
TOMM7 TOMM7 translocase of outer mitochondrial membrane 7 homolog (yeast) (TOMM7), mRNA13.4946019 13.5666092 13.153662 13.3930264 13.590982 13.168386 14.1165104 14.2929397 13.983894
GBF1 GBF1 golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), transcript variant 1, mRNA ||| golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), transcript variant 2, mRNA ||| golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), transcript variant 3, mRNA11.9210311 11.8860985 11.788233 12.2983353 11.951764 11.774144 12.4987879 12.6078103 12.632954
SGTA SGTA small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha (SGTA), mRNA11.0283441 10.7672352 10.5093795 10.6600516 10.864619 10.800861 11.4662453 11.4107193 11.372624
RNF144A RNF144A ring finger protein 144A (RNF144A), mRNA8.98932635 9.57637088 10.6540001 10.2370213 9.8136072 10.178609 1.71763312 1.52654882
PFDN4 PFDN4 prefoldin subunit 4 (PFDN4), mRNA 10.0863412 9.3351902 9.19325317 9.12727184 6.7499125 9.95154 1.30259562 2.26351442 0.0642853
LRRC57 LRRC57 leucine rich repeat containing 57 (LRRC57), mRNA10.2509827 8.3148543 6.27303225 7.75183196 7.7763847 8.1464189 -0.0584137 0.0642853
C4orf3 C4orf3 chromosome 4 open reading frame 3 (C4orf3), transcript variant 1, mRNA ||| chromosome 4 open reading frame 3 (C4orf3), transcript variant 2, mRNA8.38534947 8.24013495 8.0460671 9.35441538 8.2476905 6.1619598 -0.0584137 0.0642853
GGCX GGCX gamma-glutamyl carboxylase (GGCX), transcript variant 1, mRNA ||| gamma-glutamyl carboxylase (GGCX), transcript variant 2, mRNA7.70008207 7.12545635 9.05405989 9.06442219 9.1009335 9.6176392 2.30259562 3.40101794 2.0642853
TRIM16L TRIM16L tripartite motif containing 16-like (TRIM16L), mRNA8.54807897 7.67185119 7.83961622 8.02919972 8.3744034 9.6891016 2.30259562 1.94158632
LOC93622 LOC93622 Morf4 family associated protein 1-like 1 pseudogene (LOC93622), non-coding RNA9.67534539 9.02888309 9.08559546 7.04556316 8.2711494 9.1307088 2.52654882 3.0642853
FAM129B FAM129B family with sequence similarity 129, member B (FAM129B), transcript variant 1, mRNA ||| family with sequence similarity 129, member B (FAM129B), transcript variant 2, mRNA9.65465064 9.45978591 9.21954992 9.67853104 8.8653897 10.102798 4.10995054 3.40101794 2.0642853
SELK SELK selenoprotein K (SELK), mRNA 8.86100226 10.203732 9.69717195 9.61050055 10.593078 10.565033 3.71763312 5.64202604 5.3122129
JRKL JRKL JRK-like (JRKL), transcript variant 1, mRNA8.10062 7.68599537 8.56170854 9.23583344 7.6745051 7.7051021 4.74894125 4.7081415
TPMT TPMT thiopurine S-methyltransferase (TPMT), mRNA10.1595137 10.400978 10.4459977 10.5761822 11.020857 11.427139 7.80509596 7.57094294 7.7367107
CYB5A CYB5A cytochrome b5 type A (microsomal) (CYB5A), transcript variant 1, mRNA ||| cytochrome b5 type A (microsomal) (CYB5A), transcript variant 2, mRNA ||| cytochrome b5 type A (microsomal) (CYB5A), transcript variant 3, mRNA8.84803995 8.58771586 9.3068734 9.30089351 10.208129 9.6044294 6.4591001 6.68305331
DSC2 DSC2 desmocollin 2 (DSC2), transcript variant Dsc2a, mRNA ||| desmocollin 2 (DSC2), transcript variant Dsc2b, mRNA9.6841 449 9.49033105 9.2661677 9.468039 9.1774194 10.298292 6.47252062 6.78707637
CTBS CTBS chitobiase, di-N-acetyl- (CTBS), mRNA 8.6539737 8.96643098 7.96182428 8.6532365 7.8844258 5.69491304 6.0866532
SLC25A46 SLC25A46 solute carrier family 25, member 46 (SLC25A46), transcript variant 1, mRNA10.2529509 10.349701 10.6094964 10.6049906 9.3459642 10.84966 7.66600035 6.91886625 7.9530286
ZDHHC13 ZDHHC13 zinc finger, DHHC-type containing 13 (ZDHHC13), transcript variant 1, mRNA ||| zinc finger, DHHC-type containing 13 (ZDHHC13), transcript variant 2, mRNA9.4690074 9.76640346 9.67661063 9.27336908 8.843648 9.5795712 6.88755812 7.32529062 7.7577723
EFNA2 EFNA2 ephrin-A2 (EFNA2), mRNA 10.0730342 8.92239465 8.59860812 9.72159976 9.1774194 10.082525 7.63649635 8.38037818 7.5318909
NUCB1 NUCB1 nucleobindin 1 (NUCB1), mRNA 11.0556622 11.0309624 10.5190362 11.2952024 11.261812 11.022781 9.67037436 9.34885409 9.40636
PDZD8 PDZD8 PDZ domain containing 8 (PDZD8), mRNA10.8564787 11.9220212 11.8380741 11.4776183 11.815603 12.121465 10.0099547 9.97225346 10.381698
TNKS1BP1 TNKS1BP1 tankyrase 1 binding protein 1, 182kDa (TNKS1BP1), mRNA10.4459648 9.85043632 10.2136153 9.87902398 9.7829276 9.6980127 8.83916663 9.16317344 9.1141339
TCEAL3 TCEAL3 transcription elongation factor A (SII)-like 3 (TCEAL3), transcript variant 1, mRNA ||| transcription elongation factor A (SII)-like 3 (TCEAL3), transcript variant 2, mRNA10.5368141 11.1241584 11.2604222 11.0285139 10.739018 11.243348 9.72185358 9.93310817 10.1504 2
LSM3 LSM3 LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) (LSM3), mRNA12.2203786 11.6041023 12.4147837 12.0143815 12.055721 12.17606 10.9117744 10.9763853 11.181928
ETV3 ETV3 ets variant 3 (ETV3), transcript variant 1, mRNA ||| ets variant 3 (ETV3), transcript variant 2, mRNA9.23613497 9.21108642 8.97768012 9.11440204 9.5930775 8.46917718 8.31662575
DEF8 DEF8 differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 1, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 2, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 3, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 4, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 5, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 6, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 7, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 8, mRNA ||| differentially expressed in FDCP 8 homolog (mouse) (DEF8), transcript variant 9, mRNA10.4364705 10.6376923 10.4307309 10.5079501 10.471771 10.888324 9.45572538 9.84396144 9.8158294
SNX13 SNX13 sorting nexin 13 (SNX13), mRNA 11.5683737 11.7151681 11.4153009 11.3593327 12.00065 11.374196 10.9037474 10.8529783 10.534944
PTPN3 PTPN3 protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 1, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 2, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 3, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 4, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 5, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 6, mRNA ||| protein tyrosine phosphatase, non-receptor type 3 (PTPN3), transcript variant 7, non-coding RNA11.8326589 11.2791451 11.5146987 11.7899671 11.586547 11.630264 10.6689178 10.8611946 11.060052
MARK3 MARK3 MAP/microtubule affinity-regulating kinase 3 (MARK3), transcript variant 1, mRNA ||| MAP/microtubule affinity-regulating kinase 3 (MARK3), transcript variant 2, mRNA ||| MAP/microtubule affinity-regulating kinase 3 (MARK3), transcript variant 3, mRNA ||| MAP/microtubule affinity-regulating kinase 3 (MARK3), transcript variant 4, mRNA ||| MAP/microtubule affinity-regulating kinase 3 (MARK3), transcript variant 5, mRNA11.1271518 11.3750217 11.337758 11.0717642 11.363531 11.42177 10.6305225 10.4434235 10.484246
NOP2 NOP2 NOP2 nucleolar protein (NOP2), transcript variant 1, mRNA ||| NOP2 nucleolar protein (NOP2), transcript variant 2, mRNA11.4862602 11.7701426 11.5257576 11.1400278 11.743637 11.758043 10.7253612 11.0887912 10.828328
PTK2B PTK2B protein tyrosine kinase 2 beta (PTK2B), transcript variant 1, mRNA ||| protein tyrosine kinase 2 beta (PTK2B), transcript variant 2, mRNA ||| protein tyrosine kinase 2 beta (PTK2B), transcript variant 3, mRNA ||| protein tyrosine kinase 2 beta (PTK2B), transcript variant 4, mRNA5.94375115 4.9692515 4.74516823 3.9019156 0.0326767 8.56625606 9.26125844
ARL17A ARL17A ADP-ribosylation factor-like 17A (ARL17A), transcript variant 1, mRNA ||| ADP-ribosylation factor-like 17A (ARL17A), transcript variant 2, mRNA3.32844337 5.05671434 8.1092218 3.8023799 6.1201396 9.40937664 9.5780129
KCTD2 KCTD2 potassium channel tetramerization domain containing 2 (KCTD2), transcript variant 1, mRNA8.97270252 8.42858004 7.53910711 4.7499125 4.7875642 9.38828937 9.80577247 9.1032043
GABARAPL1 GABARAPL1 GABA(A) receptor-associated protein like 1 (GABARAPL1), mRNA7.65316102 0.00651527 8.68692792 7.63413692 7.4544566 8.1041391 9.9012685 9.6015037
C1orf115 C1orf115 chromosome 1 open reading frame 115 (C1orf115), mRNA3.73429778 6.43278003 7.08819257 8.15015207 5.352577 8.9545177 9.97913328 9.9175949
PHLDB2 PHLDB2 pleckstrin homology-like domain, family B, member 2 (PHLDB2), transcript variant 1, mRNA ||| pleckstrin homology-like domain, family B, member 2 (PHLDB2), transcript variant 2, mRNA ||| pleckstrin homology-like domain, family B, member 2 (PHLDB2), transcript variant 3, mRNA ||| pleckstrin homology-like domain, family B, member 2 (PHLDB2), transcript variant 4, mRNA7.78787499 5.84826172 5.4544566 9.31940391 9.71142417
AVPI1 AVPI1 arginine vasopressin-induced 1 (AVPI1), mRNA 6.93725261 7.11899862 8.4128775 3.7331165 9.50879601 9.7455238
ESYT3 ESYT3 extended synaptotagmin-like protein 3 (ESYT3), mRNA4.05622588 7.26390312 7.05671434 6.63413692 7.7499125 5.3902287 9.3865181 9.3996757
SSTR2 SSTR2 somatostatin receptor 2 (SSTR2), mRNA6.47576477 7.60642812 7.25465372 9.81523947 8.4462361 9.7365803 10.1811575 9.63507328 10.866802
ZNF676 ZNF676 zinc finger protein 676 (ZNF676), mRNA6.59227878 8.30113602 7.82100054 8.37829801 9.0475931 9.2200288 10.8730626 10.400792
TAF6L TAF6L TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa (TAF6L), mRNA8.15626239 6.19807019 7.32119761 5.9492213 5.8140365 9.24706367 9.34246576
FCHO2 FCHO2 FCH domain only 2 (FCHO2), transcript variant 1, mRNA ||| FCH domain only 2 (FCHO2), transcript variant 2, mRNA8.26567924 8.61014162 8.47704614 9.6941843 10.152372 9.4941562 11.4150351 11.0415915
SYTL3 SYTL3 synaptotagmin-like 3 (SYTL3), transcript variant 1, mRNA ||| synaptotagmin-like 3 (SYTL3), transcript variant 2, mRNA ||| synaptotagmin-like 3 (SYTL3), transcript variant 3, mRNA ||| synaptotagmin-like 3 (SYTL3), transcript variant 4, mRNA6.19633983 7.09853452 6.11956 75 6.7763847 7.5872656 8.70915496 9.49809238 10.017027
HSD17B8 HSD17B8 hydroxysteroid (17-beta) dehydrogenase 8 (HSD17B8), mRNA6.8138702 6.95606501 6.1201396 9.23390796 9.2906975
GFPT2 GFPT2 glutamine-fructose-6-phosphate transaminase 2 (GFPT2), mRNA7.54668033 7.25706727 6.2988058 7.5949192 9.49425542 9.6789952
FAN1 FAN1 FANCD2/FANCI-associated nuclease 1 (FAN1), transcript variant 1, mRNA ||| FANCD2/FANCI-associated nuclease 1 (FAN1), transcript variant 2, mRNA ||| FANCD2/FANCI-associated nuclease 1 (FAN1), transcript variant 3, mRNA ||| FANCD2/FANCI-associated nuclease 1 (FAN1), transcript variant 4, mRNA8.7371128 8.53007723 8.6022467 9.16270824 6.518587 7.8205793 10.272222 10.9770728 9.8587012
SERAC1 SERAC1 serine active site containing 1 (SERAC1), transcript variant 1, mRNA9.80843925 9.64856697 8.83961622 7.18010529 9.0530167 9.5503461 11.0715133 11.168884
IGSF9 IGSF9 immunoglobulin superfamily, member 9 (IGSF9), transcript variant 1, mRNA ||| immunoglobulin superfamily, member 9 (IGSF9), transcript variant 2, mRNA5.34900763 7.45306728 7.11956375 6.6954647 4.9395673 8.45572538 8.93310817  
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ProbeID Symbol Description DMSO1 DMSO2 DMSO3 CABO1 CABO2 CABO3 FORE1 FORE2 FORE3
GOLGA8B GOLGA8B golgin A8 family, member B (GOLGA8B), transcript variant 1, mRNA ||| golgin A8 family, member B (GOLGA8B), transcript variant 2, non-coding RNA7.50248211 7.17644027 7.82723249 9.65739227 6.736492 10.177335 9.94284055 9.8091192
C6orf162 SMIM8 small integral membrane protein 8 (SMIM8), transcript variant 1, mRNA ||| small integral membrane protein 8 (SMIM8), transcript variant 2, mRNA6.9534663 6.4822487 7.45306728 9.00987146 7.9837097 .9634141 9.41112007 9.89723623 8.6716157
ZNF724P ZNF724P zinc finger protein 724, pseudogene (ZNF724P), non-coding RNA9.62608149 7.80093114 5.21717901 8.45788628 8.3700645 8.1307088 9.80376934 10.0330217 9.8057523
ABCC5 ABCC5 ATP binding cassette subfamily C member 5 (ABCC5), transcript variant 1, mRNA ||| ATP binding cassette subfamily C member 5 (ABCC5), transcript variant 2, mRNA9.40318277 8.76140278 8.39551625 8.90017381 9.8913574 10.151618 11.2303736 11.0766543
CLK1 CLK1 CDC-like kinase 1 (CLK1), transcript variant 1, mRNA ||| CDC-like kinase 1 (CLK1), transcript variant 2, mRNA ||| CDC-like kinase 1 (CLK1), transcript variant 3, non-coding RNA ||| CDC-like kinase 1 (CLK1), transcript variant 4, non-coding RNA9.8415 486 9.28031087 9.04071386 8.47409651 7.4212898 9.4589415 10.7483003 11.1492108 10.353151
SENP8 SENP8 SUMO/sentrin specific peptidase family member 8 (SENP8), transcript variant 1, mRNA ||| SUMO/sentrin specific peptidase family member 8 (SENP8), transcript variant 2, mRNA ||| SUMO/sentrin specific peptidase family member 8 (SENP8), transcript variant 3, mRNA ||| SUMO/sentrin specific peptidase family member 8 (SENP8), transcript variant 4, mRNA ||| SUMO/sentrin specific peptidase family member 8 (SENP8), transcript variant 5, mRNA7.11899862 8.01818673 6.8405151 6.6620334 9.59874708 9.1330636
IER2 IER2 immediate early response 2 (IER2), mRNA6.93397013 9.30572329 7.94653142 6.60499057 9.4379685 8.4420677 10.5654735 10.0263947
CC2D2A CC2D2A coiled-coil and C2 domain containing 2A (CC2D2A), transcript variant 1, mRNA ||| coiled-coil and C2 domain containing 2A (CC2D2A), transcript variant 2, mRNA ||| coiled-coil and C2 domain containing 2A (CC2D2A), transcript variant 3, mRNA8.9092 346 8.74798226 7.41219499 6.89717132 8.81 0086 8.9061209 10.576391 10.2958357
FAM50B FAM50B family with sequence similarity 50 member B (FAM50B), mRNA7.05090939 8.03534069 7.36532016 8.6674504 8.8812997 9.71904131 9.8274977
QTRTD1 QTRT2 queuine tRNA-ribosyltransferase domain containing 1 (QTRTD1), transcript variant 1, mRNA ||| queuine tRNA-ribosyltransferase domain containing 1 (QTRTD1), transcript variant 2, mRNA ||| queuine tRNA-ribosyltransferase domain containing 1 (QTRTD1), transcript variant 3, mRNA ||| queuine tRNA-ribosyltransferase domain containing 1 (QTRTD1), transcript variant 4, mRNA7.57350157 7.3988327 9.10367782 8.80085236 6.124308 8.9868731 10.2693414 10.6922933 9.5359606
CLDN3 CLDN3 claudin 3 (CLDN3), mRNA 6.81111338 6.73443573 8.28666411 7.26640513 8.7331165 9.55841104 9.36365109
ENOSF1 ENOSF1 enolase superfamily member 1 (ENOSF1), transcript variant 1, mRNA ||| enolase superfamily member 1 (ENOSF1), transcript variant 2, mRNA ||| enolase superfamily member 1 (ENOSF1), transcript variant 3, mRNA7.71729136 7.40739471 5.82723249 7.66270607 5.9257624 6.4249942 9.0685723 8.5956668
ATG7 ATG7 autophagy related 7 (ATG7), transcript variant 1, mRNA ||| autophagy related 7 (ATG7), transcript variant 2, mRNA ||| autophagy related 7 (ATG7), transcript variant 3, mRNA8.42429575 7.53007723 8.39967167 7.2524129 7.0987659 9.463186 6 9.9831486
CASP6 CASP6 caspase 6, apoptosis-related cysteine peptidase (CASP6), transcript variant alpha, mRNA ||| caspase 6, apoptosis-related cysteine peptidase (CASP6), transcript variant beta, mRNA8.49584901 5.59147777 9.31576523 7.99590528 7.4948709 7.9868731 9.70489713 10.175206
DTX2 DTX2 deltex 2, E3 ubiquitin ligase (DTX2), transcript variant 1, mRNA ||| deltex 2, E3 ubiquitin ligase (DTX2), transcript variant 2, mRNA ||| deltex 2, E3 ubiquitin ligase (DTX2), transcript variant 3, mRNA ||| deltex 2, E3 ubiquitin ligase (DTX2), transcript variant 4, mRNA7.4822487 8.60587612 8.22390041 9.2334298 7.4838879 10.1821789 10.170405
SLC24A1 SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 (SLC24A1), transcript variant 1, mRNA ||| solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 (SLC24A1), transcript variant 2, mRNA8.31926028 6.59147777 7.3091015 8. 3322423 8.7465691 7.2421301 9.37405798 9.6398246
SNORA40 SNORA40 small nucleolar RNA, H/ACA box 40 (SNORA40), small nucleolar RNA7.28263968 6.29117959 6.49807537 6.7469223 8.68629991 8.6972805
C15orf61 C15orf61 chromosome 15 open reading frame 61 (C15orf61), mRNA8.82705492 9.75134911 8.85189455 8.64491676 8.9109044 7.6620334 10.4523427 10.2521991 10.72071
MXD3 MXD3 MAX dimerization protein 3 (MXD3), transcript variant 1, mRNA ||| MAX dimerization protein 3 (MXD3), transcript variant 2, mRNA8.96791746 7.37283749 7.43685705 8.96756065 7.4948709 8.3946205 9.84046111 10.1190059
SYDE1 SYDE1 synapse defective 1, Rho GTPase, homolog 1 (C. elegans) (SYDE1), transcript variant 1, mRNA8.61999416 7.06179771 6.94653142 8.36532016 7.688512 7.95154 9.88254004 9.81349156 9.0642853
HOXA3 HOXA3 homeobox A3 (HOXA3), transcript variant 1, mRNA ||| homeobox A3 (HOXA3), transcript variant 2, mRNA7.72865122 8.91039712 9.12912283 8.1092218 8.8989069 9.3272975 10.5489166 10.496827
PAPOLG PAPOLG poly(A) polymerase gamma (PAPOLG), mRNA8.12231507 9.89373589 9.5802763 9.70966955 10.061114 10.128074 11.0861396 11.1473796 11.129028
TAB1 TAB1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 (TAB1), transcript variant alpha, mRNA ||| TGF-beta activated kinase 1/MAP3K7 binding protein 1 (TAB1), transcript variant beta, mRNA8.8244102 10.0726045 9.98466655 7.85446687 8.66391 9.4631293 10.8443376 10.6210664 10.199995
TMEM9B TMEM9B TMEM9 domain family, member B (TMEM9B), transcript variant 1, mRNA7.10 33721 8.54179065 7.90588944 8.49012662 7.4626306 8.5910975 9.92342637 9.54149917
TOR2A TOR2A torsin family 2, member A (TOR2A), transcript variant 1, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 2, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 3, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 4, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 5, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 6, mRNA ||| torsin family 2, member A (TOR2A), transcript variant 7, mRNA7.04718074 9.37064993 8.75061121 7.56770956 8.6603609 7.8400317 9.83787099 9.91312988
CDKN2AIP CDKN2AIP CDKN2A interacting protein (CDKN2AIP), transcript variant 1, mRNA9.44682478 8.73443573 8.57287784 9.77981437 7.7499125 8.2566784 10.552894 10.2499254
KIAA1430 CFAP97 cilia and flagella associated protein 97 (CFAP97), transcript variant 1, mRNA9.43647047 10.1839348 10.1454246 10.4507366 10.572454 10.025615 11.7264119 11.6506701 11.763858
ZXDB ZXDB zinc finger, X-linked, duplicated B (ZXDB), mRNA9.43126531 7.82029646 9.50258123 9.73679505 9.7127014 8.3635936 10.5144839 10.901125
MOCS3 MOCS3 molybdenum cofactor synthesis 3 (MOCS3), mRNA7.7566656 8.8041768 7.3091015 6.96756065 8.6568031 8.5834235 10.2941175 9.53591093 9.4085813
GATS GATS GATS, stromal antigen 3 opposite strand (GATS), transcript variant 1, mRNA ||| GATS, stromal antigen 3 opposite strand (GATS), transcript variant 2, non-coding RNA ||| GATS, stromal antigen 3 opposite strand (GATS), transcript variant 3, non-coding RNA ||| GATS, stromal antigen 3 opposite strand (GATS), transcript variant 4, non-coding RNA9.28888663 8.15117352 10.1811398 10.2239004 8.4254776 9.3134475 11.139172 10.993475 10.849738
ILKAP ILKAP integrin-linked kinase-associated serine/threonine phosphatase (ILKAP), mRNA6.83232987 8.87379401 7.16892384 8.08831281 7.9492213 6.3725267 9.28748873 9.11151132 9.3427348
TBCC TBCC tubulin folding cofactor C (TBCC), mRNA 8.51430991 8.72079556 9.64849221 10.264152 8.2274336 10.5386098 9.93452466 10.694552
TBL1X TBL1X transducin (beta)-like 1X-linked (TBL1X), transcript variant 1, mRNA ||| transducin (beta)-like 1X-linked (TBL1X), transcript variant 2, mRNA ||| transducin (beta)-like 1X-linked (TBL1X), transcript variant 3, mRNA ||| transducin (beta)-like 1X-linked (TBL1X), transcript variant 4, mRNA9.88277436 10.4628697 10.4419423 10.3804497 9.799156 9.2274336 11.142849 11.612685 11.909383
ZBED3 ZBED3 zinc finger, BED-type containing 3 (ZBED3), mRNA8.58916617 6.54567408 7.43685705 6.59019357 7.1035495 7.2421301 8.7148126 8.7437654
GALNT12 GALNT12 polypeptide N-acetylgalactosaminyltransferase 12 (GALNT12), mRNA8.43820136 7.441 435 9.35079445 7.05636992 8.2664881 8.8999555 9.61093465 10.0197371 9.7681889
GLTSCR2 GLTSCR2 glioma tumor suppressor candidate region gene 2 (GLTSCR2), mRNA8.8687241 9.67717152 10.0933728 9.1776328 10.23343 10.618578 11.1821789 11.5562962 11.068506
RHBDD1 RHBDD1 rhomboid domain containing 1 (RHBDD1), transcript variant 1, mRNA ||| rhomboid domain containing 1 (RHBDD1), transcript variant 2, mRNA9.97508911 7.36406728 8.4967285 7.96182428 8.63527 9.5365025 10.1522613 10.6166612 10.154398
TBCCD1 TBCCD1 TBCC domain containing 1 (TBCCD1), transcript variant 1, mRNA ||| TBCC domain containing 1 (TBCCD1), transcript variant 2, mRNA9.7427264 8.70695499 9.08299366 9.82000346 8.9138883 7.6620334 10.1760397 10.9195817 10.358906
ACVR2B ACVR2B activin A receptor, type IIB (ACVR2B), mRNA10.4364705 8.67540026 9.65400012 10.1221377 9.8868087 9.3134475 11.2114886 11.6758726 10.845645
FRMD6 FRMD6 FERM domain containing 6 (FRMD6), transcript variant 1, mRNA ||| FERM domain containing 6 (FRMD6), transcript variant 2, mRNA9.77184474 10.3508112 10.5419517 9.28490148 8.7861879 9.4120551 10.8680151 10.601504
HIST1H2BN HIST1H2BN histone cluster 1, H2bn (HIST1H2BN), mRNA9.5671878 9.44530713 8.04071386 9.08039315 9.111369 7.7741437 9.8090685 10.5387078 10.226677
CTXN1 CTXN1 cortexin 1 (CTXN1), mRNA 11.2884069 9.57637088 8.92344781 9.33013073 9.9794435 10.195068 11.3528978 11.6960563 10.995762
CNST CNST consortin, connexin sorting protein (CNST), transcript variant 1, mRNA ||| consortin, connexin sorting protein (CNST), transcript variant 2, mRNA9.04718074 10.2012721 10.782231 9.86833164 9.7910646 9.0688504 10.6703744 11.3171688 11.273129
USP32 USP32 ubiquitin specific peptidase 32 (USP32), mRNA9.23015281 9.40312005 10.0894894 10.6241841 10.444174 10.633519 10.878765 11.1637775 11.209581
TRIP10 TRIP10 thyroid hormone receptor interactor 10 (TRIP10), transcript variant 2, mRNA8.07414779 8.32844337 9.80687943 9.17267508 9.5087526 8.7331165 10.3551637 10.135748
ZNF544 ZNF544 zinc finger protein 544 (ZNF544), transcript variant 1, mRNA7.31926028 9.55533718 8.25465372 8.47006099 8.736492 8.7842208 10.2731809 9.75215796 9.6092498
RNF31 RNF31 ring finger protein 31 (RNF31), mRNA10.4715451 9.80741517 10.0699138 10.1614575 9.2238437 9.0770709 10.6245237 11.081777 11.241705
TRAF3 TRAF3 TNF receptor-associated factor 3 (TRAF3), transcript variant 1, mRNA ||| TNF receptor-associated factor 3 (TRAF3), transcript variant 2, mRNA ||| TNF receptor-associated factor 3 (TRAF3), transcript variant 3, mRNA ||| TNF receptor-associated factor 3 (TRAF3), transcript variant 4, mRNA9.50743699 10.6754003 9.75224971 10.3804497 10.66391 9.904582 11.255822 11.5723085 11.542549
SLC39A8 SLC39A8 solute carrier family 39 (zinc transporter), member 8 (SLC39A8), transcript variant 1, mRNA ||| solute carrier family 39 (zinc transporter), member 8 (SLC39A8), transcript variant 2, mRNA ||| solute carrier family 39 (zinc transporter), member 8 (SLC39A8), transcript variant 3, mRNA ||| solute carrier family 39 (zinc transporter), member 8 (SLC39A8), transcript variant 4, mRNA8.61081473 9.07797764 8.51614596 9.82000346 9.6867685 9.753775 10.0530235 10.349688
S100PBP S100PBP S100P binding protein (S100PBP), transcript variant 1, mRNA ||| S100P binding protein (S100PBP), transcript variant 3, mRNA7.1937294 9.3837258 9.38076249 9.39967167 9.1345764 9.0879592 10.0519064 10.2419389 10.054389
EPHA10 EPHA10 EPH receptor A10 (EPHA10), transcript variant 2, mRNA ||| EPH receptor A10 (EPHA10), transcript variant 3, mRNA9.00809338 7.78787499 8.35726878 7.89717132 9.0394191 8.9634141 9.84691613 9.76336031
PIAS1 PIAS1 protein inhibitor of activated STAT 1 (PIAS1), transcript variant 2, mRNA8.55 28141 9.15626239 9.55045208 9.71649889 9.8231615 9.5795712 10.1729603 10.8394318 10.502037
PAR5 PWAR5 Prader Willi/Angelman region RNA 5 (PWAR5), long non-coding RNA7.34900763 7.91940461 9.12406961 8.25237557 8.7127014 8.7015617 9.57094267 9.4821379
ZNF92 ZNF92 zinc finger protein 92 (ZNF92), transcript variant 1, mRNA ||| zinc finger protein 92 (ZNF92), transcript variant 2, mRNA11.1839623 10.293073 10.5025812 9.65561665 10.40123 10.468347 11.1688442 11.663967 11.695008
ULK1 ULK1 unc-51 like autophagy activating kinase 1 (ULK1), mRNA9. 1367615 9.31257696 9.70396112 9.26407633 10.786188 10.319235 10.6132084 10.7561688
TOM1L2 TOM1L2 target of myb1-like 2 (chicken) (TOM1L2), transcript variant 1, mRNA ||| target of myb1-like 2 (chicken) (TOM1L2), transcript variant 3, mRNA8.6855825 9.22326 13 9.37439296 9.16270824 8.9109044 10.017095 10.4749161 10.244194
LITAF LITAF lipopolysaccharide-induced TNF factor (LITAF), transcript variant 1, mRNA ||| lipopolysaccharide-induced TNF factor (LITAF), transcript variant 2, mRNA ||| lipopolysaccharide-induced TNF factor (LITAF), transcript variant 3, mRNA ||| lipopolysaccharide-induced TNF factor (LITAF), transcript variant 4, non-coding RNA8.24209242 8.92537851 9.00542511 8.79118063 8.3830423 7.7400359 9.49406615 9.61754336
EMILIN3 EMILIN3 elastin microfibril interfacer 3 (EMILIN3), mRNA7.70008207 8.29653412 8.87914458 9.12470705 8.5572674 8.5679521 9.51901515 9.5339272
ZNF611 ZNF611 zinc finger protein 611 (ZNF611), transcript variant 1, mRNA ||| zinc finger protein 611 (ZNF611), transcript variant 2, mRNA ||| zinc finger protein 611 (ZNF611), transcript variant 3, mRNA ||| zinc finger protein 611 (ZNF611), transcript variant 4, mRNA9.26567924 9.56684811 7.894064 9.48813257 8.3830423 9.2566784 9.94404531 10.4553139 9.9484559
STRADA STRADA STE20-related kinase adaptor alpha (STRADA), transcript variant 1, mRNA ||| STE20-related kinase adaptor alpha (STRADA), transcript variant 2, mRNA ||| STE20-related kinase adaptor alpha (STRADA), transcript variant 3, mRNA ||| STE20-related kinase adaptor alpha (STRADA), transcript variant 4, mRNA ||| STE20-related kinase adaptor alpha (STRADA), transcript variant 5, mRNA ||| STE20-related kinase adaptor alpha (STRADA), transcript variant 6, mRNA9.33792413 9.30801147 0.2136153 8.72499035 9.6621366 10.191286 10.461626 11.1196287 10.601504
AIMP2 AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2), mRNA9.37634948 9.29883691 9.08038717 9.24766857 10.408653 10.234801 10.3016561 10.6532533 10.394082
TOR1AIP1 TOR1AIP1 torsin A interacting protein 1 (TOR1AIP1), transcript variant 2, mRNA10.9017159 10.2220483 10.2592703 9.80726435 9.5686722 9.4631293 10.709155 10.8723237
CTDP1 CTDP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1), transcript variant 1, mRNA ||| CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1), transcript variant 2, mRNA ||| CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1), transcript variant 3, mRNA8.68266501 8.92239465 8.81474155 8.91805869 9.30 0867 10.12014 9.98090232 10.1954338 9.7699177
SLC25A15 SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 (SLC25A15), mRNA9.08964888 9.51826793 10.1139097 8.701087 6 9.7861879 9.4249942 10.2865393 10.6350733 10.506192
ERH ERH enhancer of rudimentary homolog (Drosophila) (ERH), mRNA10.7821033 11.0839986 10.2877943 10.7871315 10.862304 10.790067 11.5193415 12.0316987 12.008265
MGAT5B MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B (MGAT5B), transcript variant 1, mRNA ||| mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B (MGAT5B), transcript variant 2, mRNA ||| mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B (MGAT5B), transcript variant 3, mRNA9.70440367 10.1726784 9.57658181 9.25706727 8.8958918 8.7808696 9.77427083 10.3999929 10.1 3633
AK1 AK1 adenylate kinase 1 (AK1), mRNA 8.79228951 9.67894062 9.20287117 9.3522245 9.6815256 8.9781206 10.138646 10.6796786 10.222895
SOX18 SOX18 SRY (sex determining region Y)-box 18 (SOX18), mRNA9.4347375 8.75805933 9.43277587 9.13493897 8.6424834 9.4610369 10.0669998 10.289493
ZNF841 ZNF841 zinc finger protein 841 (ZNF841), mRNA8.56084627 9.83940529 8.37013093 8.34783273 9.1009335 8.9955727 9.97384181 9.83337003
BIN1 BIN1 bridging integrator 1 (BIN1), transcript variant 1, mRNA ||| bridging integrator 1 (BIN1), transcript variant 10, mRNA ||| bridging integrator 1 (BIN1), transcript variant 2, mRNA ||| bridging integrator 1 (BIN1), transcript variant 3, mRNA ||| bridging integrator 1 (BIN1), transcript variant 4, mRNA ||| bridging integrator 1 (BIN1), transcript variant 5, mRNA ||| bridging integrator 1 (BIN1), transcript variant 6, mRNA ||| bridging integrator 1 (BIN1), transcript variant 7, mRNA ||| bridging integrator 1 (BIN1), transcript variant 8, mRNA ||| bridging integrator 1 (BIN1), transcript variant 9, mRNA10.455397 9.85826431 9.99300585 10.8200035 9.6989286 10.061964 11.4451282 11.2101283 10.901913
LOC100190938RAMP2-AS1 RAMP2 antisense RNA 1 (RAMP2-AS1), transcript variant 1, long non-coding RNA ||| RAMP2 antisense RNA 1 (RAMP2-AS1), transcript variant 2, long non-coding RNA9.25393404 9.21840357 9.85951578 8.32119761 9.3393209 9.5679521 10.1014577 10.145103
IP6K1 IP6K1 inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 1, mRNA ||| inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 2, mRNA ||| inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 3, mRNA11. 777594 10.8386141 10.405963 10.8767394 10.839731 0.246996 11.6256504 11.8715844 11.594692
UMPS UMPS uridine monophosphate synthetase (UMPS), transcript variant 1, mRNA ||| uridine monophosphate synthetase (UMPS), transcript variant 2, non-coding RNA ||| uridine monophosphate synthetase (UMPS), transcript variant 3, non-coding RNA8.48249063 8.51826793 9.50258123 9.29634242 8.033944 9.3546048 9.83527622 9.91886625
SPATA20 SPATA20 spermatogenesis associated 20 (SPATA20), transcript variant 1, mRNA10.0808115 10.1045474 10.0606869 10.6059104 9.5967958 10.409887 11.0546975 11.4424282 10.84892
SEPW1 SEPW1 selenoprotein W, 1 (SEPW1), mRNA 10.4146573 9.37720268 10.5410041 9.81523947 10.151108 10.370299 11.144422 11.2200358 11.011192
CD99L2 CD99L2 CD99 molecule-like 2 (CD99L2), transcript variant 1, mRNA ||| CD99 molecule-like 2 (CD99L2), transcript variant 2, mRNA ||| CD99 molecule-like 2 (CD99L2), transcript variant 3, mRNA ||| CD99 molecule-like 2 (CD99L2), transcript variant 4, mRNA ||| CD99 molecule-like 2 (CD99L2), transcript variant 5, mRNA10.4866784 9.77635312 10.9923127 9.78307102 10.60143 10.695345 11.5104234 11.1177595 11.4 1074
IGF1R IGF1R insulin-like growth factor 1 receptor (IGF1R), transcript variant 1, mRNA10.653161 10.6349608 10.6696912 10.5158015 9.9680048 10.045301 11.185748 11.1522577 11.072714
GALNT1 GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1), mRNA8.50908484 10.1124238 10.0353407 9.8759771 9.6727447 9.825467 10.5560492 10.43715
RYK RYK receptor-like tyrosine kinase (RYK), transcript variant 1, mRNA ||| receptor-like tyrosine kinase (RYK), transcript variant 2, mRNA8.99639263 9.69651324 10.5922184 10.0223265 9.3547746 9.7892331 10.4716855 10.752158 10.692731
NCOA3 NCOA3 nuclear receptor coactivator 3 (NCOA3), transcript variant 1, mRNA ||| nuclear receptor coactivator 3 (NCOA3), transcript variant 2, mRNA ||| nuclear receptor coactivator 3 (NCOA3), transcript variant 3, mRNA ||| nuclear receptor coactivator 3 (NCOA3), transcript variant 4, mRNA11.511142 10.5053645 10.8005587 10.3367945 11.297664 11.168386 11.8456274 11.9479124 11.727399
MID1 MID1 midline 1 (MID1), transcript variant 1, mRNA ||| midline 1 (MID1), transcript variant 2, mRNA ||| midline 1 (MID1), transcript variant 3, mRNA ||| midline 1 (MID1), transcript variant 4, mRNA ||| midline 1 (MID1), transcript variant 5, mRNA ||| midline 1 (MID1), transcript variant 6, mRNA ||| midline 1 (MID1), transcript variant 7, mRNA ||| midline 1 (MID1), transcript variant 8, mRNA ||| midline 1 (MID1), transcript variant 9, mRNA12.6592958 11.8994375 11.9497481 12.660273 12.327621 12.267494 13.0333488 12.9111527 13.278756
TM9SF4 TM9SF4 transmembrane 9 superfamily protein member 4 (TM9SF4), mRNA9.96431822 9.41590621 9.80055874 9.36532016 9.5303004 10.173507 10.7372238 10.3762146 10.566123
RBM26 RBM26 RNA binding motif protein 26 (RBM26), transcript variant 3, mRNA11.5711371 11.0205357 11.0868946 10.8451491 10.551531 10.527532 11.6086573 11.5640958 11.331657
DAG1 DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 1, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 10, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 11, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 12, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 13, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 2, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 3, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 4, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 5, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 6, mRNA ||| dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), transcript variant 7, mRNA |11.6921253 2.1406207 11.4515553 11.7687686 11.524944 12.410972 12.5169147 12.789818 12.446909
H2AFY2 H2AFY2 H2A histone family, member Y2 (H2AFY2), mRNA10.0057608 10.662046 10.2124255 10.9625426 10.459571 10.446305 11.0179857 11.3493852 10.977175
ANP32E ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E (ANP32E), transcript variant 1, mRNA ||| acidic (leucine-rich) nuclear phosphoprotein 32 family, member E (ANP32E), transcript variant 2, mRNA ||| acidic (leucine-rich) nuclear phosphoprotein 32 family, member E (ANP32E), transcript variant 3, mRNA13.1188117 13.0578942 12.9966392 13.6092397 13.522013 13.874536 13.7566378 13.8990512 13.797936
NEURL4 NEURL4 neuralized E3 ubiquitin protein ligase 4 (NEURL4), transcript variant 1, mRNA ||| neuralized E3 ubiquitin protein ligase 4 (NEURL4), transcript variant 2, mRNA10.63365 7 9.86605006 8.25927035 9.28260236 9.2919412 9.4505293 10.1206 51 10.2316052 9.9238201
C16orf62 C16orf62 chromosome 16 open reading frame 62 (C16orf62), transcript variant 1, mRNA11.0500134 10.2953813 10.1750447 9.97042031 10.744894 10.630729 11.3096229 11.0323604 11.215936
CCNI CCNI cyclin I (CCNI), mRNA 10.5222003 10.7911501 10.6247822 11.4517602 10.594008 11.036195 11.3997499 11.4860678 11.194212
SREBF2 SREBF2 sterol regulatory element binding transcription factor 2 (SREBF2), transcript variant 1, mRNA12.286006 12.161966 12.0119369 12.1479435 12.174623 11.758895 12.7842269 12.6720565 12.599075
AP2M1 AP2M1 adaptor-related protein complex 2, mu 1 subunit (AP2M1), transcript variant 1, mRNA ||| adaptor-related protein complex 2, mu 1 subunit (AP2M1), transcript variant 2, mRNA1 .5930559 11.4291057 11.6040625 11.5318614 11.729735 11.259089 11.9914287 12.288654 12.064638
HIST2H2AC HIST2H2AC histone cluster 2, H2ac (HIST2H2AC), mRNA14.2374403 13.9325332 13.7329826 13.8865185 13.767443 13.818129 14.313182 14.5007244 14.45311
EID2 EID2 EP300 interacting inhibitor of differentiation 2 (EID2), mRNA10.035794 9.92984276 9.41219499 8.75183196 8.8310754 8.8270926 0.94158632 0.0642853
TMEM189 TMEM189 transmembrane protein 189 (TMEM189), transcript variant 1, mRNA ||| transmembrane protein 189 (TMEM189), transcript variant 2, mRNA ||| transmembrane protein 189 (TMEM189), transcript variant 3, non-coding RNA8.84543345 9.24492001 5.49281345 9.07242977 9.2804272 9.0185187 0.94158632 0.0642853
IRF1 IRF1 interferon regulatory factor 1 (IRF1), mRNA8.673877 1.00651527 6.92344781 8.07242977 8.4212898 8.5365025 -0.2823669 -0.0584137
EXPH5 EXPH5 exophilin 5 (EXPH5), mRNA 9.15003955 9.23051695 7.894064 8.80085236 8.0503075 7.5562387 1.30259562 0.0642853
LOC100132832PMS2P9 postmeiotic segregation increased 2 pseudogene 9 (PMS2P9), non-coding RNA7.9534663 8.64676021 7.11899862 5.69072045 6.6532365 6.8140365 -0.2823669 0.0642853  
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Appendix K (Continued)
ProbeID Symbol Description DMSO1 DMSO2 DMSO3 CABO1 CABO2 CABO3 FORE1 FORE2 FORE3
ANK3 ANK3 ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 1, mRNA ||| ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 2, mRNA ||| ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 3, mRNA ||| ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 4, mRNA0.00651527 5.42868312 6.82 17074 8.3033641 8.5834235 -0.2823669 0.0642853
FAM122C FAM122C family with sequence similarity 122C (FAM122C), transcript variant 1, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 2, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 3, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 4, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 5, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 6, mRNA ||| family with sequence similarity 122C (FAM122C), transcript variant 7, mRNA8.95 04364 7.23603804 8.55252315 7.5724539 5.7605972 -0.2823669 0.94158632
MFSD11 MFSD11 major facilitator superfamily domain containing 11 (MFSD11), transcript variant 1, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 2, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 3, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 4, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 5, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 6, mRNA ||| major facilitator superfamily domain containing 11 (MFSD11), transcript variant 7, mRNA0.73429778 5.78787499 7.37013093 7.26640513 6.7229455 9.0411054 -0.0584137 0.0642853
CLDN15 CLDN15 claudin 15 (CLDN15), transcript variant 1, mRNA ||| claudin 15 (CLDN15), transcript variant 2, mRNA8. 3943925 7.20618762 7.45306728 5.87292378 3.16495 7.4838879 1.71763312 1.6492478
MBNL3 MBNL3 muscleblind-like splicing regulator 3 (MBNL3), transcript variant 1, mRNA ||| muscleblind-like splicing regulator 3 (MBNL3), transcript variant 2, mRNA ||| muscleblind-like splicing regulator 3 (MBNL3), transcript variant 3, mRNA ||| muscleblind-like splicing regulator 3 (MBNL3), transcript variant 4, mRNA ||| muscleblind-like splicing regulator 3 (MBNL3), transcript variant 5, mRNA ||| muscleblind-like splicing regulator 3 (MBNL3), transcript variant 6, mRNA8.72581963 10.0604412 10.1049608 8.99590528 10.112668 9.7724573 4.67182943 3.6420 604
C15orf38 ARPIN actin-related protein 2/3 complex inhibitor (ARPIN), transcript variant 1, mRNA5.37815397 8.10880285 8.79441175 7.6674504 8.7015617 4.02904916 3.0642853
ZNF500 ZNF500 zinc finger protein 500 (ZNF500), transcript variant 1, mRNA7.96651721 7.85799475 7.85446687 6.16495 8.6400071 3.71763312 2.74894125
KIAA1875 WDR97 KIAA1875 (KIAA1875), long non-coding RNA8.9265906 8.17644027 6.84826172 8.5067777 6.4420677 4.03956121 4.7647251
SMPD3 SMPD3 sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) (SMPD3), mRNA10.3889338 9.19386735 8.15412684 9.47812076 10.312438 7.7400359 5.30259562 5.1086795
ADAT1 ADAT1 adenosine deaminase, tRNA-specific 1 (ADAT1), transcript variant 1, mRNA ||| adenosine deaminase, tRNA-specific 1 (ADAT1), transcript variant 2, non-coding RNA0.9486 69 8.63222412 6.80214151 9.20702659 8.9463097 8.3410158 4.67182943 5.18951384 6.4566028
SH3BP1 SH3BP1 SH3-domain binding protein 1 (SH3BP1), mRNA10.5464751 10.1032304 10.1787049 9.86526208 9.0448736 10.187495 7.55052313 7.01840192
PIGM PIGM phosphatidylinositol glycan anchor biosynthesis, class M (PIGM), mRNA7.67093572 9.29653412 8.30016838 5.69072045 7.6745051 9.4756202 5.47252062 5.49617517
SLC6A15 SLC6A15 solute carrier family 6 (neutral amino acid transporter), member 15 (SLC6A15), transcript variant 1, mRNA ||| solute carrier family 6 (neutral amino acid transporter), member 15 (SLC6A15), transcript variant 2, mRNA ||| solute carrier family 6 (neutral amino acid transporter), member 15 (SLC6A15), transcript variant 3, mRNA6.33421062 8.64313989 7.48495134 8.29406148 7.3 69531 5.02904916 4.8716403
ANKRD5 ANKEF1 ankyrin repeat and EF-hand domain containing 1 (ANKEF1), transcript variant 1, mRNA ||| ankyrin repeat and EF-hand domain containing 1 (ANKEF1), transcript variant 2, mRNA9.95709269 8.72076079 9.06728358 10.4039087 10.046234 8.981044 6.66014762 7.25446928 7.9831486
SMCR7 MIEF2 mitochondrial elongation factor 2 (MIEF2), transcript variant 1, mRNA ||| mitochondrial elongation factor 2 (MIEF2), transcript variant 2, mRNA ||| mitochondrial elongation factor 2 (MIEF2), transcript variant 3, mRNA9.41729237 8.15626239 5.66969122 8.46601416 7.6460767 7.7605972 5.80509596 5.2342103
ZKSCAN5 ZKSCAN5 zinc finger with KRAB and SCAN domains 5 (ZKSCAN5), transcript variant 1, mRNA ||| zinc finger with KRAB and SCAN domains 5 (ZKSCAN5), transcript variant 2, mRNA8.48918528 7.72761446 9.05936392 8.43736396 9.5949379 9.0298562 6.44555357 6.93027101
MTCP1NB CMC4 C-x(9)-C motif containing 4 (CMC4), mRNA8.36729298 9.7845924 7.71744435 9.55252315 7.3700645 8.8528557 6.63649635 6.61401167
DIMT1 DIMT1 DIM1 dimethyladenosine transferase 1 homolog (S. cerevisiae) (DIMT1), mRNA10.5448694 8.71732171 10.4142663 10.2722108 10.418141 10.441006 8.71966345 8.293104
ZNF41 ZNF41 zinc finger protein 41 (ZNF41), transcript variant 1, mRNA ||| zinc finger protein 41 (ZNF41), transcript variant 2, mRNA10.6351646 10.5143099 10.2707477 0.3566029 8.7398589 8.6583856 9.20144889 8.65239276 8.4694268
PAIP1 PAIP1 poly(A) binding protein interacting protein 1 (PAIP1), transcript variant 1, mRNA ||| poly(A) binding protein interacting protein 1 (PAIP1), transcript variant 2, mRNA ||| poly(A) binding protein interacting protein 1 (PAIP1), transcript variant 3, mRNA11.7926278 11.8508287 10.7341231 11.541989 10.850672 10.974458 10.3249634 9.56729517 9.4757963
FRA10AC1 FRA10AC1 fragile site, folic acid type, rare, fra(10)(q23.3) or fra(10)(q24.2) candidate 1 (FRA10AC1), mRNA9.25785974 8.7845924 9.44903 76 8. 8303787 9.4001665 8.5285318 7.79444871 7.69647383
APC APC adenomatous polyposis coli (APC), transcript variant 1, mRNA ||| adenomatous polyposis coli (APC), transcript variant 2, mRNA ||| adenomatous polyposis coli (APC), transcript variant 3, mRNA11.5652091 12.0969585 11.418916 11.8667977 10.927978 11.913408 10.2421748 10.4061321 10.181928
AMMECR1 AMMECR1 Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 (AMMECR1), transcript variant 1, mRNA ||| Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 (AMMECR1), transcript variant 2, mRNA ||| Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 (AMMECR1), transcript variant 3, mRNA11.0306405 10.4731016 11.1291228 11.4543159 10.659472 10.997739 9.81698093 9.41731975 9.7768123
GZF1 GZF1 GDNF inducible zinc finger protein 1 (GZF1), transcript variant 2, mRNA10.9828184 9.60083988 10.4266324 11.0624133 11.607894 11.348392 9.87118515 9.95001495 10.114134
POLR1B POLR1B polymerase (RNA) I polypeptide B, 128kDa (POLR1B), transcript variant 1, mRNA ||| polymerase (RNA) I polypeptide B, 128kDa (POLR1B), transcript variant 2, mRNA10.3736385 10.7688973 11.3970881 11.7964275 11.112668 11.37197 9.9867598 10.3198812 10.154398
SAPCD2 SAPCD2 suppressor APC domain containing 2 (SAPCD2), mRNA10.7065596 11.2190117 11.7287236 11.8903928 12.139683 12.262697 10.8228869 11.3029819 11.049416
GOLPH3 GOLPH3 golgi phosphoprotein 3 (coat-protein) (GOLPH3), mRNA10.3709224 10.6539737 10.5598385 11.302029 10.496862 11.443658 10.1354856 10.1014577 9.9034891
SNX2 SNX2 sorting nexin 2 (SNX2), transcript variant 1, mRNA11.2286534 11.2129192 10.5466803 10.9754111 11.31808 10.611993 10.0530235 9.86788232 10.022838
SOGA2 MTCL1 microtubule crosslinking factor 1 (MTCL1), mRNA10.9786616 10.3329448 10.5513935 9.89265584 11.021548 10.902271 9.54259186 9.90592719 9.3862134
MYO5B MYO5B myosin VB (MYO5B), mRNA 9.19986419 9.21108642 7.29117959 9.03193988 9.5087526 9.1645337 8.47252062 8.2725032 7.9530286
PAPD5 PAPD5 PAP associated domain containing 5 (PAPD5), transcript variant 1, mRNA ||| PAP associated domain containing 5 (PAPD5), transcript variant 2, mRNA11.3126705 11.4837676 11.6839263 11.0657599 11.282737 11.243348 10.2654916 10.7987898 10.421837
BMP2K BMP2K BMP2 inducible kinase (BMP2K), transcript variant 1, mRNA ||| BMP2 inducible kinase (BMP2K), transcript variant 2, mRNA10.2080035 11.0001613 10.2911796 10.1602057 10.569619 10.201349 9.60027617 9.6454899 9.4905501
KLHL15 KLHL15 kelch-like family member 15 (KLHL15), mRNA12.8608409 12.5413045 12.6892819 12.6395369 12.729735 12.11016 11.9258675 11.4870335 11.932336
CLVS1 CLVS1 clavesin 1 (CLVS1), mRNA 10.2470382 10.0302696 10.4661053 10.6404349 9.6745051 10.30414 9.34698974 9.29473315 9.3726244
SIPA1L2 SIPA1L2 signal-induced proliferation-associated 1 like 2 (SIPA1L2), mRNA1 .3476268 11.0184413 11.3897381 11.616446 11.674945 11.816903 10.6094168 11.0369833 10.814992
ORAI2 ORAI2 ORAI calcium release-activated calcium modulator 2 (ORAI2), transcript variant 1, mRNA ||| ORAI calcium release-activated calcium modulator 2 (ORAI2), transcript variant 2, mRNA11.2816743 10.2196195 11.2100428 10.765891 10.840515 11.516996 10.3044729 10.0036325 10.322851
AFTPH AFTPH aftiphilin (AFTPH), transcript variant 1, mRNA ||| aftiphilin (AFTPH), transcript variant 2, mRNA ||| aftiphilin (AFTPH), transcript variant 3, mRNA11.2430829 10.7112835 11.5247993 10.9459306 10.763209 11.34556 10.4189396 10.5396388 10.508265  
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